

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 April 2001 (05.04.2001)

PCT

(10) International Publication Number
WO 01/23533 A2

(51) International Patent Classification⁷: **C12N 9/00**

[US/IS]; Lynghals 1, 110 Reykjavik (IS). **BIENKOWSKI, Michael, Jerome** [US/US]; 3431 Hollow Wood, Portage, MI 49024 (US).

(21) International Application Number: **PCT/US00/26080**

(74) Agents: **MERKEL, William, K.** et al.; Marshall, O'Toole, Gerstein, Murray & Borun, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL 60606-6402 (US).

(22) International Filing Date:
22 September 2000 (22.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/US99/20881

60/155,493	23 September 1999 (23.09.1999)	US
09/416,901	23 September 1999 (23.09.1999)	US
60/169,232	13 October 1999 (13.10.1999)	US
	6 December 1999 (06.12.1999)	US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US	09/416,901 (CIP)
Filed on	13 October 1999 (13.10.1999)
US	PCT/US99/20881 (CIP)
Filed on	23 September 1999 (23.09.1999)

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001-0199 (US).

Published:
— Without international search report and to be republished upon receipt of that report.

(72) Inventors; and

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(75) Inventors/Applicants (*for US only*): **GURNEY, Mark**



A2

WO 01/23533

(54) Title: ALZHEIMER'S DISEASE SECRETASE, APP SUBSTRATES THEREFOR, AND USES THEREFOR

(57) Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the β secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and isolates and assays. An enzyme that cleaves the α -secretase site of APP also is provided. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.

Alzheimer's Disease Secretase, APP Substrates Therefor, and Uses Therefor

The present application is a continuation-in-part of United States Patent Application 09/416,901, filed October 13, 1999 which claims priority benefit of United States Provisional Patent Application No. 60/155,493, filed September 23, 1999 and United States Provisional Patent Application 60/169,232, filed December 6, 1999. The present application also claims priority benefit as a continuation-in-part of United States Patent Application Serial No. 09/404,133 and PCT/US99/20881, both filed September 23, 1999, both of which in turn claim priority benefit of United States Provisional Patent Application No. 60/101,594, filed September 24, 1998. All of 10 these priority applications are hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION

The present invention relates to Alzheimer's Disease, amyloid protein precursor, amyloid beta peptide, and human aspartyl proteases, as well as a method 15 for the identification of agents that modulate the activity of these polypeptides and thereby are candidates to modulate the progression of Alzheimer's disease.

BACKGROUND OF THE INVENTION

Alzheimer's disease (AD) causes progressive dementia with consequent formation of amyloid plaques, neurofibrillary tangles, gliosis and neuronal loss. The disease occurs in both genetic and sporadic forms whose clinical course and pathological features are quite similar. Three genes have been discovered to date which, when mutated, cause an autosomal dominant form of Alzheimer's disease. 20 These encode the amyloid protein precursor (APP) and two related proteins, presenilin-1 (PS1) and presenilin-2 (PS2), which, as their names suggest, are structurally and functionally related. Mutations in any of the three proteins have been observed to enhance proteolytic processing of APP via an intracellular pathway that produces amyloid beta peptide (A β peptide, or sometimes here as Abeta), a 40-42 25 amino acid long peptide that is the primary component of amyloid plaque in AD.

Dysregulation of intracellular pathways for proteolytic processing may be central to the pathophysiology of AD. In the case of plaque formation, mutations in APP, PS1 or PS2 consistently alter the proteolytic processing of APP so as to enhance formation of A β 1-42, a form of the A β peptide which seems to be particularly amyloidogenic, and thus very important in AD. Different forms of APP range in size from 695-770 amino acids, localize to the cell surface, and have a single C-terminal transmembrane domain. Examples of specific isotypes of APP which are currently known to exist in humans are the 695-amino acid polypeptide described by Kang *et. al.* (1987), *Nature* 325: 733-736 which is designated as the "normal" APP; the 751 amino acid polypeptide described by Ponte *et al.* (1988), *Nature* 331: 525-527 (1988) and Tanzi *et al.* (1988), *Nature* 331: 528-530; and the 770 amino acid polypeptide described by Kitaguchi *et. al.* (1988), *Nature* 331: 530-532. The Abeta peptide is derived from a region of APP adjacent to and containing a portion of the transmembrane domain. Normally, processing of APP at the α -secretase site cleaves the midregion of the A β sequence adjacent to the membrane and releases the soluble, extracellular domain of APP from the cell surface. This α -secretase APP processing creates soluble APP- α , (sAPP α) which is normal and not thought to contribute to AD.

Pathological processing of APP at the β - and γ -secretase sites, which are located N-terminal and C-terminal to the α -secretase site, respectively, produces a very different result than processing at the α site. Sequential processing at the β - and γ -secretase sites releases the A β peptide, a peptide possibly very important in AD pathogenesis. Processing at the β - and γ -secretase sites can occur in both the endoplasmic reticulum (in neurons) and in the endosomal/lysosomal pathway after reinternalization of cell surface APP (in all cells). Despite intense efforts, for 10 years or more, to identify the enzymes responsible for processing APP at the β and γ sites, to produce the A β peptide, those proteases remained unknown until this disclosure.

SUMMARY OF THE INVENTION

Here, for the first time, we report the identification and characterization of the β secretase enzyme, termed Aspartyl Protease 2 (Asp2). We disclose some known and some novel human aspartic proteases that can act as β -secretase proteases and, for 5 the first time, we explain the role these proteases have in AD. We describe regions in the proteases critical for their unique function and for the first time characterize their substrate. This is the first description of expressed isolated purified active protein of this type, assays that use the protein, in addition to the identification and creation of useful cell lines and inhibitors. We also identify and characterize both α -secretase and 10 β -secretase activities of a protease, designated as Asp1.

Here we disclose a number of variants of the Asp2 gene and peptide.

In one aspect, the invention provides any isolated or purified nucleic acid polynucleotide that codes for a protease capable of cleaving the beta (β) secretase cleavage site of APP that contains two or more sets of special nucleic acids, where 15 the special nucleic acids are separated by nucleic acids that code for about 100 to 300 amino acid positions, where the amino acids in those positions may be any amino acids, where the first set of special nucleic acids consists of the nucleic acids that code for the peptide DTG, where the first nucleic acid of the first special set of nucleic acids is the first special nucleic acid, and where the second set of nucleic acids code 20 for either the peptide DSG or DTG, where the last nucleic acid of the second set of nucleic acids is the last special nucleic acid, with the proviso that the nucleic acids disclosed in SEQ ID NO. 1 and SEQ ID NO. 3 are not included. In a preferred embodiment, the two sets of special nucleic acids are separated by nucleic acids that code for about 125 to 222 amino acid positions, which may be any amino acids. In a 25 highly preferred embodiment, the two sets of special nucleic acids are separated by nucleic acids that code for about 150 to 196, or 150-190, or 150 to 172 amino acid positions, which may be any amino acids. In a particular preferred embodiment, the two sets are separated by nucleic acids that code for about 172 amino acid positions, which may be any amino acids. An exemplary nucleic acid polynucleotide comprises 30 the acid nucleotide sequence in SEQ ID NO. 5. In another particular preferred

embodiment, the two sets are separated by nucleic acids that code for about 196 amino acids. An exemplary polynucleotide comprises the nucleotide sequence in SEQ ID NO. 5. In another particular embodiment, the two sets of nucleotides are separated by nucleic acids that code for about 190 amino acids. An exemplary 5 polynucleotide comprises the nucleotide sequence in SEQ ID NO. 1. Preferably, the first nucleic acid of the first special set of amino acids, that is, the first special nucleic acid, is operably linked to any codon where the nucleic acids of that codon codes for any peptide comprising from 1 to 10,000 amino acid (positions). In one variation, the first special nucleic acid is operably linked to nucleic acid polymers that code for any 10 peptide selected from the group consisting of: any reporter proteins or proteins which facilitate purification. For example, the first special nucleic acid is operably linked to nucleic acid polymers that code for any peptide selected from the group consisting of: immunoglobulin-heavy chain, maltose binding protein, glutathione S transferase, Green Fluorescent protein, and ubiquitin. In another variation, the last nucleic acid of the 15 second set of special amino acids, that is, the last special nucleic acid, is operably linked to nucleic acid polymers that code for any peptide comprising any amino acids from 1 to 10,000 amino acids. In still another variation, the last special nucleic acid is operably linked to nucleic acid polymers that code for any peptide selected from the group consisting of: any reporter proteins or proteins which facilitate purification. For 20 example, the last special nucleic acid is operably linked to nucleic acid polymers that code for any peptide selected from the group consisting of: immunoglobulin-heavy chain, maltose binding protein, glutathione S transferase, Green Fluorescent protein, and ubiquitin.

In a related aspect, the invention provides any isolated or purified nucleic acid 25 polynucleotide that codes for a protease capable of cleaving the beta secretase cleavage site of APP that contains two or more sets of special nucleic acids, where the special nucleic acids are separated by nucleic acids that code for about 100 to 300 amino acid positions, where the amino acids in those positions may be any amino acids, where the first set of special nucleic acids consists of the nucleic acids that code 30 for DTG, where the first nucleic acid of the first special set of nucleic acids is the first

special nucleic acid, and where the second set of nucleic acids code for either DSG or DTG, where the last nucleic acid of the second set of special nucleic acids is the last special nucleic acid, where the first special nucleic acid is operably linked to nucleic acids that code for any number of amino acids from zero to 81 amino acids and where
5 each of those codons may code for any amino acid. In a preferred embodiment, the first special nucleic acid is operably linked to nucleic acids that code for any number of from 64 to 77 amino acids where each codon may code for any amino acid. In a particular embodiment, the first special nucleic acid is operably linked to nucleic acids that code for 71 amino acids. For example, the first special nucleic acid is operably
10 linked to 71 amino acids and where the first of those 71 amino acids is the amino acid T. In a preferred embodiment, the polynucleotide comprises a sequence that is at least 95% identical to a human Asp1 or Asp2 sequence as taught herein. In another preferred embodiment, the first special nucleic acid is operably linked to nucleic acids that code for any number of from 30 to 54 amino acids, or 35 to 47 amino acids, or
15 40 to 54 amino acids where each codon may code for any amino acid. In a particular embodiment, the first special nucleic acid is operably linked to nucleic acids that code for 47 amino acids. For example, the first special nucleic acid is operably linked to 47 codons where the first those 47 amino acids is the amino acid E.

In another related aspect, the invention provides for any isolated or purified
20 nucleic acid polynucleotide that codes for a protease capable of cleaving the beta (β) secretase cleavage site of APP and that contains two or more sets of special nucleic acids, where the special nucleic acids are separated by nucleic acids that code for about 100 to 300 amino acid positions, where the amino acids in those positions may be any amino acids, where the first set of special nucleic acids consists of the nucleic
25 acids that code for the peptide DTG, where the first nucleic acid of the first special set of amino acids is, the first special nucleic acid, and where the second set of special nucleic acids code for either the peptide DSG or DTG, where the last nucleic acid of the second set of special nucleic acids, the last special nucleic acid, is operably linked to nucleic acids that code for any number of codons from 50 to 170 codons. In a
30 preferred embodiment, the last special nucleic acid is operably linked to nucleic acids

comprising from 100 to 170 codons. In a highly preferred embodiment, the last special nucleic acid is operably linked to nucleic acids comprising from 142 to 163 codons. In a particular embodiment, the last special nucleic acid is operably linked to nucleic acids comprising about 142 codons, or about 163 codons, or about 170

5 codons. In a highly preferred embodiment, the polynucleotide comprises a sequence that is at least 95% identical to aspartyl-protease encoding sequences taught herein. In one variation, the second set of special nucleic acids code for the peptide DSG. In another variation, the first set of nucleic acid polynucleotide is operably linked to a peptide purification tag. For example, the nucleic acid polynucleotide is operably

10 linked to a peptide purification tag which is six histidine. In still another variation, the first set of special nucleic acids are on one polynucleotide and the second set of special nucleic acids are on a second polynucleotide, where both first and second polynucleotides have at least 50 codons. In one embodiment of this type, both of the polynucleotides are in the same solution. In a related aspect, the invention provides a

15 vector which contains a polynucleotide as described above, or a cell or cell line which is transformed or transfected with a polynucleotide as described above or with a vector containing such a polynucleotide.

In still another aspect, the invention provides an isolated or purified peptide or protein comprising an amino acid polymer that is a protease capable of cleaving the

20 beta (β) secretase cleavage site of APP that contains two or more sets of special amino acids, where the special amino acids are separated by about 100 to 300 amino acid positions, where each amino acid position can be any amino acid, where the first set of special amino acids consists of the peptide DTG, where the first amino acid of the first special set of amino acids is, the first special amino acid, where the second set of amino acids is selected from the peptide comprising either DSG or DTG, where the

25 last amino acid of the second set of special amino acids is the last special amino acid, with the proviso that the proteases disclosed in SEQ ID NO. 2 and SEQ ID NO. 4 are not included. In preferred embodiments, the two sets of amino acids are separated by about 125 to 222 amino acid positions or about 150 to 196 amino acids, or about 150-

30 190 amino acids, or about 150 to 172 amino acids, where in each position it may be

any amino acid. In a particular embodiment, the two sets of amino acids are separated by about 172 amino acids. For example, the protease has the amino acid sequence described in SEQ ID NO 6. In another particular embodiment, the two sets of amino acids are separated by about 196 amino acids. For example, the two sets of amino acids are separated by the same amino acid sequences that separate the same set of special amino acids in SEQ ID NO 4. In another particular embodiment, the two sets of nucleotides are separated by about 190 amino acids. For example, the two sets of nucleotides are separated by the same amino acid sequences that separate the same set of special amino acids in SEQ ID NO 2. In one embodiment, the first amino acid of the first special set of amino acids, that is, the first special amino acid, is operably linked to any peptide comprising from 1 to 10,000 amino acids. In another embodiment, the first special amino acid is operably linked to any peptide selected from the group consisting of: any reporter proteins or proteins which facilitate purification. In particular embodiments, the first special amino acid is operably linked to any peptide selected from the group consisting of: immunoglobulin-heavy chain, maltose binding protein, glutathione S transferase, Green Fluorescent protein, and ubiquitin. In still another variation, the last amino acid of the second set of special amino acids, that is, the last special amino acid, is operably linked to any peptide comprising any amino acids from 1 to 10,000 amino acids. By way of nonlimiting example, the last special amino acid is operably linked any peptide selected from the group consisting of any reporter proteins or proteins which facilitate purification. In particular embodiments, the last special amino acid is operably linked to any peptide selected from the group consisting of: immunoglobulin-heavy chain, maltose binding protein, glutathione S transferase, Green Fluorescent protein, and ubiquitin.

In a related aspect, the invention provides any isolated or purified peptide or protein comprising an amino acid polypeptide that codes for a protease capable of cleaving the beta secretase cleavage site of APP that contains two or more sets of special amino acids, where the special amino acids are separated by about 100 to 300 amino acid positions, where each amino acid in each position can be any amino acid, where the first set of special amino acids consists of the amino acids DTG, where the

first amino acid of the first special set of amino acids is, the first special amino acid, D, and where the second set of amino acids is either DSG or DTG, where the last amino acid of the second set of special amino acids is the last special amino acid, G, where the first special amino acid is operably linked to amino acids that code for any 5 number of amino acids from zero to 81 amino acid positions where in each position it may be any amino acid. In a preferred embodiment, the first special amino acid is operably linked to a peptide from about 30-77 or about 64 to 77 amino acids positions where each amino acid position may be any amino acid. In a particular embodiment, the first special amino acid is operably linked to a peptide 35, 47, 71, or 77 amino acids. In a very particular embodiment, the first special amino acid is operably linked to 10 71 amino acids and the first of those 71 amino acids is the amino acid T. For example, the polypeptide comprises a sequence that is at least 95% identical to an aspartyl protease sequence as described herein. In another embodiment, the first special amino acid is operably linked to any number of from 40 to 54 amino acids 15 (positions) where each amino acid position may be any amino acid. In a particular embodiment, the first special amino acid is operably linked to amino acids that code for a peptide of 47 amino acids. In a very particular embodiment, the first special amino acid is operably linked to a 47 amino acid peptide where the first those 47 amino acids is the amino acid E. In another particular embodiment, the first special 20 amino acid is operably linked to the same corresponding peptides from SEQ ID NO. 3 that are 35, 47, 71, or 77 peptides in length, beginning counting with the amino acids on the first special sequence, DTG, towards the N-terminal of SEQ ID NO. 3. In another particular embodiment, the polypeptide comprises a sequence that is at least 95% identical to the same corresponding amino acids in SEQ ID NO. 4, that is, 25 identical to that portion of the sequences in SEQ ID NO. 4, including all the sequences from both the first and or the second special nucleic acids, toward the – terminal, through and including 71, 47, 35 amino acids before the first special amino acids. For example, the complete polypeptide comprises the peptide of 71 amino acids, where the first of the amino acid is T and the second is Q.

In still another related aspect, the invention provides any isolated or purified amino acid polypeptide that is a protease capable of cleaving the beta (β) secretase cleavage site of APP that contains two or more sets of special amino acids, where the special amino acids are separated by about 100 to 300 amino acid positions, where

5 each amino acid in each position can be any amino acid, where the first set of special amino acids consists of the amino acids that code for DTG, where the first amino acid of the first special set of amino acids is, the first special amino acid, D, and where the second set of amino acids are either DSG or DTG, where the last amino acid of the second set of special amino acids is the last special amino acid, G, which is operably

10 linked to any number of amino acids from 50 to 170 amino acids, which may be any amino acids. In preferred embodiments, the last special amino acid is operably linked to a peptide of about 100 to 170 amino acids or about 142-163 amino acids. In particular embodiments, the last special amino acid is operably linked to a peptide of about 142 amino acids, or about 163 amino acids, or about 170 amino acids. For

15 example, the polypeptide comprises a sequence that is at least 95% identical (and preferably 100% identical) to an aspartyl protease sequence as described herein. In one particular embodiment, the second set of special amino acids is comprised of the peptide with the amino acid sequence DSG. Optionally, the amino acid polypeptide is operably linked to a peptide purification tag, such as purification tag which is six

20 histidine. In one variation, the first set of special amino acids are on one polypeptide and the second set of special amino acids are on a second polypeptide, where both first and second polypeptide have at least 50 amino acids, which may be any amino acids. In one embodiment of this type, both of the polypeptides are in the same vessel. The invention further includes a process of making any of the polynucleotides,

25 vectors, or cells described herein; and a process of making any of the polypeptides described herein.

In yet another related aspect, the invention provides a purified polynucleotide comprising a nucleotide sequence that encodes a polypeptide having aspartyl protease activity, wherein the polypeptide has an amino acid sequence characterized by: (a) a

30 first tripeptide sequence DTG; (b) a second tripeptide sequence selected from the

group consisting of DSG and DTG; and (c) about 100 to 300 amino acids separating the first and second tripeptide sequences, wherein the polypeptide cleaves the beta secretase cleavage site of amyloid protein precursor. In one embodiment, the polypeptide comprises an amino acid sequence depicted in SEQ ID NO: 2 or 4,

5 whereas in another embodiment, the polypeptide comprises an amino acid sequence other than the amino acid sequences set forth in SEQ ID NOs: 2 and 4. Similarly, the invention provides a purified polynucleotide comprising a nucleotide sequence that encodes a polypeptide that cleaves the beta secretase cleavage site of amyloid protein precursor; wherein the polynucleotide includes a strand that hybridizes to one or more

10 of SEQ ID NOs: 3, 5, and 7 under the following hybridization conditions: hybridization overnight at 42°C for 2.5 hours in 6 X SSC/0.1% SDS, followed by washing in 1.0 X SSC at 65°C, 0.1% SDS. In one embodiment, the polypeptide comprises an amino acid sequence depicted in SEQ ID NO: 2 or 4, whereas in another embodiment, the polypeptide comprises an amino acid sequence other than the amino

15 acid sequences set forth in SEQ ID NOs: 2 and 4. Likewise, the invention provides a purified polypeptide having aspartyl protease activity, wherein the polypeptide is encoded by polynucleotides as described in the preceding sentences. The invention also provides a vector or host cell comprising such polynucleotides, and a method of making the polypeptides using the vectors or host cells to recombinantly express the

20 polypeptide.

In yet another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide, said polynucleotide encoding a Hu-Asp polypeptide and having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

- 25 (a) a nucleotide sequence encoding a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b), wherein said Hu-Asp1, Hu-Asp2(a) and Hu-Asp2(b) polypeptides have the complete amino acid sequence of SEQ ID NO. 2, SEQ ID NO. 4, and SEQ ID NO. 6, respectively; and
- (b) a nucleotide sequence complementary to the nucleotide
- 30 sequence of (a).

Several species are particularly contemplated. For example, the invention provides a nucleic acid and molecule wherein said Hu-Asp polypeptide is Hu-Asp1, and said polynucleotide molecule of 1(a) comprises the nucleotide sequence of SEQ ID NO. 1; and a nucleic acid molecule wherein said Hu-Asp polypeptide is
5 Hu-Asp2(a), and said polynucleotide molecule of 1(a) comprises the nucleotide sequence of SEQ ID NO. 4; and a nucleic acid molecule wherein said Hu-Asp polypeptide is Hu-Asp2(b), and said polynucleotide molecule of 1(a) comprises the nucleotide sequence of SEQ ID NO. 5. In addition to the foregoing, the invention provides an isolated nucleic acid molecule comprising polynucleotide which
10 hybridizes under stringent conditions to a polynucleotide having the nucleotide sequence in (a) or (b) as described above.

Additionally, the invention provides a vector comprising a nucleic acid molecule as described in the preceding paragraph. In a preferred embodiment, the nucleic acid molecule is operably linked to a promoter for the expression of a Hu-Asp polypeptide. Individual vectors which encode Hu-Asp1, and Hu-Asp2(a), and
15 Hu-Asp2(b) are all contemplated. Likewise, the invention contemplates a host cell comprising any of the foregoing vectors, as well as a method of obtaining a Hu-Asp polypeptide comprising culturing such a host cell and isolating the Hu-Asp polypeptide. Host cells of the invention include bacterial cells, such as *E. coli*, and
20 eukaryotic cells. Among the eukaryotic cells that are contemplated are insect cells, such as sf9 or High 5 cells; and mammalian cells, such as human, rodent, lagomorph, and primate. Preferred human cells include HEK293, and IMR-32 cells. Other preferred mammalian cells include COS-7, CHO-K1, Neuro-2A, and 3T3 cells. Also among the eukaryotic cells that are contemplated are a yeast cell and an avian cell.
25

In a related aspect, the invention provides an isolated Hu-Asp1 polypeptide comprising an amino acid sequence at least 95% identical to a sequence comprising the amino acid sequence of SEQ ID NO. 2. The invention also provides an isolated Hu-Asp2(a) polypeptide comprising an amino acid sequence at least 95% identical to a sequence comprising the amino acid sequence of SEQ ID NO. 4. The invention also provides an isolated Hu-Asp2(a) polypeptide comprising an amino acid sequence at
30

least 95% identical to a sequence comprising the amino acid sequence of SEQ ID NO. 8.

5 In still another aspect, the invention provides an isolated antibody that binds specifically to any Hu-Asp polypeptide described herein, especially the polypeptide described in the preceding paragraphs.

The invention also provides several assays involving aspartyl protease enzymes of the invention. For example, the invention provides

a method to identify a cell that can be used to screen for inhibitors of β secretase activity comprising:

10 (a) identifying a cell that expresses a protease capable of cleaving APP at the β secretase site, comprising:

i) collect the cells or the supernatant from the cells to be identified

15 ii) measure the production of a critical peptide, where the critical peptide is selected from the group consisting of either the APP C-terminal peptide or soluble APP,

iii) select the cells which produce the critical peptide.

In one variation, the cells are collected and the critical peptide is the APP C-terminal peptide created as a result of the β secretase cleavage. In another 20 variation, the supernatant is collected and the critical peptide is soluble APP, where the soluble APP has a C-terminus created by β secretase cleavage. In preferred embodiments, the cells contain any of the nucleic acids or polypeptides described above and the cells are shown to cleave the β -secretase site of any peptide having the following peptide structure, P₂, P₁, P_{1'}, P_{2'}, where P₂ is K or N, where P₁ is M or L, where P_{1'} is D, where P_{2'} is A. The method where P₂ is K and P₁ is M. The 25 method where P₂ is N and P₁ is L.

In still another aspect, the invention provides novel isoforms of amyloid protein precursor (APP) where the last two carboxy terminus amino acids of that isoform are both lysine residues. In this context, the term "isoform" is defined as any 30 APP polypeptide, including APP-variants (including mutations), and APP fragments

that exists in humans, such as those described in US 5,766,846, col 7, lines 45-67, incorporated into this document by reference, modified as described herein by the inclusion of two C-terminal lysine residues. For example, the invention provides a polypeptide comprising the isoform known as APP695, modified to include two 5 lysine residues as its last two carboxy terminus amino acids. An exemplary polypeptide comprises the amino acid sequence set forth in SEQ ID NO. 16. The invention further includes APP isoform variants as set forth in SEQ ID NOS. 18 and 20. The invention further includes all polynucleotides that encode an APP protein that has been modified to include two C-terminal lysines; as well has any eukaryotic 10 cell line comprising such nucleic acids or polypeptides. Preferred cell lines include a mammalian cell line (*e.g.*, HEK293, Neuro2a).

Thus, in one embodiment, the invention provides a polypeptide comprising the amino acid sequence of a mammalian amyloid protein precursor (APP) or fragment thereof containing an APP cleavage site recognizable by a mammalian β -secretase, 15 and further comprising two lysine residues at the carboxyl terminus of the amino acid sequence of the mammalian APP or APP fragment. As taught herein in detail, the addition of two additional lysine residues to APP sequences has been found to greatly increase A β processing of the APP in APP processing assays. Thus, the di-lysine modified APP reagents of the invention are particularly useful in assays to identify 20 modulators of A β production, for use in designing therapeutics for the treatment or prevention of Alzheimer's disease. In one embodiment, the polypeptide comprises the complete amino acid sequence of a mammalian amyloid protein precursor (APP), and further comprises the two lysine residues at the carboxyl terminus of the amino acid sequence of the mammalian amyloid protein precursor. In an alternative 25 embodiment, the polypeptide comprises only a fragment of the APP, the fragment containing at least that portion of APP that is cleaved by a mammalian β -secretase (or α -secretase or γ -secretase) in the formation of A β peptides.

The practice of assays that monitor cleavage of APP can be facilitated by attaching a marker to a portion of the APP. Measurement of retained or liberated 30 marker can be used to quantitate the amount of APP cleavage that occurs in the assay,

e.g., in the presence or absence of a putative modulator of cleavage activity. Thus, in one preferred embodiment, the polypeptide of the invention further includes a marker. For example, the marker comprises a reporter protein amino acid sequence attached to the APP amino acid sequence. Exemplary reporter proteins include a fluorescing protein (e.g., green fluorescing proteins, luciferase) or an enzyme that is used to cleave a substrate to produce a colorimetric cleavage product. Also contemplated are tag sequences which are commonly used as epitopes for quantitative immunoassays.

In a preferred embodiment, the di-lysine-modified APP of the invention is a human APP. For example, human APP isoforms such as APP695, APP751, and APP770, modified to include the two lysines, are contemplated. In a preferred embodiment, the APP isoform comprises at least one variation selected from the group consisting of a Swedish KM-NL mutation and a London V717-F mutation, or any other mutation that has been observed in a subpopulation that is particularly prone to development of Alzheimer's disease. These mutations are recognized as mutations that influence APP processing into A β . In a highly preferred embodiment, the APP protein or fragment thereof comprises the APP-Sw β -secretase peptide sequence NLDA, which is associated with increased levels of A β processing and therefore is particularly useful in assays relating to Alzheimer's research. More particularly, the APP protein or fragment thereof preferably comprises the APP-Sw β -secretase peptide sequence SEVNLDAEFR (SEQ ID NO: 63).

In one preferred embodiment, the APP protein or fragment thereof further includes an APP transmembrane domain carboxy-terminal to the APP-Sw β -secretase peptide sequence. Polypeptides that include the TM domain are particularly useful in cell-based APP processing assays. In contrast, embodiments lacking the TM domain are useful in cell-free assays of APP processing.

In addition to working with APP from humans and various animal models, researchers in the field of Alzheimer's also have construct chimeric APP polypeptides which include stretches of amino acids from APP of one species (e.g., humans) fused to stretches of APP from one or more other species (e.g., rodent). Thus, in another embodiment of the polypeptide of the invention, the APP protein or fragment thereof

comprises a chimeric APP, the chimeric APP including partial APP amino acid sequences from at least two species. A chimeric APP that includes amino acid sequence of a human APP and a rodent APP is particularly contemplated.

In a related aspect, the invention provides a polynucleotide comprising a nucleotide sequence that encodes a polypeptide as described in the preceding paragraphs. Such a polynucleotide is useful for recombinant expression of the polypeptide of the invention for use in APP processing assays. In addition, the polynucleotide is useful for transforming into cells to produce recombinant cells that express the polypeptide of the invention, which cells are useful in cell-based assays to identify modulators of APP processing. Thus, in addition to polynucleotides, the invention provides a vector comprising such polynucleotides, especially expression vectors where the polynucleotide is operably linked to a promoter to promote expression of the polypeptide encoded by the polynucleotide in a host cell. The invention further provides a host cell transformed or transfected with such a polynucleotide or a vector. Among the preferred host cells are mammalian cells, especially human cells.

In another, related embodiment, the invention provides a polypeptide useful for assaying for modulators of β -secretase activity, said polypeptide comprising an amino acid sequence of the formula $\text{NH}_2\text{-X-Y-Z-KK-COOH}$; wherein X, Y, and Z each comprise an amino acid sequence of at least one amino acid; wherein $\text{NH}_2\text{-X}$ comprises an amino-terminal amino acid sequence having at least one amino acid residue; wherein Y comprises an amino acid sequence of a β -secretase recognition site of a mammalian amyloid protein precursor (APP); and wherein Z-KK-COOH comprises a carboxy-terminal amino acid sequence ending in two lysine (K) residues.

In one preferred variation, the carboxyl-terminal amino acid sequence Z includes a hydrophobic domain that is a transmembrane domain in host cells that express the polypeptide. Host cells that express such a polypeptide are particularly useful in assays described herein for identifying modulators of APP processing. In another preferred variation, the amino-terminal amino acid sequence X includes an amino acid sequence of a reporter or marker protein, as described above. In still another preferred

variation, the β -secretase recognition site Y comprises the human APP-Sw β -secretase peptide sequence NLDA. It will be apparent that these preferred variations are not mutually exclusive of each other -- they may be combined in a single polypeptide.

5 The invention further provides a polynucleotide comprising a nucleotide sequence that encodes such polypeptides, vectors which comprise such polynucleotides, and host cells which comprises such vectors, polynucleotides, and/or polypeptides.

In yet another aspect, the invention provides a method for identifying inhibitors of an enzyme that cleaves the beta secretase cleavable site of APP comprising:

- 10 a) culturing cells in a culture medium under conditions in which the enzyme causes processing of APP and release of amyloid beta-peptide into the medium and causes the accumulation of CTF99 fragments of APP in cell lysates,
- b) exposing the cultured cells to a test compound; and specifically determining whether the test compound inhibits the function of the enzyme by
- 15 measuring the amount of amyloid beta-peptide released into the medium and/or the amount of CTF99 fragments of APP in cell lysates;
- c) identifying test compounds diminishing the amount of soluble amyloid beta peptide present in the culture medium and diminution of CTF99 fragments of APP in cell lysates as Asp2 inhibitors. In preferred embodiments, the cultured cells
- 20 are a human, rodent or insect cell line. It is also preferred that the human or rodent cell line exhibits β secretase activity in which processing of APP occurs with release of amyloid beta-peptide into the culture medium and accumulation of CTF99 in cell lysates. Among the contemplated test compounds are antisense oligomers directed against the enzyme that exhibits β secretase activity, which oligomers reduce release
- 25 of soluble amyloid beta-peptide into the culture medium and accumulation of CTF99 in cell lysates.

In yet another aspect, the invention provides a method for the identification of an agent that decreases the activity of a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b), the method comprising:

- a) determining the activity of said Hu-Asp polypeptide in the presence of a test agent and in the absence of a test agent; and
- b) comparing the activity of said Hu-Asp polypeptide determined in the presence of said test agent to the activity of said Hu-Asp polypeptide determined in the absence of said test agent; whereby a lower level of activity in the presence of said test agent than in the absence of said test agent indicates that said test agent has decreased the activity of said Hu-Asp polypeptide.

In a related aspect, the invention provides a method for assaying for modulators of β -secretase activity, comprising the steps of:

- (a) contacting a first composition with a second composition both in the presence and in the absence of a putative modulator compound, wherein the first composition comprises a mammalian β -secretase polypeptide or biologically active fragment thereof, and wherein the second composition comprises a substrate polypeptide having an amino acid sequence comprising a β -secretase cleavage site;
- (b) measuring cleavage of the substrate polypeptide in the presence and in the absence of the putative modulator compound; and (c) identifying modulators of β -secretase activity from a difference in cleavage in the presence versus in the absence of the putative modulator compound. A modulator that is a β -secretase antagonist (inhibitor) reduces such cleavage, whereas a modulator that is a β -secretase agonist increases such cleavage. Since such assays are relevant to development of Alzheimer's disease therapeutics for humans, it will be readily apparent that, in one preferred embodiment, the first composition comprises a purified human Asp2 polypeptide. In one variation, the first composition comprises a soluble fragment of a human Asp2 polypeptide that retains Asp2 β -secretase activity. Several such fragments (including Δ TM fragments) are described herein in detail. Thus, in a particular embodiment, the soluble fragment is a fragment lacking an Asp2 transmembrane domain. Assaying to identify inhibitors of Asp1 β -secretase activity also is contemplated.

The β -secretase cleavage site in APP is known, and it will be appreciated that the assays of the invention can be performed with either intact APP or

fragments or analogs of APP that retain the β -secretase recognition and cleavage site. Thus, in one variation, the substrate polypeptide of the second composition comprises the amino acid sequence SEVNLDAEFR, which includes the β -secretase recognition site of human APP that contains the "Swiss" mutation. In another variation, the 5 substrate polypeptide of the second composition comprises the amino acid sequence EVKMDAEF. In another variation, the second composition comprises a polypeptide having an amino acid sequence of a human amyloid precursor protein (APP). For example, the human amyloid precursor protein is selected from the group consisting of: APP695, APP751, and APP770. Preferably, the human amyloid precursor protein 10 (irrespective of isoform selected) includes at least one mutation selected from a KM-NL Swiss mutation and a V-F London mutation. As explained elsewhere, one preferred embodiment involves a variation wherein the polypeptide having an amino acid sequence of a human APP further comprises an amino acid sequence comprising a marker sequence attached amino-terminal to the amino acid sequence of the human amyloid precursor protein. Preferably, the polypeptide having an amino acid sequence of a human APP further comprises two lysine residues attached to the 15 carboxyl terminus of the amino acid sequence of the human APP. The assays can be performed in a cell free setting, using cell-free enzyme and cell-free substrate, or can be performed in a cell-based assay wherein the second composition comprises a eukaryotic cell that expresses amyloid precursor protein (APP) or a fragment thereof containing a β -secretase cleavage site. Preferably, the APP expressed by the host cell 20 is an APP variant that includes two carboxyl-terminal lysine residues. It will also be appreciated that the β -secretase enzyme can be an enzyme that is expressed on the surface of the same cells.

25 The present invention provides isolated nucleic acid molecules comprising a polynucleotide that codes for a polypeptide selected from the group consisting of human aspartyl proteases. In particular, human aspartyl protease 1 (Hu-Asp1) and two alternative splice variants of human aspartyl protease-2 (Hu-Asp2), a "long" (L) form designated herein as Hu-Asp2(a) and a "short" (S) form designated Hu-Asp2(b).

30 As used herein, all references to "Hu-Asp" should be understood to refer to all of

Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b). In addition, as used herein, all references to "Hu-Asp2" should be understood to refer to both Hu-Asp2(a) and Hu-Asp2(b).
Hu-Asp1 is expressed most abundantly in pancreas and prostate tissues, while
Hu-Asp2(a) and Hu-Asp2(b) are expressed most abundantly in pancreas and brain
5 tissues. The invention also provides isolated Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b)
polypeptides, as well as fragments thereof which exhibit aspartyl protease activity.

In a preferred embodiment, the nucleic acid molecules comprise a polynucleotide having a nucleotide sequence selected from the group consisting of residues 1-1554 of SEQ ID NO. 1, encoding Hu-Asp1, residues 1-1503 of SEQ ID NO. 3, encoding
10 Hu-Asp2(a), and residues 1-1428 of SEQ ID NO. 5, encoding Hu-Asp2(b). In another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent conditions to a polynucleotide encoding Hu-Asp1, Hu-Asp2(a), Hu-Asp2(b), or fragments thereof. European patent application EP 0 848 062 discloses a polypeptide referred to as "Asp 1," that bears substantial homology to Hu-Asp1, while international application WO 98/22597 discloses a
15 polypeptide referred to as "Asp 2," that bears substantial homology to Hu-Asp2(a).

The present invention also provides vectors comprising the isolated nucleic acid molecules of the invention, host cells into which such vectors have been introduced, and recombinant methods of obtaining a Hu-Asp1, Hu-Asp2(a), or Hu-Asp2(b) polypeptide
20 comprising culturing the above-described host cell and isolating the relevant polypeptide.

In another aspect, the invention provides isolated Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides, as well as fragments thereof. In a preferred embodiment, the Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides have the amino acid sequence given in SEQ ID NO. 2, SEQ ID NO. 4, or SEQ ID NO. 6, respectively. The present invention
25 also describes active forms of Hu-Asp2, methods for preparing such active forms, methods for preparing soluble forms, methods for measuring Hu-Asp2 activity, and substrates for Hu-Asp2 cleavage. The invention also describes antisense oligomers targeting the Hu-Asp1, Hu-Asp2(a) and Hu-Asp2(b) mRNA transcripts and the use of such antisense reagents to decrease such mRNA and consequently the production of the
30 corresponding polypeptide. Isolated antibodies, both polyclonal and monoclonal, that

binds specifically to any of the Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides of the invention are also provided.

The invention also provides a method for the identification of an agent that modulates the activity of any of Hu-Asp-1, Hu-Asp2(a), and Hu-Asp2(b). The inventions 5 describes methods to test such agents in cell-free assays to which Hu-Asp2 polypeptide is added, as well as methods to test such agents in human or other mammalian cells in which Hu-Asp2 is present.

The invention provides for methods for assaying for human Asp1(hu-Asp1) α -secretase activity comprising contacting the hu-Asp1 protein with an amyloid precursor 10 protein (APP) substrate, wherein the substrate contains an α -secretase cleavage site; and measuring cleavage of the APP substrate at the α -secretase cleavage site, thereby assaying hu-Asp1 α -secretase activity. An example of α -secretase activity is APP processing wherein the APP substrate is cleaved at a site adjacent to the cell membrane 15 (at residues Phe²⁰,Ala²¹ in relation to the A β peptide). This cleavage results in the release of a soluble, extracellular domain of APP, known as amyloid alpha peptide (sAPP α), from the cell surface into the cytoplasm. The sAPP α within the cytoplasm can be detected and quantitated thereby measuring α -secretase activity.

The hu-Asp1 enzyme used in the methods of the invention can be purified and isolated from a cell which is transfected or transformed with a polynucleotide that 20 encodes hu-Asp1, such as SEQ ID NO: 1, or a polynucleotide sequence that encodes the the amino acid sequence of SEQ ID NO: 2. Further, the hu-Asp1 protein used in the methods may be a fragment of the amino acid sequence of SEQ ID NO: 2 which retains α -secretase activity. Possible fragments that may be of use for the methods include those lacking the transmembrane domain amino acids 469-492 of SEQ ID NO: 2, those 25 fragments that lack the cytoplasmic amino acids 493-492 of SEQ ID NO: 2, those fragments that lack the amino terminal amino acids 1-62 of SEQ ID NO: 2 or combinations thereof.

The invention also encompasses methods of assaying for α -secretase activity where hu-Asp1 protein and its substrate are brought into contact by a growing cell 30 transfected or transformed with a polynucleotide encoding the hu-Asp1 protein or a

fragment thereof that retains α -secretase activity under conditions where the cell expresses hu-Asp1 protein in the presence of the APP substrate. The APP substrate in such circumstances can be exogenously introduced, or more preferably, is expressed by the cell that expresses Asp1. These methods also encompass contacting hu-Asp1 protein with a cell that expresses a polynucleotide that encodes an APP substrate containing an α -secretase cleavage site. For example, the cell may express a polynucleotide that encodes a polypeptide having an α -secretase cleavage site comprising the amino acid sequence LVFFAEDF or KLVFFAED. In addition, the APP substrate may comprise any human isoform of APP, such as "normal" APP (APP695), APP 751, or APP770. These APP substrates can be further modified to comprise a carboxy-terminal di-lysine motif.

To measure the cleavage of the substrates for the methods of assaying for α -secretase activity of the invention, the substrates of the method can be further modified to comprise detectable labels such as radioactive, enzymatic, chemiluminescent or fluorescent labels. In particular, shorter peptide substrates preferably comprise internally quenched labels that result in increased detectability after cleavage of the peptide substrates. The peptide substrates may be modified to have attached a paired fluorophore and quencher including but not limited to 7-amino-4-methyl coumarin and dinitrophenol, respectively, such that cleavage of the peptide by the hu-Asp1 results in increased fluorescence due to physical separation of the fluorophore and quencher. Other paired fluorophores and quenchers include bodipy-tetramethylrhodamine and QSY-5 (Molecular Probes, Inc.) In a variant of this assay, biotin or another suitable tag may be placed on one end of the peptide to anchor the peptide to a substrate assay plate and a fluorophore may be placed at the other end of the peptide. Useful fluorophores include those listed above as well as Europium labels such as W8044 (EG&G Wallac, Inc.). A preferred label is oregon green that may be attached to a Cys residue. Cleavage of the peptide by Asp1 will release the fluorophore or other tag from the plate, allowing compounds to be assayed for inhibition of Asp1 proteolytic cleavage as shown by an increase in retained fluorescence. Preferred colorimetric assays of hu-Asp1 proteolytic activity utilize other suitable substrates that include the P₂ and P₁ amino acids comprising the recognition site for cleavage linked to o-nitrophenol through an amide linkage, such that cleavage by the

hu-Asp1 results in an increase in optical density after altering the assay buffer to alkaline pH.

The prevent invention also provides for methods of assaying for α -secretase activity comprising contacting hu-Asp1 protein with an APP substrate, determining the level of hu-Asp1 α -secretase activity in the presence and absence of a modulator of hu-Asp1 α -secretase activity and comparing the hu-Asp1 secretase activity in the presence and absence of the modulator. The modulators determined to increase hu-Asp1 α -secretase activity will be identified as candidate Alzheimer's disease therapeutics. The invention also encompasses methods which comprise a step for treating Alzheimer's disease with identified candidate Alzheimer disease therapeutics. The invention also provides for compositions comprising a candidate Alzheimer's disease therapeutic identified by the α -secretase assaying methods of the invention. Asp1 modulators that reduce Asp1 β -secretase activity and increase Asp1 α -secretase activity are highly preferred. Assays for Asp1 β -secretase activity are preferred essentially as described in detail herein for Asp2.

The invention provides for Asp1 protease substrate peptides or fragments thereof, wherein said peptides comprise an amino acid sequence consisting of fifty or fewer amino acids which comprise the Asp1 cleavage site having the amino acid sequence GLALALEP. This peptide was derived from the Asp1 amino acid sequence and the discovery of an apparent Asp1 autocatalytic cleavage in acidic conditions. The Asp1 substrate of the invention may also comprise a detectable label, such as a radioactive label, chemiluminescent label, enzymatic label or a florescent label. The floressently labeled substrate can consist of internally quenched labels as described above.

The invention also encompasses methods comprising the steps of contacting hu-Asp1 protein with an Asp1 substrate under acidic conditions and determining the level of Asp1 proteolytic activity. An example of Asp1 proteolytic activity is the auto-catalytic processing hu-Asp undergoes in acidic environments, wherein cleavage occurs at an amino acid site surrounding Ala⁶³ and cleaves the amino terminal amino acids of the hu-Asp1 pro-peptide. The hu-Asp1 pro-peptide refers to a secreted form of Asp1 that has completed intercellular processing which resulted in cleavage of its signal sequence.

For the methods of assaying Asp1 proteolytic activity, the hu-Asp1 may be produced in a cell transformed or transfected with a polynucleotide that encodes hu-Asp1. The hu-Asp1 protein may be isolated and purified from these cells or the method may utilize a cell growing under conditions that it expresses hu-Asp1. The method may also 5 be carried out with a fragment of hu-Asp1 that retains its proteolytic activity. The fragments provided for by the invention include hu-Asp1 polypeptide sequences which lack the amino acids that encode a transmembrane domain such as amino acids 469-492 of SEQ ID NO: 2 or fragments that lacks the cytoplasmic domain such as amino acids 493-518 of SEQ ID NO: 2.

10 The invention provides for a purified polynucleotide comprising a nucleotide sequence encoding a polypeptide that comprises a fragment of a hu-Asp1 protein, wherein said nucleotide sequence lacks the sequence that encodes amino acids 23-62 of SEQ ID NO: 2, and wherein the polypeptide has hu-Asp1 α -secretase activity. This portion of the Asp1 sequence corresponds to a punitive pro-peptide that is removed, 15 apparently through autocatalysis, under acidic conditions. These polypeptide fragments also include those lacking the amino terminal amino acids 1-62 of SEQ ID NO: 2.

20 The invention encompasses a purified polynucleotide comprising a nucleotide sequence that hybridizes under stringent conditions to the non-coding strand complementary to SEQ ID NO: 1, wherein the nucleotide sequence encodes a polypeptide having Asp1 proteolytic activity and wherein the polynucleotide lacks nucleotides encoding a transmembrane domain. Further, the invention also provides for a purified polynucleotide sequence comprising a nucleotide sequence that hybridizes under stringent conditions to the non-coding strand complementary to SEQ ID NO: 1, , wherein the nucleotide sequence encodes a polypeptide further lacking a pro-peptide 25 domain corresponding to amino acids 23-62 of SEQ ID NO: 2.

The invention also provides for vectors comprising the hu-Asp1 polynucleotide of the invention and host cells transfected or transformed with these vectors. The invention also encompasses host cells transfected or transformed with the hu-Asp1 polynucleotides of the invention.

Another embodiment of the invention is a purified polypeptide comprising a fragment of a hu-Asp1 protein, wherein said polypeptide lacks the hu-Asp1 transmembrane domain and retains hu-Asp1 α -secretase activity. These polypeptides include fragments of hu-Asp1 having the amino acid sequence set forth in SEQ ID NO: 2, and wherein the polypeptide optionally lacks the transmembrane domain amino acids 469-492 of SEQ ID NO: 2, wherein the polypeptide lacks the cytoplasmic domain amino acids 493-518 of SEQ ID NO: 2 as well. In one variation, the invention provides a polypeptide that lacks amino terminal amino acids 1-62 of SEQ ID NO: 2 but retains Asp1 proteolytic activity. Fragments lacking both the aforementioned amino-terminal and carboxy terminal residues are contemplated.

The invention provides for a polypeptide comprising a fragment of hu-Asp1 having the amino acid sequence set forth in SEQ ID NO: 2 and wherein said polypeptide lacks the amino terminal amino acids 1-62 and retains APP processing activity. For example, referring to the Asp1 sequence in SEQ ID NO: 2, this pre-pro portion would correspond to residues 22 to 62. By performing conventional sequence analysis, the corresponding portions of the Asp1 sequence can also be identified.

Another embodiment of the invention is a polypeptide comprising the amino acid sequence at least 95% identical to a fragment of hu-Asp1 protein, wherein said polypeptide and said fragment lack a transmembrane domain and retain hu-Asp1 α -secretase activity. In addition, the invention embodies a polypeptide comprising an amino acid sequence at least 95% identical to a fragment of hu-Asp1 protein, wherein said polypeptide and said fragment lack the amino terminal amino acids corresponding to the pre-pro portion of hu-Asp1 and retain APP processing activity.

Additional features and variations of the invention will be apparent to those skilled in the art from the entirety of this application, including the drawing and detailed description, and all such features are intended as aspects of the invention. Likewise, features of the invention described herein can be re-combined into additional embodiments that are also intended as aspects of the invention, irrespective of whether the combination of features is specifically mentioned above as an aspect or embodiment of the invention. Also, only such limitations which are described herein as critical to the

invention should be viewed as such; variations of the invention lacking limitations which have not been described herein as critical are intended as aspects of the invention.

In addition to the foregoing, the invention includes, as an additional aspect, all embodiments of the invention narrower in scope in any way than the variations specifically mentioned above. Although the applicant(s) invented the full scope of the claims appended hereto, the claims appended hereto are not intended to encompass within their scope the prior art work of others. Therefore, in the event that statutory prior art within the scope of a claim is brought to the attention of the applicants by a Patent Office or other entity or individual, the applicant(s) reserve the right to exercise amendment rights under applicable patent laws to redefine the subject matter of such a claim to specifically exclude such statutory prior art or obvious variations of statutory prior art from the scope of such a claim. Variations of the invention defined by such amended claims also are intended as aspects of the invention.

15

BRIEF DESCRIPTION OF THE SEQUENCE LISTING

Sequence ID No. 1: Human Asp-1, nucleotide sequence.

Sequence ID No. 2: Human Asp-1, predicted amino acid sequence.

Sequence ID No. 3: Human Asp-2(a), nucleotide sequence.

Sequence ID No. 4: Human Asp-2(a), predicted amino acid sequence. The Asp2(a) amino acid sequence includes a putative signal peptide comprising residues 1 to 21; and a putative pre-propeptide after the signal peptide that extends through residue 45 (as assessed by processing observed of recombinant Asp2(a) in CHO cells), and a putative propeptide that may extend to at least about residue 57, based on the observation of an observed GRRIGS sequence which has characteristics of a protease recognition sequence. The Asp2(a) further includes a transmembrane domain comprising residues 455-477, a cytoplasmic domain comprising residues 478-501, and a putative alpha-helical spacer region, comprising residues 420-454, believed to be unnecessary for proteolytic activity, between the protease catalytic domain and the transmembrane domain.

30

Sequence ID No. 5: Human Asp-2(b), nucleotide sequence.

Sequence ID No. 6: Human Asp-2(b), predicted amino acid sequence. The Asp2(b) amino acid sequence includes a putative signal peptide, pre-propeptide, and propeptide as described above for Asp2(a). The Asp2(b) further includes a transmembrane domain comprising residues 430-452, a cytoplasmic domain comprising residues 453-476, and a putative alpha-helical spacer region, comprising residues 395-429, believed to be unnecessary for proteolytic activity, between the protease catalytic domain and the transmembrane domain.

5 Sequence ID No. 7: Murine Asp-2(a), nucleotide sequence.

Sequence ID No. 8: Murine Asp-2(a), predicted amino acid sequence. The 10 proteolytic processing of murine Asp2(a) is believed to be analogous to the processing described above for human Asp2(a). In addition, a variant lacking amino acid residues 190-214 of SEQ ID NO: 8 is specifically contemplated as a murine Asp2(b) polypeptide.

Sequence ID No. 9: Human APP695, nucleotide sequence.

15 Sequence ID No.10: Human APP695, predicted amino acid sequence.

Sequence ID No.11: Human APP695-Sw, nucleotide sequence.

Sequence ID No.12: Human APP695-Sw. predicted amino acid sequence. In the APP695 isoform, the Sw mutation is characterized by a KM-NL alteration at positions 595-596 (compared to normal APP695).

20 Sequence ID No.13: Human APP695-VF, nucleotide sequence.

Sequence ID No.14: Human APP695-VF, predicted amino acid sequence. In the APP 695 isoform, the VF mutation is characterized by a V-F alteration at position 642 (compared to normal APP 695).

Sequence ID No.15: Human APP695-KK, nucleotide sequence.

25 Sequence ID No.16: Human APP695-KK, predicted amino acid sequence.
(APP695 with two carboxy-terminal lysine residues.)

Sequence ID No.17: Human APP695-Sw-KK, nucleotide sequence.

Sequence ID No.18: Human APP695-Sw-KK, predicted amino acid sequence

Sequence ID No.19: Human APP695-VF-KK, nucleotide sequence

30 Sequence ID No.20: Human APP695-VF-KK, predicted amino acid sequence

- Sequence ID No.21: T7-Human-pro-Asp-2(a)ΔTM, nucleotide sequence
Sequence ID No.22: T7-Human-pro-Asp-2(a)ΔTM, amino acid sequence
Sequence ID No.23: T7-Caspase-Human-pro-Asp-2(a)ΔTM, nucleotide
sequence
- 5 Sequence ID No.24: T7-Caspase-Human-pro-Asp-2(a)ΔTM, amino acid
sequence
Sequence ID No.25: Human-pro-Asp-2(a)ΔTM (low GC), nucleotide
sequence
Sequence ID No.26: Human-pro-Asp-2(a)ΔTM, (low GC), amino acid
10 sequence
Sequence ID No.27: T7-Caspase-Caspase 8
cleavage-Human-pro-Asp-2(a)ΔTM, nucleotide sequence
Sequence ID No.28: T7-Caspase-Caspase 8
cleavage-Human-pro-Asp-2(a)ΔTM, amino acid sequence
- 15 Sequence ID No.29: Human Asp-2(a)ΔTM, nucleotide sequence
Sequence ID No.30: Human Asp-2(a)ΔTM, amino acid sequence
Sequence ID No.31: Human Asp-2(a)ΔTM(His)₆, nucleotide sequence
Sequence ID No. 32: Human Asp-2(a)ΔTM(His)₆, amino acid sequence
Sequence ID Nos. 33-49 are short synthetic peptide and oligonucleotide
20 sequences that are described below in the Detailed Description of the Invention.
Sequence ID No. 50: Human Asp2(b)ΔTM polynucleotide sequence.
Sequence ID No. 51: Human Asp2(b)ΔTM polypeptide sequence (exemplary
variant of Human Asp2(b) lacking transmembrane and intracellular domains of Hu-
Asp2(b) set forth in SEQ ID NO: 6.
- 25 Sequence ID No. 52: Human Asp2(b)ΔTM(His)₆ polynucleotide sequence.
Sequence ID No. 53: Human Asp2(b)ΔTM(His)₆ polypeptide sequence
(Human Asp2(b)ΔTM with six histidine tag attached to C-terminus)
Sequence ID No. 54: Human APP770-encoding polynucleotide sequence.

Sequence ID No. 55: Human APP770 polypeptide sequence. To introduce the KM-NL Swedish mutation, residues KM at positions 670-71 are changed to NL. To introduce the V-F London mutation, the V residue at position 717 is changed to F.

Sequence ID No. 56: Human APP751 encoding polynucleotide sequence.

5 Sequence ID No. 57: Human APP751 polypeptide sequence (Human APP751 isoform).

Sequence ID No. 58: Human APP770-KK encoding polynucleotide sequence.

Sequence ID No. 59: Human APP770-KK polypeptide sequence. (Human APP770 isoform to which two C-terminal lysines have been added).

10 Sequence ID No. 60: Human APP751-KK encoding polynucleotide sequence.

Sequence ID No. 61: Human APP751-KK polypeptide sequence (Human APP751 isoform to which two C-terminal lysines have been added).

Sequence ID Nos. 62-65: Various short peptide sequences described in detail in detailed description.

15 Sequence ID No. 66: Predicted amino acid sequence of human Asp-1 Δ TM(His)₆ as described in Example 14.

Sequence ID No. 67: Amino acid sequence of secreted recombinant Asp-1 Δ TM(His)6 as described in Example 14.

20 Sequence ID No. 68: Amino acid sequence of acid-processed form of Asp1 Δ (His)₆.

Sequence ID No. 69: Amino acid sequence of the self-activated acid processing site within Asp-1 Δ TM.

Sequence ID No. 70: Amino acid sequence of a peptide that includes the β -secretase processing site within the Swedish mutant form of APP.

25 Sequence ID No. 71: Amino acid sequence of a peptide (residues 17-24) that includes the α -secretase processing site within the A β peptide (A β ₁₂₋₂₈).

Sequence ID No. 72: Amino acid sequence of a peptide (residues 16-23) that includes the α -secretase processing site within the A β peptide (A β ₁₂₋₂₈).

Sequence ID No. 73-74: PCR primers described in Example 14.

Sequence ID No.75: Amino acid sequence of a γ -secretase substrate polypeptide described in Example 15.

BRIEF DESCRIPTION OF THE FIGURES

5 Figure 1: Figure 1 shows the nucleotide (SEQ ID NO:1) and predicted amino acid sequence (SEQ ID NO:2) of human Asp1.

Figure 2: Figure 2 shows the nucleotide (SEQ ID NO:3) and predicted amino acid sequence (SEQ ID NO:4) of human Asp2(a).

10 Figure 3: Figure 3 shows the nucleotide (SEQ ID NO:5) and predicted amino acid sequence (SEQ ID NO:6) of human Asp2(b). The predicted transmembrane domain of Hu-Asp2(b) is enclosed in brackets.

Figure 4: Figure 4 shows the nucleotide (SEQ ID No. 7) and predicted amino acid sequence (SEQ ID No. 8) of murine Asp2(a)

15 Figure 5: Figure 5 shows the BestFit alignment of the predicted amino acid sequences of Hu-Asp2(a) and murine Asp2(a)

Figure 6: Figure 6 shows the nucleotide (SEQ ID No. 21) and predicted amino acid sequence (SEQ ID No. 22) of T7-Human-pro-Asp-2(a) Δ TM

Figure 7: Figure 7 shows the nucleotide (SEQ ID No. 23) and predicted amino acid sequence (SEQ ID No. 24) of T7-caspase-Human-pro-Asp-2(a) Δ TM

20 Figure 8: Figure 8 shows the nucleotide (SEQ ID No. 25) and predicted amino acid sequence (SEQ ID No. 26) of Human-pro-Asp-2(a) Δ TM (low GC)

Figure 9: Western blot showing reduction of CTF99 production by HEK125.3 cells transfected with antisense oligomers targeting the Hu-Asp2 mRNA.

25 Figure 10: Western blot showing increase in CTF99 production in mouse Neuro-2a cells cotransfected with APP-KK with and without Hu-Asp2 only in those cells cotransfected with Hu-Asp2. A further increase in CTF99 production is seen in cells cotransfected with APP-Sw-KK with and without Hu-Asp2 only in those cells cotransfected with Hu-Asp2

30 Figure 11: Figure 11 shows the predicted amino acid sequence (SEQ ID No. 30) of Human-Asp2(a) Δ TM

Figure 12: Figure 11 shows the predicted amino acid sequence (SEQ ID No. 30) of Human-Asp2(a) Δ TM(His)₆

DETAILED DESCRIPTION OF THE INVENTION

5 A few definitions used in this invention follow, most definitions to be used are those that would be used by one ordinarily skilled in the art.

The term " β amyloid peptide" means any peptide resulting from beta secretase cleavage of APP. This includes peptides of 39, 40, 41, 42 and 43 amino acids, extending from the β -secretase cleavage site to 39, 40, 41, 42 and 43 amino acids C-terminal to the 10 β -secretase cleavage site. β amyloid peptide also includes sequences 1-6, SEQ ID NOs. 1-6 of US 5,750,349, issued 12 May 1998 (incorporated into this document by reference). A β -secretase cleavage fragment disclosed here is called CTF-99, which extends from β -secretase cleavage site to the carboxy terminus of APP.

15 When an isoform of APP is discussed then what is meant is any APP polypeptide, including APP variants (including mutations), and APP fragments that exists in humans such as those described in US 5,766,846, col 7, lines 45-67, incorporated into this document by reference.

The term " β -amyloid precursor protein" (APP) as used herein is defined as a 20 polypeptide that is encoded by a gene of the same name localized in humans on the long arm of chromosome 21 and that includes " β AP – here " β -amyloid protein" see above, within its carboxyl third. APP is a glycosylated, single-membrane spanning protein expressed in a wide variety of cells in many mammalian tissues. Examples of specific isotypes of APP which are currently known to exist in humans are the 695 amino acid polypeptide described by Kang et. al. (1987) Nature 325:733-736 which is 25 designated as the "normal" APP (SEQ ID NOs: 9-10); the 751 amino acid polypeptide described by Ponte et al. (1988) Nature 331:525-527 (1988) and Tanzi et al. (1988) Nature 331:528-530 (SEQ ID NOs: 56-57); and the 770-amino acid polypeptide described by Kitaguchi et. al. (1988) Nature 331:530-532 (SEQ ID NOs: 54-55). Examples of specific variants of APP include point mutation which can differ in both 30 position and phenotype (for review of known variant mutation see Hardy (1992)

Nature Genet. 1:233-234). All references cited here incorporated by reference. The term "APP fragments" as used herein refers to fragments of APP other than those which consist solely of β AP or β AP fragments. That is, APP fragments will include amino acid sequences of APP in addition to those which form intact β AP or a fragment of β AP.

When the term "any amino acid" is used, the amino acids referred to are to be selected from the following, three letter and single letter abbreviations - which may also be used, are provided as follows:

Alanine, Ala, A; Arginine, Arg, R; Asparagine, Asn, N; Aspartic acid, Asp, D; Cysteine, Cys, C; Glutamine, Gln, Q; Glutamic Acid, Glu, E; Glycine, Gly, G; Histidine, His, H; Isoleucine, Ile, I; Leucine, Leu, L; Lysine, Lys, K; Methionine, Met, M; Phenylalanine, Phe, F; Proline, Pro, P; Serine, Ser, S; Threonine, Thr, T; Tryptophan, Trp, W; Tyrosine, Tyr, Y; Valine, Val, V; Aspartic acid or Asparagine, Asx, B; Glutamic acid or Glutamine, Glx, Z; Any amino acid, Xaa, X.

The present invention describes a method to scan gene databases for the simple active site motif characteristic of aspartyl proteases. Eukaryotic aspartyl proteases such as pepsin and renin possess a two-domain structure which folds to bring two aspartyl residues into proximity within the active site. These are embedded in the short tripeptide motif DTG, or more rarely, DSG. Most aspartyl proteases occur as proenzyme whose N-terminus must be cleaved for activation. The DTG or DSG active site motif appears at about residue 65-70 in the proenzyme (prorenin, pepsinogen), but at about residue 25-30 in the active enzyme after cleavage of the N-terminal prodomain. The limited length of the active site motif makes it difficult to search collections of short, expressed sequence tags (EST) for novel aspartyl proteases. EST sequences typically average 250 nucleotides or less, and so would encode 80-90 amino acid residues or less. That would be too short a sequence to span the two active site motifs. The preferred method is to scan databases of hypothetical or assembled protein coding sequences. The present invention describes a computer method to identify candidate aspartyl proteases in protein sequence databases. The method was used to identify seven candidate aspartyl protease sequences in the

Caenorhabditis elegans genome. These sequences were then used to identify by homology search Hu-Asp1 and two alternative splice variants of Hu-Asp2, designated herein as Hu-Asp2(a) and Hu-Asp2(b).

In a major aspect of the invention disclosed here we provide new information 5 about APP processing. Pathogenic processing of the amyloid precursor protein (APP) via the A β pathway requires the sequential action of two proteases referred to as β -secretase and γ -secretase. Cleavage of APP by the β -secretase and γ -secretase generates the N-terminus and C-terminus of the A β peptide, respectively. Because over production of the A β peptide, particularly the A β_{1-42} , has been implicated in the 10 initiation of Alzheimer's disease, inhibitors of either the β -secretase and/or the γ -secretase have potential in the treatment of Alzheimer's disease. Despite the importance of the β -secretase and γ -secretase in the pathogenic processing of APP, molecular definition of these enzymes has not been accomplished to date. That is, it was not known what enzymes were required for cleavage at either the β -secretase or 15 the γ -secretase cleavage site. The sites themselves were known because APP was known and the A β_{1-42} , peptide was known, see US 5,766,846 and US 5,837,672, (incorporated by reference, with the exception to reference to "soluble" peptides). But what enzyme was involved in producing the A β_{1-42} , peptide was unknown.

Alignment of the amino acid sequences of Hu-Asp2 with other known aspartyl 20 proteases reveals a similar domain organization. All of the sequences contain a signal sequence followed by a pro-segment and the catalytic domain containing 2 copies of the aspartyl protease active site motif (DTG/DSG) separated by approximately 180 amino acid residues. Comparison of the processing site for proteolytic removal of the pro-segment in the mature forms of pepsin A, pepsin C, cathepsin D, cathepsin E and 25 renin reveals that the mature forms of these enzymes contain between 31-35 amino acid residues upstream of the first DTG motif. Inspection of this region in the Hu-Asp-2 amino acid sequence indicates a preferred processing site within the sequence GRR!GS as proteolytic processing of pro-protein precursors commonly occurs at site following dibasic amino acid pairs (eg. RR). Also, processing at this 30 site would yield a mature enzyme with 35 amino acid residues upstream of the first

DTG, consistent with the processing sites for other aspartyl proteases. In the absence of self-activation of Hu-Asp2 or a knowledge of the endogenous protease that processes Hu-Asp2 at this site, a recombinant form was engineered by introducing a recognition site for the PreSission protease (LEVLFQ¹GP) into the expression plasmids for bacterial, insect cell, and mammalian cell expression of pro-Hu-Asp2. In each case, the Gly residue in P1' position corresponds to the Gly residue 35 amino acids upstream of the first DTG motif in Hu-Asp2.

The present invention involves the molecular definition of several novel human aspartyl proteases and one of these, referred to as Hu-Asp-2(a) and Hu-Asp2(b), has been characterized in detail. Previous forms of asp1 and asp 2 have been disclosed, see EP 0848062 A2 and EP 0855444A2, inventors David Powel et al., assigned to Smith Kline Beecham Corp. (incorporated by reference). Herein are disclosed old and new forms of Hu-Asp 2. For the first time they are expressed in active form, their substrates are disclosed, and their specificity is disclosed. Prior to this disclosure cell or cell extracts were required to cleave the β -secretase site, now purified protein can be used in assays, also described here. Based on the results of (1) antisense knock out experiments, (2) transient transfection knock in experiments, and (3) biochemical experiments using purified recombinant Hu-Asp-2, we demonstrate that Hu-Asp-2 is the β -secretase involved in the processing of APP. Although the nucleotide and predicted amino acid sequence of Hu-Asp-2(a) has been reported, see above, see EP 0848062 A2 and EP 0855444A2, no functional characterization of the enzyme was disclosed. Here the authors characterize the Hu-Asp-2 enzyme and are able to explain why it is a critical and essential enzyme required in the formation of A β ₁₋₄₂, peptide and possible a critical step in the development of AD.

In another embodiment the present invention also describes a novel splice variant of Hu-Asp2, referred to as Hu-Asp-2(b), that has never before been disclosed.

In another embodiment, the invention provides isolated nucleic acid molecules comprising a polynucleotide encoding a polypeptide selected from the group consisting of human aspartyl protease 1 (Hu-Asp1) and two alternative splice variants of human aspartyl protease-2 (Hu-Asp2), designated herein as Hu-Asp2(a) and

Hu-Asp2(b). As used herein, all references to "Hu-Asp2" should be understood to refer to both Hu-Asp2(a) and Hu-Asp2(b). Hu-Asp1 is expressed most abundantly in pancreas and prostate tissues, while Hu-Asp2(a) and Hu-Asp2(b) are expressed most abundantly in pancreas and brain tissues. The invention also provides isolated

5 Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides, as well as fragments thereof which exhibit aspartyl protease activity.

The predicted amino acid sequences of Hu-Asp1, Hu-Asp2(a) and Hu-Asp2(b) share significant homology with previously identified mammalian aspartyl proteases such as pepsinogen A, pepsinogen B, cathepsin D, cathepsin E, and renin. P.B.Szecs,

10 *Scand. J. Clin. Lab. Invest.* 52:(Suppl. 210 5-22 (1992)). These enzymes are characterized by the presence of a duplicated DTG/DSG sequence motif. The Hu-Asp1 and HuAsp2 polypeptides disclosed herein also exhibit extremely high homology with the ProSite consensus motif for aspartyl proteases extracted from the SwissProt database.

15 The nucleotide sequence given as residues 1-1554 of SEQ ID NO:1 corresponds to the nucleotide sequence encoding Hu-Asp1, the nucleotide sequence given as residues 1-1503 of SEQ ID NO:3 corresponds to the nucleotide sequence encoding Hu-Asp2(a), and the nucleotide sequence given as residues 1-1428 of SEQ ID NO:5 corresponds to the nucleotide sequence encoding Hu-Asp2(b). The isolation

20 and sequencing of DNA encoding Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) is described below in Examples 1 and 2.

As is described in Examples 1 and 2, automated sequencing methods were used to obtain the nucleotide sequence of Hu-Asp1, Hu-Asp2(a), and Hu-Asp-2(b). The Hu-Asp nucleotide sequences of the present invention were obtained for both

25 DNA strands, and are believed to be 100% accurate. However, as is known in the art, nucleotide sequence obtained by such automated methods may contain some errors. Nucleotide sequences determined by automation are typically at least about 90%, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of a given nucleic acid molecule. The actual sequence may be

30 more precisely determined using manual sequencing methods, which are well known

- in the art. An error in sequence which results in an insertion or deletion of one or more nucleotides may result in a frame shift in translation such that the predicted amino acid sequence will differ from that which would be predicted from the actual nucleotide sequence of the nucleic acid molecule, starting at the point of the mutation.
- 5 The Hu-Asp DNA of the present invention includes cDNA, chemically synthesized DNA, DNA isolated by PCR, genomic DNA, and combinations thereof. Genomic Hu-Asp DNA may be obtained by screening a genomic library with the Hu-Asp2 cDNA described herein, using methods that are well known in the art, or with oligonucleotides chosen from the Hu-Asp2 sequence that will prime the polymerase
- 10 chain reaction (PCR). RNA transcribed from Hu-Asp DNA is also encompassed by the present invention.

Due to the degeneracy of the genetic code, two DNA sequences may differ and yet encode identical amino acid sequences. The present invention thus provides isolated nucleic acid molecules having a polynucleotide sequence encoding any of the 15 Hu-Asp polypeptides of the invention, wherein said polynucleotide sequence encodes a Hu-Asp polypeptide having the complete amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or fragments thereof.

Also provided herein are purified Hu-Asp polypeptides, both recombinant and non-recombinant. Most importantly, methods to produce Hu-Asp2 polypeptides in 20 active form are provided. These include production of Hu-Asp2 polypeptides and variants thereof in bacterial cells, insect cells, and mammalian cells, also in forms that allow secretion of the Hu-Asp2 polypeptide from bacterial, insect or mammalian cells into the culture medium, also methods to produce variants of Hu-Asp2 polypeptide incorporating amino acid tags that facilitate subsequent purification. In a preferred 25 embodiment of the invention the Hu-Asp2 polypeptide is converted to a proteolytically active form either in transformed cells or after purification and cleavage by a second protease in a cell-free system, such active forms of the Hu-Asp2 polypeptide beginning with the N-terminal sequence TQHGIR or ETDEEP. The sequence TQHGIR represents the amino-terminus of Asp2(a) or Asp2(b) beginning 30 with residue 22 of SEQ ID NO: 4 or 6, after cleavage of a putative 21 residue signal

peptide. Recombinant Asp2(a) expressed in and purified from insect cells was observed to have this amino terminus, presumably as a result of cleavage by a signal peptidase. The sequence ETDEEP represents the amino-terminus of Asp2(a) or Asp2(b) beginning with residue 46 of SEQ ID NO: 4 or 6, as observed when Asp2(a) has been recombinantly produced in CHO cells (presumably after cleavage by both a rodent signal peptidase and another rodent peptidase that removes a propeptide sequence). The Asp2(a) produced in the CHO cells possesses β -secretase activity, as described in greater detail in Examples 11 and 12. Variants and derivatives, including fragments, of Hu-Asp proteins having the native amino acid sequences given in SEQ ID Nos: 2, 4, and 6 that retain any of the biological activities of Hu-Asp are also within the scope of the present invention. Of course, one of ordinary skill in the art will readily be able to determine whether a variant, derivative, or fragment of a Hu-Asp protein displays Hu-Asp activity by subjecting the variant, derivative, or fragment to a standard aspartyl protease assay. Fragments of Hu-Asp within the scope of this invention include those that contain the active site domain containing the amino acid sequence DTG, fragments that contain the active site domain amino acid sequence DSG, fragments containing both the DTG and DSG active site sequences, fragments in which the spacing of the DTG and DSG active site sequences has been lengthened, fragments in which the spacing has been shortened. Also within the scope of the invention are fragments of Hu-Asp in which the transmembrane domain has been removed to allow production of Hu-Asp2 in a soluble form. In another embodiment of the invention, the two halves of Hu-Asp2, each containing a single active site DTG or DSG sequence can be produced independently as recombinant polypeptides, then combined in solution where they reconstitute an active protease.

Thus, the invention provides a purified polypeptide comprising a fragment of a mammalian Asp2 protein, wherein said fragment lacks the Asp2 transmembrane domain of said Asp2 protein, and wherein the polypeptide and the fragment retain the β -secretase activity of said mammalian Asp2 protein. In a preferred embodiment, the purified polypeptide comprises a fragment of a human Asp2 protein that retains the β -

secretase activity of the human Asp2 protein from which it was derived. Examples include:

- 5 a purified polypeptide that comprises a fragment of Asp2(a) having the amino acid sequence set forth in SEQ ID NO: 4, wherein the polypeptide lacks transmembrane domain amino acids 455 to 477 of SEQ ID NO: 4;
- 10 a purified polypeptide as described in the preceding paragraph that further lacks cytoplasmic domain amino acids 478 to 501 of SEQ ID NO: 4;
- 15 a purified polypeptide as described in either of the preceding paragraphs that further lacks amino acids 420-454 of SEQ ID NO: 4, which constitute a putative alpha helical region between the catalytic domain and the transmembrane domain that is believed to be unnecessary for β -secretase activity;
- 20 a purified polypeptide that comprises an amino acid sequence that includes amino acids 58 to 419 of SEQ ID NO: 4, and that lacks amino acids 22 to 57 of SEQ ID NO: 4;
- 25 a purified polypeptide that comprises an amino acid sequence that includes amino acids 46 to 419 of SEQ ID NO: 4, and that lacks amino acids 22 to 45 of SEQ ID NO: 4;
- 30 a purified polypeptide that comprises an amino acid sequence that includes amino acids 22 to 454 of SEQ ID NO: 4.
- a purified polypeptide that comprises a fragment of Asp2(b) having the amino acid sequence set forth in SEQ ID NO: 6, and wherein said polypeptide lacks transmembrane domain amino acids 430 to 452 of SEQ ID NO: 6;
- a purified polypeptide as described in the preceding paragraph that further lacks cytoplasmic domain amino acids 453 to 476 of SEQ ID NO: 6;
- a purified polypeptide as described in either of the preceding two paragraphs that further lacks amino acids 395-429 of SEQ ID NO: 4, which constitute a putative alpha helical region between the catalytic domain and the transmembrane domain that is believed to be unnecessary for β -secretase activity;

a purified polypeptide comprising an amino acid sequence that includes amino acids 58 to 394 of SEQ ID NO: 4, and that lacks amino acids 22 to 57 of SEQ ID NO: 4;

5 a purified polypeptide comprising an amino acid sequence that includes amino acids 46 to 394 of SEQ ID NO: 4, and that lacks amino acids 22 to 45 of SEQ ID NO: 4; and

a purified polypeptide comprising an amino acid sequence that includes amino acids 22 to 429 of SEQ ID NO: 4.

Also included as part of the invention is a purified polynucleotide comprising a 10 nucleotide sequence that encodes such polypeptides; a vector comprising a polynucleotide that encodes such polypeptides; and a host cell transformed or transfected with such a polynucleotide or vector.

Hu-Asp variants may be obtained by mutation of native Hu-Asp-encoding 15 nucleotide sequences, for example. A Hu-Asp variant, as referred to herein, is a polypeptide substantially homologous to a native Hu-Asp polypeptide but which has an amino acid sequence different from that of native Hu-Asp because of one or more deletions, insertions, or substitutions in the amino acid sequence. The variant amino acid or nucleotide sequence is preferably at least about 80% identical, more preferably at least about 90% identical, and most preferably at least about 95% identical, to a native Hu-Asp sequence. Thus, a variant nucleotide sequence which contains, for example, 5 point mutations for every one hundred nucleotides, as compared to a native Hu-Asp gene, will be 95% identical to the native protein. The percentage of sequence identity, also termed homology, between a native and a variant 20 Hu-Asp sequence may also be determined, for example, by comparing the two sequences using any of the computer programs commonly employed for this purpose, such as the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wisconsin), which 25 uses the algorithm of Smith and Waterman (*Adv. Appl. Math.* 2: 482-489 (1981)).

Alterations of the native amino acid sequence may be accomplished by any of 30 a number of known techniques. For example, mutations may be introduced at

particular locations by procedures well known to the skilled artisan, such as oligonucleotide-directed mutagenesis, which is described by Walder *et al.* (*Gene* 42:133 (1986)); Bauer *et al.* (*Gene* 37:73 (1985)); Craik (*BioTechniques*, January 1985, pp. 12-19); Smith *et al.* (*Genetic Engineering: Principles and Methods*, Plenum Press (1981)); and U.S. Patent Nos. 4,518,584 and 4,737,462.

Hu-Asp variants within the scope of the invention may comprise conservatively substituted sequences, meaning that one or more amino acid residues of a Hu-Asp polypeptide are replaced by different residues that do not alter the secondary and/or tertiary structure of the Hu-Asp polypeptide. Such substitutions may include the replacement of an amino acid by a residue having similar physicochemical properties, such as substituting one aliphatic residue (Ile, Val, Leu or Ala) for another, or substitution between basic residues Lys and Arg, acidic residues Glu and Asp, amide residues Gln and Asn, hydroxyl residues Ser and Tyr, or aromatic residues Phe and Tyr. Further information regarding making phenotypically silent amino acid exchanges may be found in Bowie *et al.*, *Science* 247:1306-1310 (1990). Other Hu-Asp variants which might retain substantially the biological activities of Hu-Asp are those where amino acid substitutions have been made in areas outside functional regions of the protein.

In another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent conditions to a portion of the nucleic acid molecules described above, e.g., to at least about 15 nucleotides, preferably to at least about 20 nucleotides, more preferably to at least about 30 nucleotides, and still more preferably to at least about from 30 to at least about 100 nucleotides, of one of the previously described nucleic acid molecules. Such portions of nucleic acid molecules having the described lengths refer to, e.g., at least about 15 contiguous nucleotides of the reference nucleic acid molecule. By stringent hybridization conditions is intended overnight incubation at about 42°C for about 2.5 hours in 6 X SSC/0.1% SDS, followed by washing of the filters four times for 15 minutes in 1.0 X SSC at 65°C, 0.1% SDS.

Fragments of the Hu-Asp encoding nucleic acid molecules described herein, as well as polynucleotides capable of hybridizing to such nucleic acid molecules may be used as a probe or as primers in a polymerase chain reaction (PCR). Such probes may be used, e.g., to detect the presence of Hu-Asp nucleic acids in *in vitro* assays, as well 5 as in Southern and northern blots. Cell types expressing Hu-Asp may also be identified by the use of such probes. Such procedures are well known, and the skilled artisan will be able to choose a probe of a length suitable to the particular application. For PCR, 5' and 3' primers corresponding to the termini of a desired Hu-Asp nucleic acid molecule are employed to isolate and amplify that sequence using conventional 10 techniques.

Other useful fragments of the Hu-Asp nucleic acid molecules are antisense or sense oligonucleotides comprising a single stranded nucleic acid sequence capable of binding to a target Hu-Asp mRNA (using a sense strand), or Hu-Asp DNA (using an antisense strand) sequence. In a preferred embodiment of the invention these Hu-Asp 15 antisense oligonucleotides reduce Hu-Asp mRNA and consequent production of Hu-Asp polypeptides.

In another aspect, the invention includes Hu-Asp polypeptides with or without associated native pattern glycosylation. Both Hu-Asp1 and Hu-Asp2 have canonical acceptor sites for Asn-linked sugars, with Hu-Asp1 having two of such sites, and 20 Hu-Asp2 having four. Hu-Asp expressed in yeast or mammalian expression systems (discussed below) may be similar to or significantly different from a native Hu-Asp polypeptide in molecular weight and glycosylation pattern. Expression of Hu-Asp in bacterial expression systems will provide non-glycosylated Hu-Asp.

The polypeptides of the present invention are preferably provided in an 25 isolated form, and preferably are substantially purified. Hu-Asp polypeptides may be recovered and purified from tissues, cultured cells, or recombinant cell cultures by well-known methods, including ammonium sulfate or ethanol precipitation, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, and high performance liquid chromatography.

(HPLC). In a preferred embodiment, an amino acid tag is added to the Hu-Asp polypeptide using genetic engineering techniques that are well known to practitioners of the art which include addition of six histidine amino acid residues to allow purification by binding to nickel immobilized on a suitable support, epitopes for 5 polyclonal or monoclonal antibodies including but not limited to the T7 epitope, the myc epitope, and the V5a epitope, and fusion of Hu-Asp2 to suitable protein partners including but not limited to glutathione-S-transferase or maltose binding protein. In a preferred embodiment these additional amino acid sequences are added to the C-terminus of Hu-Asp but may be added to the N-terminus or at intervening positions 10 within the Hu-Asp2 polypeptide.

The present invention also relates to vectors comprising the polynucleotide molecules of the invention, as well as host cell transformed with such vectors. Any of the polynucleotide molecules of the invention may be joined to a vector, which generally includes a selectable marker and an origin of replication, for propagation in 15 a host. Because the invention also provides Hu-Asp polypeptides expressed from the polynucleotide molecules described above, vectors for the expression of Hu-Asp are preferred. The vectors include DNA encoding any of the Hu-Asp polypeptides described above or below, operably linked to suitable transcriptional or translational regulatory sequences, such as those derived from a mammalian, microbial, viral, or insect gene. Examples of regulatory sequences include transcriptional promoters, 20 operators, or enhancers, mRNA ribosomal binding sites, and appropriate sequences which control transcription and translation. Nucleotide sequences are operably linked when the regulatory sequence functionally relates to the DNA encoding Hu-Asp. Thus, a promoter nucleotide sequence is operably linked to a Hu-Asp DNA sequence 25 if the promoter nucleotide sequence directs the transcription of the Hu-Asp sequence.

Selection of suitable vectors to be used for the cloning of polynucleotide molecules encoding Hu-Asp, or for the expression of Hu-Asp polypeptides, will of course depend upon the host cell in which the vector will be transformed, and, where applicable, the host cell from which the Hu-Asp polypeptide is to be expressed.

Suitable host cells for expression of Hu-Asp polypeptides include prokaryotes, yeast, and higher eukaryotic cells, each of which is discussed below.

The Hu-Asp polypeptides to be expressed in such host cells may also be fusion proteins which include regions from heterologous proteins. Such regions may be included to allow, e.g., secretion, improved stability, or facilitated purification of the polypeptide. For example, a sequence encoding an appropriate signal peptide can be incorporated into expression vectors. A DNA sequence for a signal peptide (secretory leader) may be fused inframe to the Hu-Asp sequence so that Hu-Asp is translated as a fusion protein comprising the signal peptide. A signal peptide that is functional in the intended host cell promotes extracellular secretion of the Hu-Asp polypeptide. Preferably, the signal sequence will be cleaved from the Hu-Asp polypeptide upon secretion of Hu-Asp from the cell. Nonlimiting examples of signal sequences that can be used in practicing the invention include the yeast Ifactor and the honeybee melatin leader in sf9 insect cells.

In a preferred embodiment, the Hu-Asp polypeptide will be a fusion protein which includes a heterologous region used to facilitate purification of the polypeptide. Many of the available peptides used for such a function allow selective binding of the fusion protein to a binding partner. For example, the Hu-Asp polypeptide may be modified to comprise a peptide to form a fusion protein which specifically binds to a binding partner, or peptide tag. Nonlimiting examples of such peptide tags include the 6-His tag, thioredoxin tag, hemagglutinin tag, GST tag, and OmpA signal sequence tag. As will be understood by one of skill in the art, the binding partner which recognizes and binds to the peptide may be any molecule or compound including metal ions (e.g., metal affinity columns), antibodies, or fragments thereof, and any protein or peptide which binds the peptide, such as the FLAG tag.

Suitable host cells for expression of Hu-Asp polypeptides includes prokaryotes, yeast, and higher eukaryotic cells. Suitable prokaryotic hosts to be used for the expression of Hu-Asp include bacteria of the genera *Escherichia*, *Bacillus*, and *Salmonella*, as well as members of the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*. For expression in, e.g., *E. coli*, a Hu-Asp polypeptide may include

an N-terminal methionine residue to facilitate expression of the recombinant polypeptide in a prokaryotic host. The N-terminal Met may optionally then be cleaved from the expressed Hu-Asp polypeptide. Other N-terminal amino acid residues can be added to the Hu-Asp polypeptide to facilitate expression in

5 Escherichia coli including but not limited to the T7 leader sequence, the T7-caspase 8 leader sequence, as well as others leaders including tags for purification such as the 6-His tag (Example 9). Hu-Asp polypeptides expressed in E. coli may be shortened by removal of the cytoplasmic tail, the transmembrane domain, or the membrane proximal region. Hu-Asp polypeptides expressed in E. coli may be obtained in either

10 a soluble form or as an insoluble form which may or may not be present as an inclusion body. The insoluble polypeptide may be rendered soluble by guanidine HCl, urea or other protein denaturants, then refolded into a soluble form before or after purification by dilution or dialysis into a suitable aqueous buffer. If the inactive proform of the Hu-Asp was produced using recombinant methods, it may be rendered

15 active by cleaving off the prosegment with a second suitable protease such as human immunodeficiency virus protease.

Expression vectors for use in prokaryotic hosts generally comprises one or more phenotypic selectable marker genes. Such genes generally encode, e.g., a protein that confers antibiotic resistance or that supplies an auxotrophic requirement.

20 A wide variety of such vectors are readily available from commercial sources. Examples include pSPORT vectors, pGEM vectors (Promega), pPROEX vectors (LTI, Bethesda, MD), Bluescript vectors (Stratagene), pET vectors (Novagen) and pQE vectors (Qiagen).

Hu-Asp may also be expressed in yeast host cells from genera including

25 *Saccharomyces*, *Pichia*, and *Kluveromyces*. Preferred yeast hosts are *S. cerevisiae* and *P. pastoris*. Yeast vectors will often contain an origin of replication sequence from a 2T yeast plasmid, an autonomously replicating sequence (ARS), a promoter region, sequences for polyadenylation, sequences for transcription termination, and a selectable marker gene. Vectors replicable in both yeast and *E. coli* (termed shuttle

30 vectors) may also be used. In addition to the above-mentioned features of yeast

vectors, a shuttle vector will also include sequences for replication and selection in *E. coli*. Direct secretion of Hu-Asp polypeptides expressed in yeast hosts may be accomplished by the inclusion of nucleotide sequence encoding the yeast I-factor leader sequence at the 5' end of the Hu-Asp-encoding nucleotide sequence.

5 Insect host cell culture systems may also be used for the expression of Hu-Asp polypeptides. In a preferred embodiment, the Hu-Asp polypeptides of the invention are expressed using an insect cell expression system (see Example 10). Additionally, a baculovirus expression system can be used for expression in insect cells as reviewed by Luckow and Summers, *Bio/Technology* 6:47 (1988).

10 In another preferred embodiment, the Hu-Asp polypeptide is expressed in mammalian host cells. Nonlimiting examples of suitable mammalian cell lines include the COS7 line of monkey kidney cells (Gluzman *et al.*, *Cell* 23:175 (1981)), human embryonic kidney cell line 293, and Chinese hamster ovary (CHO) cells. Preferably, Chinese hamster ovary (CHO) cells are used for expression of Hu-Asp proteins (Example 11).

15 The choice of a suitable expression vector for expression of the Hu-Asp polypeptides of the invention will of course depend upon the specific mammalian host cell to be used, and is within the skill of the ordinary artisan. Examples of suitable expression vectors include pcDNA3 (Invitrogen) and pSVL (Pharmacia Biotech). A preferred vector for expression of Hu-Asp polypeptides is pcDNA3.1-Hygro (Invitrogen). Expression vectors for use in mammalian host cells may include transcriptional and translational control sequences derived from viral genomes. Commonly used promoter sequences and enhancer sequences which may be used in the present invention include, but are not limited to, those derived from human 20 cytomegalovirus (CMV), Adenovirus 2, Polyoma virus, and Simian virus 40 (SV40). Methods for the construction of mammalian expression vectors are disclosed, for example, in Okayama and Berg (*Mol. Cell. Biol.* 3:280 (1983)); Cosman *et al.* (*Mol. Immunol.* 23:935 (1986)); Cosman *et al.* (*Nature* 312:768 (1984)); EP-A-0367566; 25 and WO 91/18982.

The polypeptides of the present invention may also be used to raise polyclonal and monoclonal antibodies, which are useful in diagnostic assays for detecting Hu-Asp polypeptide expression. Such antibodies may be prepared by conventional techniques. See, for example, *Antibodies: A Laboratory Manual*, Harlow and Land 5 (eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1988); *Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses*, Kennet et al. (eds.), Plenum Press, New York (1980). Synthetic peptides comprising portions of Hu-Asp containing 5 to 20 amino acids may also be used for the production of polyclonal or monoclonal antibodies after linkage to a suitable carrier 10 protein including but not limited to keyhole limpet hemacyanin (KLH), chicken ovalbumin, or bovine serum albumin using various cross-linking reagents including carbodimides, glutaraldehyde, or if the peptide contains a cysteine, N-methylmaleimide. A preferred peptide for immunization when conjugated to KLH contains the C-terminus of Hu-Asp1 or Hu-Asp2 comprising 15 QRRPRDPEVVNDESSLVRHRWK (SEQ ID NO: 2, residues 497-518) or LRQQHDDFADDISLLK (SEQ ID NO:4, residues 486-501), respectively. See SEQ ID Nos. 33-34.

The Hu-Asp nucleic acid molecules of the present invention are also valuable for chromosome identification, as they can hybridize with a specific location on a 20 human chromosome. Hu-Asp1 has been localized to chromosome 21, while Hu-Asp2 has been localized to chromosome 11q23.3-24.1. There is a current need for identifying particular sites on the chromosome, as few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for 25 marking chromosomal location. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. The relationship between genes and diseases that have been mapped to the same chromosomal region can then be identified through linkage analysis, wherein the coinheritance of physically adjacent genes is determined. Whether a gene appearing to be related to a particular disease is in fact the cause of

the disease can then be determined by comparing the nucleic acid sequence between affected and unaffected individuals.

In another embodiment, the invention relates to a method of assaying Hu-Asp function, specifically Hu-Asp2 function which involves incubating in solution the 5 Hu-Asp polypeptide with a suitable substrate including but not limited to a synthetic peptide containing the β -secretase cleavage site of APP, preferably one containing the mutation found in a Swedish kindred with inherited AD in which KM is changed to NL, such peptide comprising the sequence SEVNLDAEFR in an acidic buffering solution, preferably an acidic buffering solution of pH5.5 (see Example 12) using 10 cleavage of the peptide monitored by high performance liquid chromatography as a measure of Hu-Asp proteolytic activity. Preferred assays for proteolytic activity utilize internally quenched peptide assay substrates. Such suitable substrates include peptides which have attached a paired fluorophore and quencher including but not limited to 7-amino-4-methyl coumarin and dinitrophenol, respectively, such that 15 cleavage of the peptide by the Hu-Asp results in increased fluorescence due to physical separation of the fluorophore and quencher. Other paired fluorophores and quenchers include bodipy-tetramethylrhodamine and QSY-5 (Molecular Probes, Inc.). In a variant of this assay, biotin or another suitable tag may be placed on one end of the peptide to anchor the peptide to a substrate assay plate and a fluorophore may be 20 placed at the other end of the peptide. Useful fluorophores include those listed above as well as Europium labels such as W8044 (EG&g Wallac, Inc.). Cleavage of the peptide by Asp2 will release the fluorophore or other tag from the plate, allowing compounds to be assayed for inhibition of Asp2 proteolytic cleavage as shown by an increase in retained fluorescence. Preferred colorimetric assays of Hu-Asp proteolytic 25 activity utilize other suitable substrates that include the P2 and P1 amino acids comprising the recognition site for cleavage linked to o-nitrophenol through an amide linkage, such that cleavage by the Hu-Asp results in an increase in optical density after altering the assay buffer to alkaline pH.

In another embodiment, the invention relates to a method for the identification of an agent that increases the activity of a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b), the method comprising

5 (a) determining the activity of said Hu-Asp polypeptide in the presence of a test agent and in the absence of a test agent; and

(b) comparing the activity of said Hu-Asp polypeptide determined in the presence of said test agent to the activity of said Hu-Asp polypeptide determined in the absence of said test agent;

10 whereby a higher level of activity in the presence of said test agent than in the absence of said test agent indicates that said test agent has increased the activity of said Hu-Asp polypeptide. Such tests can be performed with Hu-Asp polypeptide in a cell free system and with cultured cells that express Hu-Asp as well as variants or isoforms thereof.

15 In another embodiment, the invention relates to a method for the identification of an agent that decreases the activity of a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b), the method comprising

20 (a) determining the activity of said Hu-Asp polypeptide in the presence of a test agent and in the absence of a test agent; and

(b) comparing the activity of said Hu-Asp polypeptide determined in the presence of said test agent to the activity of said Hu-Asp polypeptide determined in the absence of said test agent; whereby a lower level of activity in the presence of said test agent than in the absence of said test agent indicates that said test agent has decreased the activity of said Hu-Asp polypeptide. Such tests can be performed with Hu-Asp polypeptide in a cell free system and with cultured cells that express Hu-Asp as well as variants or isoforms thereof.

25 In another embodiment, the invention relates to a novel cell line (HEK125.3 cells) for measuring processing of amyloid β peptide ($A\beta$) from the amyloid protein precursor (APP). The cells are stable transformants of human embryonic kidney 293 cells (HEK293) with a bicistronic vector derived from pIRES-EGFP (Clontech) containing a modified human APP cDNA, an internal ribosome entry site and an

enhanced green fluorescent protein (EGFP) cDNA in the second cistron. The APP cDNA was modified by adding two lysine codons to the carboxyl terminus of the APP coding sequence. This increases processing of A β peptide from human APP by 2-4 fold. This level of A β peptide processing is 60 fold higher than is seen in nontransformed HEK293 cells. HEK125.3 cells will be useful for assays of compounds that inhibit A β peptide processing. This invention also includes addition of two lysine residues to the C-terminus of other APP isoforms including the 751 and 770 amino acid isoforms, to isoforms of APP having mutations found in human AD including the Swedish KM-NL and V717-F mutations, to C-terminal fragments of APP, such as those beginning with the β -secretase cleavage site, to C-terminal fragments of APP containing the β -secretase cleavage site which have been operably linked to an N-terminal signal peptide for membrane insertion and secretion, and to C-terminal fragments of APP which have been operably linked to an N-terminal signal peptide for membrane insertion and secretion and a reporter sequence including but not limited to green fluorescent protein or alkaline phosphatase, such that β -secretase cleavage releases the reporter protein from the surface of cells expressing the polypeptide.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

Example 1

Development of a Search Algorithm Useful for the Identification of Aspartyl Proteases, and Identification of *C. elegans* Aspartyl Protease Genes in Wormpep 12

Materials and Methods:

Classical aspartyl proteases such as pepsin and renin possess a two-domain structure which folds to bring two aspartyl residues into proximity within the active site. These are embedded in the short tripeptide motif DTG, or more rarely, DSG. The DTG or DSG active site motif appears at about residue 25-30 in the enzyme, but at about 65-70 in the proenzyme (prorenin, pepsinogen). This motif appears again about

150-200 residues downstream. The proenzyme is activated by cleavage of the N-terminal prodomain. This pattern exemplifies the double domain structure of the modern day aspartyl enzymes which apparently arose by gene duplication and divergence. Thus;



where X denotes the beginning of the enzyme, following the N-terminal prodomain, and Y denotes the center of the molecule where the gene repeat begins again.

In the case of the retroviral enzymes such as the HIV protease, they represent only a half of the two-domain structures of well-known enzymes like pepsin, 10 cathepsin D, renin, etc. They have no prosegment, but are carved out of a polyprotein precursor containing the *gag* and *pol* proteins of the virus. They can be represented by:



This "monomer" only has about 100 aa, so is extremely parsimonious as compared to 15 the other aspartyl protease "dimers" which have of the order of 330 or so aa, not counting the N-terminal prodomain.

The limited length of the eukaryotic aspartyl protease active site motif makes it difficult to search EST collections for novel sequences. EST sequences typically average 250 nucleotides, and so in this case would be unlikely to span both aspartyl 20 protease active site motifs. Instead, we turned to the *C. elegans* genome. The *C. elegans* genome is estimated to contain around 13,000 genes. Of these, roughly 12,000 have been sequenced and the corresponding hypothetical open reading frame (ORF) has been placed in the database Wormpep12. We used this database as the basis for a whole genome scan of a higher eukaryote for novel aspartyl proteases, 25 using an algorithm that we developed specifically for this purpose. The following AWK script for locating proteins containing two DTG or DSG motifs was used for the search, which was repeated four times to recover all pairwise combinations of the aspartyl motif.

```
BEGIN{RS=">"} /* defines ">" as record separator for FASTA format */
30 {
  pos = index($0,"DTG") /* finds "DTG" in record*/
```

```
if (pos>0) {  
    rest = substr($0,pos+3)      /*get rest of record after first DTG*/  
    pos2 = index(rest,"DTG")    /*find second DTG*/  
    if (pos2>0) printf ("%s%s\n",">>",$0)}      /*report hits*/  
5 }  
}
```

The AWK script shown above was used to search Wormpep12, which was downloaded from [ftp.sanger.ac.uk/pub/databases/wormpep](ftp://ftp.sanger.ac.uk/pub/databases/wormpep), for sequence entries containing at least two DTG or DSG motifs. Using AWK limited each record to 3000 characters or less. Thus, 35 or so larger records were eliminated manually from Wormpep12 as in any case these were unlikely to encode aspartyl proteases.

Results and Discussion:

The Wormpep 12 database contains 12,178 entries, although some of these (<10%) represent alternatively spliced transcripts from the same gene. Estimates of the number of genes encoded in the *C. elegans* genome is on the order of 13,000 genes, so Wormpep12 may be estimated to cover greater than 90% of the *C. elegans* genome.

Eukaryotic aspartyl proteases contain a two-domain structure, probably arising from ancestral gene duplication. Each domain contains the active site motif D(S/T)G located from 20-25 amino acid residues into each domain. The retroviral (e.g., HIV protease) or retrotransposon proteases are homodimers of subunits which are homologous to a single eukaryotic aspartyl protease domain. An AWK script was used to search the Wormpep12 database for proteins in which the D(S/T)G motif occurred at least twice. This identified >60 proteins with two DTG or DSG motifs. Visual inspection was used to select proteins in which the position of the aspartyl domains was suggestive of a two-domain structure meeting the criteria described above.

In addition, the PROSITE eukaryotic and viral aspartyl protease active site pattern PS00141 was used to search Wormpep12 for candidate aspartyl proteases. (Bairoch A., Bucher P., Hofmann K., The PROSITE database: its status in 1997, *Nucleic Acids Res.* 24:217-221(1997)). This generated an overlapping set of Wormpep12 sequences. Of these, seven sequences contained two DTG or DSG

motifs and the PROSITE aspartyl protease active site pattern. Of these seven, three were found in the same cosmid clone (F21F8.3, F21F8.4, and F21F8.7) suggesting that they represent a family of proteins that arose by ancestral gene duplication. Two other ORFs with extensive homology to F21F8.3, F21F8.4 and F21F8.7 are present in the same gene cluster (F21F8.2 and F21F8.6), however, these contain only a single DTG motif. Exhaustive BLAST searches with these seven sequences against Wormpep12 failed to reveal additional candidate aspartyl proteases in the *C. elegans* genome containing two repeats of the DTG or DSG motif.

BLASTX search with each *C. elegans* sequence against SWISS-PROT, GenPep and TREMBL revealed that R12H7.2 was the closest worm homologue to the known mammalian aspartyl proteases, and that T18H9.2 was somewhat more distantly related, while CEASP1, F21F8.3, F21F8.4, and F21F8.7 formed a subcluster which had the least sequence homology to the mammalian sequences.

Discussion:

APP, the presenilins, and p35, the activator of cdk5, all undergo intracellular proteolytic processing at sites which conform to the substrate specificity of the HIV protease. Dysregulation of a cellular aspartyl protease with the same substrate specificity, might therefore provide a unifying mechanism for causation of the plaque and tangle pathologies in AD. Therefore, we sought to identify novel human aspartyl proteases. A whole genome scan in *C. elegans* identified seven open reading frames that adhere to the aspartyl protease profile that we had identified. These seven aspartyl proteases probably comprise the complete complement of such proteases in a simple, multicellular eukaryote. These include four closely related aspartyl proteases unique to *C. elegans* which probably arose by duplication of an ancestral gene. The other three candidate aspartyl proteases (T18H9.2, R12H7.2 and C11D2.2) were found to have homology to mammalian gene sequences.

Example 2**Identification of Novel Human Aspartyl Proteases Using Database Mining by Genome Bridging**5 ***Materials and Methods:***

Computer-assisted analysis of EST databases, cDNA , and predicted polypeptide sequences:

Exhaustive homology searches of EST databases with the CEASP1, F21F8.3, F21F8.4, and F21F8.7 sequences failed to reveal any novel mammalian homologues.

10 TBLASTN searches with R12H7.2 showed homology to cathepsin D, cathepsin E, pepsinogen A, pepsinogen C and renin, particularly around the DTG motif within the active site, but also failed to identify any additional novel mammalian aspartyl proteases. This indicates that the *C. elegans* genome probably contains only a single lysosomal aspartyl protease which in mammals is represented by a gene family that 15 arose through duplication and consequent modification of an ancestral gene.

TBLASTN searches with T18H9.2, the remaining *C. elegans* sequence, identified several ESTs which assembled into a contig encoding a novel human aspartyl protease (Hu-ASP1). As is described above in Example 1, BLASTX search with the Hu-ASP1 contig against SWISS-PROT revealed that the active site motifs in 20 the sequence aligned with the active sites of other aspartyl proteases. Exhaustive, repetitive rounds of BLASTN searches against LifeSeq, LifeSeqFL, and the public EST collections identified 102 EST from multiple cDNA libraries that assembled into a single contig. The 51 sequences in this contig found in public EST collections also have been assembled into a single contig (THC213329) by The Institute for Genome 25 Research (TIGR). The TIGR annotation indicates that they failed to find any hits in the database for the contig. Note that the TIGR contig is the reverse complement of the LifeSeq contig that we assembled. BLASTN search of Hu-ASP1 against the rat and mouse EST sequences in ZooSeq revealed one homologous EST in each database (Incyte clone 700311523 and IMAGE clone 313341, GenBank accession number 30 W10530, respectively).

TBLASTN searches with the assembled DNA sequence for Hu-Asp1 against both LifeSeqFL and the public EST databases identified a second, related human sequence (Hu-Asp2) represented by a single EST (2696295). Translation of this partial cDNA sequence reveals a single DTG motif which has homology to the active site motif of a bovine aspartyl protease, NM1.

BLAST searches, contig assemblies and multiple sequence alignments were performed using the bioinformatics tools provided with the LifeSeq, LifeSeqFL and LifeSeq Assembled databases from Incyte. Predicted protein motifs were identified using either the ProSite dictionary (Motifs in GCG 9) or the Pfam database.

10 *Full-length cDNA cloning of Hu-Asp1*

The open reading frame of *C. elegans* gene T18H9.2CE was used to query Incyte LifeSeq and LifeSeq-FL databases and a single electronic assembly referred to as 1863920CE1 was detected. The 5' most cDNA clone in this contig, 1863920, was obtained from Incyte and completely sequenced on both strands. Translation of the 15 open reading frame contained within clone 1863920 revealed the presence of the duplicated aspartyl protease active site motif (DTG/DSG) but the 5' end was incomplete. The remainder of the Hu-Asp1 coding sequence was determined by 5' Marathon RACE analysis using a human placenta Marathon ready cDNA template (Clontech). A 3'-antisense oligonucleotide primer specific for the 5' end of clone 20 1863920 was paired with the 5'-sense primer specific for the Marathon ready cDNA synthetic adaptor in the PCR. Specific PCR products were directly sequenced by cycle sequencing and the resulting sequence assembled with the sequence of clone 1863920 to yield the complete coding sequence of Hu-Asp-1 (SEQ ID No. 1).

Several interesting features are present in the primary amino acid sequence of 25 Hu-Asp1 (Figure 1, SEQ ID No. 2). The sequence contains a signal peptide (residues 1-20 in SEQ ID No. 2), a pro-segment, and a catalytic domain containing two copies of the aspartyl protease active site motif (DTG/DSG). The spacing between the first and second active site motifs is about 200 residues which should correspond to the expected size of a single, eukaryotic aspartyl protease domain. More interestingly, the 30 sequence contains a predicted transmembrane domain (residues 469-492 in SEQ ID

No.2) near its C-terminus which suggests that the protease is anchored in the membrane. This feature is not found in any other aspartyl protease.

Cloning of a full-length Hu-Asp-2 cDNAs:

5 As is described above in Example 1, genome wide scan of the *Caenorhabditis elegans* database WormPep12 for putative aspartyl proteases and subsequent mining of human EST databases revealed a human ortholog to the *C. elegans* gene T18H9.2 referred to as Hu-Asp1. The assembled contig for Hu-Asp1 was used to query for human paralogs using the BLAST search tool in human EST databases and a single
10 significant match (2696295CE1) with approximately 60% shared identity was found in the LifeSeq FL database. Similar queries of either gb105PubEST or the family of human databases available from TIGR did not identify similar EST clones. cDNA clone 2696295, identified by single pass sequence analysis from a human uterus cDNA library, was obtained from Incyte and completely sequenced on both strands.
15 This clone contained an incomplete 1266 bp open-reading frame that encoded a 422 amino acid polypeptide but lacked an initiator ATG on the 5' end. Inspection of the predicted sequence revealed the presence of the duplicated aspartyl protease active site motif DTG/DSG, separated by 194 amino acid residues. Subsequent queries of later releases of the LifeSeq EST database identified an additional ESTs, sequenced
20 from a human astrocyte cDNA library (4386993), that appeared to contain additional 5' sequence relative to clone 2696295. Clone 4386993 was obtained from Incyte and completely sequenced on both strands. Comparative analysis of clone 4386993 and clone 2696295 confirmed that clone 4386993 extended the open-reading frame by 31 amino acid residues including two in-frame translation initiation codons. Despite the
25 presence of the two in-frame ATGs, no in-frame stop codon was observed upstream of the ATG indicating that the 4386993 may not be full-length. Furthermore, alignment of the sequences of clones 2696295 and 4386993 revealed a 75 base pair insertion in clone 2696295 relative to clone 4386993 that results in the insertion of 25 additional amino acid residues in 2696295. The remainder of the Hu-Asp2 coding
30 sequence was determined by 5' Marathon RACE analysis using a human

hippocampus Marathon ready cDNA template (Clontech). A 3'-antisense oligonucleotide primer specific for the shared 5'-region of clones 2696295 and 4386993 was paired with the 5'-sense primer specific for the Marathon ready cDNA synthetic adaptor in the PCR. Specific PCR products were directly sequenced by 5 cycle sequencing and the resulting sequence assembled with the sequence of clones 2696295 and 4386993 to yield the complete coding sequence of Hu-Asp2(a) (SEQ ID No. 3) and Hu-Asp2(b) (SEQ ID No. 5), respectively.

Several interesting features are present in the primary amino acid sequence of Hu-Asp2(a) (Figure 2 and SEQ ID No. 4) and Hu-Asp2(b) (Figure 3, SEQ ID No. 6). 10 Both sequences contain a signal peptide (residues 1-21 in SEQ ID No. 4 and SEQ ID No. 6), a pro-segment, and a catalytic domain containing two copies of the aspartyl protease active site motif (DTG/DSG). The spacing between the first and second active site motifs is variable due to the 25 amino acid residue deletion in Hu-Asp2(b) and consists of 168-versus-194 amino acid residues, for Hu-Asp2(b) and 15 Hu-Asp2(a), respectively. More interestingly, both sequences contains a predicted transmembrane domain (residues 455-477 in SEQ ID No. 4 and 430-452 in SEQ ID No. 6) near their C-termini which indicates that the protease is anchored in the membrane. This feature is not found in any other aspartyl protease except Hu-Asp1.

20

Example 3

Molecular cloning of mouse Asp2 cDNA and genomic DNA.

Cloning and characterization of murine Asp2 cDNA.

The murine ortholog of Hu-Asp2 was cloned using a combination of cDNA library screening, PCR, and genomic cloning. Approximately 500,000 independent 25 clones from a mouse brain cDNA library were screened using a ³²P-labeled coding sequence probe prepared from Hu-Asp2. Replicate positives were subjected to DNA sequence analysis and the longest cDNA contained the entire 3' untranslated region and 47 amino acids in the coding region. PCR amplification of the same mouse brain cDNA library with an antisense oligonucleotide primer specific for the 5'-most 30 cDNA sequence determined above and a sense primer specific for the 5' region of

human Asp2 sequence followed by DNA sequence analysis gave an additional 980 bp of the coding sequence. The remainder of the 5' sequence of murine Asp-2 was derived from genomic sequence (see below).

5 *Isolation and sequence analysis of the murine Asp-2 gene.*

A murine EST sequence encoding a portion of the murine Asp2 cDNA was identified in the GenBank EST database using the BLAST search tool and the Hu-Asp2 coding sequence as the query. Clone g3160898 displayed 88% shared identity to the human sequence over 352 bp. Oligonucleotide primer pairs specific for 10 this region of murine Asp2 were then synthesized and used to amplify regions of the murine gene. Murine genomic DNA, derived from strain 129/SvJ, was amplified in the PCR (25 cycles) using various primer sets specific for murine Asp2 and the products analyzed by agarose gel electrophoresis. The primer set Zoo-1 and Zoo-4 amplified a 750 bp fragment that contained approximately 600 bp of intron sequence 15 based on comparison to the known cDNA sequence. This primer set was then used to screen a murine BAC library by PCR, a single genomic clone was isolated and this cloned was confirmed contain the murine Asp2 gene by DNA sequence analysis. Shotgun DNA sequencing of this Asp2 genomic clone and comparison to the cDNA sequences of both Hu-Asp2 and the partial murine cDNA sequences defined the 20 full-length sequence of murine Asp2 (SEQ ID No. 7). The predicted amino acid sequence of murine Asp2 (SEQ ID No. 8) showed 96.4% shared identity (GCG BestFit algorithm) with 18/501 amino acid residue substitutions compared to the human sequence (Figure 4). The proteolytic processing of murine Asp2(a) is believed to be analogous to the processing described above for human Asp2(a). In addition, a 25 variant lacking amino acid residues 190-214 of SEQ ID NO: 8 is specifically contemplated as a murine Asp2(b) polypeptide. All forms of murine Asp2(b) gene and protein are intended as aspects of the invention.

Example 4**Tissue Distribution of Expression of Hu-Asp2 Transcripts****Materials and Methods:**

The tissue distribution of expression of Hu-Asp-2 was determined using
5 multiple tissue Northern blots obtained from Clontech (Palo Alto, CA). Incyte clone
2696295 in the vector pINCY was digested to completion with *EcoRI/NotI* and the 1.8
kb cDNA insert purified by preparative agarose gel electrophoresis. This fragment
was radiolabeled to a specific activity $> 1 \times 10^9$ dpm/ μ g by random priming in the
presence of [α -³²P-dATP] (>3000 Ci/mmol, Amersham, Arlington Heights, IL) and
10 Klenow fragment of DNA polymerase I. Nylon filters containing denatured, size
fractionated poly A⁺ RNAs isolated from different human tissues were hybridized
with 2×10^6 dpm/ml probe in ExpressHyb buffer (Clontech, Palo Alto, CA) for 1 hour
at 68 °C and washed as recommended by the manufacture. Hybridization signals were
visualized by autoradiography using BioMax XR film (Kodak, Rochester, NY) with
15 intensifying screens at -80 °C.

Results and Discussion:

Limited information on the tissue distribution of expression of Hu-Asp-2
transcripts was obtained from database analysis due to the relatively small number of
20 ESTs detected using the methods described above (< 5). In an effort to gain further
information on the expression of the Hu-Asp2 gene, Northern analysis was employed
to determine both the size(s) and abundance of Hu-Asp2 transcripts. PolyA⁺ RNAs
isolated from a series of peripheral tissues and brain regions were displayed on a solid
support following separation under denaturing conditions and Hu-Asp2 transcripts
25 were visualized by high stringency hybridization to radiolabeled insert from clone
2696295. The 2696295 cDNA probe visualized a constellation of transcripts that
migrated with apparent sizes of 3.0kb, 4.4 kb and 8.0 kb with the latter two transcript
being the most abundant.

Across the tissues surveyed, Hu-Asp2 transcripts were most abundant in
30 pancreas and brain with lower but detectable levels observed in all other tissues

examined except thymus and PBLs. Given the relative abundance of Hu-Asp2 transcripts in brain, the regional expression in brain regions was also established. A similar constellation of transcript sizes were detected in all brain regions examined [cerebellum, cerebral cortex, occipital pole, frontal lobe, temporal lobe and putamen] 5 with the highest abundance in the medulla and spinal cord.

Example 5

Northern Blot Detection of HuAsp-1 and HuAsp-2 Transcripts in Human Cell Lines

10 A variety of human cell lines were tested for their ability to produce Hu-Asp1 and Asp2 mRNA. Human embryonic kidney (HEK-293) cells, African green monkey (Cos-7) cells, Chinese hamster ovary (CHO) cells, HELA cells, and the neuroblastoma cell line IMR-32 were all obtained from the ATCC. Cells were cultured in DME containing 10% FCS except CHO cells which were maintained in 15 α -MEM/10% FCS at 37 °C in 5% CO₂ until they were near confluence. Washed monolayers of cells (3×10^7) were lysed on the dishes and poly A⁺ RNA extracted using the Qiagen Oligotex Direct mRNA kit. Samples containing 2 μ g of poly A⁺ RNA from each cell line were fractionated under denaturing conditions (glyoxal-treated), transferred to a solid nylon membrane support by capillary action, 20 and transcripts visualized by hybridization with random-primed labeled (³²P) coding sequence probes derived from either Hu-Asp1 or Hu-Asp2. Radioactive signals were detected by exposure to X-ray film and by image analysis with a PhosphorImager.

The Hu-Asp1 cDNA probe visualized a similar constellation of transcripts (2.6 kb and 3.5 kb) that were previously detected in human tissues. The relative abundance 25 determined by quantification of the radioactive signal was Cos-7 > HEK 292 = HELA > IMR32.

The Hu-Asp2 cDNA probe also visualized a similar constellation of transcripts compared to tissue (3.0 kb, 4.4 kb, and 8.0 kb) with the following relative abundance; HEK 293 > Cos 7 > IMR32 > HELA.

Example 6**Modification of APP to increase A_β processing for in vitro screening**

Human cell lines that process A_β peptide from APP provide a means to screen in cellular assays for inhibitors of β- and γ-secretase. Production and release of A_β peptide into the culture supernatant is monitored by an enzyme-linked immunosorbent assay (ELA). Although expression of APP is widespread and both neural and non-neuronal cell lines process and release A_β peptide, levels of endogenous APP processing are low and difficult to detect by ELA. A_β processing can be increased by expressing in transformed cell lines mutations of APP that enhance A_β processing.

We made the serendipitous observation that addition of two lysine residues to the carboxyl terminus of APP695 increases A_β processing still further. This allowed us to create a transformed cell line that releases A_β peptide into the culture medium at the remarkable level of 20,000 pg/ml.

15 Materials And Methods**Materials:**

Human embryonic kidney cell line 293 (HEK293 cells) were obtained internally. The vector pIRES-EGFP was purchased from Clontech. Oligonucleotides for mutation using the polymerase chain reaction (PCR) were purchased from Genosys. A plasmid containing human APP695 (SEQ ID No. 9 [nucleotide] and SEQ ID No. 10 [amino acid]) was obtained from Northwestern University Medical School. This was subcloned into pSK (Stratagene) at the *Not*1 site creating the plasmid pAPP695.

Mutagenesis protocol:

The Swedish mutation (K670N, M671L) was introduced into pAPP695 using the Stratagene Quick Change Mutagenesis Kit to create the plasmid pAPP695NL (SEQ ID No. 11 [nucleotide] and SEQ ID No. 12 [amino acid]). To introduce a di-lysine motif at the C-terminus of APP695, the forward primer #276 5' GACTGACCACTCGACCAGGTTC (SEQ ID No. 47) was used with the "patch" primer #274 5'

CGAATTAAATTCCAGCACACTGGCTACTTCTGTCATCTCAAAGAAC
(SEQ ID No. 48) and the flanking primer #275

CGAATTAAATTCCAGCACACTGGCTA (SEQ ID No. 49) to modify the 3' end of
the APP695 cDNA (SEQ ID No. 15 [nucleotide] and SEQ ID No. 16 [amino acid]).

- 5 This also added a BstX1 restriction site that will be compatible with the BstX1 site in
the multiple cloning site of pIRES-EGFP. PCR amplification was performed with a
Clontech HF Advantage cDNA PCR kit using the polymerase mix and buffers
supplied by the manufacturer. For "patch" PCR, the patch primer was used at 1/20th
the molar concentration of the flanking primers. PCR amplification products were
10 purified using a QIAquick PCR purification kit (Qiagen). After digestion with
restriction enzymes, products were separated on 0.8% agarose gels and then excised
DNA fragments were purified using a QIAquick gel extraction kit (Qiagen).

To reassemble a modified APP695-Sw cDNA, the 5' Not1-Bgl2 fragment of
the APP695-Sw cDNA and the 3' Bgl2-BstX1 APP695 cDNA fragment obtained by
15 PCR were ligated into pIRES-EGFP plasmid DNA opened at the Not1 and BstX1
sites. Ligations were performed for 5 minutes at room temperature using a Rapid
DNA Ligation kit (Boehringer Mannheim) and transformed into Library Efficiency
DH5a Competent Cells (GibcoBRL Life Technologies). Bacterial colonies were
screened for inserts by PCR amplification using primers #276 and #275. Plasmid
20 DNA was purified for mammalian cell transfection using a QIAprep Spin Miniprep
kit (Qiagen). The construct obtained was designated pMG125.3 (APPSW-KK, SEQ
ID No. 17 [nucleotide] and SEQ ID No. 18 [amino acid]).

Mammalian Cell Transfection:

HEK293 cells for transfection were grown to 80% confluence in Dulbecco's
25 modified Eagle's medium (DMEM) with 10% fetal bovine serum. Cotransfections
were performed using LipofectAmine (Gibco-BRL) with 3 µg pMG125.3 DNA and 9
µg pcDNA3.1 DNA per 10 x 10⁶ cells. Three days posttransfection, cells were
passaged into medium containing G418 at a concentration of 400 µg/ml. After three
days growth in selective medium, cells were sorted by their fluorescence.

30 Clonal Selection of 125.3 cells by FACS:

Cell samples were analyzed on an EPICS Elite ESP flow cytometer (Coulter, Hialeah, FL) equipped with a 488 nm excitation line supplied by an air-cooled argon laser. EGFP emission was measured through a 525 nm band-pass filter and fluorescence intensity was displayed on a 4-decade log scale after gating on viable cells as determined by forward and right angle light scatter. Single green cells were separated into each well of one 96 well plate containing growth medium without G418. After a four day recovery period, G418 was added to the medium to a final concentration of 400 µg/ml. After selection, 32% of the wells contained expanding clones. Wells with clones were expanded from the 96 well plate to a 24 well plate and then a 6 well plate with the fastest growing colonies chosen for expansion at each passage. The final cell line selected was the fastest growing of the final six passaged. This clone, designated 125.3, has been maintained in G418 at 400 ug/ml with passage every four days into fresh medium. No loss of A β production of EGFP fluorescence has been seen over 23 passages.

15

A β EIA Analysis (Double Antibody Sandwich ELISA for hA β 1-40/42):

Cell culture supernatants harvested 48 hours after transfection were analyzed in a standard A β EIA as follows. Human A β 1-40 or 1-42 was measured using monoclonal antibody (mAb) 6E10 (Senetek, St. Louis, MO) and biotinylated rabbit antiserum 162 or 164 (New York State Institute for Basic Research, Staten Island, NY) in a double antibody sandwich ELISA. The capture antibody 6E10 is specific to an epitope present on the N-terminal amino acid residues 1-16 of hA β . The conjugated detecting antibodies 162 and 164 are specific for hA β 1-40 and 1-42, respectively. Briefly, a Nunc Maxisorp 96 well immunoplate was coated with 100 µl/well of mAb 6E10 (5µg/ml) diluted in 0.1M carbonate-bicarbonate buffer, pH 9.6 and incubated at 4°C overnight. After washing the plate 3x with 0.01M DPBS (Modified Dulbecco's Phosphate Buffered Saline (0.008M sodium phosphate, 0.002M potassium phosphate, 0.14M sodium chloride, 0.01 M potassium chloride, pH 7.4) from Pierce, Rockford, IL) containing 0.05% of Tween-20 (DPBST), the plate 20 was blocked for 60 minutes with 200 µl of 10% normal sheep serum (Sigma) in

0.01M DPBS to avoid non-specific binding. Human A β 1-40 or 1-42 standards 100 μ l/well (Bachem, Torrance, CA) diluted, from a 1mg/ml stock solution in DMSO, in culture medium was added after washing the plate, as well as 100 μ l/well of sample, e.g., conditioned medium of transfected cells.

5 The plate was incubated for 2 hours at room temperature and 4°C overnight. The next day, after washing the plate, 100 μ l/well biotinylated rabbit antiserum 162 1:400 or 164 1:50 diluted in DPBST + 0.5% BSA was added and incubated at room temperature for 1hour, 15 minutes. Following washes, 100 μ l/well
10 neutravidin-horseradish peroxidase (Pierce, Rockford, IL) diluted 1:10,000 in DPBST was applied and incubated for 1 hour at room temperature. After the last washes 100 μ l/well of o-phenylenediamine dihydrochloride (Sigma Chemicals, St. Louis, MO) in 50mM citric acid/100mM sodium phosphate buffer (Sigma Chemicals, St. Louis, MO), pH 5.0, was added as substrate and the color development was monitored at 450nm in a kinetic microplate reader for 20 minutes using Soft max Pro software. All
15 standards and samples were run in triplicates. The samples with absorbance values falling within the standard curve were extrapolated from the standard curves using Soft max Pro software and expressed in pg/ml culture medium.

Results:

20 Addition of two lysine residues to the carboxyl terminus of APP695 greatly increases A β processing in HEK293 cells as shown by transient expression (Table 1). Addition of the di-lysine motif to APP695 increases A β processing to that seen with the APP695 containing the Swedish mutation. Combining the di-lysine motif with the Swedish mutation further increases processing by an additional 2.8 fold.

25 Cotransformation of HEK293 cells with pMG125.3 and pcDNA3.1 allowed dual selection of transformed cells for G418 resistance and high level expression of EGFP. After clonal selection by FACS, the cell line obtained, produces a remarkable 20,000 pg A β peptide per ml of culture medium after growth for 36 hours in 24 well plates. Production of A β peptide under various growth conditions is summarized in Table 2.

TABLE 1

Release of A β peptide into the culture medium 48 hours after transient transfection of HEK293 cells with the indicated vectors containing wildtype or modified APP. Values tabulated are mean + SD and P-value for pairwise comparison using Student's t-test assuming unequal variances.

APP Construct	A β 1-40 peptide (pg/ml)	Fold Increase	P-value
pIRES-EGFP vector	147 + 28	1.0	
wt APP695 (142.3)	194 + 15	1.3	0.051
wt APP695-KK (124.1)	424 + 34	2.8	3 x 10 ⁻⁵
APP695-Sw (143.3)	457 + 65	3.1	2 x 10 ⁻³
APP695-SwKK (125.3)	1308 + 98	8.9	3 x 10 ⁻⁴

20

25

TABLE 2

Release of A β peptide from HEK125.3 cells under various growth conditions.

5	Type of Culture Plate	Volume of Medium	Duration of Culture	A β 1-40 (pg/ml)	A β 1-42 (pg/ml)
10	24 well plate	400 ul	36 hr	28,036	1,439

Example 7

Antisense oligomer inhibition of Abeta processing in HEK125.3 cells

The sequences of Hu-Asp1 and Hu-Asp2 were provided to Sequitur, Inc (Natick, MA) for selection of targeted sequences and design of 2nd generation chimeric antisense oligomers using proprietary technology (Sequitur Ver. D Pat pending #3002). Antisense oligomers Lot# S644, S645, S646 and S647 were targeted against Asp1. Antisense oligomers Lot# S648, S649, S650 and S651 were targeted against Asp2. Control antisense oligomers Lot# S652, S653, S655, and S674 were targeted against an irrelevant gene and antisense oligomers Lot #S656, S657, S658, and S659 were targeted against a second irrelevant gene.

For transfection with the antisense oligomers, HEK125.3 cells were grown to about 50% confluence in 6 well plates in Minimal Essential Medium (MEM) supplemented with 10% fetal calf serum. A stock solution of oligofectin G (Siquitur Inc., Natick, MA) at 2 mg/ml was diluted to 50 μ g/ml in serum free MEM. Separately, the antisense oligomer stock solution at 100 μ M was diluted to 800 nM in Opti-MEM (GIBCO-BRL, Grand Island, NY). The diluted stocks of oligofectin G and antisense oligomer were then mixed at a ratio of 1:1 and incubated at room temperature. After 15 minutes incubation, the reagent was diluted 10 fold into MEM containing 10% fetal calf serum and 2 ml was added to each well of the 6 well plate

after first removing the old medium. After transfection, cells were grown in the continual presence of the oligofectin G/antisense oligomer. To monitor A β peptide release, 400 μ l of conditioned medium was removed periodically from the culture well and replaced with fresh medium beginning 24 hours after transfection. A β peptides in the conditioned medium were assayed via immunoprecipitation and Western blotting. Data reported are from culture supernatants harvested 48 hours after transfection.

The 16 different antisense oligomers obtained from Sequitur Inc. were transfected separately into HEK125.3 cells to determine their affect on A β peptide processing. Only antisense oligomers targeted against Asp2 significantly reduced Abeta processing by HEK125.3 cells. Both A β (1-40) and A β (1-42) were inhibited by the same degree. In Table 3, percent inhibition is calculated with respect to untransfected cells. Antisense oligomer reagents giving greater than 50% inhibition are marked with an asterisk. Of the reagents tested, 3 or 4 antisense oligomers targeted against Asp1 gave an average 52% inhibition of A β (1-40) processing and 47% inhibition of A β (1-42) processing. For Asp2, 4 of 4 antisense oligomers gave greater than 50% inhibition with an average inhibition of 62% of A β (1-40) processing and 60% for A β (1-42) processing.

20

25

30

TABLE 3

Inhibition of A β peptide release from HEK125.3 cells treated with antisense oligomers.

	Gene Targeted	Antisense Oligomer	Abeta (1-40)	Abeta (1-42)
	Asp1-1	S644	62%*	56%*
	Asp1-2	S645	41%*	38%*
	Asp1-3	S646	52%*	46%*
5	Asp1-4	S647	6%	25%*
	Asp2-1	S648	71%*	67%*
	Asp2-2	S649	83%*	76%*
	Asp2-3	S650	46%*	50%*
	Asp2-4	S651	47%*	46%*
10	Con1-1	S652	13%	18%
	Con1-2	S653	35%	30%
	Con1-3	S655	9%	18%
	Con1-4	S674	29%	18%
	Con2-1	S656	12%	18%
15	Con2-2	S657	16%	19%
	Con2-3	S658	8%	35%
	Con2-4	S659	3%	18%
20				

Since HEK293 cells derive from kidney, the experiment was extended to 25 human IMR-32 neuroblastoma cells which express all three APP isoforms and which release A β peptides into conditioned medium at measurable levels. [See Neill *et al.*, *J. NeuroSci. Res.*, (1994) 39: 482-93; and Asami-Odaka *et al.*, *Biochem.*, (1995) 34:10272-8.] Essentially identical results were obtained in the neuroblastoma cells as the HEK293 cells. As shown in Table 3B, the pair of Asp2 antisense oligomers

reduced Asp2 mRNA by roughly one-half, while the pair of reverse control oligomers lacked this effect (Table 3B).

Table 3B

5 Reduction of A β 40 and A β 42 in human neuroblastoma IMR-32 cells and mouse neuroblastoma Neuro-2A cells treated with Asp2 antisense and control oligomers as indicated. Oligomers were transfected in quadruplicate cultures. Values tabulated are normalized against cultures treated with oligofectin-G™ only (mean + SD, ** p<0.001 compared to reverse control oligomer).

10

		IMR-32 cells		Neuro-2A cells	
	Asp2 mRNA	A β 40	A β 42	A β 40	A β 42
	Asp2-1A	-75%	-49 + 2%**	-42 + 14%**	-70 + 7%**
	Asp2-1R	0.16	-0 + 3%	21.26	-9 + 15%
15	Asp2-2A	-39%	-43 + 3%**	-44 + 18%**	-61 + 12%**
	Asp2-2R	0.47	12.2	19.22	6.15 - 8 + 10%

15

Together with the reduction in Asp2 mRNA there was a concomitant reduction in the release of A β 40 and A β 42 peptides into the conditioned medium. Thus, Asp2 functions directly or indirectly in a human kidney and a human neuroblastoma cell line to facilitate the processing of APP into A β peptides. Molecular cloning of the mouse Asp2 cDNA revealed a high degree of homology to human (>96% amino acid identity, see Example 3), and indeed, complete nucleotide identity at the sites targeted by the Asp2-1A and Asp2-2A antisense oligomers. Similar results were obtained in mouse Neuro-2a cells engineered to express APP-Sw-KK. The Asp2 antisense oligomers reduced release of A β peptides into the medium while the reverse control oligomers did not (Table 3B). Thus, the three antisense experiments with HEK293,

20

25

IMR-32 and Neuro-2a cells indicate that Asp2 acts directly or indirectly to facilitate A β processing in both somatic and neural cell lines.

Example 8

5 Demonstration of Hu-Asp2 β -Secretase Activity in Cultured Cells

Several mutations in APP associated with early onset Alzheimer's disease have been shown to alter A β peptide processing. These flank the – and C-terminal cleavage sites that release A β from APP. These cleavage sites are referred to as the β -secretase and γ -secretase cleavage sites, respectively. Cleavage of APP at the 10 β -secretase site creates a C-terminal fragment of APP containing 99 amino acids of 11,145 daltons molecular weight. The Swedish KM-NL mutation immediately upstream of the β -secretase cleavage site causes a general increase in production of 15 both the 1-40 and 1-42 amino acid forms of A β peptide. The London VF mutation (V717-F in the APP770 isoform) has little effect on total A β peptide production, but appears to preferentially increase the percentage of the longer 1-42 amino acid form of A β peptide by affecting the choice of β -secretase cleavage site used during APP processing. Thus, we sought to determine if these mutations altered the amount and type of A β peptide produced by cultured cells cotransfected with a construct directing expression of Hu-Asp2.

20 Two experiments were performed which demonstrate Hu-Asp2 β -secretase activity in cultured cells. In the first experiment, treatment of HEK125.3 cells with antisense oligomers directed against Hu-Asp2 transcripts as described in Example 7 was found to decrease the amount of the C-terminal fragment of APP created by β -secretase cleavage (CTF99) (Figure 9). This shows that Hu-Asp2 acts directly or 25 indirectly to facilitate β -secretase cleavage. In the second experiment, increased expression of Hu-Asp2 in transfected mouse Neuro2A cells is shown to increase accumulation of the CTF99 β -secretase cleavage fragment (Figure 10). This increase is seen most easily when a mutant APP-KK clone containing a C-terminal di-lysine motif is used for transfection. A further increase is seen when Hu-Asp2 is

cotransfected with APP-Sw-KK containing the Swedish mutation KM -NL. The Swedish mutation is known to increase cleavage of APP by the β -secretase.

A second set of experiments demonstrate Hu-Asp2 facilitates γ -secretase activity in cotransfection experiments with human embryonic kidney HEK293 cells.

5 Cotransfection of Hu-Asp2 with an APP-KK clone greatly increases production and release of soluble A β 1-40 and A β 1-42 peptides from HEK293 cells. There is a proportionately greater increase in the release of A β 1-42. A further increase in production of A β 1-42 is seen when Hu-Asp2 is cotransfected with APP-VF (SEQ ID No. 13 [nucleotide] and SEQ ID No. 14 [amino acid]) or APP-VF-KK SEQ ID No. 19

10 [nucleotide] and SEQ ID No. 20 [amino acid]) clones containing the London mutation V717-F. The V717-F mutation is known to alter cleavage specificity of the APP γ -secretase such that the preference for cleavage at the A β 42 site is increased. Thus, Asp2 acts directly or indirectly to facilitate γ -secretase processing of APP at the β 42 cleavage site.

15 *Materials*

Antibodies 6E10 and 4G8 were purchased from Senetek (St. Louis, MO).

Antibody 369 was obtained from the laboratory of Paul Greengard at the Rockefeller University. Antibody C8 was obtained from the laboratory of Dennis Selkoe at the Harvard Medical School and Brigham and Women's Hospital.

20 *APP Constructs used*

The APP constructs used for transfection experiments comprised the following APP: wild-type APP695 (SEQ ID No. 9 and No. 10)

APP-Sw: APP695 containing the Swedish KM-NL mutation (SEQ ID No. 11 and No. 12 , wherein the lysine (K) at residue 595 of APP695 is changed to asparagine (N) and the methionine (M) at residue 596 of APP695 is changed to leucine (L).),

APP-VF: APP695 containing the London V-F mutation (SEQ ID Nos. 13 & 14) (Affected residue 717 of the APP770 isoform corresponds with residue 642 of the APP695 isoform. Thus, APP-VF as set in SEQ ID NO: 14 comprises the APP695 sequence, wherein the valine (V) at residue 642 is changed to phenylalanine (F).)

APP-KK: APP695 containing a C-terminal KK motif (SEQ ID Nos. 15 & 16),

APP-Sw-KK: APP695-Sw containing a C-terminal KK motif (SEQ ID No. 17
& 18),

APP-VF-KK: APP695-VF containing a C-terminal KK motif (SEQ ID Nos.
5 19 & 20).

These were inserted into the vector pIRES-EGFP (Clontech, Palo Alto CA)
between the *Not*1 and *Bst*X1 sites using appropriate linker sequences introduced by
PCR.

10 *Transfection of antisense oligomers or plasmid DNA constructs in HEK293 cells,
HEK125.3 cells and Neuro-2A cells,*

Human embryonic kidney HEK293 cells and mouse Neuro-2a cells were
transfected with expression constructs using the Lipofectamine Plus reagent from
Gibco/BRL. Cells were seeded in 24 well tissue culture plates to a density of 70-80%
15 confluence. Four wells per plate were transfected with 2 µg DNA (3:1,
APP:cotransfector), 8 µl Plus reagent, and 4 µl Lipofectamine in OptiMEM.
OptiMEM was added to a total volume of 1 ml, distributed 200 µl per well and
incubated 3 hours. Care was taken to hold constant the ratios of the two plasmids used
for cotransfection as well as the total amount of DNA used in the transfection. The
20 transfection media was replaced with DMEM, 10%FBS, NaPyruvate, with
antibiotic/antimycotic and the cells were incubated under normal conditions (37°C,
5% CO₂) for 48 hours. The conditioned media were removed to polypropylene tubes
and stored at -80°C until assayed for the content of Aβ1-40 and Aβ1-42 by EIA as
described in the preceding examples. Transfection of antisense oligomers into
25 HEK125.3 cells was as described in Example 7.

Preparation of cell extracts, Western blot protocol

Cells were harvested after being transfected with plasmid DNA for about 60
hours. First, cells were transferred to 15-ml conical tube from the plate and
centrifuged at 1,500 rpm for 5 minutes to remove the medium. The cell pellets were
30 washed once with PBS. We then lysed the cells with lysis buffer (10 mM HEPES, pH

7.9, 150 mM NaCl, 10% glycerol, 1 mM EGTA, 1 mM EDTA, 0.1 mM sodium vanadate and 1% NP-40). The lysed cell mixtures were centrifuged at 5000 rpm and the supernatant was stored at -20°C as the cell extracts. Equal amounts of extracts from HEK125.3 cells transfected with the Asp2 antisense oligomers and controls were precipitated with antibody 369 that recognizes the C-terminus of APP and then CTF99 was detected in the immunoprecipitate with antibody 6E10. The experiment was repeated using C8, a second precipitating antibody that also recognizes the C-terminus of APP. For Western blot of extracts from mouse Neuro-2a cells cotransfected with Hu-Asp2 and APP-KK, APP-Sw-KK, APP-VF-KK or APP-VF, equal amounts of cell extracts were electrophoresed through 4-10% or 10-20% Tricine gradient gels (NOVEX, San Diego, CA). Full length APP and the CTF99 β -secretase product were detected with antibody 6E10.

Results

Transfection of HEK125.3 cells with Asp2-1 or Asp2-2 antisense oligomers reduces production of the CTF β -secretase product in comparison to cells similarly transfected with control oligomers having the reverse sequence (Asp2-1 reverse & Asp2-2 reverse), see Figure 9. Correspondingly, cotransfection of Hu-Asp2 into mouse Neuro-2a cells with the APP-KK construct increased the formation of CTF99. (See Fig. 10.) This was further increased if Hu-Asp2 was coexpressed with APP-Sw-KK, a mutant form of APP containing the Swedish KM-NL mutation that increases β -secretase processing.

Effects of Asp2 on the production of Ab peptides from endogenously expressed APP isoforms were assessed in HEK293 cells transfected with a construct expressing Asp2 or with the empty vector after selection of transformants with the antibiotic G418. A β 40 production was increased in cells transformed with the Asp2 construct in comparison to those transformed with the empty vector DNA. A β 40 levels in conditioned medium collected from the Asp2 transformed and control cultures was 424 ± 45 pg /ml and 113 ± 58 pg/ml, respectively ($p<0.001$). A β 42 release was below the limit of detection by the EIA, while the release of sAPP α was unaffected, 112 ± 8 ng/ml versus 111 ± 40 ng/ml. This further indicates that Asp2

acts directly or indirectly to facilitate the processing and release of A β from endogenously expressed APP.

Co-transfection of Hu-Asp2 with APP has little effect on A β 40 production but increases A β 42 production above background (Table 4). Addition of the di-lysine 5 motif to the C-terminus of APP increases A β peptide processing about two fold, although A β 40 and A β 42 production remain quite low (352 pg/ml and 21 pg/ml, respectively). Cotransfection of Asp2 with APP-KK further increases both A β 40 and A β 42 production.

The APP V717-F mutation has been shown to increase γ -secretase processing at the A β 42 cleavage site. Cotransfection of Hu-Asp2 with the APP-VF or APP-VF-KK constructs increased A β 42 production (a two fold increase with APP-VF and a four-fold increase with APP-VF-KK, Table 4), but had mixed effects on A β 40 production (a slight decrease with APP-VF, and a two fold increase with APP-VF-KK in comparison to the pcDNA cotransfection control. Thus, the effect of Asp2 on 10 A β 42 production was proportionately greater leading to an increase in the ratio of A β 42/total Ab. Indeed, the ratio of A β 42/total A β reaches a very high value of 42% in 15 HEK293 cells cotransfected with Hu-Asp2 and APP-VF-KK.

20

25

30

Table 4

Results of cotransfected Hu-Asp2 or pcDNA plasmid DNA with various APP constructs containing the V717-F mutation that modifies γ -secretase processing.

5 Cotransfection with Asp2 consistently increases the ratio of A β 42/total A β . Values tabulated are A β peptide pg/ml.

	pcDNA			Asp2		
	Cotransfection		A β 42/Tot	Cotransfection		A β 42/Tot
	A β 40	A β 42	al	A β 40	A β 42	al
10						
	APP	192 \pm 1	<4	<2%	188 \pm 40	8 \pm 10
		8				
	APP-VF	118 \pm 1	15 \pm 19	11.5%	85 \pm 7	24 \pm 12
		5				
15	APP-KK	352 \pm 2	21 \pm 6	5.5%	1062 \pm 101	226 \pm 4
		4				9
	APP-VF-K	230 \pm 3	88 \pm 24	27.7%	491 \pm 35	355 \pm 3
	K	1				6
20						

Example 9**Bacterial expression of human Asp2(a)**5 *Expression of recombinant Hu-Asp2(a) in E. coli.*

Hu-Asp2(a) can be expressed in *E. coli* after addition of N-terminal sequences such as a T7 tag (SEQ ID No. 21 and No. 22) or a T7 tag followed by a caspase 8 leader sequence (SEQ ID No. 23 and No. 24). Alternatively, reduction of the GC content of the 5' sequence by site directed mutagenesis can be used to increase the 10 yield of Hu-Asp2 (SEQ ID No. 25 and No. 26). In addition, Asp2(a) can be engineered with a proteolytic cleavage site (SEQ ID No. 27 and No. 28). To produce a soluble protein after expression and refolding, deletion of the transmembrane domain and cytoplasmic tail, or deletion of the membrane proximal region, transmembrane domain, and cytoplasmic tail is preferred. Any materials (vectors, 15 host cells, etc.) and methods described herein to express Hu-Asp2(a) should in principle be equally effective for expression of Hu-Asp2(b).

Methods

PCR with primers containing appropriate linker sequences was used to assemble fusions of Asp2(a) coding sequence with N-terminal sequence modifications 20 including a T7 tag (SEQ ID Nos. 21 and 22) or a T7-caspase 8 leader (SEQ ID Nos. 23 and 24). These constructs were cloned into the expression vector pet23a(+) [Novagen] in which a T7 promoter directs expression of a T7 tag preceding a sequence of multiple cloning sites. To clone Hu-Asp2 sequences behind the T7 leader of pet23a+, the following oligonucleotides were used for amplification of the selected 25 Hu-Asp2(a) sequence: #553=GTGGATCCACCCAGCACGGCATCCGGCTG (SEQ ID No. 35), #554=GAAAGCTTCATGACTCATCTGTCTGTGGAATGTTG (SEQ ID No. 36) which placed BamHI and HindIII sites flanking the 5' and 3' ends of the insert, respectively. The Asp2(a) sequence was amplified from the full length Asp2(a) cDNA cloned into pcDNA3.1 using the Advantage-GC cDNA PCR [Clontech] 30 following the manufacturer's supplied protocol using annealing & extension at 68°C in

a two-step PCR cycle for 25 cycles. The insert and vector were cut with BamHI and HindIII, purified by electrophoresis through an agarose gel, then ligated using the Rapid DNA Ligation kit [Boehringer Mannheim]. The ligation reaction was used to transform the *E. coli* strain JM109 (Promega) and colonies were picked for the purification of plasmid (Qiagen,Qiaprep minispin) and DNA sequence analysis . For inducible expression using induction with isopropyl b-D-thiogalactopyranoside (IPTG), the expression vector was transferred into *E. coli* strain BL21 (Statagene). Bacterial cultures were grown in LB broth in the presence of ampicillin at 100 ug/ml, and induced in log phase growth at an OD600 of 0.6-1.0 with 1 mM IPTG for 4 hour 5 at 37°C. The cell pellet was harvested by centrifugation.

10 To clone Hu-Asp2 sequences behind the T7 tag and caspase leader (SEQ ID Nos. 23 and 24), the construct created above containing the T7-Hu-Asp2 sequence (SEQ ID Nos. 21 and 22) was opened at the BamHI site, and then the phosphorylated caspase 8 leader oligonucleotides

15 #559=GATCGATGACTATCTCTGACTCTCCGCGTGAACAGGGACG (SEQ ID No. 37), #560=GATCCGT CCTGTTCACGCCGGAGAGTCAGAGATAGTCATC (SEQ ID No. 38) were annealed and ligated to the vector DNA. The 5' overhang for each set of oligonucleotides was designed such that it allowed ligation into the BamHI site but not subsequent digestion with BamHI. The ligation reaction was transformed into

20 JM109 as above for analysis of protein expression after transfer to *E. coli* strain BL21.

In order to reduce the GC content of the 5' terminus of asp2(a), a pair of antiparallel oligos were designed to change degenerate codon bases in 15 amino acid positions from G/C to A/T (SEQ ID Nos. 25 and 26). The new nucleotide sequence at the 5' end of asp2 did not change the encoded amino acid and was chosen to optimize 25 *E. Coli* expression. The sequence of the sense linker is 5'
CGGCATCCGGCTGCCCTGCGTAGCGGTCTGGGTGGTGCTCCACTGGGTCT
GCGTCTGCCCGGGAGACCGACGAA G 3' (SEQ ID No. 39). The sequence of
the antisense linker is : 5'
CTTCGTCGGTCTCCGGGGCAGACGCAGACCCAGTGGAGCACCACCCAGA
30 CCGCTACGCAGGGGCAGCCGGATGCCG 3' (SEQ ID No. 40). After annealing

the phosphorylated linkers together in 0.1 M NaCl-10 mM Tris, pH 7.4 they were ligated into unique Cla I and Sma I sites in Hu-Asp2 in the vector pTAC. For inducible expression using induction with isopropyl b-D-thiogalactopyranoside (IPTG), bacterial cultures were grown in LB broth in the presence of ampicillin at 100 ug/ml, and induced in log phase growth at an OD600 of 0.6-1.0 with 1 mM IPTG for 4 hour at 37°C. The cell pellet was harvested by centrifugation.

To create a vector in which the leader sequences can be removed by limited proteolysis with caspase 8 such that this liberates a Hu-Asp2 polypeptide beginning with the N-terminal sequence GSFV (SEQ ID Nos. 27 and 28), the following procedure was followed. Two phosphorylated oligonucleotides containing the caspase 8 cleavage site IETD, #571=5'

GATCGATGACTATCTCTGACTCTCCGCTGGACTCTGGTATCGAAACCGACG (SEQ ID No. 41) and #572= GATCCGTCGGTTTCGATAACCAGAGTCCAGCGGAGAGTCAGAGATAGTCAT C (SEQ ID No. 42) were annealed and ligated into pET23a+ that had been opened with BamHI. After transformation into JM109, the purified vector DNA was recovered and orientation of the insert was confirmed by DNA sequence analysis.

The following oligonucleotides were used for amplification of the selected Hu-Asp2(a) sequence:

#573=5'AAGGATCCTTGAGATGGTGGACAACCTG, (SEQ ID No. 43)
#554=GAAAGCTTCATGACTCATCTGTCTGGAATGTTG (SEQ ID No. 44)
which placed BamHI and HindIII sites flanking the 5' and 3' ends of the insert, respectively. The Hu-Asp2(a) sequence was amplified from the full length Hu-Asp2(a) cDNA cloned into pcDNA3.1 using the Advantage-GC cDNA PCR [Clontech] following the manufacturer's supplied protocol using annealing & extension at 68°C in a two-step PCR cycle for 25 cycles. The insert and vector were cut with BamHI and HindIII, purified by electrophoresis through an agarose gel, then ligated using the Rapid DNA Ligation kit [Boehringer Mannheim]. The ligation reaction was used to transform the *E. coli* strain JM109 [Promega] and colonies were picked for the purification of plasmid (Qiagen,Qiaprep minispin) and DNA sequence

analysis . For inducible expression using induction with isopropyl b-D-thiogalactopyranoside (IPTG), the expression vector was transferred into *E. coli* strain BL21 (Statagene). Bacterial cultures were grown in LB broth in the presence of ampicillin at 100 ug/ml, and induced in log phase growth at an OD600 of 0.6-1.0 with 5 1 mM IPTG for 4 hour at 37°C. The cell pellet was harvested by centrifugation.

To assist purification, a 6-His tag can be introduced into any of the above constructs following the T7 leader by opening the construct at the BamHI site and then ligating in the annealed, phosphorylated oligonucleotides containing the six histidine sequence #565=GATCGCATCATCACCATCACCATG (SEQ ID No. 45), 10 #566=GATCCATGGTGATGGTATGATGC (SEQ ID No. 46). The 5' overhang for each set of oligonucleotides was designed such that it allowed ligation into the BamHI site but not subsequent digestion with BamHI.

Preparation of Bacterial Pellet:

15 36.34g of bacterial pellet representing 10.8L of growth was dispersed into a total volume of 200ml using a 20mm tissue homogenizer probe at 3000 to 5000 rpm in 2M KCl, 0.1M Tris, 0.05M EDTA, 1mM DTT. The conductivity adjusted to about 193mMhos with water. After the pellet was dispersed, an additional amount of the KCl solution was added, bringing the total volume to 500 ml. This suspension was homogenized further for about 3 minutes at 5000 rpm using the same probe. The 20 mixture was then passed through a Rannie high-pressure homogenizer at 10,000psi.

In all cases, the pellet material was carried forward, while the soluble fraction was discarded. The resultant solution was centrifuged in a GSA rotor for 1 hour at 12,500 rpm. The pellet was resuspended in the same solution (without the DTT) using the same tissue homogenizer probe at 2,000 rpm. After homogenizing for 5 minutes 25 at 3000 rpm, the volume was adjusted to 500ml with the same solution, and spun for 1 hour at 12,500 rpm. The pellet was then resuspended as before, but this time the final volume was adjusted to 1.5L with the same solution prior to homogenizing for 5 minutes. After centrifuging at the same speed for 30 minutes, this procedure was repeated. The pellet was then resuspended into about 150ml of cold water, pooling 30 the pellets from the six centrifuge tubes used in the GSA rotor. The pellet has

homogenized for 5 minutes at 3,000 rpm, volume adjusted to 250ml with cold water, then spun for 30 minutes. Weight of the resultant pellet was 17.75g.

Summary: Lysis of bacterial pellet in KCl solution, followed by centrifugation in a GSA rotor was used to initially prepare the pellet. The same solution was then 5 used an additional three times for resuspension/homogenization. A final water wash/homogenization was then performed to remove excess KCl and EDTA.

Solubilization of Recombinant Hu-Asp2(a):

A ratio of 9-10ml/gram of pellet was utilized for solubilizing the rHuAsp2L from the 10 pellet previously described. 17.75g of pellet was thawed, and 150ml of 8M guanidine HCl, 5mM β ME, 0.1% DEA, was added. 3M Tris was used to titrate the pH to 8.6. The pellet was initially resuspended into the guanidine solution using a 20 mm tissue homogenizer probe at 1000 rpm. The mixture was then stirred at 4°C for 1 hour prior to centrifugation at 12,500 rpm for 1 hour in GSA rotor. The resultant supernatant 15 was then centrifuged for 30 minutes at 40,000 x g in an SS-34 rotor. The final supernatant was then stored at -20°C, except for 50 ml.

Immobilized Nickel Affinity Chromatography of Solubilized Recombinant Hu-Asp2(a):

20 The following solutions were utilized:

A) 6M Guanidine HCl, 0.1M NaP, pH 8.0, 0.01M Tris, 5mM β ME, 0.5mM Imidazole

A') 6M Urea, 20mM NaP, pH 6.80, 50mM NaCl

25 B') 6M Urea, 20mM NaP, pH 6.20, 50mM NaCl, 12mM Imidazole

C') 6M Urea, 20mM NaP, pH 6.80, 50mM NaCl, 300mM Imidazole

Note: Buffers A' and C' were mixed at the appropriate ratios to give intermediate concentrations of Imidazole.

The 50ml of solubilized material was combined with 50ml of buffer A prior to adding 30 to 100-125ml Qiagen Ni-NTA SuperFlow (pre-equilibrated with buffer A) in a 5 x

10cm Bio-Rad econo column. This was shaken gently overnight at 4°C in the cold room.

Chromatography Steps:

- 5 Drained the resultant flow through.
 Washed with 50ml buffer A (collecting into flow through fraction)
 Washed with 250ml buffer A (wash 1)
 Washed with 250ml buffer A (wash 2)
 Washed with 250ml buffer A'
- 10 Washed with 250ml buffer B'
 Washed with 250ml buffer A'
 Eluted with 250ml 75mM Imidazole
 Eluted with 250ml 150mM Imidazole (150-1)
 Eluted with 250ml 150mM Imidazole (150-2)
- 15 Eluted with 250ml 300mM Imidazole (300-1)
 Eluted with 250ml 300mM Imidazole (300-2)
 Eluted with 250ml 300mM Imidazole (300-3)

Chromatography Results:

- 20 The Hu-Asp(a) eluted at 75mM Imidazole through 300mM Imidazole. The 75mM fraction, as well as the first 150mM Imidazole (150-1) fraction contained contaminating proteins as visualized on Coomassie Blue stained gels. Therefore, fractions 150-2 and 300-1 will be utilized for refolding experiments since they contained the greatest amount of protein as visualized on a Coomassie Blue stained gel.

Refolding Experiments of Recombinant Hu-Asp2(a):

Experiment 1:

- 30 Forty ml of 150-2 was spiked with 1M DTT, 3M Tris, pH 7.4 and DEA to a final concentration of 6mM, 50mM, and 0.1% respectively. This was diluted suddenly

(while stirring) with 200ml of (4°C) cold 20mM NaP, pH 6.8, 150mM NaCl. This dilution gave a final Urea concentration of 1M. This solution remained clear, even if allowed to set open to the air at room temperature (RT) or at 4°C.

5 After setting open to the air for 4-5 hours at 4°C, this solution was then dialyzed overnight against 20 mM NaP, pH 7.4, 150 mM NaCl, 20% glycerol. This method effectively removes the urea in the solution without precipitation of the protein.

Experiment 2:

Some of the 150-2 eluate was concentrated 2x on an Amicon Centriprep, 10,000 MWCO, then treated as in Experiment 1. This material also stayed in solution, with no visible precipitation.

Experiment 3:

89ml of the 150-2 eluate was spiked with 1M DTT, 3M Tris, pH 7.4 and DEA to a final concentration of 6mM, 50mM, and 0.1% respectively. This was diluted suddenly (while stirring) with 445 ml of (4°C) cold 20 mM NaP, pH 6.8, 150 mM NaCl. This solution appeared clear, with no apparent precipitation. The solution was removed to RT and stirred for 10 minutes prior to adding MEA to a final concentration of 0.1 mM. This was stirred slowly at RT for 1 hour. Cystamine and CuSO₄ were then added to final concentrations of 1 mM and 10 μM respectively. The solution was stirred slowly at RT for 10 minutes prior to being moved to the 4°C cold room and shaken slowly overnight, open to the air.

The following day, the solution (still clear, with no apparent precipitation) was centrifuged at 100,000 x g for 1 hour. Supernatants from multiple runs were pooled, and the bulk of the stabilized protein was dialyzed against 20mM NaP, pH 7.4, 150 mM NaCl, 20% glycerol. After dialysis, the material was stored at -20°C.

Some (about 10 ml) of the protein solution (still in 1M Urea) was saved back for biochemical analyses, and frozen at -20°C for storage.

Example 10**Expression of Hu-Asp2 and Derivatives in Insect Cells**

Any materials (vectors, host cells, etc.) and methods that are useful to express

Hu-Asp2(a) should in principle be equally effective for expression of Hu-Asp2(b).

5 *Expression by baculovirus infection.*

The coding sequence of Hu-Asp2(a) and Hu-Asp2(b) and several derivatives were engineered for expression in insect cells using the PCR. For the full-length sequence, a 5'-sense oligonucleotide primer that modified the translation initiation site to fit the Kozak consensus sequence was paired with a 3'-antisense primer that 10 contains the natural translation termination codon in the Hu-Asp2 sequence. PCR amplification of the pcDNA3.1(hygro)/Hu-Asp2(a) template was used to prepare two derivatives of Hu-Asp2(a) or Hu-Asp(b) that delete the C-terminal transmembrane domain (SEQ ID Nos. 29-30 and 50-51, respectively) or delete the transmembrane domain and introduce a hexa-histidine tag at the C-terminus (SEQ ID Nos. 31-32 and 15 52-53) respectively, were also engineered using PCR. The same 5'-sense oligonucleotide primer described above was paired with either a 3'-antisense primer that (1) introduced a translation termination codon after codon 453 (SEQ ID No. 3) or (2) incorporated a hexa-histidine tag followed by a translation termination codon in the PCR using pcDNA3.1(hygro)/Hu-Asp2(a) as the template. In all cases, the PCR reactions were performed amplified for 15 cycles using *Pwo*I DNA polymerase 20 (Boehringer-Mannheim) as outlined by the supplier. The reaction products were digested to completion with *Bam*H I and *Not*I and ligated to *Bam*H I and *Not*I digested baculovirus transfer vector pVL1393 (Invitrogen). A portion of the ligations was used to transform competent *E. coli* DH5₋ cells followed by antibiotic selection on 25 LB-Amp. Plasmid DNA was prepared by standard alkaline lysis and banding in CsCl to yield the baculovirus transfer vectors pVL1393/Asp2(a), pVL1393/Asp2(a)ΔTM and pVL1393/Asp2(a)ΔTM(His)₆. Creation of recombinant baculoviruses and infection of sf9 insect cells was performed using standard methods.

Expression by transfection

Transient and stable expression of Hu-Asp2(a)ΔTM and Hu-Asp2(a)ΔTM(His)₆ in High 5 insect cells was performed using the insect expression vector pIZ/V5-His. The DNA inserts from the expression plasmids vectors pVL1393/Asp2(a), pVL1393/Asp2(a)ΔTM and pVL1393/Asp2(a)ΔTM(His)₆ were excised by double digestion with *Bam*H I and *Not*I and subcloned into *Bam*H I and *Not*I digested pIZ/V5-His using standard methods. The resulting expression plasmids, referred to as pIZ/Hu-Asp2ΔTM and pIZ/Hu-Asp2ΔTM(His)₆, were prepared as described above.

For transfection, High 5 insect cells were cultured in High Five serum free medium supplemented with 10 µg/ml gentamycin at 27 °C in sealed flasks. Transfections were performed using High five cells, High five serum free media supplemented with 10 µg/ml gentamycin, and InsectinPlus liposomes (Invitrogen, Carlsbad, CA) using standard methods.

For large scale transient transfections, 1.2 x 10⁷ high five cells were plated in a 150 mm tissue culture dish and allowed to attach at room temperature for 15-30 minutes. During the attachment time the DNA/ liposome mixture was prepared by mixing 6 ml of serum free media, 60 µg Hu-Asp2(a)ΔTM/pIZ (+/- His) DNA and 120 µl of Insectin Plus and incubating at room temperature for 15 minutes. The plating media was removed from the dish of cells and replaced with the DNA/liposome mixture for 4 hours at room temperature with constant rocking at 2 rpm. An additional 6 ml of media was added to the dish prior to incubation for 4 days at 27 °C in a humid incubator. Four days post transfection the media was harvested, clarified by centrifugation at 500 x g, assayed for Hu-Asp2(a) expression by Western blotting. For stable expression, the cells were treated with 50 µg/ml Zeocin and the surviving pool used to prepared clonal cells by limiting dilution followed by analysis of the expression level as noted above.

Purification of Hu-Asp2(a)ΔTM and Hu-Asp2(a)ΔTM(His)₆

Removal of the transmembrane segment from Hu-Asp2(a) resulted in the secretion of the polypeptide into the culture medium. Following protein production

by either baculovirus infection or transfection, the conditioned medium was harvested, clarified by centrifugation, and dialyzed against Tris-HCl (pH 8.0). This material was then purified by successive chromatography by anion exchange (Tris-HCl, pH 8.0) followed by cation exchange chromatography (Acetate buffer at pH 4.5) using NaCl gradients. The elution profile was monitored by (1) Western blot analysis and (2) by activity assay using the peptide substrate described in Example 12. For the Hu-Asp2(a)ΔTM(His)₆, the conditioned medium was dialyzed against Tris buffer (pH 8.0) and purified by sequential chromatography on IMAC resin followed by anion exchange chromatography.

10 Amino-terminal sequence analysis of the purified Hu-Asp2(a)ΔTM(His)₆ protein revealed that the signal peptide had been cleaved [TQHGIRLPLR, corresponding to SEQ ID NO: 32, residues 22-3].

Example 11

Expression of Hu-Asp2(a) and Hu-Asp(b) in CHO cells

15 The materials (vectors, host cells, etc.) and methods described herein for expression of Hu-Asp2(a) are intended to be equally applicable for expression of Hu-Asp2(b).

Heterologous expression of Hu-Asp-2(a) in CHO-K1 cells

20 The entire coding sequence of Hu-Asp2(a) was cloned into the mammalian expression vector pcDNA3.1(+)Hygro (Invitrogen, Carlsbad, CA) which contains the CMV immediate early promoter and bGH polyadenylation signal to drive over expression. The expression plasmid, pcDNA3.1(+)Hygro/Hu-Asp2(a), was prepared by alkaline lysis and banding in CsCl and completely sequenced on both strands to verify the integrity of the coding sequence.

25 Wild-type Chinese hamster ovary cells (CHO-K1) were obtained from the ATCC. The cells were maintained in monolayer cultures in α-MEM containing 10% FCS at 37°C in 5% CO₂. Two 100 mm dishes of CHO-K1 cells (60% confluent) were transfected with pcDNA3.1(+)Hygro alone (mock) or
30 pcDNA3.1(+)Hygro/Hu-Asp2(a) or pcDNA3.1(+)Hygro/Hu-Asp2(b) using the

cationic liposome DOTAP as recommended by the supplier (Roche, Indianapolis, IN).

The cells were treated with the plasmid DNA/liposome mixtures for 15 hours and then the medium replaced with growth medium containing 500 Units/ml hygromycin

B. In the case of pcDNA3.1(+)Hygro/Hu-Asp2(a) or (b) transfected CHO-K1 cells,

5 individual hygromycin B-resistant cells were cloned by limiting dilution. Following clonal expansion of the individual cell lines, expression of Hu-Asp2(a) or Hu-Asp2(b) protein was assessed by Western blot analysis using a polyclonal rabbit antiserum raised against recombinant Hu-Asp2 prepared by expression in *E. coli*. Near

confluent dishes of each cell line were harvested by scraping into PBS and the cells

10 recovered by centrifugation. The cell pellets were resuspended in cold lysis buffer (25 mM Tris-HCl (pH 8.0)/5 mM EDTA) containing protease inhibitors and the cells lysed by sonication. The soluble and membrane fractions were separated by centrifugation (105,000 x g, 60 min) and normalized amounts of protein from each fraction were then separated by SDS-PAGE. Following electrotransfer of the

15 separated polypeptides to PVDF membranes, Hu-Asp-2(a) or Hu-Asp2(b) protein was detected using rabbit anti-Hu-Asp2 antiserum (1/1000 dilution) and the antibody-antigen complexes were visualized using alkaline phosphatase conjugated goat anti-rabbit antibodies (1/2500). A specific immunoreactive protein with an apparent Mr value of 65 kDa was detected in pcDNA3.1(+)Hygro/Hu-Asp2

20 transfected cells and not mock-transfected cells. Also, the Hu-Asp2 polypeptide was only detected in the membrane fraction, consistent with the presence of a signal peptide and single transmembrane domain in the predicted sequence. Based on this analysis, clone #5 had the highest expression level of Hu-Asp2(a) protein and this production cell lines was scaled up to provide material for purification.

25 *Purification of recombinant Hu-Asp-2(a) from CHO-K1/Hu-Asp2 clone #5*

In a typical purification, clone #5 cell pellets derived from 20 150 mm dishes of confluent cells, were used as the starting material. The cell pellets were resuspended in 50 ml cold lysis buffer as described above. The cells were lysed by polytron homogenization (2 x 20 sec) and the lysate centrifuged at 338,000 x g for 20 minutes. The membrane pellet was then resuspended in 20 ml of cold lysis buffer

containing 50 mM β -octylglucoside followed by rocking at 4 °C for 1 hour. The detergent extract was clarified by centrifugation at 338,000 x g for 20 minutes and the supernatant taken for further analysis.

The β -octylglucoside extract was applied to a Mono Q anion exchange 5 column that was previously equilibrated with 25 mM Tris-HCl (pH 8.0)/50 mM β -octylglucoside. Following sample application, the column was eluted with a linear gradient of increasing NaCl concentration (0-1.0 M over 30 minutes) and individual fractions assayed by Western blot analysis and for β -secretase activity (see below). Fractions containing both Hu-Asp-2(a) immunoreactivity and β -secretase activity 10 were pooled and dialyzed against 25 mM NaOAc (pH 4.5)/50 mM β -octylglucoside. Following dialysis, precipitated material was removed by centrifugation and the soluble material chromatographed on a MonoS cation exchange column that was previously equilibrated in 25 mM NaOAc (pH 4.5)/ 50 mM β -octylglucoside. The 15 column was eluted using a linear gradient of increasing NaCl concentration (0-1.0 M over 30 minutes) and individual fractions assayed by Western blot analysis and for β -secretase activity. Fractions containing both Hu-Asp2 immunoreactivity and β -secretase activity were combined and determined to be >95% pure by SDS-PAGE/Coomassie Blue staining.

The same methods were used to express and purify Hu-Asp2(b).

20

Example 12

Assay of Hu-Asp2 β -secretase activity using peptide substrates

β -secretase assay

Recombinant human Asp2(a) prepared in CHO cells and purified as described 25 in Example 11 was used to assay Asp2(a) proteolytic activity directly. Activity assays for Asp2(a) were performed using synthetic peptide substrates containing either the wild-type APP β -secretase site (SEVKM!DAEFR), the Swedish KM-NL mutation (SEVNL!DAEFR), or the A β 40 and 42 γ -secretase sites (RRGGVV!IA!TVIVGER). Reactions were performed in 50 mM 2-[N-morpholino]ethane-sulfonate ("Na-MES," 30 pH 5.5) containing 1% β -octylglucoside, 70 mM peptide substrate, and recombinant

Asp2(a) (1-5 µg protein) for various times at 37°C. The reaction products were quantified by RP-HPLC using a linear gradient from 0-70 B over 30 minutes (A=0.1% TFA in water, B=0.1%TFA/10%water/90%AcCN). The elution profile was monitored by absorbance at 214 nm. In preliminary experiments, the two product peaks which eluted before the intact peptide substrate, were confirmed to have the sequence DAEFR and SEVNL using both Edman sequencing and MADLI-TOF mass spectrometry. Percent hydrolysis of the peptide substrate was calculated by comparing the integrated peak areas for the two product peptides and the starting material derived from the absorbance at 214 nm. The sequence of cleavage/hydrolysis products was confirmed using Edman sequencing and MADLI-TOF mass spectrometry.

The behavior of purified Asp2(a) in the proteolysis assays was consistent with the prior anti-sense studies which indicated that Asp2(a) possesses β-secretase activity. Maximal proteolysis was seen with the Swedish β-secretase peptide, which, after 6 hours, was about 10-fold higher than wild type APP.

The specificity of the protease cleavage reaction was determined by performing the β-secretase assay in the presence of 8 µM pepstatin A and the presence of a cocktail of protease inhibitors (10 µM leupeptin, 10 µM E64, and 5 mM EDTA). Proteolytic activity was insensitive to both the pepstatin and the cocktail, which are inhibitors of cathepsin D (and other aspartyl proteases), serine proteases, cysteinyl proteases, and metalloproteases, respectively.

Hu-Asp2(b) when similarly expressed in CHO cells and purified using identical conditions for extraction with β-octylglucoside and sequential chromatography over Mono Q and Mono S also cleaves the Swedish β-secretase peptide in proteolysis assays using identical assay conditions.

Collectively, this data establishes that both forms of Asp2 (Hu-Asp2(a) and Hu-Asp2(b)) act directly in cell-free assays to cleave synthetic APP peptides at the β-secretase site, and that the rate of cleavage is greatly increased by the Swedish KM-NL mutation that is associated with Alzheimer's disease.

An alternative β -secretase assay utilizes internally quenched fluorescent substrates to monitor enzyme activity using fluorescence spectroscopy in a single sample or multiwell format. Each reaction contained 50 mM Na-MES (pH 5.5), peptide substrate MCA-EVKMDAEF[K-DNP] (BioSource International) (50 μ M) and purified Hu-Asp-2 enzyme. These components were equilibrated to 37 °C for various times and the reaction initiated by addition of substrate. Excitation was performed at 330 nm and the reaction kinetics were monitored by measuring the fluorescence emission at 390 nm. To detect compounds that modulate Hu-Asp-2 activity, the test compounds were added during the preincubation phase of the reaction and the kinetics of the reaction monitored as described above. Activators are scored as compounds that increase the rate of appearance of fluorescence while inhibitors decrease the rate of appearance of fluorescence.

Example 13

15 **Demonstration that Asp1 processes APP at the α -secretase site**

Increased expression of an α -secretase candidate gene in human cells would be expected to increase basal release of sAPP α and to decrease release of A β peptides. This effect was observed when full length human Asp1 is co-expressed with APP in HEK293 cells. The experiment utilized the APP 695 amino acid isoform which had been modified by the addition of a pair of lysine residues to the C-terminus (APP-KK). The C-terminal di-lysine motif increases the intracellular half-life of glycosylated APP and consequently the production of both sAPP α and A β . As shown in Table 5, cotransfection of HEK293 cells with APP-KK with Asp1 increased the production of sAPP α by 3.5 fold ($p<0.001$) and decreased the production of A β 40 by 2.8 fold. Thus, Asp1 acts directly or indirectly to facilitate constitutive α -secretase cleavage and this effect is competitive with the amyloidogenic processing of APP to A β peptides. This implies that mutations or genetic polymorphisms in Asp1 may affect A β production by affecting the balance between the competing pathways for constitutive α -secretase cleavage and A β peptide production.

Table 5.**Asp1 stimulates basal release of sAPP α from HEK293 cells after cotransfection with APP-KK.**

5	Transfection	sAPP α µg/ml	Fold Increase	A β 40 pg/ml	Fold Decrease
	Asp1	3.5 + 1.1	+3.5	113 + 7	-2.8
	pcDNA	1.0 + 0.2		321 + 18	

Specific methods used were as follows. The full length Asp1 cDNA was cloned into the vector pcDNA3.1/hygro+(Invitrogen) for transfection studies as previously described (Yan *et al.*, (1999) *Nature* 402: 533-537). The APP-KK cDNA was cloned into the vector pIRES (Clontech) also as previously described. HEK293 cells were transfected with expression constructs using the Lipofectamine Plus reagent from Gibco/BRL. Cells were seeded in 24 well tissue culture plates to a density of 10 70-80% confluence. Four wells per plate were transfected with 2 µg DNA (3:1, APP:Asp1 or empty pcDNA3.1./hygro+ vector), 8µl Plus reagent, and 4µl Lipofectamine in OptiMEM. OptiMEM was added to a total volume of 1 ml, distributed 200 µl per well and incubated 3 hours. Care was taken to hold constant the ratios of the two plasmids used for cotransfection as well as the total amount of DNA 15 used in the transfection. The transfection media was replaced with DMEM supplemented with 10% FBS and NaPyruvate, with antibiotic/antimycotic and the cells were incubated under normal conditions (37°, 5% CO₂) for 48 hours. The conditioned media were removed to polypropylene tubes and stored at -80°C until assayed for the content of sAPP α or A β 40/A β 42 by enzyme-linked immunosorbent 20 assay (EIA) as described above in Example 6. The A β EIA followed the protocol of Pirttila *et al.* (*Neuro. Lett.* (1999) 249: 21-4) using the 6E10 monoclonal antibody (Senetek) as a capture antibody and biotinylated rabbit antiserum 162 or 165 (New York State Institute for Basic Research, Staten Island, NY) for detection of A β 40 and A β 42, respectively. The 6E10 antibody recognizes residues 1-16 of the A β peptide. 25 The sAPP α EIA used LN27 antibody as a capture antibody and biotinylated 6E10 for 30

detection as described previously (Yan *et al.*, (1999) *supra*). The LN27 antibody recognized the first 20 amino acids of the human APP peptide.

Increased α -secretase activity and concomitant reduction of A β production *in vivo* represents an effect that may be desirable for the prevention, treatment (e.g., to show the progression of), or cure of Alzheimer's disease. Thus, the activities demonstrated in this example provide an indication that modulators of Asp1 activity, that achieve the same effects *in vivo*, will have utility for Alzheimer's disease therapy. Screening methods for such modulators are contemplated as an aspect of the invention.

10

Example 14

Expression of Pre-pro-Hu-Asp1 and Derivatives in Insect Cells

Expression of hu-Asp-1TM(His)₆ by baculovirus infection.

The coding sequence of pre-pro-Hu-Asp1 was engineered for production as a soluble, secreted form by insect cells. PCR primers were designed to (1) delete the predicted transmembrane domain and cytoplasmic tail of Asp1 and (2) to introduce a Kozak consensus sequence for efficient translational initiation. The primers sequences were follows: sense CGCTTTAAGCTTGCACCATGGCGCA CTGGCCCCGGCG (SEQ ID NO: 74) and antisense CGCTTCTCGAGCTAA 15 TGGTGATGGTGATGGTGCCACAAAATGGGCTCGCTCAAAGA (SEQ ID NO: 75) which replaced the deleted C-terminal transmembrane and cytoplasmic domains 20 with a hexahistidine purification tag.

PCR reactions were carried out with 100 ng of full length Asp1 pcDNA 3.1 hygro+ construct, 200 M NTPs, 300 nM of each primer, 1x reaction buffer containing 25 2 mM MgSO₄, and 5 units of Pwo I DNA polymerase (Roche Biochemicals). The reactions were cycled under the following conditions: 94°C for 5 minutes followed by 15 cycles of 94°C for 30 seconds and 72°C for 30 seconds, and then a final extension reaction at 72°C for 10 minutes. The predicted amino acid sequence of this PCR generated derivative (denoted as Asp-1 Δ TM(His)₆) is set out as SEQ ID NO: 66.

The reaction product was digested to completion with HindIII-Xhol and ligated into the expression vector pIB (Invitrogen) to yield the pIB/Asp-1 Δ TM(His)₆ construct. Creation of recombinant baculovirus and infection of sf9 insect cells was performed using standard methods known in the art. Sf9 cells were transfected with either the pIB vector alone or the pIB/Asp-1 Δ TM(His)₆ construct utilizing Insectin Plus reagent (Invitrogen) according to the manufacturer's instructions. After the transfection, the cells were cultured in High Five serum-free media (Invitrogen) for 3 days. Subsequently, the conditioned medium was harvested and subjected to Western blot analysis. This analysis revealed specific expression and secretion of immunoreactive Asp-1 Δ TM(His)₆ polypeptide into the extracellular medium. The secreted proteins were detected on the Western blot with either the India probe (Pierce Chemicals) specific for the hexahistidine sequence tag or using a rabbit polyclonal antiserum. The polyclonal antisera (denoted as UP-199) was generated by injecting rabbits with recombinant Asp-1 Δ TM(His)₆ (SEQ ID NO: 66). This recombinant peptide was prepared by heterologous expression in *E.coli*. The UP-199 antibody recognizes the processed form of Asp-1 Δ TM.

Direct analysis with the polyclonal antiserum (UP-199) revealed an immunoreactive band of the expected molecular weight (50 kDa) only in pIB/Asp-1 Δ TM(His)₆ transfected cells. This signal was significantly enhanced in concentrated conditioned medium. A similar pattern was obtained using the India probe. No signal was detected in conditioned medium derived from mock-transfected cells using either UP-199 antisera or the India probe.

Based on this result, transient and stable transfections of the pIB/Asp-1 Δ TM(His)₆ construct in sf9 insect cells were carried out as described above. Four days post transient transfection, the culture medium was collected to provide material for further characterization. In parallel, sf9 cells were stably transfected with the pIB/Asp-1 Δ TM(His)₆ construct and cultured in High Five serum-free medium (Invitrogen) supplemented with 50 µg/ml blasticidin for approximately 2 weeks. After blasticidin selection, the resistant pool of cells was expanded to provide a stable source of conditioned medium for Asp-1 Δ TM(His)₆ purification.

Purification of recombinant Asp-1ΔTM(His)₆

Conditioned media, from either transient or stably transfected sf9 cells, were
5 concentrated approximately 10-fold using a stirred cell concentrator equipped with a
30,000 MWCO membrane (Spectrum Medical Industries). This concentrate was then
subjected to ammonium sulfate precipitation to further concentrate the sample and
provide partial purification. Material precipitating between 0-40% saturation was
discarded and the resulting supernatant was brought to 80% saturation. Western blot
10 analysis of the various ammonium sulfate precipitated fractions revealed that the
majority of the immunoreactive material was contained within the 40-80%
ammonium sulfate pellet. As a result, this material was subjected to further
purification.

The 40-80% ammonium sulfate pellet was redisolved in approximately 1/20
15 the original volume of Ni+-NTA loading buffer (25 mM Tris-HCl (pH 8.5)/0.5 M
NaCl/10 mM imidazole). Subsequently, the sample was applied to a Ni+-NTA
column previously equilibrated in Ni+-NTA buffer. Following sample application,
the column was washed with starting buffer (25 mM Tris-HCl (ph 8.5)/ 0.5 M NaCl/
20 mM imidazole) until the A^{280nm} of the column effluent returned to zero. After
20 washing, the bound recombinant protein was eluted off the column with a linear
gradient of Ni+-NTA buffer containing increasing concentrations (10 mM, 50 mM,
100 mM, 250 mM, and 500 mM) of imidazole. The elution profile was monitored by
Western blot analysis using the UP-199 antiserum. Immunoreactive Asp-1ΔTM(His)₆
was detected in the column load and eluted at 50 mM imidazole. NuPAGE gel
25 analysis of the 50 mM imidazole fraction demonstrated a purity of Asp-1ΔTM(His)₆
of approximately 50%, therefore further purification was required.

The positive fractions, eluted off the Ni+-NTA column, were then pooled
(denoted as post-IMAC pool), concentrated using a YM30 membrane (Amicon), and
dialyzed with 25 mM Tris-HCl (pH 8.0). The dialyzed post-IMAC pool was
30 fractionated by MonoQ anion exchange chromatography (Amersham-Pharmacia

Biotech) gradient elution containing increasing concentrations (0 -0.5 M) of NaCl (Buffer A: 25 mM Tris-HCl (pH 8.0) and Buffer B: 25 mM Tris-HCl (pH 8.0)/ 0.5 M NaCl). The elution profile was determined by Western blot analysis which indicated immunoreactive fractions as those displaying immunoreactivity with the UP-199 antisera. NuPAGE gel analysis with silver staining demonstrated that the material prepared in this manner was >90% pure. The immunoactive fractions eluted off the MonoQ anion exchange column were pooled, dialyzed with 25 mM HEPES-Na⁺ (pH 8.0), and stored at 4°C until further analysis.

10 *Acid-activation of recombinant Asp-1 TM(His)₆*

Recombinant Asp-1ΔTM(His)₆ migrated with an apparent molecular weight of 50 kD. Direct N-terminal sequence analysis carried out by automated Edman degradation for 20 cycles revealed a unique sequence beginning at Glu³ (SEQ ID NO: 67), confirming the identity of the recombinant protein. Computer assisted prediction of the signal peptidase cleavage site indicated that the pro-form should initiate at Ala¹, suggesting either an unusual processing site by the signal peptidase during secretion or an additional processing step that removes an additional two amino acid residues.

15 To investigate the mechanism of pro-Asp-1ΔTM(His)₆ activation, aliquots of the purified protein were incubated in various acidic environments with pH values ranging from 3.0-8.0 at 37°C for 2 hours. Subsequently, the recombinant proteins were analyzed by Western blot. A faster migrating polypeptide species was detected after incubation at pH values of 4.0, 4.5 and 5.0. The polypeptide migration was unaltered after incubation in environments which were either more acidic (pH 3.0 and 3.5) or more basic (pH 6.0, 7.0, and 8.0). Sequence analysis of this faster migrating species revealed that it initiated exclusively at Ala⁴³, consistent with removal of a 42 amino acid residue segment of the pro-peptide that was induced by treatment of the pro-enzyme at pH 4.5. The predicted amino acid sequence of the acid processed form of Asp-1ΔTM(His)₆ is set out as SEQ ID NO: 68.

20 To purify the acid-activated form of Asp-1ΔTM(His)₆, the Asp-1ΔTM(His)₆ post-IMAC pool (generated as described above) was dialyzed to pH 4.5 and then

subjected to affinity chromatography on either pepstatin A agarose or sulfolink-PHA-292593E. Following sample application, the column was washed with 25 mM NaOAc (pH 4.5) and eluted with 50 mM Na-BO₃ (pH 9.5). The positive fractions eluted off the columns were dialyzed with 25 mM Hepes-Na (pH 7.5) 5 overnight at 4°C which resulted in quantitative conversion of the pro-enzyme to the acid-processed form (SEQ ID NO: 68) described above. Western blot analysis of the elution profile revealed quantitative retention of immunoreactive Asp-1ΔTM(His)₆ on both affinity resins as evidenced by the lack of Asp-1ΔTM(His)₆ in the unbound fraction as detected by UP-199 immunoreactivity on a Western blot. Step elution 10 50 mM NaBO₃ at pH 9.5 resulted in elution of immunoreactive Asp-1 TM(His)₆, with variable recovery.

Comparison of the properties of the recombinant soluble catalytic domain of Asp1 with the properties determined for Asp2 (see Example 10) revealed a number of significant differences. Processing of the pre-pro forms of either enzyme is distinct, 15 with Asp1 undergoing efficient processing by the signal peptidase and additional processing to remove two additional amino acid residues from the N-terminus. Further processing of the pro-form of Asp1 was not detected in neutral pH. In contrast, recombinant Asp2 produced, under similar conditions, yields an eqimolar mixture of the pro-form and a processed form that has 24 amino acid residues of the 20 pro-segment removed.

Another distinction between the processing of these two enzymes involves processing initiated by acid-treatment. Systematic analysis of acid-induced processing of pro-Asp2 revealed that the purified polypeptide did not self-process. In contrast, acid dependent processing of pro-Asp1 was readily demonstrated (as described above). Alignment of the self-processing site in Asp1 with the processing site in Asp2 revealed that these two enzymes are processed at the same position, which is a different method of processing as compared with that of other known human aspartyl proteases.

In addition to providing valuable information about Asp1 activity, the 30 discovery of a site of apparent autocatalytic processing of Asp1 provides an indication

of a peptide sequences (surrounding Ala⁴³) that could be useful for performing screening assays to identify modulators of Asp1 activity. This idea is explored in greater detail in Example 15.

5

Example 15

Development of an enzymatic assay for Asp-1ΔTM(His)₆

The relationship between Asp1 and APP processing was explored by determining if APP α-secretase, APP β-secretase, or APP γ-secretase peptide substrates were cleaved by recombinant Asp-1ΔTM(His)₆. These peptide substrates included the α-secretase specific substrates Aβ₁₀₋₂₀ and Aβ₁₂₋₂₈, the β-secretase specific substrates PHA-95812E (SEVKM^{DAEFR}; SEQ ID NO: 64) and PHA-247574E (SEVNLD^{DAEFR}; SEQ ID NO: 63), and γ-secretase specific substrate PHA-179111E (RRGGVV^{IATVIVGER}; SEQ ID NO: 76). Each reaction consisted of incubating a peptide substrate (100 nM) with recombinant Asp-1ΔTM(His)₆ for 15 hours at pH 4.5 at 37°C. Reaction products were quantified by RP-HPLC at A^{214 nm}. The elution profiles for Asp-1ΔTM(His)₆ were compared to those obtained from parallel Asp1 experiments. The identity of the cleavage products was determined by MADLI-TOF mass spectrometry. Table 6 summarizes the Asp1 substrates and indicates the cleavage site.

20

Table 6
Substrate Preferences of Asp-1ΔTM

	<u>P4</u>	<u>P3</u>	<u>P2</u>	<u>P1</u>	<u>P1'</u>	<u>P2'</u>	<u>P3'</u>	<u>P4'</u>		SEQ ID NO:
	G	L	A	L	A	L	E	P	Self Activation	69
	E	V	K	M	D	A	E	F	β-Secretase, WT	70
25	E	V	N	L	D	A	E	F	β-Secretase, Sw	71
	L	V	F	F	A	E	D	V	Aβ ₁₂₋₂₈ (α-Secretase)	72
	K	L	V	F	F	A	E	D	Aβ ₁₂₋₂₈ (α-Secretase)	73

The peptides in Table 6 are described using the nomenclature by Schechter and Berger (*Biochem. Biophys. Res. Commun.* 27:157(1967) and *Biochem. Biophys. Res. Commun.* 32:898 (1968)), in which the amino acid residues in the peptide substrate that undergo the cleavage are defined as P₁ . . . P_n toward the N-terminus and P_{1'} . . . P_{n'} toward the C-terminus. Therefore, the scissile bond is between the P₁ and the P_{1'} residue of the peptide subunits and is denoted herein throughout with a hyphen between the P₁ and the P_{1'}.

Digestion of the α -secreatse substrate (A₁₂₋₂₈) revealed two Asp1 cleavage sites. The major product was cleaved at Phe²⁰,Ala²¹ and the minor product was cleaved at Phe¹⁹,Phe²⁰ (referring to the numbering convention in the APP A β) peptide. Analysis of the cleavage products obtained from the β -secretase peptide substrates revealed that both the wild-type (PHA-95812E) and the Swedish mutation (PHA-247574E) substrates were hydrolyzed exclusively at the β -secretase site. Also, the relative rates of Asp-1-dependent hydrolysis of the β -secretase peptide substrate containing the Swedish mutation was cleaved at least 10-times faster than the corresponding wild-type peptide. Conversion of the γ -secretase peptide substrate was not detected under these reaction conditions.

Measurement of the cleavage of the α -secretase and β -secretase substrates can also be carried out with substrates comprising detectable labels such as radioactive, enzymati , chemiluminescent or florescent labels. For example, the peptide substrates could comprise internally quenched labels that result in increased detectability after cleavage of the peptide substrates due to separation of the labels upon cleavage. The peptide substrates can be modified to have attached a paired fluorprobe and quencher such as 7-amino-4-methyl courarin and dinitrophenol, respectively.

This example illustrates the α -secretase and β -secretase activity exhibited by Asp-1, confirming the APP processing activity of Asp1 indicating, e.g., in Examples 7 and 13. The substrates described herein may be used in combination with recombinant Asp1 to measure Asp1 proteolytic activity at the α -secretase and β -secretase

processing sites. These substrates are useful in screening assays for identification of modulators of Asp1 proteolytic activity.

In particular, production of A β species through the processing of APP at β -and γ -secretase sites may play a central role in Alzheimer's disease pathogenesis, and 5 processing at the α -secretase site may have a protective role and may prevent A β production. Thus, a therapeutic and/or prophylactic indication exists for molecules that can increase Asp1 α -secretase activity and/or decrease Asp1 β -secretase activity *in vivo*. The present invention includes screening assays for such modulators, and the foregoing substrate peptides are useful in such assays.

10 It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples.

Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the invention. The entire disclosure of all publications cited herein are hereby incorporated by reference.

15

What is claimed is:

1. A method for assaying hu-Asp1 α -secretase activity comprising the steps of:
 - 5 (a) contacting hu-Asp1 protein with an amyloid precursor protein (APP) substrate, wherein said substrate contains an α -secretase cleavage site; and
 - (b) measuring cleavage of the APP substrate at the α -cleavage site, thereby assaying hu-Asp1 α -secretase activity.
- 10 2. A method according to claim 1, wherein the hu-Asp1 protein comprises a polypeptide produced in cell transformed or transfected with a polynucleotide comprising a nucleotide sequence that encodes hu-Asp1 or a fragment thereof that retains Asp1 α -secretase activity.
- 15 3. A method of claim 2, wherein the hu-Asp1 protein is purified and isolated from said cell.
4. A method according to claims 2 or 3, wherein the nucleotide sequence encodes a polypeptide that comprises the hu-Asp1 amino acid sequence set forth in
20 SEQ ID NO: 2 or a fragment thereof, wherein said fragment retains α -secretase activity.
- 25 5. A method according to any one of claims 2-4, wherein the polynucleotide sequence encodes a hu-Asp1 amino acid sequence lacking the transmembrane amino acids 469-492 of SEQ ID NO: 2.
6. A method according to claim 5, wherein the polynucleotide sequence encodes a hu-Asp1 amino acid sequence further lacking the cytoplasmic domain amino acids 493-518 of SEQ ID NO: 2.

7. A method according to any one of claims 1-6, wherein the hu-Asp1 amino acid sequence lacks amino terminal amino acids 1-62 of SEQ ID NO: 2.

8. A method according to claims 1 or 2, wherein the contacting step
5 comprises growing a cell transfected or transformed with a polynucleotide encoding hu-Asp1 protein or a fragment thereof that retains hu-Asp1 α -secretase activity, wherein the cell is grown under conditions in which the cell expresses the hu-Asp1 protein in the presence of the APP substrate.

10 9. A method of claim 8, wherein said cell expresses a polynucleotide encoding an APP substrate containing an α -secretase cleavage site, and wherein the contacting step comprises growing the cell under conditions in which the cell expresses the hu-Asp1 protein and the APP substrate.

15 10. A method of any one of claims 1-9, wherein the APP substrate α -secretase cleavage site comprises the amino acid sequence LVFFAEDF or KLVFFAED.

11. A method of any one of claims 1-10, wherein the APP substrate
20 comprises a human APP isoform and further comprises a carboxy-terminal di-lysine.

12. A method of claims 10 or 11, wherein the APP substrate comprises a detectable label.

25 13. A method of claim 12, wherein the detectable label is selected from the group consisting of radioactive labels, chemiluminescent labels, enzymatic labels, chemiluminescent labels and fluorescent labels.

14. A method of any one of claims 1-13, wherein the APP substrate comprises a human APP isoform and the determining step comprises measuring the production of amyloid alpha peptide (sAPP α).

5 15. A method of any one of claims 1-14, wherein the method further comprises the steps of:

- (a) determining the level of hu-Asp1 α -secretase activity in the presence and absence of a modulator of hu-Asp1 α -secretase activity; and
- (b) comparing the hu-Asp1 α -secretase activity in the presence and 10 absence of the modulator, wherein modulators that increase hu-Asp1 α -secretase activity are identified as candidate Alzheimer's disease therapeutics.

16. A method of claim 15, wherein the method further comprises a step of treating Alzheimer's disease with said candidate Alzheimer's disease therapeutic.

15

17. A composition comprising a candidate Alzheimer's disease therapeutic identified by the method of claim 15.

20

18. A hu-Asp1 protease substrate peptide or fragment thereof, wherein said peptide comprises an amino acid sequence consisting of fifty or fewer amino acids, said amino acid sequence including the hu-Asp1 cleavage site having the amino acid sequence GLALALEP

25

19. The substrate of claim 18, wherein the substrate comprises a detectable label.

20. The substrate of claim 19, wherein the detectable label is selected from the group consisting of radioactive labels, enzymatic labels, chemiluminescent labels and fluorescent labels.

30

21. A method for assaying hu-Asp1 proteolytic activity comprising the steps of:

- (a) contacting hu-Asp1 protein with an hu-Asp1 substrate according to claim 18, 19, or 20 under acidic conditions, and
5 (b) determining the level of hu-Asp1 proteolytic activity.

22. A method according to claim 20, wherein the hu-Asp1 protein comprises a polypeptide produced in cell transformed or transfected with a polynucleotide comprising the nucleotide sequence that encodes hu-Asp1.

10

23. A method of claim 21, wherein the hu-Asp1 protein is purified and isolated from said cell.

15

24. A method according to claims 22 and 23, wherein the nucleotide sequence encodes a polypeptide that comprises the hu-Asp1 amino acid sequence set forth in SEQ ID NO: 2 or a fragment thereof, wherein said fragment retains proteolytic activity.

20

25. A purified polynucleotide comprising a nucleotide sequence encoding a polypeptide that comprises a fragment of a hu-Asp1 protein, wherein said nucleotide sequence lacks the sequence that encodes the transmembrane domain of said hu-Asp1 protein, and wherein the hu-Asp1 polypeptide fragment encoded by said polynucleotide has hu-Asp1 α -secretase activity.

25

26. A polynucleotide of claim 25, wherein the polypeptide comprises a fragment of the hu-Asp1 amino acid sequence set forth in SEQ ID NO: 2, and wherein the polypeptide lacks the transmembrane domain amino acids 469-492 of SEQ ID NO: 2.

27. A polynucleotide of claim 26 wherein the polypeptide further lacks cytoplasmic domain amino acids 493-518 of SEQ ID NO: 2.
28. A purified polynucleotide comprising a nucleotide sequence encoding a polypeptide that comprises a fragment of a hu-Asp1 protein, wherein said nucleotide sequence lacks the sequence that encodes amino acids 1-62 of SEQ ID NO: 2, and wherein the polypeptide has hu-Asp1 α -secretase activity.
29. A polypeptide of claim 28, wherein said polypeptide lacks amino terminal amino acids 23-62 of SEQ ID NO: 2.
30. A purified polynucleotide comprising a nucleotide sequence that hybridizes under stringent conditions to the non-coding strand complementary to SEQ ID NO: 1, wherein the nucleotide sequence encodes a polypeptide having Asp1 proteolytic activity and wherein the polynucleotide lacks nucleotides encoding a transmembrane domain.
31. A purified polynucleotide comprising a nucleotide sequence that hybridizes under stringent conditions to the nucleic acid according to claim 30, wherein the nucleotide sequence encodes a polypeptide further lacking a pro-peptide domain corresponding to amino acids 23-62 of SEQ ID NO: 2.
32. A vector comprising the polynucleotide of any one of claims 25-31.
- 25 33. A host cell transformed or transfected with a vector of claim 32.
34. A host cell transformed or transfected with a polynucleotide of any one of claims 25-31.

35. A purified polypeptide comprising a fragment of a hu-Asp1 protein, wherein said polypeptide lacks the hu-Asp1 transmembrane domain of said hu-Asp1 protein and retains hu-Asp1 α -secretase activity.

5 36. A polypeptide of claim 35, wherein said polypeptide comprises a fragment of hu-Asp1 having the amino acid sequence set forth in SEQ ID NO: 2 and wherein said polypeptide lacks the transmembrane domain amino acids 469-492 of SEQ ID NO: 2.

10 37. A polypeptide according to claim 35 or 36, wherein said polypeptide further lacks cytoplasmic domain amino acids 493-518 of SEQ ID NO: 2.

38. A polypeptide according to any one of claims 35-37, which further lacks amino terminal amino acids 1-62 of SEQ ID NO: 2.

15 39. A polypeptide comprising a fragment of hu-Asp1 having the amino acid sequence set forth in SEQ ID NO: 2 and wherein said polypeptide lacks the amino terminal amino acids 1-62 of SEQ ID NO: 2 and retains APP processing activity.

20 40. A polypeptide comprising an amino acid sequence at least 95% identical to a fragment of hu-Asp1 protein, wherein said polypeptide and said fragment lack a transmembrane domain and retain hu-Asp1 α -secretase activity.

25 41. A polypeptide comprising an amino acid sequence at least 95% identical to a fragment of hu-Asp1 protein, wherein said polypeptide and said fragment lack the amino terminal amino acids corresponding to the pro-peptide domain of hu-Asp1 and retain APP processing activity.

FIGURE 1 (1)

ATGGGCGCACTGGCCGGGCGCTGCTGCTCTGCTGGCCCAGTGGCTCTGCGCGCC
 M G A L A R A L L L P L L A Q W L L R A

 CCCCGGAGCTGGCCCCCGGCCCTCACGCTGCCCTCCGGTGGCGCGGCCACGAAC
 A P E L A P A P F T L P L R V A A A T N

 CGCGTAGTTGCGCCCACCCCGGGACCCGGGACCCCTGCCAGCGCACGCCACGGCTTG
 R V V A P T P G P G T P A E R H A D G L

 GCGCTGCCCTGGAGCCTGCCCTGGCTCCCCGCGGGCGCCAACTTCTGGCCATG
 A L A L E P A L A S P A G A A N F L A M

 GTAGACAACCTGCAGGGGACTCTGGCCGGCTACTACCTGGAGATGCTGATCGGACC
 V D N L Q G D S G R G Y Y L E M L I G T

 CCCCCGAGAAGCTACAGATTCTCGTTGACACTGGAAGCAGTAACCTTGCCGTGGCAGGA
 P P Q K L Q I L V D T G S S N F A V A G

 ACCCCGCACTCCTACATAGACACGTACTTGACACAGAGAGGTCTAGCACATAACCGCTCC
 T P H S Y I D T Y F D T E R S S T Y R S

 AAGGGCTTGACGTACAGTGAAGTACACACAAGGAAGCTGGACGGCTTCGTTGGGAA
 K G F D V T V K Y T Q G S W T G F V G E

 GACCTCGTCACCATCCCCAAAGGCTTCAATACTCTTTCTGTCAACATTGCCACTATT
 D L V T I P K G F N T S F L V N I A T I

 TTGAAATCAGAGAATTCTTTTGCCCTGGGATTAATGGAATGGAATACTTGGCCTAGCT
 F E S E N F F L P G I K W N G I L G L A

 TATGCCACACTTGCCAAGCCATCAAGTTCTGGAGACCTTCTCGACTCCCTGGTGACA
 Y A T L A K P S S S L E T F F D S L V T

 CAAGCAAACATCCCCAACGTTTCTCCATGCAGATGTGGAGCCGGCTTGGCCGTGCT
 Q A N I P N V F S M Q M C G A G L P V A

 GGATCTGGGACCAACGGAGGTAGCTTGTCTGGTGGAAATTGAACCAAGTTGTATAAA
 G S G T N G G S L V L G G I E P S L Y K

 GGAGACATCTGGTATACCCCTATTAAGGAAGAGTGGTACTACCAGATAGAAATTCTGAAA
 G D I W Y T P I K E E W Y Y Q I E I L K

 TTGGAAATTGGAGGCCAAAGCTTAATCTGGACTGCAGAGAGTATAACGCAGACAAGGCC
 L E I G G Q S L N L D C R E Y N A D K A

 ATCGTGGACAGTGGCACCCACGCTGCTGCCCTGCCAGAAGGTGTTGATGCCGTGGTG
 I V D S G T T L L R L P Q K V F D A V V

 GAAGCTGTGGCCCGCGCATCTCTGATTCCAGAATTCTCTGATGGTTCTGGACTGGTCC
 E A V A R A S L I P E F S D G F W T G S

 CAGCTGGCGTGGACGAATTGGAAACACCTGGTCTTACCTCCCTAAATCTCCATC
 Q L A C W T N S E T P W S Y F P K I S I

 TACCTGAGAGATGAGAACTCCAGCAGGTCTCCGTATCACAACTGCCCTAGCTTAC
 Y L R D E N S S R S F R I T I L P Q L Y

 ATTCAAGCCATGATGGGGCCGGCTGAATTATGAATGTTACCGATTGGCATTCCCCA
 I Q P M M G A G L N Y E C Y R F G I S P

TCCACAAATGCGCTGGTGATCGGTGCCACGGTGATGGAGGGCTTCTACGTCACTTCGAC
S T N A L V I G A T V M E G F Y V I F D
AGAGCCCAGAAGAGGGTGGGCTTCGCAGCGAGCCCCCTGTGCAGAAATTGCAGGTGCTGCA

FIGURE 1 (2)

R A Q K R V G F A A S P C A E I A G A A
GTGTCTGAAATTCCGGGCCTTCTCAACAGAGGATGTAGCCAGCAACTGTGTCCCCGCT
V S E I S G P F S T E D V A S N C V P A
CAGTCTTGAGCGAGCCCATTGTGGATTGTGTCTATGCGCTCATGAGCGTCTGTGGA
Q S L S E P I L W I V S Y A L M S V C G
GCCATCCTCCTTGTCTTAATCGTCTGCTGCTGCCGTTCCGGTGTCAAGCTCGCCCC
A I L L V L I V L L L P F R C Q R R P
CGTGACCTTGAGGTCGTCAATGATGAGTCCTCTGGTCAGACATCGCTGGAAATGAATA
R D P E V V N D E S S L V R H R W K
GCCAGGCCTGACCTCAAGCAACCAGAACCTCAGCTATTAAGAAAATCACATTCCAGGGC
AGCAGCCGGATCGATGGTGGCGCTTCTCCTGTGCCCAACCGTCTCAATCTGTCT
GCTCCCAGATGCCCTCTAGATTCACTGTCTTTGATTCTGATTTCAGCTTCAAATC
CTCCCTACTTCCAAGAAAAATAATTAAAAAAAAAACTTCATTCTAAACCAAAAAAAA
AAAA

FIGURE 2 (1)

ATGGCCCAAGCCCTGCCCTGGCTCCTGCTGTGGATGGCGCGGGAGTGCTGCCTGCCAC
 M A Q A L P W L L L W M G A G V L P A H

 GGCACCCAGCACGGCATCCGGCTGCCCTGCGCAGCGGCCTGGGGGGCGCCCCCTGGGG
 G T Q H G I R L P L R S G L G G A P L G

 CTGCGGCTGCCCGGGAGACCGACGAAGAGCCCGAGGAGCCCGGGAGGGCAGCTTT
 L R L P R E T D E E P E E P G R R G S F

 GTGGAGATGGTGGACAACCTGAGGGCAAGTCGGGGCAGGGCTACTACGTGGAGATGACC
 V E M V D N L R G K S G Q G Y Y V E M T

 GTGGGCAGCCCCCGCAGACGCTAACATCCTGGTGGATAACGGCAGCAGTAACTTGCA
 V G S P P Q T L N I L V D T G S S N F A

 GTGGGTGCTGCCCTACCCCTTCTGCATCGCTACTACCAAGGGCAGCTGTCCAGCACA
 V G A A P H P F L H R Y Y Q R Q L S S T

 TACCGGGACCTCCGGAAGGGTGTATGTGCCCTACACCCAGGGCAAGTGGGAAGGGAG
 Y R D L R K G V Y V P Y T Q G K W E G E

 CTGGGCACCGACCTGGTAAGCATCCCCATGGCCCCAACGTCACTGTGCGTGCCAACATT
 L G T D L V S I P H G P N V T V R A N I

 GCTGCCATCACTGAATCAGACAAGTTCTCATCACGGCTCCAATGGGAAGGCATCCTG
 A A I T E S D K F F I N G S N W E G I L

 GGGCTGGCCTATGCTGAGATTGCCAGGCTTGTGGTGGCTGGCTTCCCCCTAACCAAGTCT
 G L A Y A E I A R L C G A G F P L N Q S

 GAAGTGCTGGCCTCTGTCGGAGGGAGCATGATCATTGGAGGTATCGACCACCGCTGTAC
 E V L A S V G G S M I I G G I D H S L Y

 ACAGGCAGTCTCTGGTATAACACCCATCCGGCGGGAGTGGTATTATGAGGTGATCATTGTG
 T G S L W Y T P I R R E W Y Y E V I I V

 CGGGTGGAGATCAATGGACAGGATCTGAAAATGGACTGCAAGGAGTACAACATATGACAAG
 R V E I N G Q D L K M D C K E Y N Y D K

 AGCATTGTGGACAGTGGCACCAACCTTCGTTGCCAAGAAAGTGTGAAAGCTGCA
 S I V D S G T T N L R L P K K V F E A A

 GTCAAATCCATCAAGGCAGCCTCCTCACGGAGAAGTCCCTGATGGTTCTGGCTAGGA
 V K S I K A A S S T E K F P D G F W L G

 GAGCAGCTGGTGTGGCAAGCAGGCACCACCCCTGGAACATTCCCAGTCATCTCA
 E Q L V C W Q A G T T P W N I F P V I S

 CTCTACCTAATGGGTGAGGTTACCAACCAGTCCTCCGCATCACCATCCTCCGAGCAA
 L Y L M G E V T N Q S F R I T I L P Q Q

 TACCTGCGGCCAGTGGAAAGATGTGGCCACGTCCCAAGACGACTGTTACAAGTGTGCCCCATC

FIGURE 2 (2)

Y L R P V E D V A T S Q D D C Y K F A I
 TCACAGTCATCCACGGGCACTGTTATGGGAGCTGTTATCATGGAGGGCTTCTACGTTGTC
 S Q S S T G T V M G A V I M E G F Y V V
 TTTGATCGGGCCCGAAAACGAATTGGCTTGCTGTCAAGCGCTGCCATGTGCACGATGAG
 F D R A R K R I G F A V S A C H V H D E
 TTCAGGACGGCAGCGGTGGAAGGCCCTTGTCAACCTGGACATGGAAGACTGTGGCTAC
 F R T A A V E G P F V T L D M E D C G Y
 AACATTCCACAGACAGATGAGTCAACCTCATGACCATAGCCTATGTCAATGGCTGCCATC
 N I P Q T D E S T L M T I A Y V M A A I
 TGCGCCCTCTCATGCTGCCACTCTGCCTCATGGTGTGTCAGTGGCGCTGCCTCCGCTGC
 C A L F M L P L C L M V C Q W R C L R C
 CTGCGCCAGCAGCATGATGACTTTGCTGATGACATCTCCCTGCTGAAGTGAGGAGGCCA
 L R Q Q H D D F A D D I S L L K
 TGGGCAGAACGATAGAGATTCCCCTGGACCACACCTCCGTGGTTCACTTTGGTCACAAGTA
 GGAGACACAGATGGCACCTGTGGCCAGAGCACCTCAGGACCCCTCCCCACCCACCAAATGC
 CTCTGCCTTGATGGAGAAAAGGCTGGCAAGGTGGGTTCCAGGGACTGTACCTGTAG
 GAAACAGAAAAGAGAAGAAAGAAGCCTCTGCTGGCGGGAAATACTCTGGTCACCTCAAA
 TTTAAGTCGGAAATTCTGCTGCTGAAACTTCAGCCCTGAACCTTTGTCCACCATTCCT
 TTAAATTCTCCAACCCAAAGTATTCTCTTTCTTAGTTCTAGAAGTACTGGCATCACAC
 GCAGGTTACCTGGCGTGTGTCCCTGTTGACCCCTGGCAGAGAACGACCAAGCTTGT
 CCCTGCTGGCCAAAGTCAGTAGGAGAGGATGCACAGTTGCTATTGCTTTAGAGACAGG
 GACTGTATAAACAAAGCCTAACATTGGTCAAAGATTGCCTCTGAAAAA

FIGURE 3 (1)

ATGGCCCAAGCCCTGCCCTGGCTCTGCTGTGGATGGCGCGGGAGTGCTGCCTGCCAC
 M A Q A L P W L L L W M G A G V L P A H

 GGCACCCAGCACGGCATCCGGCTGCCCTGCGCAGCGGCCTGGGGGGCGCCCCCTGGG
 G T Q H G I R L P L R S G L G G A P L G

 CTGCGGCTGCCCGGGAGACCGACGAAGAGCCGAGGAGCCGCCGGAGGGCAGCTTT
 L R L P R E T D E E P E E P G R R G S F

 GTGGAGATGGTGGACAACCTGAGGGCAAGTCGGGGCAGGGCTACTACGTGGAGATGACC
 V E M V D N L R G K S G Q G Y Y V E M T

 GTGGGCAGCCCCCGCAGACGCTAACATCCTGGTGGATACAGGCAGCAGTAACTTGCA
 V G S P P Q T L N I L V D T G S S N F A

 GTGGGTGCTGCCCTTCCACCGCTACTACCAAGAGGCAGCTGTCCAGCACAC
 V G A A P H P F L H R Y Y Q R Q L S S T

 TACCGGGACCTCCGGAAGGGTGTATGTGCCCTACACCCAGGGCAAGTGGGAAGGGAG
 Y R D L R K G V Y V P Y T Q G K W E G E

 CTGGGCACCGACCTGTAAGCATCCCCATGGCCCAACGTCACTGTGCGTGCCAACATT
 L G T D L V S I P H G P N V T V R A N I

 GCTGCCATCACTGAATCAGACAAGTTCTCATCAACGGCTCCAACGGGAAGGCATCCTG
 A A I T E S D K F F I N G S N W E G I L

 GGGCTGGCCTATGCTGAGATTGCCAGGCCTGACGACTCCCTGGAGCCTTCTTGACTCT
 G L A Y A E I A R P D D S L E P F F D S

 CTGGTAAAGCAGACCCACGTTCCAACCTCTCTCCCTGCAGCTTGTGGTGTGGCTTC
 L V K Q T H V P N L F S L Q L C G A G F

 CCCCTCAACCAGTCTGAAGTGCTGGCCTCTGTCGGAGGGAGCATGATCATGGAGGTATC
 P L N Q S E V L A S V G G S M I I G G I

 GACCACTCGCTGTACACAGGCAGTCTGGTATACACCCATCCGGCGGGAGTGGTATTAT
 D H S L Y T G S L W Y T P I R R E W Y Y

 GAGGTCATCATTGTGCGGGTGGAGATCAATGGACAGGATCTGAAAATGGACTGCAAGGAG
 E V I I V R V E I N G Q D L K M D C K E

 TACAACATGACAAGAGCATTGTGGACAGTGGCACCAACCTCGTTGCCCAGAAA
 Y N Y D K S I V D S G T T N L R L P K K

 GTGTTGAAGCTGCAGTCATCAAGGCAGCCTCCACGGAGAAGTTCCCTGAT
 V F E A A V K S I K A A S S T E K F P D

FIGURE 3 (2)

GGTTTCTGGCTAGGAGAGCAGCTGGTGTGGCAAGCAGGCACCACCCCTGGAACATT
 G F W L G E Q L V C W Q A G T T P W N I

 TTCCCAGTCATCTCACTCTACCTAATGGGTGAGGTTACCAACCAGTCCTCCGCATCACC
 F P V I S L Y L M G E V T N Q S F R I T

 ATCCTTCCGCAGCAATACTCGGGCAGTGGAAAGATGTGGCCACGTCCCAAGACGACTGT
 I L P Q Q Y L R P V E D V A T S Q D D C

 TACAAGTTGCCATCTCACAGTCATCCACGGCACTGTTATGGGAGCTGTTATCATGGAG
 Y K F A I S Q S S T G T V M G A V I M E

 GGCTTCTACGTTGTCTTGATGGGCCAAAACGAATTGGCTTGCTGTCAGCGCTTGC
 G F Y V V F D R A R K R I G F A V S A C

 CATGTGCACGATGAGTTCAAGGACGGCAGCGGTGGAAGGCCCTTGTACCTTGGACATG
 H V H D E F R T A A V E G P F V T L D M

 GAAGACTGTGGCTACAACATTCCACAGACAGATGAGTCACCCCTCATGACCATAGCCTAT
 E D C G Y N I P Q T D E S T L M T I A Y

 GTCATGGCTGCCATCTGGCCCTCTCATGCTGCCACTCTGCCTCATGGTGTGTCAGTGG
 V M A A I C A L F M L P L C L M V C Q W

 CGCTGCCTCCGCTGCCTGGCCAGCAGCATGATGACTTGTGATGACATCTCCCTGCTG
 R C L R C L R Q Q H D D F A D D I S L L

 AAGTGAGGAGGCCATGGCAGAAGATAGAGATTCCCTGGACCAACCTCCGTGGTTCA
 K

 CTTGGTCACAAGTAGGAGACACAGATGGCACCTGTGGCCAGAGCACCTCAGGACCC
 CCAACCCACAAATGCCCTGCTGATGGAGAAGGAAAGGCTGGCAAGGTGGTTCCAG
 GGACTGTACCTGTAGGAAACAGAAAAGAGAAGAAAAGAAGCACTCTGCTGGCGGG
 AACTCTTGGTCACCTCAAATTAAAGTCGGAAATTCTGCTGCTTGAACACTCAGCC
 CTGAACCTTTGTCCACCATTCCTTAAATTCTCCAACCCAAAGTATTCTCTTTCTT
 TAGTTTCAGAA
 GTACTGGCATCACACGCAGGTTACCTTGGCGTGTGTCCTGTGGTACCC
 TGCTGGCAGAGAAG
 AGACCAAGCTTGTGTTCCCTGCTGGCAAAGTCAGTAGGAGAGGATGCACAGTT
 TGCTTGTGAAAGATTGCCTTGA
 ATTAAAAAAAAAAAAAAA
 AAAAAA

FIGURE 4

ATGGCCCCAGCGCTGCACTGGCTCTGCTATGGTGGCTCGGGAAATGCTGCCCTGCCAG
 M A P A L H W L L L W V G S G M L P A Q
 GGAACCCATCTCGGCATCCGGCTGCCCTCGCAGCGGCCCTGGCAGGGCACCCCTGGC
 G T H L G I R L P L R S G L A G P P L G
 CTGAGGCTGCCCGGGAGACTGACGAGGAATCGGAGGAGCCTGGCCGGAGAGGCAGCTT
 L R L P R E T D E E S E E P G R R G S F
 GTGGAGATGGTGGACAACCTGAGGGAAAGTCGGCCAGGGCTACTATGTGGAGATGACC
 V E M V D N L R G K S G Q G Y Y V E M T
 GTAGGCAGCCCCCACAGACGCTAACATCTGGTGGACACGGCAGTAGTAACCTTGCA
 V G S P P Q T L N I L V D T G S S N F A
 GTGGGGCTGCCAACCCCTTCTGCATCGCTACTACCAAGGGCAGCTGCCAGCACA
 V G A A P H P F L H R Y Y Q R Q L S S T
 TATCGAGACCTCCGAAAGGGTGTATGTGCCCTACACCCAGGGCAAGTGGGAGGGGAA
 Y R D L R K G V Y V P Y T Q G K W E G E
 CTGGCACCGACCTGGTGGCATCCCTCATGGCCCCAACGTCACTGTGCCTGCCAACATT
 L G T D L V S I P H G P N V T V R A N I
 GCTGCCATCACTGAATCGGACAAGTTCTCATCAATGGTCCAACGGGAGGCATCCTA
 A A I T E S D K F F I N G S N W E G I L
 GGGCTGGCTATGCTGAGATTGCCAGGCCGACGACTCTTGGAGCCCTCTTGACTCC
 G L A Y A E I A R P D D S L E P P F D S
 CTGGTGAAGCAGACCCACATTCCAACATCTTCCCTGCAGCTCTGTGGCTGGCTTC
 L V K Q T H I P N I F S L Q L C G A G F
 CCCCTCAACCAGACCGAGGCACTGGCTCGTGGAGGGAGCATGATCATTGGTGGTATC
 P L N Q T E A L A S V G G S M I I G G I
 GACCACTCGCTATACACGGCAGTCCTGGTACACACCCATCCGGGGAGTGGTATTAT
 D H S L Y T G S L W Y T P I R R E W Y Y
 GAAGTGAATGGTACGTGTGGAAATCAATGGTCAAGATCTCAAGATGGACTGCAAGGAG
 E V I I V R V E I N G Q D L K M D C K E
 TACAAC TACGACAAGAGCATTGTGGACAGTGGGACCACCAACCTCGCTGCCAACAAA
 Y N Y D K S I V D S G T T N L R L P K K
 GTATTTGAAGCTGCCGTCAGTCATCAAGGCAGCCTCTCGACGGAGAAGTCCGGAT
 V F E A A V K S I K A A S S T E K F P D
 GGCTTTGGCTAGGGGAGCAGCTGGTGTGGCAAGCAGGACGACCCCTGGAACATT
 G F W L G E Q L V C W Q A G T T P W N I
 TTCCCAGTCATTCACTTACCTCATGGTGAAGTCACCAATCAGCTTCCGATCACC
 F P V I S L Y L M G E V T N Q S F R I T
 ATCCCTCTCAGCAATACCTACGGCGGTGGAGGACGTGGCACGTCCAAAGACGACTGT
 I L P Q Q Y L R P V E D V A T S Q D D C
 TACAAGTTCGCTGTCTCACAGTCATCCACGGCACTGTTATGGGAGCCGTATGGAA
 Y K F A V S Q S S T G T V M G A V I M E
 GTTTCTATGTCGCTTCGATCGAGCCGAAAGCGAATTGGTTGTCAGCGCTTGC
 G F Y V V F D R A R K R I G F A V S A C
 CATGTGCACGATGAGITCAGGACGGCGGAGTGGAGGTGGTTACGGCAGACATG
 H V H D E F R T A A V E G P F V T A D M
 GAAGACTGTGGCTACAACATTCCCCAGACAGATGAGTCACACTATGACCATAGCCTAT
 E D C G Y N I P Q T D E S T L M T I A Y
 GTCATGGCGGCCATCTCGCCCTCTCATGGTGCACACTCTGCCATGGTATGTCAGTGG
 V M A A I C A L F M L P L C L M V C Q W
 CGCTGCCCTGCTGGCTGCCACAGCACGATGACTTGTGATGACATCTCCCTGCTC
 R C L R C L R H Q H D D F A D D I S L L
 AAGTAAGGAGGCTCGTGGCAGATGATGGAGACGCCCTGGACCACATCTGGTGGTCC
 K
 CTTGGTCACTGAGTTGGAGCTATGGATGGTACCTGTGGCCAGAGCACCTCAGGACCC
 CACCAACCTGCCATGCTTCTGGCGTACAGAACAGAGAAATCAGCAAGCTGGATTACA
 GGGCTTGACCTGTAGGACACAGGAGAGGAAGGAAGCAGCGTTGGCAGGAATAT
 CCTTAGGCACCAACAACTTGAGTTGGAAATTGCTGCTGAAAGCTTCAGCCCTGACCC
 CTGCCAGCATCCTTGTAGAGTCCTAACAAAGTATTCTTATGTCCTCCAGAAGTAC

TGGCGTCATACTCAGGCTACCCGGCATGTGTCCCTGTGGTACCCGGCAGAGAAAGGGC
AATCTCATTCCTGCTGGCAAAGTCAGCAGAAGAAGGTGAAGTTGCCAGTTGCTTTAG
TGATAGGGACTGCAGACTCAAGCCTACACTGGTACAAAGACTGCGTCTTGAGATAAACAA
GAA

FIGURE 5

1 MAQALPWLLLWMGAGVLPAGHTQHGIRLPLRSGLGGAPLGLRLPRTDEE 50
1 MAPALHWLLLWVGSGMLPAQGTHLGIRLPLRSGLAGPPLGLRLPRTDEE 50

51 PEEPGRGFSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNIVDTGSSNFA 100
51 SEEPGRGFSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNIVDTGSSNFA 100

101 VGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEDELGTDLVSIPH 150
101 VGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEDELGTDLVSIPH 150

151 GPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLPFFDS 200
151 GPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLPFFDS 200

201 LVKQTHVPNLFLSQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLW 250
201 LVKQTHIPNIFSLSQLCGAGFPLNQTEALASVGGSMIIGGIDHSLYTGSLW 250

251 YTPIRREWYYEVIIVRVEINGQDLKMDCKEINYDKSIVDSGTTNLRLPKK 300
251 YTPIRREWYYEVIIVRVEINGQDLKMDCKEINYDKSIVDSGTTNLRLPKK 300

301 VFEAAVKSIIKAASSTEKFPGFWLGEQLVCWQAGTTPWNIFPVISLYLMG 350
301 VFEAAVKSIIKAASSTEKFPGFWLGEQLVCWQAGTTPWNIFPVISLYLMG 350

351 EVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIME 400
351 EVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAVSQSSTGTVMGAVIME 400

401 GFYVVFDRAKRIGFAVSACHVHDEFRTAAVEGPFTLDMEDCGYNIPQT 450
401 GFYVVFDRAKRIGFAVSACHVHDEFRTAAVEGPFTADMEDCGYNIPQT 450

451 DESTLMTIAYVMAAICALFMLPLCLMVCQWRCLRCLRHQHDDFADDISLL 500
451 DESTLMTIAYVMAAICALFMLPLCLMVCQWRCLRCLRHQHDDFADDISLL 500

501 K 501
501 K 501

FIGURE 6 (1)

ATGGCTAGCATGACTGGTGGACAGCAAATGGTCGGATCCACCCAGCACGGCATCCGG
 M A S M T G G Q Q M G R G S T Q H G I R

 CTGCCCTGCGCAGCGGCCTGGGGCGCCCCCTGGGCTGCGGCTGCCCGGGAGACC
 L P L R S G L G G A P L G L R L P R E T

 GACGAAGAGCCCAGGGAGCCCGGCCGGAGGGCAGCTTGTGGAGATGGTGACAACCTG
 D E E P E E P G R R G S F V E M V D N L

 AGGGGCAAGTCGGGCAGGGCTACTACGTGGAGATGACCGTGGCAGCCCCCGCAGACG
 R G K S G Q G Y Y V E M T V G S P P Q T

 CTCAACATCCTGGTGGATAACAGGCAGCAGTAACCTTGCACTGGGTGCTGCCACCC
 L N I L V D T G S S N F A V G A A P H P

 TTCCCTGCATCGCTACTACCAGAGGCAGCTGTCCAGCACATACCGGGACCTCCGGAAAGGGC
 F L H R Y Y Q R Q L S S T Y R D L R K G

 GTGTATGTGCCCTACACCCAGGGCAAGTGGGAAGGGAGCTGGGCACCGACCTGGTAAGC
 V Y V P Y T Q G K W E G E L G T D L V S

 ATCCCCCATGGCCCCAACGTCACTGTGCGCCAACATTGCTGCCATCACTGAATCAGAC
 I P H G P N V T V R A N I A A I T E S D

 AAGTTCTTCATCAACGGCTCCAACGGAGGCATCTGGGCTGGCTATGCTGAGATT
 K F F I N G S N W E G I L G L A Y A E I

 GCCAGGCCTGACGACTCCCTGGAGCCTTCTTGACTCTCTGGTAAAGCAGACCCACGTT
 A R P D D S L E P F F D S L V K Q T H V

 CCCAACCTCTTCTCCCTGCAGCTTGTGGCTGGCTTCCCCCTAACCGAGTCTGAAGTG
 P N L F S L Q L C G A G F P L N Q S E V

 CTGGCCTCTGTCGGAGGGAGCATGATCATGGAGGTATGACCACTCGCTGTACACAGGC
 L A S V G G S M I I G G I D H S L Y T G

 AGTCTCTGGTATACACCCATCCGGGGAGTGGTATTATGAGGTATCATTGTGCGGGTG
 S L W Y T P I R R E W Y Y E V I I V R V

 GAGATCAATGGACAGGGATCTGAAAATGGACTGCAAGGAGTACAACATATGACAAGAGCATT
 E I N G Q D L K M D C K E Y N Y D K S I

 GTGGACAGTGGCACCAACCTTCGTTGCCAAGAAAGTGGTGAAGCTGCAGTC
 V D S G T T N L R L P K K V F E A A V K

 TCCATCAAGGCAGCCTCTCCACGGAGAAGTCCCTGATGGTTCTGGCTAGGAGAGCAG
 S I K A A S S T E K F P D G F W L G E Q

 CTGGTGTGCTGGCAAGCAGGCACCACCCCTGGAACATTTCCAGTC
 L V C W Q A G T T P W N I F P V I S L Y

 CTAATGGGTGAGGTTACCAACCAGTCCTCCGCATCACCATCCTCCGCAGCAATACCTG
 L M G E V T N Q S F R I T I L P Q Q Y L

 CGGCCAGTGGAAAGATGTGGCCACGTCCCAAGACGACTGTTACAAGTTGCCATCTCACAG

FIGURE 6 (2)

R P V E D V A T S Q D D D C Y K F A I S Q
TCATCCACGGGCACTGTTATGGGAGCTGTATCATGGAGGGCTTCTACGTTGTCTTGAT
S S T G T V M G A V I M E G F Y V V V F D
CGGGCCCAGAAACGAATTGGCTTGCTGTCAGCGCTGCCATGTGCACGATGAGTTCAAGG
R A R K R I G F A V S A C H V H D E F R
ACGGCAGCGGTGGAAGGCCCTTGTCACCTGGACATGGAAGACTGTGGCTACAACATT
T A A V E G P F V T L D M E D C G Y N I
CCACAGACAGATGAGTCATGA
P Q T D E S *

FIGURE 7 (1)

ATGGCTAGCATGACTGGTGGACAGCAAATGGTCGGATCGATGACTATCTCTGACTCT
 M A S M T G G Q Q M G R G S M T I S D S

 CCGCGTGAAACAGGACGGATCCACCCAGCACGGCATCCGGCTGCCCTGCGCAGCGGCCTG
 P R E Q D G S T Q H G I R L P L R S G L

 GGGGGCGCCCCCTGGGCTGCGCTGCCCGGGAGACCGACGAAGAGCCCAGGAGCCC
 G G A P L G L R L P R E T D E E P E E P

 GGCGGGAGGGCAGCTTGAGATGGGACAACCTGAGGGCAAGTCGGGCAGGGC
 G R R G S F V E M V D N L R G K S G Q G

 TACTACGTGGAGATGACCGTGGCAGCCCCCGCAGACGCTAACATCCTGGTGGATACA
 Y Y V E M T V G S P P Q T L N I L V D T

 GGCAGCAGTAACTTGCAGTGGTGGCTGCCCTACCCCTTCATCGCTACTACCAG
 G S S N F A V G A A P H P F L H R Y Y Q

 AGGCAGCTGTCCAGCACATACCGGGACCTCCGAAGGGCGTGTATGTGCCCTACACCCAG
 R Q L S S T Y R D L R K G V Y V P Y T Q

 GGCAAGTGGGAAGGGAGCTGGCACCGACCTGGTAAGCATCCCCATGGCCCCAACGTC
 G K W E G E L G T D L V S I P H G P N V

 ACTGTGGTGCACATTGCTGCCATCACTGAATCAGACAAGTTCTTCATCAACGGCTCC
 T V R A N I A A I T E S D K F F I N G S

 AACCTGGGAAGGCATCCTGGGCTGGCCTATGCTGAGATTGCCAGGCCTGACGACTCCCTG
 N W E G I L G L A Y A E I A R P D D S L

 GAGCCTTCTTGACTCTGGTAAAGCAGACCCACGTTCCAACCTCTTCATGGCAG
 E P F F D S L V K Q T H V P N L F S L Q

 CTTTGTGGTGTGGCTGGCTCCCTCAACCAGTCTGAAGTGTGGCTCTGTGGAGGGAGC
 L C G A G F P L N Q S E V L A S V G G S

 ATGATCATTGGAGGTATCGACCACTCGCTGTACACAGGCAGTCTCTGGTATAACACCCATC
 M I I G G I D H S L Y T G S L W Y T P I

 CGCGGGAGTGGTATTATGAGGTATCATCATTGTGGCTGGAGATCAATGGACAGGATCTG
 R R E W Y Y E V I I V R V E I N G Q D L

 AAAATGGACTGCAAGGAGTACAACATGACAAGAGCATTGTGGACAGTGGCACCAAC
 K M D C K E Y N Y D K S I V D S G T T N

 CTTCGTTGCCAAGAAAGTGTGAGCTGCAGTCATCAAGGCAGCCTCC
 L R L P K K V F E A A V K S I K A A S S

 ACGGAGAAGTCCCTGATGGTTCTGGCTAGGAGAGCAGCTGGTGTGCTGGCAAGCAGGC
 T E K F P D G F W L G E Q L V C W Q A G

 ACCACCCCTGGAACATTCCCAGTCATCTCACTCTACCTAATGGGTGAGGTTACCAAC
 T T P W N I F P V I S L Y L M G E V T N

FIGURE 7 (2)

CAGTCCTTCCGCATCACCATCCTCCGAGCAATACCTGCGGCCAGTGGAAAGATGTGGCC
Q S F R I T I L P Q Q Y L R P V E D V A

ACGTCCCAGACGACTGTTACAAGTTGCCATCTCACAGTCATCCACGGGACTGTTATG
T S Q D D C Y K F A I S Q S S T G T V M

GGAGCTGTTATCATGGAGGGCTTCTACGTTGTCTTGATCGGGCCCGAAAACGAATTGGC
G A V I M E G F Y V V F D R A R K R I G

TTTGTGTCAGCGCTTGCCATGTGCACGATGAGTTCAAGGACGGCAGCGGTGGAAGGCCCT
F A V S A C H V H D E F R T A A V E G P

TTTGTACCTTGGACATGGAAGACTGTGGCTACAACATTCCACAGACAGATGAGTCATGA
F V T L D M E D C G Y N I P Q T D E S *

FIGURE 8 (1)

ATGACTCAGCATGGTATTCTGCTGCCACTGCGTAGCGGTCTGGGTGGTGCCTCACTGGGT
 M T Q H G I R L P L R S G L G G A P L G -

 CTGCGTCTGCCCGGGAGACCGACGAAGAGCCCGAGGAGCCCGGCCGGAGGGGCAGCTTT
 L R L P R E T D E E P E E P G R R G S F -

 GTGGAGATGGTGGACAACCTGAGGGGCAAGTCGGGGCAGGGCTACTACGTGGAGATGACC
 V E M V D N L R G K S G Q G Y Y V E M T -

 GTGGGCAGCCCCCGCAGACGCTAACATCCTGGTGGATAACAGGCAGCAGTAACTTGCA
 V G S P P Q T L N I L V D T G S S N F A -

 GTGGGTGCTGCCCTCACCCCTTCATCGCTACTACCAAGAGGCAGCTGTCCAGCACA
 V G A A P H P F L H R Y Y Q R Q L S S T -

 TACCGGGACCTCCCGAAGGGCGTGTATGTGCCCTACACCCAGGGCAAGTGGGAAGGGGAG
 Y R D L R K G V Y V P Y T Q G K W E G E -

 CTGGGCACCGACCTGGTAAGCATCCCCATGGCCCAACGTCACTGTGCGTGCCAACATT
 L G T D L V S I P H G P N V T V R A N I -

 GCTGCCATCACTGAATCAGACAAGTTCTTCATCAACGGCTCCAACGGAAAGGCATCCTG
 A A I T E S D K F F I N G S N W E G I L -

 GGGCTGGCCTATGCTGAGATTGCCAGGCCGTGACGACTCCCTGGAGGCCCTTCTTGACTCT
 G L A Y A E I A R P D D S L E P F F D S

 CTGGTAAAGCAGACCCACGTTCCAACCTCTTCTCCCTGCAGCTTGTGGTGCTGGCTTC
 L V K Q T H V P N L F S L Q L C G A G F -

 CCCCTCAACCAGTCTGAAGTGCTGCCCTCTGCGGAGGGAGCATGATCATTGGAGGTATC
 P L N Q S E V L A S V G G S M I I G G I -

 GACCACTCGCTGTACACAGGCAGTCTGGTATACACCCATCCGGCGGGAGTGGTATTAT
 D H S L Y T G S L W Y T P I R R E W Y Y -

 GAGGTCACTATTGTGCGGGTGGAGATCAATGGACAGGATCTGAAAATGGACTGCAAGGAG
 E V I I V R V E I N G Q D L K M D C K E

 TACAACATGACAAGAGCATTGTGGACAGTGGCACCAACCTTCGTTGCCAAGAAA
 Y N Y D K S I V D S G T T N L R L P K K -

 GTGTTGAAGCTGCAGTCAAATCCATCAAGGCAGCCTCTCCACGGAGAAGTCCCTGAT
 V F E A A V K S I K A A S S T E K F P D -

 GGTTCTGGCTAGGAGAGCAGCTGGTGTGCTGCCAAGCAGGCACCAACCCCTGGAACATT
 G F W L G E Q L V C W Q A G T T P W N I -

 TTCCCAGTCATCTCACTCTACCTAATGGTGAGGTTACCAACCAAGTCCTTCGATCACC
 F P V I S L Y L M G E V T N Q S F R I T -

 ATCCTTCCGCAGCAATACCTGCGGCCAGTGGAGATGTGGCACGTCCCAAGACGACTGT
 I L P Q Q Y L R P V E D V A T S Q D D C -

FIGURE 8 (2)

TACAAGTTGCCATCTCACAGTCATCCACGGGACTGTTATGGGAGCTGTTATCATGGAG
Y K F A I S Q S S T G T V M G A V I M E -
GGCTTCTACGTTGTCTTGATCGGGCCCGAAAACGAATTGGCTTGCTGTCAGCGCTTGC
G F Y V V F D R A R K R I G F A V S A C -
CATTAG
H *


FIGURE 9


FIGURE 10

FIGURE 11

MAQALPWLLLWMGAGVLPAHGTQHGIRLPLRSGLGGAPLGLRLPRETDEE
PEEPGRGSFVEMVDNLRGKSGQGYVEMTVGSPPQTLNILVDTGSSNFA
VGAAPHFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGETGTDLVSIPH
GPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLFPFFDS
LVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIIGGIDHSLYTGSLW
YTPIRREWYYEVIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKK
VFEAAVKSIAASSTEKFDPDFWLGEQLVCWQAGTPWNIFPVISLYLMG
EVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIME
GFYVVFDRAKRIGFAVSACHVDEFRTAAVEGPFTLDMEDCGYNIPQT
DES

FIGURE 12

MAQALPWLLLWMGAGVLPAHGTQHGIRLPLRSGLGGAPLGLRLPRETDEE
PEEPGRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFA
VGAAPHFLHRYYQRQLSSTYRDLRKGVYVPYTQGWEGELGTDLVSIPH
GPNVTVRANIAAITESDKFFINGSNWEGLAYAEIARPDDSLEPFFDS
LVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLW
YTPIRREWYYEVIIIVRVEINGQDLKMDCKEINYDKSIVDSGTTNLRLPKK
VFEAAVKSIAASSTEKFPDGFWLGEQLVCWQAGTPWNIFPVISLYLMG
EVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIME
GFYVVFDRAKRIGFAVSACHVDEFRTAAVEGPFTLDMEDCGYNIPQT
DESHHHHHHH

- 1 -

SEQUENCE LISTING

<110> Pharmacia & Upjohn

<120> ALZHEIMER'S DISEASE SECRETASE, APP SUBSTRATES THEREFOR, AND USES THEREFOR

<130> 28341/6280.1

<140>

<141>

<150> 60/169,232

<151> 1999-12-06

<150> 09/416,901

<151> 1999-10-13

<150> 60/155,493

<151> 1999-09-23

<150> 09/404,133

<151> 1999-09-23

<150> PCT/US99/20881

<151> 1999-09-23

<150> 60/101,594

<151> 1998-09-24

<160> 76

<170> PatentIn Ver. 2.0

<210> 1

<211> 1804

<212> DNA

<213> Homo sapiens

<400> 1

atgggcgcac tggcccgccc gctgctgctg cctctgctgg cccagtggct cctgcgcgcc 60
gccccggagc tggcccccgc gcccttcacg ctgccccctcc ggggtggccgc ggccacgaac 120
cgcgtatgtt cgccccacccc gggaccggg accccctgccc agcgccacgc cgacggcttg 180
gcgcctcgccc tggagcctgc cctggcgtcc cccgcggggcg ccgcacaactt ctggccatg 240
gtagacaacc tgcaggggga ctctggccgc ggctactacc tggagatgct gatcgggacc 300
cccccgccaga agctacagat tctcggtgac actggaagca gtaactttgc cgtggcagga 360
accccgccact cctacataga cacgtacttt gacacagaga ggtctagcac ataccgctcc 420
aagggcattt acgtcacagt gaagtacaca caaggaagct ggacgggctt cgttggggaa 480
gacctcgatca ccatccccaa aggcttcaat acttctttc ttgtcaacat tgccactatt 540
tttgaatcag agaattttttt tttgccttggg attaaatggg atgaaatact tggcctagct 600
tatgccacac ttgccaagcc atcaaggttt ctggagaccc tcttcgactc cctggtgaca 660
caagcaaaca tcccccaacgt ttttcctcatg cagatgtgt gagccggctt gcccgttgc 720
ggatctggga ccaacggagg tagtctgtc ttgggtggaa ttgaaccaag ttgtataaaa 780
ggagacatct ggtataacccc tattaaggaa gagtggtaact accagataga aattctgaaa 840
ttggaaattt gaggccaaag ccttaatctg gactgcagag agtataacgc agacaaggcc 900
atcggtggaca gtggcaccac gctgctgccc ctgccccaga aggtgttga tgcgggtgg 960
gaagctgtgg cccgcgcatac tctgatcca gaattctctg atggttctg gactgggtcc 1020
cagctggcgt gctggacgaa ttggaaaca cttggctt acttccctaa aatctccatc 1080
tacctgagag atgagaactc cagcaggtaa ttccgtatca caatccgcc tcagctttac 1140
attcagccca tggatggggc cggcctgaat tatgaatgtt accgattcgg catttcccc 1200
tccacaaatg cgctgggtgat cggtgccacg gtgatggagg gcttctacgt catttcgac 1260
agagcccaaga agagggtggg cttcgacgc agccctgtg cagaaattgc aggtgtgc 1320

- 2 -

gtgtctgaaa tttccgggcc tttctcaaca gaggatgtag ccagcaactg tgtccccgt 1380
 cagtcttga gcgagccat ttgtggatt gtgcctatg cgctcatgag cgtctgtgga 1440
 gccatcctcc ttgtcttaat cgtcctgctg ctgctggcg 1500
 cgtgaccctg aggtcgtaa tgatgagtc tctctggtca gacatcgctg gaaatgaata 1560
 gccaggcctg acctaagca accatgaact cagttattaa gaaaatcaca tttccaggc 1620
 agcagccggg atcgatggt gcgcttctc ctgtgcccac ccgtcttcaa tctctgttct 1680
 gctcccaat gctttctaga ttcaactgtct tttgattctt gattttcaag ctttcaaattc 1740
 ctccctactt ccaagaaaaa taattaaaaa aaaaacttca ttctaaacca aaaaaaaaaa 1800
 aaaa 1804

<210> 2
<211> 518
<212> PRT
<213> Homo sapiens

<400> 2
Met Gly Ala Leu Ala Arg Ala Leu Leu Leu Pro Leu Leu Ala Gln Trp
1 5 10 15
Leu Leu Arg Ala Ala Pro Glu Leu Ala Pro Ala Pro Phe Thr Leu Pro
20 25 30
Leu Arg Val Ala Ala Ala Thr Asn Arg Val Val Ala Pro Thr Pro Gly
35 40 45
Pro Gly Thr Pro Ala Glu Arg His Ala Asp Gly Leu Ala Leu Ala Leu
50 55 60
Glu Pro Ala Leu Ala Ser Pro Ala Gly Ala Ala Asn Phe Leu Ala Met
65 70 75 80
Val Asp Asn Leu Gln Gly Asp Ser Gly Arg Gly Tyr Tyr Leu Glu Met
85 90 95
Leu Ile Gly Thr Pro Pro Gln Lys Leu Gln Ile Leu Val Asp Thr Gly
100 105 110
Ser Ser Asn Phe Ala Val Ala Gly Thr Pro His Ser Tyr Ile Asp Thr
115 120 125
Tyr Phe Asp Thr Glu Arg Ser Ser Thr Tyr Arg Ser Lys Gly Phe Asp
130 135 140
Val Thr Val Lys Tyr Thr Gln Gly Ser Trp Thr Gly Phe Val Gly Glu
145 150 155 160
Asp Leu Val Thr Ile Pro Lys Gly Phe Asn Thr Ser Phe Leu Val Asn
165 170 175
Ile Ala Thr Ile Phe Glu Ser Glu Asn Phe Phe Leu Pro Gly Ile Lys
180 185 190
Trp Asn Gly Ile Leu Gly Leu Ala Tyr Ala Thr Leu Ala Lys Pro Ser
195 200 205
Ser Ser Leu Glu Thr Phe Phe Asp Ser Leu Val Thr Gln Ala Asn Ile
210 215 220
Pro Asn Val Phe Ser Met Gln Met Cys Gly Ala Gly Leu Pro Val Ala
225 230 235 240

- 3 -

Gly Ser Gly Thr Asn Gly	Gly Ser Leu Val	Leu Gly Gly Ile Glu Pro	
245	250	255	
Ser Leu Tyr Lys Gly Asp Ile Trp	Tyr Thr Pro Ile Lys Glu Glu Trp		
260	265	270	
Tyr Tyr Gln Ile Glu Ile Leu Lys	Leu Glu Ile Gly Gly Gln Ser Leu		
275	280	285	
Asn Leu Asp Cys Arg Glu	Tyr Asn Ala Asp Lys Ala Ile Val Asp Ser		
290	295	300	
Gly Thr Thr Leu Leu Arg	Leu Pro Gln Lys Val Phe Asp Ala Val Val		
305	310	315	320
Glu Ala Val Ala Arg Ala Ser	Leu Ile Pro Glu Phe Ser Asp Gly Phe		
325	330	335	
Trp Thr Gly Ser Gln Leu Ala Cys	Trp Thr Asn Ser Glu Thr Pro Trp		
340	345	350	
Ser Tyr Phe Pro Lys Ile Ser	Ile Tyr Leu Arg Asp Glu Asn Ser Ser		
355	360	365	
Arg Ser Phe Arg Ile Thr	Ile Leu Pro Gln Leu Tyr Ile Gln Pro Met		
370	375	380	
Met Gly Ala Gly Leu Asn	Tyr Glu Cys Tyr Arg Phe Gly Ile Ser Pro		
385	390	395	400
Ser Thr Asn Ala Leu Val Ile Gly	Ala Thr Val Met Glu Gly Phe Tyr		
405	410	415	
Val Ile Phe Asp Arg Ala Gln Lys	Arg Val Gly Phe Ala Ala Ser Pro		
420	425	430	
Cys Ala Glu Ile Ala Gly	Ala Ala Val Ser Glu Ile Ser Gly Pro Phe		
435	440	445	
Ser Thr Glu Asp Val Ala Ser Asn Cys	Val Pro Ala Gln Ser Leu Ser		
450	455	460	
Glu Pro Ile Leu Trp Ile Val Ser	Tyr Ala Leu Met Ser Val Cys Gly		
465	470	475	480
Ala Ile Leu Leu Val Leu Ile Val	Leu Leu Leu Pro Phe Arg Cys		
485	490	495	
Gln Arg Arg Pro Arg Asp Pro	Glu Val Val Asn Asp Glu Ser Ser Leu		
500	505	510	
Val Arg His Arg Trp Lys			
515			

<210> 3
<211> 2070
<212> DNA
<213> Homo sapiens

<400> 3
atggcccaag ccctgccctg gtcctgtcg tggatggcgc cgggagtgt gcctgcccac 60

- 4 -

ggcacccagc acggcatccg gctgcccctg cgcaagcgcc tggggggcgc cccccctgggg 120
 ctgcggctgc cccgggagac cgacgaagag cccgaggagc ccggccggag gggcagctt 180
 gtggagatgg tggacaacct gaggggcaag tcggggcagg gctactacgt ggagatgacc 240
 gtgggcagcc ccccgagac gctcaacatc ctggtgata cagggcagcag taactttgca 300
 gtgggtgctg ccccccaccc cttcctgcat cgctactacc agaggcagct gtccagcaca 360
 taccgggacc tccggaaggg tgtgtatgtg ccctacaccc agggcaagtg ggaaggggag 420
 ctgggcaccc acctggtaag catccccat ggcggcaacg tcactgtcg tgccaaacatt 480
 gctgccatca ctgaatcaga caagtttcc atcaacggct ccaactggga aggcatcctg 540
 gggctggcct atgctgagat tgccaggct gacgactccc tggagcctt cttgactct 600
 ctggtaaagg agacccacgt tcccaaccc ttctccctc acctttgtgg tgctggctc 660
 cccctaacc agtctgaaat gctggcctct gtcggaggaa gcatgtcat tggaggtatc 720
 gaccactcgc tggcacacagg cagtctctgg tatacaccca tccggggga tgggtattat 780
 gaggtcatca ttgtgcgggt ggagatcaat ggacaggatc tggaaatggg ctgcaaggag 840
 tacaactatg acaagagcat tggacagt ggcaccacca accttcgtt gcccaagaaa 900
 gtgtttaaag ctgcagtcaa atccatcaag gcagcctctt ccacggagaa gttccctgtat 960
 ggtttctggc taggagagca gctggtgtgc tgccaaggcag gcaccacccc ttggaacatt 1020
 ttcccagtca tctcaactcta cctaatgggt gaggttacca accagtccctt cegcatcacc 1080
 atcctccgc agaataactt gcccggcactg gaagatgtgg ccacgtccca agacgactgt 1140
 tacaagtttgc ccatctcaca gtcatccacg ggcaactgtt tggagctgt tatcatggag 1200
 ggcttctacg ttgtcttga tccggcccgaa aaacgaattt gcttgcgtt cagcgcttgc 1260
 catgtgcacg atgagttcag gacggcagcg gtggaaaggcc ctttgcac ctggacatg 1320
 gaagactgtg gctacaacat tccacagaca gatgagtcaa ccctcatgac catagcctat 1380
 gtcatggctg ccacatgcgc ccttttcatg ctggcactctt gcctcatggt gtgtcagtgg 1440
 cgctgcctcc gtcgcctgcg ccagcagcat gatgactttt ctgatgacat ctccctgctg 1500
 aagtgaggag gcccattggc agaagataga gatccccctg gaccacaccc cctgggttca 1560
 ctttggtcac aagttaggaga cacagatggc acctgtggcc agagcaccc aggaccctcc 1620
 ccacccacca aatgcctctg ccttgcgtt gaaaggaaaag gctggcaagg tgggttccag 1680
 ggactgtacc tggtagaaac agaaaagaga agaaaagaagc actctgcgtt cggaaatact 1740
 ctttggtcacc tcaaaattttaa gtcggggaaat tctgcgtt gaaacttcag ccctgaacct 1800
 ttgtccacca ttccctttaa ttctccaaacc caaagtattt ttctttctt agtttcagaa 1860
 gtactggcat cacacgcagg ttaccttgcg gtgtgtccctt gtttgcgtt ggcagagaag 1920
 agaccaagct tggtaggactg ctggccaaag tcaatggactg aggtatgcaca gtttgcgtt 1980
 tgcttttagag acagggactg tataaacaag cctaacaattt gtcgaaagat tgcctcttga 2040
 attaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaa 2070

<210> 4

<211> 501

<212> PRT

<213> Homo sapiens

<400> 4

Met Ala Gln Ala Leu Pro Trp Leu Leu Leu Trp Met Gly Ala Gly Val
 1 5 10 15

Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser
 20 25 30

Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp
 35 40 45

Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val
 50 55 60

Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr
 65 70 75 80

Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser
 85 90 95

Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr
 100 105 110

- 5 -

Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val
 115 120 125
 Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp
 130 135 140
 Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile
 145 150 155 160
 Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp
 165 170 175
 Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu Ile Ala Arg Pro Asp Asp
 180 185 190
 Ser Leu Glu Pro Phe Asp Ser Leu Val Lys Gln Thr His Val Pro
 195 200 205
 Asn Leu Phe Ser Leu His Leu Cys Gly Ala Gly Phe Pro Leu Asn Gln
 210 215 220
 Ser Glu Val Leu Ala Ser Val Gly Gly Ser Met Ile Ile Gly Gly Ile
 225 230 235 240
 Asp His Ser Leu Tyr Thr Gly Ser Leu Trp Tyr Thr Pro Ile Arg Arg
 245 250 255
 Glu Trp Tyr Tyr Glu Val Ile Ile Val Arg Val Glu Ile Asn Gly Gln
 260 265 270
 Asp Leu Lys Met Asp Cys Lys Glu Tyr Asn Tyr Asp Lys Ser Ile Val
 275 280 285
 Asp Ser Gly Thr Thr Asn Leu Arg Leu Pro Lys Lys Val Phe Glu Ala
 290 295 300
 Ala Val Lys Ser Ile Lys Ala Ala Ser Ser Thr Glu Lys Phe Pro Asp
 305 310 315 320
 Gly Phe Trp Leu Gly Glu Gln Leu Val Cys Trp Gln Ala Gly Thr Thr
 325 330 335
 Pro Trp Asn Ile Phe Pro Val Ile Ser Leu Tyr Leu Met Gly Glu Val
 340 345 350
 Thr Asn Gln Ser Phe Arg Ile Thr Ile Leu Pro Gln Gln Tyr Leu Arg
 355 360 365
 Pro Val Glu Asp Val Ala Thr Ser Gln Asp Asp Cys Tyr Lys Phe Ala
 370 375 380
 Ile Ser Gln Ser Ser Thr Gly Thr Val Met Gly Ala Val Ile Met Glu
 385 390 395 400
 Gly Phe Tyr Val Val Phe Asp Arg Ala Arg Lys Arg Ile Gly Phe Ala
 405 410 415
 Val Ser Ala Cys His Val His Asp Glu Phe Arg Thr Ala Ala Val Glu
 420 425 430
 Gly Pro Phe Val Thr Leu Asp Met Glu Asp Cys Gly Tyr Asn Ile Pro
 435 440 445

- 6 -

Gln Thr Asp Glu Ser Thr Leu Met Thr Ile Ala Tyr Val Met Ala Ala
 450 455 460

Ile Cys Ala Leu Phe Met Leu Pro Leu Cys Leu Met Val Cys Gln Trp
 465 470 475 480

Arg Cys Leu Arg Cys Leu Arg Gln Gln His Asp Asp Phe Ala Asp Asp
 485 490 495

Ile Ser Leu Leu Lys
 500

<210> 5
<211> 1977
<212> DNA
<213> *Homo sapiens*

<400> 5
atggcccaag ccctgcccctg gctcctgctg tggatggcg cgggagtgct gcctgccccac 60
ggcacccagc acggcatccg gtcgccccctg cgcacgccgc tggggggcgc cccctgggg 120
ctgcggctgc cccggagac cgacgaagag cccgaggagc cccggccggag gggcagcttt 180
gtggagatgg tggacaacct gagggcaag tcggggcagg gctactacgt ggagatgacc 240
gtgggcagcc ccccgagac gtcacacatc ctggtgata caggcagcag taactttgca 300
gtgggtgctg cccccccacc ttccctgcat cgctactacc agaggcagct gtccagcaca 360
taccgggacc tccgaaggg tgttatgtg ccctacaccc agggcaagt ggaaggggag 420
ctgggcaccc acctggtaag catccccat gccccaacg tcactgtcg tgccaacatt 480
gctgccatca ctgaatcaga caagttttc atcaacggct ccaactggga aggcatctg 540
gggctggcct atgctgagat tgccaggctt tgggtgctg gttccccc caaccagtct 600
gaagtgtctgg cctctgtcgg agggagcatg atcattggag gtatcgacca ctgcgtgtac 660
acaggcagtc tctgttatac accccatccgg cgggagtggt attatgaggt gatcattgtg 720
cggttggaga tcaatggaca ggatctgaaa atgactgca aggagtacaa ctatgacaag 780
agcattgtgg acagttggcac caccacccct cgtttgcaca agaaagtgtt tgaagctgca 840
gtcaaatcca tcaaggcagc ctccctccacg gagaagttcc ctgatggtt ctggcttagga 900
gagcagctgg tggctggca agcaggcacc accccttggaa acatttttcc agtcatctca 960
ctctaccta tgggtgaggt taccacccag tccttccgca tcaccatctt tccgcagcaa 1020
tacctggcgc cagtggaaaga tggccacg tcccaagacg actgttacaa gttgcccattc 1080
tcacagttcat ccacgggcac tggatggga gctgttatca tggagggtt ctacgttgc 1140
tttgateggg cccggaaaacg aattgggtt gctgtcagcg cttggcatgt gcacgatgag 1200
ttcaggacgg cagcggtgaa agccctttt gtcaccttgg acatggaaaga ctgtggctac 1260
aacattccac agacagatga gtcaacccctc atgaccatag cctatgtcat ggctggccatc 1320
tgcgcctctt tcatgtgtcc actctggctc atggtgtgtc agtggcgctg cctccgctgc 1380
ctgcgcacgc agcatgtga ctttgctgtat gacatctccc tgctgaagt aggaggccca 1440
tggcagaag atagagattc ccctggacca caccctccgtg gttcaacttgc tcaacaagta 1500
ggagacacag atggcacctg tggccagagc acctcaggac cctccccacc caccaaatgc 1560
ctctgccttg atggagaagg aaaaggctgg caaggtgggt tccagggact gtacctgttag 1620
gaaacagaaa agagaagaaa gaagcactt gctggcgaaa atacttgg tcacctcaaa 1680
ttaaagtgg gaaattctgc tgcttggaaac ttcaagccctg aacctttgtc caccattctt 1740
ttaaatttctc caacccaaag tattttttt ttcttagttt cagaagtaact ggcatcacac 1800
gcagggttacc ttggcgtgtc tccctgtggt accctggcag agaagagacc aagcttgg 1860
ccctgctggc caaagtcaatcaggat gcaagtttgc tattttgtttt tagagacagg 1920
gactgtataa acaaggctaa cattggtgca aagattgcctt cttaaaaaaa aaaaaaaa 1977

<210> 6
<211> 476
<212> PRT
<213> *Homo sapiens*

<400> 6
Met Ala Gln Ala Leu Pro Trp Leu Leu Leu Trp Met Gly Ala Gly Val
1 5 10 15

- 7 -

Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser
 20 25 30
 Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp
 35 40 45
 Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val
 50 55 60
 Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr
 65 70 75 80
 Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser
 85 90 95
 Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr
 100 105 110
 Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val
 115 120 125
 Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp
 130 135 140
 Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile
 145 150 155 160
 Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp
 165 170 175
 Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu Ile Ala Arg Leu Cys Gly
 180 185 190
 Ala Gly Phe Pro Leu Asn Gln Ser Glu Val Leu Ala Ser Val Gly Gly
 195 200 205
 Ser Met Ile Ile Gly Gly Ile Asp His Ser Leu Tyr Thr Gly Ser Leu
 210 215 220
 Trp Tyr Thr Pro Ile Arg Arg Glu Trp Tyr Tyr Glu Val Ile Ile Val
 225 230 235 240
 Arg Val Glu Ile Asn Gly Gln Asp Leu Lys Met Asp Cys Lys Glu Tyr
 245 250 255
 Asn Tyr Asp Lys Ser Ile Val Asp Ser Gly Thr Thr Asn Leu Arg Leu
 260 265 270
 Pro Lys Lys Val Phe Glu Ala Ala Val Lys Ser Ile Lys Ala Ala Ser
 275 280 285
 Ser Thr Glu Lys Phe Pro Asp Gly Phe Trp Leu Gly Glu Gln Leu Val
 290 295 300
 Cys Trp Gln Ala Gly Thr Thr Pro Trp Asn Ile Phe Pro Val Ile Ser
 305 310 315 320
 Leu Tyr Leu Met Gly Glu Val Thr Asn Gln Ser Phe Arg Ile Thr Ile
 325 330 335
 Leu Pro Gln Gln Tyr Leu Arg Pro Val Glu Asp Val Ala Thr Ser Gln
 340 345 350

- 8 -

Asp	Asp	Cys	Tyr	Lys	Phe	Ala	Ile	Ser	Gln	Ser	Ser	Thr	Gly	Thr	Val
355					360										365

Met	Gly	Ala	Val	Ile	Met	Glu	Gly	Phe	Tyr	Val	Val	Phe	Asp	Arg	Ala
370					375										380

Arg	Lys	Arg	Ile	Gly	Phe	Ala	Val	Ser	Ala	Cys	His	Val	His	Asp	Glu
385					390					395					400

Phe	Arg	Thr	Ala	Ala	Val	Glu	Gly	Pro	Phe	Val	Thr	Leu	Asp	Met	Glu
					405			410							415

Asp	Cys	Gly	Tyr	Asn	Ile	Pro	Gln	Thr	Asp	Glu	Ser	Thr	Leu	Met	Thr
					420			425							430

Ile	Ala	Tyr	Val	Met	Ala	Ala	Ile	Cys	Ala	Leu	Phe	Met	Leu	Pro	Leu
					435			440							445

Cys	Leu	Met	Val	Cys	Gln	Trp	Arg	Cys	Leu	Arg	Cys	Leu	Arg	Gln	Gln
					450			455							460

His	Asp	Asp	Phe	Ala	Asp	Asp	Ile	Ser	Leu	Leu	Lys				
					465			470			475				

<210> 7

<211> 2043

<212> DNA

<213> Mus musculus

<400> 7

atggcccccag	cgctgcactg	gctcctgcta	tgggtggct	cgggaatgct	gcctgcccag	60
ggaaccatc	tcggcatccg	gctgccccctt	cgcagcggcc	tggcagggcc	accctgggc	120
ctgaggctgc	cccgggagac	tgacgagaa	tggaggagc	ctggccggag	aggcagcttt	180
gtggagatgg	tggacaaacct	gagggaaag	tccggccagg	gctactatgt	ggagatgacc	240
gtagggcagcc	ccccacagac	gctcaacatc	ctggtgaca	cgggcagtag	taactttgca	300
gtgggggctg	ccccacaccc	tttcctgcat	cgctactacc	agaggcagct	gtccagcaca	360
tatcgagacc	tccgaaaggg	tgtgtatgt	ccctacaccc	agggcaagtg	ggagggggaa	420
ctgggcaccc	acctggtag	catccctcat	ggccccaacg	tcactgtgcg	tgccaacatt	480
gctgccatca	ctgaatcgga	caagttctc	atcaatggtt	ccaactggga	ggcataccta	540
gggctggct	atgctgagat	tgccaggccc	gacgactt	tggagccctt	ctttgactcc	600
ctggtgaagc	agacccacat	tcccaacatc	tttccctgc	agctctgtgg	cgctggcttc	660
ccccctaacc	agaccgaggc	actggcctcg	gtgggaggg	gcatgatcat	tggtgtatc	720
gaccactcgc	tatacacggg	cagtctctgg	tacacaccca	tccggcgaaa	gtgttattat	780
gaagtgtatca	ttgtacgtgt	ggaaatcaat	ggtaagatc	tcaagatgga	ctgcaaggag	840
tacaactacg	acaagagcat	tgtggacagt	gggaccacca	acccatcgctt	gcccaagaaa	900
gtatttgaag	ctggcgatca	gtccatcaag	gcagccctt	cgacggagaa	gttcccgat	960
ggtttttggc	tagggagca	gctgggtgc	tggcaagcag	gcacgacccc	ttgaaacatt	1020
tteccagatcg	tttacttta	cctcatgggt	gaagtccatc	atcagtctt	ccgcatcacc	1080
atccttcctc	agcaataacct	acggccgggt	gaggacgtgg	ccacgtccca	agacgactgt	1140
tacaagttcg	ctgtctcaca	gtcatccacg	ggcactgtta	tgggagccgt	catcatggaa	1200
ggtttctatcg	tcgtcttcga	tcgagccca	aagcgaattt	gctttctgt	cagcgcttgc	1260
catgtgcacg	atgagttcg	gacggcgca	gtgaaaggtc	cgtttgcac	ggcagacatg	1320
gaagactgtg	gctacaacat	tccccagaca	gatgagtcaa	cacttatgac	catagcctat	1380
gtcatggcgg	ccatctgcgc	cctttcatg	ttgccactct	gcctcatgtt	atgtcagtgg	1440
cgctgcctgc	gttgccctgc	ccaccagcac	gatgactttg	ctgatgacat	ctccctgctc	1500
aagaaggag	gctcgtggc	agatgatgga	gacgcccctg	gaccacatct	gggtggttcc	1560
ctttggtcac	atgagttgga	gctatggatg	gtacccgtgg	ccagagcacc	tcaggaccct	1620
caccaacctg	ccaatgttc	tggcgtgaca	gaacagagaa	atcaggcaag	ctggattaca	1680
gggcttgac	ctgtaggaca	caggagaggg	aagaaggag	cgttctggtg	gcaggaatat	1740
ccttaggcac	cacaaacttg	agttggaaat	tttgcgtctt	gaagcttcag	ccctgaccct	1800
ctgcccagca	tccttttagag	tctccaaacct	aaagtattct	tatgtcctt	ccagaagtac	1860

- 9 -

tggcgtcata ctcaggctac ccggcatgtg tccctgtggc accctggcag agaaagggcc 1920
 aatctcattc cctgctggcc aaagtca gaaagaagggtg aagtttgcga gttgcttttag 1980
 tgatagggac tgcagactca agcctacact ggtacaaaga ctgcgtcttg agataaaacaa 2040
 gaa 2043

<210> 8
 <211> 501
 <212> PRT
 <213> Mus musculus

<400> 8
 Met Ala Pro Ala Leu His Trp Leu Leu Leu Trp Val Gly Ser Gly Met
 1 5 10 15

Leu Pro Ala Gln Gly Thr His Leu Gly Ile Arg Leu Pro Leu Arg Ser
 20 25 30

Gly Leu Ala Gly Pro Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp
 35 40 45

Glu Glu Ser Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val
 50 55 60

Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr
 65 70 75 80

Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser
 85 90 95

Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr
 100 105 110

Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val
 115 120 125

Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp
 130 135 140

Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile
 145 150 155 160

Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp
 165 170 175

Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu Ile Ala Arg Pro Asp Asp
 180 185 190

Ser Leu Glu Pro Phe Phe Asp Ser Leu Val Lys Gln Thr His Ile Pro
 195 200 205

Asn Ile Phe Ser Leu Gln Leu Cys Gly Ala Gly Phe Pro Leu Asn Gln
 210 215 220

Thr Glu Ala Leu Ala Ser Val Gly Gly Ser Met Ile Ile Gly Gly Ile
 225 230 235 240

Asp His Ser Leu Tyr Thr Gly Ser Leu Trp Tyr Thr Pro Ile Arg Arg
 245 250 255

Glu Trp Tyr Tyr Glu Val Ile Ile Val Arg Val Glu Ile Asn Gly Gln
 260 265 270

- 10 -

Asp	Leu	Lys	Met	Asp	Cys	Lys	Glu	Tyr	Asn	Tyr	Asp	Lys	Ser	Ile	Val
275						280						285			
Asp	Ser	Gly	Thr	Thr	Asn	Leu	Arg	Leu	Pro	Lys	Lys	Val	Phe	Glu	Ala
290						295					300				
Ala	Val	Lys	Ser	Ile	Lys	Ala	Ala	Ser	Ser	Thr	Glu	Lys	Phe	Pro	Asp
305					310				315			320			
Gly	Phe	Trp	Leu	Gly	Glu	Gln	Leu	Val	Cys	Trp	Gln	Ala	Gly	Thr	Thr
325					330				335						
Pro	Trp	Asn	Ile	Phe	Pro	Val	Ile	Ser	Leu	Tyr	Leu	Met	Gly	Glu	Val
340					345						350				
Thr	Asn	Gln	Ser	Phe	Arg	Ile	Thr	Ile	Leu	Pro	Gln	Gln	Tyr	Leu	Arg
355					360						365				
Pro	Val	Glu	Asp	Val	Ala	Thr	Ser	Gln	Asp	Asp	Cys	Tyr	Lys	Phe	Ala
370					375					380					
Val	Ser	Gln	Ser	Ser	Thr	Gly	Thr	Val	Met	Gly	Ala	Val	Ile	Met	Glu
385					390				395			400			
Gly	Phe	Tyr	Val	Val	Phe	Asp	Arg	Ala	Arg	Lys	Arg	Ile	Gly	Phe	Ala
405					410				415						
Val	Ser	Ala	Cys	His	Val	His	Asp	Glu	Phe	Arg	Thr	Ala	Ala	Val	Glu
420					425						430				
Gly	Pro	Phe	Val	Thr	Ala	Asp	Met	Glu	Asp	Cys	Gly	Tyr	Asn	Ile	Pro
435					440						445				
Gln	Thr	Asp	Glu	Ser	Thr	Leu	Met	Thr	Ile	Ala	Tyr	Val	Met	Ala	Ala
450					455				460						
Ile	Cys	Ala	Leu	Phe	Met	Leu	Pro	Leu	Cys	Leu	Met	Val	Cys	Gln	Trp
465					470				475			480			
Arg	Cys	Leu	Arg	Cys	Leu	Arg	His	Gln	His	Asp	Asp	Phe	Ala	Asp	Asp
485					490						495				
Ile	Ser	Leu	Leu	Lys											
500															

<210> 9

<211> 2088

<212> DNA

<213> Homo sapiens

<400> 9

atgctccccg	gtttggca	ct gctcctgctg	gccgcctgga	cggctcgggc	gctggaggta	60
cccaactgatg	gtaatgctgg	cctgctggct	gaaccccaga	ttgccatgtt	ctgtggcaga	120
ctgaacatgc	acatgaatgt	ccagaatggg	aagtggatt	cagatccatc	aggacccaaa	180
acctgcattg	ataccaagga	aggcatcctg	cagtattgcc	aagaagtcta	ccctgaactg	240
cagatcacca	atgtggtaga	agccaaaccaa	ccagtgacca	tccagaactg	gtgcaagcgg	300
ggccgcaga	agtcaagac	ccatccccac	tttgtgattc	cctaccgctg	cttagttgg	360
gagtttgtaa	gtgatgcct	tctcggttct	gacaagtgc	aatttttaca	ccaggagagg	420
atggatgttt	gcgaaactca	tcttcactgg	cacaccgtcg	ccaaagagac	atgcagtgag	480
aagagtacca	acttgcatga	ctacggcatg	ttgtgcct	gcggatttga	caagttccga	540
ggggtagagt	ttgtgtgttg	cccactggct	gaagaaaatg	acaatgtgga	ttctgctgat	600

- 11 -

gcggaggagg atgactcgga tgcgtggcgg ggcggagcag acacagacta tgcagatggg 660
 agtgaagaca aagttaga agtagcagag gagaagaag tggctgaggt ggaagaagaa 720
 gaagccgatg atgacgagga cgatgaggat ggtatgagg tagaggaaga ggctgaggaa 780
 ccctacaaag aagccacaga gagaaccacc agattgcca ccaccaccac caccaccaca 840
 gagtctgtgg aagaggtgt tcgagttcct acaacacgag ccagtacccc tgatgccgtt 900
 gacaagtatc tcgagacacc tggggatgag aatgaacatg cccatttcca gaaagccaaa 960
 gagaggcttg aggccaagca ccgagagaga atgtcccagg tcatgagaga atgggaagag 1020
 gcagaacgtc aagcaaagaa ctgcctaaa gctgataaga aggcaggatcc ccagcatttc 1080
 caggagaaag tggaaatctt ggaacaggaa gcagccaacg agagacagca gctgggtggag 1140
 acacacatgg ccagagtgg a gccatgctc aatgaccgccc gccgcctggc cctggagaac 1200
 tacatcaccc ctctgcaggc tgccttcct cggcctcgatc acgtgttcaa tatgctaaag 1260
 aagtatgtcc ggcagaaca gaaggacaga cagcacaccc taaagcattt cgacatgtg 1320
 cgcatggtgg atccaaagaa agccgctcag atccgggtccc aggttatgac acacccctcg 1380
 gtgatttatg agcgcattgaa tcagtccttc tcctctgtt acaacgtgccc tgcaatggcc 1440
 gaggagattc agatgaagt tgatgagctg ctccagaaag agcaaaacta ttcatgatgac 1500
 gtcttggcca acatgattag tgaaccaagg atcagttacg gaaacgatgc tctcatgcca 1560
 tctttgaccg aaacgaaaac caccgtggag ctccctcccg tgaatggaga gttcagcctg 1620
 gacgatctcc agccgtggca ttctttggg gctgactctg tgccagccaa cacagaaaac 1680
 gaagttgagc ctgttgcattt cccgcctgtt gccgaccgag gactgaccac tcgaccaggt 1740
 tctgggttga caaatatcaa gacggaggag atctctgaag tgaagatgga tgcagaattc 1800
 cgacatgact caggatatga agttcatcat caaaaattgg tggatcttgc agaagatgtg 1860
 ggttcaaaca aagggtcaat cattggactc atggtggcgt gttgttgc aegcagactg 1920
 atcgtcatca ccttgggtat gctgaagaag aaacagtaca catccattca tcatgggtgt 1980
 gtggagggttgc acggccgtgtt caccggcag gagegcccacc tgcataatgatgc gacgagaac 2040
 ggctacgaaa atccaaccta caagttttt gagcagatgc agaactag 2088

<210> 10

<211> 695

<212> PRT

<213> Homo sapiens

<400> 10

Met Leu Pro Gly Leu Ala Leu Leu Leu Ala Ala Trp Thr Ala Arg
 1 5 10 15

Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
 20 25 30

Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
 35 40 45

Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
 50 55 60

Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
 65 70 75 80

Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
 85 90 95

Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
 100 105 110

Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
 115 120 125

Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
 130 135 140

Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
 145 150 155 160

- 12 -

Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
 165 170 175

Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
 180 185 190

Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
 195 200 205

Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
 210 215 220

Val Val Glu Val Ala Glu Glu Glu Val Ala Glu Val Glu Glu Glu
 225 230 235 240

Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
 245 250 255

Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
 260 265 270

Ala Thr Thr Thr Thr Thr Glu Ser Val Glu Val Val Val Arg
 275 280 285

Val Pro Thr Thr Ala Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu
 290 295 300

Glu Thr Pro Gly Asp Glu Asn Glu His Ala His Phe Gln Lys Ala Lys
 305 310 315 320

Glu Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gln Val Met Arg
 325 330 335

Glu Trp Glu Glu Ala Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp
 340 345 350

Lys Lys Ala Val Ile Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu
 355 360 365

Gln Glu Ala Ala Asn Glu Arg Gln Gln Leu Val Glu Thr His Met Ala
 370 375 380

Arg Val Glu Ala Met Leu Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn
 385 390 395 400

Tyr Ile Thr Ala Leu Gln Ala Val Pro Pro Arg Pro Arg His Val Phe
 405 410 415

Asn Met Leu Lys Lys Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His
 420 425 430

Thr Leu Lys His Phe Glu His Val Arg Met Val Asp Pro Lys Lys Ala
 435 440 445

Ala Gln Ile Arg Ser Gln Val Met Thr His Leu Arg Val Ile Tyr Glu
 450 455 460

Arg Met Asn Gln Ser Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala
 465 470 475 480

Glu Glu Ile Gln Asp Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn
 485 490 495

- 13 -

Tyr Ser Asp Asp Val Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser		
500	505	510
Tyr Gly Asn Asp Ala Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr		
515	520	525
Val Glu Leu Leu Pro Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln		
530	535	540
Pro Trp His Ser Phe Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn		
545	550	555
Glu Val Glu Pro Val Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr		
565	570	575
Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser		
580	585	590
Glu Val Lys Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val		
595	600	605
His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys		
610	615	620
Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val		
625	630	635
Ile Val Ile Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile		
645	650	655
His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg		
660	665	670
His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys		
675	680	685
Phe Phe Glu Gln Met Gln Asn		
690	695	

<210> 11
<211> 2088
<212> DNA
<213> Homo sapiens

<400> 11
atgctggccg gtttggact gctcctgctg gccgcctgga cggctcgccc gctggaggta 60
cccaactgatg gtaatgctgg cctgctggct gaacccaga ttgccatgtt ctgtggcaga 120
ctgaacatgc acatgaatgt ccagaatggg aagtggatt cagatccatc agggaccaaa 180
acctgcattg ataccaagga aggcatctg cagtattgcc aagaagtcta ccctgaactg 240
cagatcacca atgtggtaga agccaaccaa ccagtgacca tccagaactg gtgcaagcgg 300
ggccgcaagc atgtcaagac ccatccccac ttgtgattc cctaccgctg cttagttgg 360
gagtttgtaa gtgatgccct ttcgttccct gacaagtgc aattcttaca ccaggagagg 420
atggatgtt gcaaaactca tcttcaactgg cacaccgtcg ccaaagagac atgcagttag 480
aagagtacca acttgcata ctagggcatg ttgctgcctt gccaattgtt caagttccga 540
ggggtagatgt ttgtgttgtt cccactggct gaagaaagtg acaatgtgga ttctgctgat 600
gcggaggagg atgactcgga tgtctggtgg ggcggaggcag acacagacta tgcatggg 660
agtgaagaca aagttagtga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720
gaagccgatg atgacgagga ctagggat ggtgatgagg tagaggaaga ggctgaggaa 780
ccctaccaag aagccacaga gagaacccacc agcattgcca ccaccaccc caccaccaca 840
gagtctgtgg aagagggtgt tcgagttccct acaacagcag ccagtacccc tgatgccgtt 900
gacaagtatc tcgagacacc tggggatgag aatgaacatg cccatttcca gaaagccaaa 960

- 14 -

gagaggcttt	aggccaagca	ccgagagaga	atgtccccagg	tcatgagaga	atgggaagag	1020
gcagaacgtc	aagcaaagaa	cttgccctaaa	gctgataaga	aggcagttat	ccagcatttc	1080
caggagaaaag	tggaatcttt	ggaacaggaa	gcagccaaacg	agagacagca	gctgggtggag	1140
acacacatgg	ccagagtgg	agccatgctc	aatgaccgccc	gcccgcctggc	cctggagaac	1200
tacatcacgg	ctctgcaggc	tgttccctct	cgccctcgtc	acgtgttcaa	tatgtctaaag	1260
aagtatgtcc	gcgcagaaca	gaaggacaga	cagcacacccc	taaaggcattt	cgagcatgtg	1320
cgcatggtgg	atcccaagaa	agccgctcag	atccggtccc	aggttatgac	acacacctccgt	1380
gtgattttatg	agcgcattgaa	tcagttcttc	tccctgtct	acaacgtgcc	tgcagtggcc	1440
gaggagattc	aggatgaagt	tgatgagctg	cttcagaaaaag	agcaaaaacta	ttcagatgac	1500
gtcttggcca	acatgatttag	tgaaccaagg	atcagttacg	gaaacgtatgc	tctcatgcca	1560
tctttgaccg	aaacgaaaac	caccgtggag	ctccctcccg	tgaatggaga	gttcagcctg	1620
gacgatctcc	agccgtggca	ttctttttggg	gctgactctg	tgccagccaa	cacagaaaaac	1680
gaagttgagc	cttggatgc	ccggccctgt	gcccggccgg	gactgaccac	tgcaccagg	1740
tctgggttga	caaataatcaa	gacggggagg	atctctgaag	tgaatctgg	tgcagaattc	1800
cgacatgact	caggatatga	agttcatcat	caaaaattgg	tgttctttgc	agaagatgtg	1860
ggttcaaaaca	aaggtgtcaat	cattggactc	atggtggggcg	gtgttgcata	agcgcacagt	1920
atcgatcatca	ccttgggtat	gctgaagaag	aaacagtaca	catccattca	tcatgggtgt	1980
gtggagggtt	acggcgctgt	caccccccagag	gagcgccacc	tgtccaagat	gcagcagaac	2040
ggctacgaaa	atccaaccta	caagttcttt	gagcagatgc	agaactag		2088

<210> 12

<211> 695

<212> PRT

<213> Homo sapiens

<400> 12

Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
 1 5 10 15

Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
20 25 30

Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
35 40 45

Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
50 55 60

Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
 65 70 75 80

Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
85 90 95

Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
100 105 110

Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
115 120 125

Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
130 135 140

Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
 145 150 155 160

Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
165 170 175

Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
180 185 190

- 15 -

Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
195 200 205

Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
210 215 220

Val Val Glu Val Ala Glu Glu Glu Val Ala Glu Val Glu Glu Glu
225 230 235 240

Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
245 250 255

Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
260 265 270

Ala Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
275 280 285

Val Pro Thr Thr Ala Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu
290 295 300

Glu Thr Pro Gly Asp Glu Asn Glu His Ala His Phe Gln Lys Ala Lys
305 310 315 320

Glu Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gln Val Met Arg
325 330 335

Glu Trp Glu Glu Ala Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp
340 345 350

Lys Lys Ala Val Ile Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu
355 360 365

Gln Glu Ala Ala Asn Glu Arg Gln Gln Leu Val Glu Thr His Met Ala
370 375 380

Arg Val Glu Ala Met Leu Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn
385 390 395 400

Tyr Ile Thr Ala Leu Gln Ala Val Pro Pro Arg Pro Arg His Val Phe
405 410 415

Asn Met Leu Lys Lys Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His
420 425 430

Thr Leu Lys His Phe Glu His Val Arg Met Val Asp Pro Lys Lys Ala
435 440 445

Ala Gln Ile Arg Ser Gln Val Met Thr His Leu Arg Val Ile Tyr Glu
450 455 460

Arg Met Asn Gln Ser Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala
465 470 475 480

Glu Glu Ile Gln Asp Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn
485 490 495

Tyr Ser Asp Asp Val Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser
500 505 510

- 16 -

Tyr Gly Asn Asp Ala Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr
515 520 525

Val Glu Leu Leu Pro Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln
530 535 540

Pro Trp His Ser Phe Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn
545 550 555 560

Glu Val Glu Pro Val Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr
565 570 575

Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser
580 585 590

Glu Val Asn Leu Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val
595 600 605

His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
610 615 620

Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val
625 630 635 640

Ile Val Ile Thr Leu Val Met Leu Lys Lys Gln Tyr Thr Ser Ile
645 650 655

His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg
660 665 670

His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys
675 680 685

Phe Phe Glu Gln Met Gln Asn
690 695

<210> 13

<211> 2088

<212> DNA

<213> Homo sapiens

<400> 13

atgctgcccg gttggcaact gtcctgctg gccgcctgga cggctcgccc gctggaggta 60
cccaactgatg gtaatgctgg cctgctggct gaacccccaga ttgccatgtt ctgtggcaga 120
ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc aggaccaaaa 180
acctgcattg ataccaagga aggcattctg cagattgcc aagaagtcta ccctgaactg 240
cagatcacca atgtggtaga agccaaccaa ccagtgacca tccagaactg gtgcaagcgg 300
ggccgcaagc agtgcacagac ccatccccac tttgtgattc cctaccgctg cttagtttgt 360
gagtttgtaa gtgatgccct tctcgttctt gacaagtgc aattcttaca ccaggagagg 420
atggatgttt gcgaaactca tcttcactgg cacaccgtcg ccaaagagac atgcagttag 480
aagagtacca acttgcatga ctacggcatg ttgctgccct gcggaaattga caagttccga 540
ggggtagagt ttgtgttgtt cccactggct gaagaaaagtg acaatgtgga ttctgctgat 600
gcggaggagg atgactcgga tgtctggtgg ggccggagcag acacagacta tgcagatggg 660
agtgaagaca aagtagttaga agtagcagag gagaagaag tggctgaggt ggaagaagaa 720
gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
ccctacgaag aagccacaga gagaaccacc agcattgcc ccaccacacc caccaccaca 840
gagtctgtgg aagagggtgt tcgagttctt acaacagcag ccagtacccc tgatgccgtt 900
gacaagtatc tcgagacacc tggggatgag aatgaacatg cccatttcca gaaagccaaa 960
gagaggcttg aggccaagca cccgagagaga atgtcccagg tcatgagaga atggaaagag 1020
gcagaacgtc aagcaaagaa cttgcctaaa gctgataaga aggcaggat tatccagcatttc 1080
caggagaaaag tggaaatcttt ggaacaggaa gcagccaaacg agagacacca gctgggtggag 1140
acacacatgg ccagagtggaa agccatgctc aatgaccgac gccgcctggc cctggagaac 1200

- 17 -

```
tacatcaccc ctctgcaggc tgttcctctt cggcctcgac acgtgttcaa tatgctaaag 1260
aagtatgtcc ggcgagaaca gaaggacaga cagcacaccc taaagcattt cgagcatgtg 1320
cgcatggtgg atcccaagaa agccgctcgatcccg aggttatgac acacccgt 1380
gtgattttatg agcgcattgaa tcagtcttc tccctgtct acaacgtgcc tgcagtggcc 1440
gaggagatc aggtgaaatg tgatgagtg cttcagaaag agcaaaaactt ttcagatgac 1500
gtcttggcca acatgatttag tgaacccaagg atcagttacg gaaacgtgc tctcatgcca 1560
tctttgaccg aaacgaaaac caccgtggag ctccttccc tgaatggaga gttcagcctg 1620
gacgatcttc agccgtggca ttcttttggg gctgactctg tgccagccaa cacagaaaac 1680
gaagttgagc ctgttgatgc ccggccctgtccggcggaccgag gactgaccac tcgaccagg 1740
tctgggttga caaatatcaa gacggaggag atctctgaag tgaagatgga tgcagaattc 1800
cgacatgact caggatataa agttcatcat caaaaaattgg ttttttttc tgaagatgtg 1860
ggttcaaaaca aagggtgcaat cattggactc atgggtggcg gtgttgtcat agcgcacagt 1920
atcttcatca ctttgggtat gctgaagaag aaacagtaca catccatca tcattgggtg 1980
gtggagggtt acgcgcgtgt caccggcagag gagcgcacc ttttccaaatgat gcagcagaac 2040
ggctacgaaa atccaaccta caagttctt gacgacatgc agaactag 2088
```

<210> 14

<211> 695

<212> PRT

<213> Homo sapiens

<400> 14

Met	Leu	Pro	Gly	Leu	Ala	Leu	Leu	Leu	Leu	Ala	Ala	Trp	Thr	Ala	Arg
1														15	

Ala	Leu	Glu	Val	Pro	Thr	Asp	Gly	Asn	Ala	Gly	Leu	Leu	Ala	Glu	Pro
														30	

Gln	Ile	Ala	Met	Phe	Cys	Gly	Arg	Leu	Asn	Met	His	Met	Asn	Val	Gln
														45	

Asn	Gly	Lys	Trp	Asp	Ser	Asp	Pro	Ser	Gly	Thr	Lys	Thr	Cys	Ile	Asp
														50	
															55

Thr	Lys	Glu	Gly	Ile	Leu	Gln	Tyr	Cys	Gln	Glu	Val	Tyr	Pro	Glu	Leu
															60
															65

Gln	Ile	Thr	Asn	Val	Val	Glu	Ala	Asn	Gln	Pro	Val	Thr	Ile	Gln	Asn
															95
															85

Trp	Cys	Lys	Arg	Gly	Arg	Lys	Gln	Cys	Lys	Thr	His	Pro	His	Phe	Val
															100
															105

Ile	Pro	Tyr	Arg	Cys	Leu	Val	Gly	Glu	Phe	Val	Ser	Asp	Ala	Leu	Leu
															115
															120

Val	Pro	Asp	Lys	Cys	Lys	Phe	Leu	His	Gln	Glu	Arg	Met	Asp	Val	Cys
															130
															135

Glu	Thr	His	Leu	His	Trp	His	Thr	Val	Ala	Lys	Glu	Thr	Cys	Ser	Glu
															145
															150

Lys	Ser	Thr	Asn	Leu	His	Asp	Tyr	Gly	Met	Leu	Leu	Pro	Cys	Gly	Ile
															165
															170

Asp	Lys	Phe	Arg	Gly	Val	Glu	Phe	Val	Cys	Cys	Pro	Leu	Ala	Glu	Glu
															180
															185

Ser	Asp	Asn	Val	Asp	Ser	Ala	Asp	Ala	Glu	Glu	Asp	Asp	Ser	Asp	Val
															195
															200

205

- 18 -

Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
210 215 220

Val Val Glu Val Ala Glu Glu Glu Val Ala Glu Val Glu Glu Glu
225 230 235 240

Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
245 250 255

Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
260 265 270

Ala Thr Thr Thr Thr Thr Glu Ser Val Glu Val Val Arg
275 280 285

Val Pro Thr Thr Ala Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu
290 295 300

Glu Thr Pro Gly Asp Glu Asn Glu His Ala His Phe Gln Lys Ala Lys
305 310 315 320

Glu Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gln Val Met Arg
325 330 335

Glu Trp Glu Glu Ala Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp
340 345 350

Lys Lys Ala Val Ile Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu
355 360 365

Gln Glu Ala Ala Asn Glu Arg Gln Gln Leu Val Glu Thr His Met Ala
370 375 380

Arg Val Glu Ala Met Leu Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn
385 390 395 400

Tyr Ile Thr Ala Leu Gln Ala Val Pro Pro Arg Pro Arg His Val Phe
405 410 415

Asn Met Leu Lys Lys Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His
420 425 430

Thr Leu Lys His Phe Glu His Val Arg Met Val Asp Pro Lys Lys Ala
435 440 445

Ala Gln Ile Arg Ser Gln Val Met Thr His Leu Arg Val Ile Tyr Glu
450 455 460

Arg Met Asn Gln Ser Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala
465 470 475 480

Glu Glu Ile Gln Asp Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn
485 490 495

Tyr Ser Asp Asp Val Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser
500 505 510

Tyr Gly Asn Asp Ala Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr
515 520 525

Val Glu Leu Leu Pro Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln
530 535 540

- 19 -

Pro Trp His Ser Phe Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn
545 550 555 560

Glu Val Glu Pro Val Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr
565 570 575

Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser
580 585 590

Glu Val Lys Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val
595 600 605

His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
610 615 620

Gly Ala Ile Ile Gly Leu Met Val Gly Val Val Ile Ala Thr Val
625 630 635 640

Ile Phe Ile Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile
645 650 655

His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg
660 665 670

His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys
675 680 685

Phe Phe Glu Gln Met Gln Asn
690 695

<210> 15

<211> 2094

<212> DNA

<213> Homo sapiens

<400> 15

atgctgcccc gttggcaact gtcctgtcg gcccttggc cggctcgccc gctggaggta 60
 cccactgatg gtaatgtctgg cctgtgtgcgtaa gaaaaacccaga ttgcattgtt ctgtggcaga 120
 ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggacccaa 180
 acctgcattt ataccaagga aggcatctcg cagatgtcc aagaagtcta ccctgaactg 240
 cagatcacca atgtggtaga agccaaccaa ccagtgcacca tccagaactg gtgcacgg 300
 ggccgcaagc agtcaagac ccatccccac tttgtattt cctaccgtcg cttagtttgt 360
 gagtttgaa gtgatgccct tctgtttctt gacaagtgc aattcttaca ccaggagagg 420
 atggatgttt gcgaaaactca tcttcaactgg cacaccgtcg ccaaagagac atgcagttag 480
 aagagtacca acttgcattt ctacggcatg ttgtgtccct gccaatgttca caagttccga 540
 ggggttagagt ttgtgtgtt cccactggct gaagaaagtg acaatgttgc ttctgtgtat 600
 gcgaggagg atgactcgaa tgtctgtgg ggccggagcg acacagacta tgcatgggg 660
 agtgaagaca aagtagttaga agtagcagag gaggagaagat tggctgagggt ggaagaagaa 720
 gaagccgatg atgacgagga cgatgaggat ggtgtatgggg tagaggaaga ggctgaggaa 780
 ccctacgaag aagccacaga gagaaccacc agcattgcac ccaccaccc caccaccaca 840
 gagtctgtgg aagagggtgt tcgagtttccct acaacagcag ccagtacccc tgatgccgtt 900
 gacaagtatc tcgagacacc tggggatgag aatgaacatg cccatttcca gaaagccaaa 960
 gagaggcttgg aggccaaagca ccgagagaga atgtcccagg tcatgagaga atggaaagag 1020
 gcagaacgtc aagcaaaagaa cttgcctaaa gctgataaga aggcagttat ccagcatttc 1080
 caggagaaag tggaatctttt ggaacaggaa gcagccaaacg agagacagca gctgggtggag 1140
 acacacatgg ccagagtggaa agccatgttc aatgaccggcc gccgcctggc cctggagaac 1200
 tacatcaccc ctctgcaggc tggttccctt cggcctcgtc acgtgttcaa tatgctaaag 1260
 aagtatgtcc ggcagaaca gaaggacaga cagcacaccc taaagcattt cgagcatgtg 1320
 cgcatgggtgg atcccaagaa agccgctcag atccggtccc aggttatgac acacctccgt 1380
 gtgatttatg agcgtatgaa tcagtccttc tccctgtct acaacgtgcc tgcagtggcc 1440
 gaggagatc aggtatgaaatg tgatgagctg cttcagaaag agcaaaaacta ttcatgatgac 1500

- 20 -

gtcttggcca	acatgattag	tgaaccaagg	atcagttacg	gaaacgatgc	tctcatgc	1560
tctttgaccg	aaacgaaaac	caccgtggag	ctcccttccc	tgaatggaga	gttcagc	1620
gacgatctcc	agccgtggca	ttctttggg	gctgactctg	tgccagccaa	cacagaaaac	1680
gaagttgagc	ctgttcatgc	ccgccccgtct	ggccgaccgag	gactgaccac	tcgaccagg	1740
tctgggttga	caaataatcaa	gacggaggag	atctctgaag	tgaagatgga	tgcagaattc	1800
cgacatgact	caggatatga	agttcatcat	caaaaattgg	tggtcttgc	agaagatgt	1860
ggttcaaaaca	aagggtgcaat	cattggactc	atggtgggcg	gtgttgtcat	agcgcacagt	1920
atcgcatca	ccttgggtat	gctgaagaag	aaacagtaca	catccattca	tcatgggtgt	1980
gtggagggtt	acgccgcgt	caccccaagag	gagcgccacc	tgtccaagat	gcagcagaac	2040
ggctacgaaa	atccaaccta	caagttttt	gagcagatgc	agaacaagaa	gtag	2094

<210> 16

<211> 697

<212> PRT

<213> Homo sapiens

<400> 16

Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
1 5 10 15

Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
20 25 30

Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
35 40 45

Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
50 55 60

Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
65 70 75 80

Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
85 90 95

Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
100 105 110

Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
115 120 125

Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
130 135 140

Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
 145 150 155 160

Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
165 170 175

Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
180 185 190

Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
195 200 205

Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
210 215 220

Val Val Glu Val Ala Glu Glu Glu Glu Val Ala Glu Val Glu Glu Glu
225 230 235 240

- 21 -

Glu	Ala	Asp	Asp	Asp	Glu	Asp	Asp	Glu	Asp	Gly	Asp	Glu	Val	Glu	Glu
245					250								255		
Glu	Ala	Glu	Glu	Pro	Tyr	Glu	Glu	Ala	Thr	Glu	Arg	Thr	Thr	Ser	Ile
260					265								270		
Ala	Thr	Thr	Thr	Thr	Thr	Thr	Glu	Ser	Val	Glu	Glu	Val	Val	Arg	
275					280							285			
Val	Pro	Thr	Thr	Ala	Ala	Ser	Thr	Pro	Asp	Ala	Val	Asp	Lys	Tyr	Leu
290					295							300			
Glu	Thr	Pro	Gly	Asp	Glu	Asn	Glu	His	Ala	His	Phe	Gln	Lys	Ala	Lys
305					310							315			320
Glu	Arg	Leu	Glu	Ala	Lys	His	Arg	Glu	Arg	Met	Ser	Gln	Val	Met	Arg
325					330							335			
Glu	Trp	Glu	Glu	Ala	Glu	Arg	Gln	Ala	Lys	Asn	Leu	Pro	Lys	Ala	Asp
340					345							350			
Lys	Lys	Ala	Val	Ile	Gln	His	Phe	Gln	Glu	Lys	Val	Glu	Ser	Leu	Glu
355					360							365			
Gln	Glu	Ala	Ala	Asn	Glu	Arg	Gln	Gln	Leu	Val	Glu	Thr	His	Met	Ala
370					375							380			
Arg	Val	Glu	Ala	Met	Leu	Asn	Asp	Arg	Arg	Arg	Leu	Ala	Leu	Glu	Asn
385					390							395			400
Tyr	Ile	Thr	Ala	Leu	Gln	Ala	Val	Pro	Pro	Arg	Pro	Arg	His	Val	Phe
405					410							415			
Asn	Met	Leu	Lys	Lys	Tyr	Val	Arg	Ala	Glu	Gln	Lys	Asp	Arg	Gln	His
420					425							430			
Thr	Leu	Lys	His	Phe	Glu	His	Val	Arg	Met	Val	Asp	Pro	Lys	Lys	Ala
435					440							445			
Ala	Gln	Ile	Arg	Ser	Gln	Val	Met	Thr	His	Leu	Arg	Val	Ile	Tyr	Glu
450					455							460			
Arg	Met	Asn	Gln	Ser	Leu	Ser	Leu	Leu	Tyr	Asn	Val	Pro	Ala	Val	Ala
465					470							475			480
Glu	Glu	Ile	Gln	Asp	Glu	Val	Asp	Glu	Leu	Leu	Gln	Lys	Glu	Gln	Asn
485					490							495			
Tyr	Ser	Asp	Asp	Val	Leu	Ala	Asn	Met	Ile	Ser	Glu	Pro	Arg	Ile	Ser
500					505							510			
Tyr	Gly	Asn	Asp	Ala	Leu	Met	Pro	Ser	Leu	Thr	Glu	Thr	Lys	Thr	Thr
515					520							525			
Val	Glu	Leu	Leu	Pro	Val	Asn	Gly	Glu	Phe	Ser	Leu	Asp	Asp	Leu	Gln
530					535							540			
Pro	Trp	His	Ser	Phe	Gly	Ala	Asp	Ser	Val	Pro	Ala	Asn	Thr	Glu	Asn
545					550							555			560
Glu	Val	Glu	Pro	Val	Asp	Ala	Arg	Pro	Ala	Ala	Asp	Arg	Gly	Leu	Thr
565					570							575			

- 22 -

Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser
580 585 590

Glu Val Lys Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val
595 600 605

His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
610 615 620

Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Val Ile Ala Thr Val
625 630 635 640

Ile Val Ile Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile
645 650 655

His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg
660 665 670

His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys
675 680 685

Phe Phe Glu Gln Met Gln Asn Lys Lys
690 695

<210> 17
<211> 2094
<212> DNA
<213> *Homo sapiens*

- 23 -

ggttcaaaaca aagggtgcaat cattggactc atgggtggcg gtgttgcata agcgacagt 1920
 atcgcatca ccttggat gctgaagaag aaacagtaca catccattca tcatggtgt 1980
 gtggaggtt acgcccgtgt caccccagag gagcgcacc tgtccaagat gcagcagaac 2040
 ggctacgaaa atccaaccta caagttttt gagcagatgc agaacaagaa gtag 2094

<210> 18
 <211> 697
 <212> PRT
 <213> Homo sapiens

<400> 18
 Met Leu Pro Gly Leu Ala Leu Leu Leu Ala Ala Trp Thr Ala Arg
 1 5 10 15

Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
 20 25 30

Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
 35 40 45

Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
 50 55 60

Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
 65 70 75 80

Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
 85 90 95

Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
 100 105 110

Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
 115 120 125

Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
 130 135 140

Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
 145 150 155 160

Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
 165 170 175

Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
 180 185 190

Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
 195 200 205

Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
 210 215 220

Val Val Glu Val Ala Glu Glu Glu Val Ala Glu Val Glu Glu Glu
 225 230 235 240

Glu Ala Asp Asp Asp Glu Asp Asp Gly Asp Glu Val Glu Glu
 245 250 255

Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
 260 265 270

- 24 -

Ala Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
 275 280 285
 Val Pro Thr Thr Ala Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu
 290 295 300
 Glu Thr Pro Gly Asp Glu Asn Glu His Ala His Phe Gln Lys Ala Lys
 305 310 315 320
 Glu Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gln Val Met Arg
 325 330 335
 Glu Trp Glu Glu Ala Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp
 340 345 350
 Lys Lys Ala Val Ile Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu
 355 360 365
 Gln Glu Ala Ala Asn Glu Arg Gln Gln Leu Val Glu Thr His Met Ala
 370 375 380
 Arg Val Glu Ala Met Leu Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn
 385 390 395 400
 Tyr Ile Thr Ala Leu Gln Ala Val Pro Pro Arg Pro Arg His Val Phe
 405 410 415
 Asn Met Leu Lys Lys Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His
 420 425 430
 Thr Leu Lys His Phe Glu His Val Arg Met Val Asp Pro Lys Lys Ala
 435 440 445
 Ala Gln Ile Arg Ser Gln Val Met Thr His Leu Arg Val Ile Tyr Glu
 450 455 460
 Arg Met Asn Gln Ser Leu Ser Leu Tyr Asn Val Pro Ala Val Ala
 465 470 475 480
 Glu Glu Ile Gln Asp Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn
 485 490 495
 Tyr Ser Asp Asp Val Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser
 500 505 510
 Tyr Gly Asn Asp Ala Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr
 515 520 525
 Val Glu Leu Leu Pro Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln
 530 535 540
 Pro Trp His Ser Phe Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn
 545 550 555 560
 Glu Val Glu Pro Val Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr
 565 570 575
 Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser
 580 585 590
 Glu Val Asn Leu Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val
 595 600 605

- 25 -

His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
 610 615 620

Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val
 625 630 635 640

Ile Val Ile Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile
 645 650 655

His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg
 660 665 670

His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys
 675 680 685

Phe Phe Glu Gln Met Gln Asn Lys Lys
 690 695

<210> 19

<211> 2094

<212> DNA

<213> Homo sapiens

<400> 19

atgctggccg gttggcaact gtcctgtctg gccgccttggc cggctcgccc gctggaggta 60
 cccactgtatg gtaatgtctgg cctgtgtgtt gaacccccaga ttgccatgtt ctgtggcaga 120
 ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggacaaaa 180
 acctgcattt ataccaagga aggcatctg cagatttgc aagaagtcta ccctgaactg 240
 cagatcacca atgtggtaga agccaaccaa ccagtgcacca tccagaactg gtgcaagcgg 300
 ggccgcaagc agtgcacagac ccatccccac tttgtgattt cctaccgtt ctttagtttgt 360
 gagtttgtaa gtgatggccct tctcggttctt gacaagtgc aatttttaca ccaggagagg 420
 atggatgttt gcgaaactca tcttcacttgg cacaccgtcg ccaaagagac atgcagttag 480
 aagagtacca acttgcatttgc ctacggcatg ttgtgtccctt gcggaatgtt caagttccga 540
 gggtagatgt ttgtgtgtt cccactggctt gaagaaagtg acaatgttgc ttctgtgtat 600
 gcggaggagg atgactcgga tgcgtgttgg ggcggagcag acacagacta tgcagatggg 660
 agtgcacaca aagtagtgc aatgcacatgc tggctgaggat ggaagaagaa 720
 gaagccgatg atgacgagga cgatgaggat ggtgtatggc tagaggaaga ggctgaggaa 780
 ccctacgaag aagccacaga gagaaccacc accatgttgc ccaccaccac caccaccaca 840
 gagttgttgg aagagggtgtt tcgagtttctt acaacacgcg ccagtacccc tgatgccgtt 900
 gacaagtatc tcgagacacc tggggatggc aatgcacatgc cccatttcca gaaagccaaa 960
 gagaggcttggc agggcaagca ccgagagaga atgtcccagg tcatgagaga atggaaagag 1020
 gcagaacgtc aagcaaaagaa cttgcctaaa gctgataaga aggcagttt ccagcatttc 1080
 caggagaaag tggaatctttt ggaacagaa gcaagccaaacg agagacagca gctgggtggag 1140
 acacacatgg ccagatgttgc accatgttgc aatgcacatgc gccgccttgc cctggagaac 1200
 tacatcacccg ctctgcaggc tggcccttgc acgttttca tatgttcaat 1260
 aagtatgtcc gcgacaaaca gaaggacaga cagcacaccc taaaggatcc ttgcgtatgt 1320
 cgcgtgttgg atcccaagaa agccgtcttgc atccgttgc agtttatgc acacccctcg 1380
 gtgattttatg agccatgttgc tcaatgttgc tccctgttgc acaacgttgc tgcgtggcc 1440
 gaggagatttcc aggtatgttgc tggccatgttgc ttcgttgc aatgcacatgc 1500
 gtcttggcca acatgatttttgc tggccatgttgc ttcgttgc tcaatgttgc ttcgttgc 1560
 tctttgttggc aaacgaaaac caccgttggc tggccatgttgc tggccatgttgc ttcgttgc 1620
 gacgttgc accgttgc tggccatgttgc ttcgttgc tcaatgttgc ttcgttgc 1680
 gaagttgttgc ctgttgc tggccatgttgc ttcgttgc tcaatgttgc ttcgttgc 1740
 tctgggttgc caaatatcaa gacggaggatgttgc tggccatgttgc ttcgttgc tcaatgttgc 1800
 cgacatgttgc caggatgttgc tggccatgttgc ttcgttgc tcaatgttgc ttcgttgc 1860
 ggttcaaaaca aaggtgttgc tggccatgttgc ttcgttgc tcaatgttgc ttcgttgc 1920
 atcttcatca cttgttgc tggccatgttgc ttcgttgc tcaatgttgc ttcgttgc 1980
 gtggagggttgc acggccgttgc tggccatgttgc ttcgttgc tcaatgttgc ttcgttgc 2040
 ggctacgaaa atccaaacccatca caagtttgc tggccatgttgc ttcgttgc tcaatgttgc 2094

<210> 20

<211> 697

- 26 -

<212> PRT

<213> Homo sapiens

<400> 20

Met Leu Pro Gly Leu Ala Leu Leu Leu Ala Ala Trp Thr Ala Arg
1 5 10 15

Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
20 25 30

Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
35 40 45

Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
50 55 60

Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
65 70 75 80

Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
85 90 95

Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
100 105 110

Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
115 120 125

Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
130 135 140

Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
145 150 155 160

Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
165 170 175

Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
180 185 190

Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
195 200 205

Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
210 215 220

Val Val Glu Val Ala Glu Glu Glu Val Ala Glu Val Glu Glu Glu
225 230 235 240

Glu Ala Asp Asp Asp Glu Asp Asp Gly Asp Glu Val Glu Glu
245 250 255

Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
260 265 270

Ala Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Val Arg
275 280 285

Val Pro Thr Thr Ala Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu
290 295 300

- 27 -

Glu	Thr	Pro	Gly	Asp	Glu	Asn	Glu	His	Ala	His	Phe	Gln	Lys	Ala	Lys
305					310				315					320	
Glu	Arg	Leu	Glu	Ala	Lys	His	Arg	Glu	Arg	Met	Ser	Gln	Val	Met	Arg
	325					330			330				335		
Glu	Trp	Glu	Glu	Ala	Glu	Arg	Gln	Ala	Lys	Asn	Leu	Pro	Lys	Ala	Asp
		340				345				345			350		
Lys	Lys	Ala	Val	Ile	Gln	His	Phe	Gln	Glu	Lys	Val	Glu	Ser	Leu	Glu
		355				360			360			365			
Gln	Glu	Ala	Ala	Asn	Glu	Arg	Gln	Gln	Leu	Val	Glu	Thr	His	Met	Ala
		370				375			375			380			
Arg	Val	Glu	Ala	Met	Leu	Asn	Asp	Arg	Arg	Arg	Leu	Ala	Leu	Glu	Asn
	385				390				395			400			
Tyr	Ile	Thr	Ala	Leu	Gln	Ala	Val	Pro	Pro	Arg	Pro	Arg	His	Val	Phe
		405					410			410			415		
Asn	Met	Leu	Lys	Lys	Tyr	Val	Arg	Ala	Glu	Gln	Lys	Asp	Arg	Gln	His
		420					425			425			430		
Thr	Leu	Lys	His	Phe	Glu	His	Val	Arg	Met	Val	Asp	Pro	Lys	Lys	Ala
		435				440			435			445			
Ala	Gln	Ile	Arg	Ser	Gln	Val	Met	Thr	His	Leu	Arg	Val	Ile	Tyr	Glu
		450				455			450			460			
Arg	Met	Asn	Gln	Ser	Leu	Ser	Leu	Leu	Tyr	Asn	Val	Pro	Ala	Val	Ala
	465				470			470			475			480	
Glu	Glu	Ile	Gln	Asp	Glu	Val	Asp	Glu	Leu	Leu	Gln	Lys	Glu	Gln	Asn
		485				490			485			490			495
Tyr	Ser	Asp	Asp	Val	Leu	Ala	Asn	Met	Ile	Ser	Glu	Pro	Arg	Ile	Ser
		500					505			500			510		
Tyr	Gly	Asn	Asp	Ala	Leu	Met	Pro	Ser	Leu	Thr	Glu	Thr	Lys	Thr	Thr
		515				520			515			525			
Val	Glu	Leu	Leu	Pro	Val	Asn	Gly	Glu	Phe	Ser	Leu	Asp	Asp	Leu	Gln
		530				535			530			540			
Pro	Trp	His	Ser	Phe	Gly	Ala	Asp	Ser	Val	Pro	Ala	Asn	Thr	Glu	Asn
	545			550				550			555			560	
Glu	Val	Glu	Pro	Val	Asp	Ala	Arg	Pro	Ala	Ala	Asp	Arg	Gly	Leu	Thr
		565				570			565			575			
Thr	Arg	Pro	Gly	Ser	Gly	Leu	Thr	Asn	Ile	Lys	Thr	Glu	Glu	Ile	Ser
		580				585			580			590			
Glu	Val	Lys	Met	Asp	Ala	Glu	Phe	Arg	His	Asp	Ser	Gly	Tyr	Glu	Val
		595				600			595			605			
His	His	Gln	Lys	Leu	Val	Phe	Phe	Ala	Glu	Asp	Val	Gly	Ser	Asn	Lys
		610				615			610			620			
Gly	Ala	Ile	Ile	Gly	Leu	Met	Val	Gly	Gly	Val	Val	Ile	Ala	Thr	Val
		625				630			625			635			640

- 28 -

Ile Phe Ile Thr Leu Val Met Leu Lys Lys Gln Tyr Thr Ser Ile
 645 650 655

His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg
 660 665 670

His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys
 675 680 685

Phe Phe Glu Gln Met Gln Asn Lys Lys
 690 695

<210> 21
<211> 1341
<212> DNA
<213> Homo sapiens

<400> 21
atggctagca tgactggtag acagcaaattt ggtcgccgat ccacccagca cggcatccgg 60
ctggccctgc gcagcggcct gggggcgcc cccctggggc tgcggctgcc cggggagacc 120
gacgaagagc ccgaggagcc cggccggagg ggcagctttg tggagatggt ggacaacctg 180
aggggcaagt cggggcaggg ctactacgt gagatgaccg tggcagccc cccgcagacg 240
ctcaacatcc tggtgatac aggcagcagt aaccttgcag tgggtgcgtc cccccacccc 300
ttcctgcatac gctactacca gaggcagctg tccagcacat accgggaccc tccgaaagggt 360
gtgtatgtgc cttacaccca gggcaagtgg gaaggggagc tggcaccga cctggtaagc 420
atccccatg gccccaaacgt cactgtgcgt gccaacattt ctgccatcac tgaatcagac 480
aagttcttca tcaacggctc caactggaa ggcatcctgg ggctggcta tgctgagatt 540
gccaggcctg acgactccct ggagccttc ttgactctc tggtaaagca gaccacgtt 600
cccaacccct tctccctgca ctttgggt gctggcttc ccctcaacca gtctgaagt 660
ctggcctctg tcggagggag catgatcatt ggaggtatcg accactcgct gtacacaggg 720
agtctcttgtt atacacccat cccgcgggag tggattatg aggtcatcat tggcgggtg 780
gagatcaatg gacaggatct gaaaatggac tgcaaggagt acaactatgaa caagagcatt 840
gtggacagtgc caccacccaa ctttcgtttg cccaaagaaag tggtaagc tgcagtcaaa 900
tccatcaagg caggcctcctc cacggagaag ttccctgtat gtttctggct aggagagcag 960
ctggtgtgtc ggcacggcagg caccacccct tggAACATT tcccagtcat ctcaactctac 1020
ctaattgggtg aggttaccaa ccagtccttc cgcacatcacca tccttcgcga gcaataccgt 1080
cgcccaatgg aagatgtggc cacgtcccaa gacgactgtt acaagttgc catctcacag 1140
tcatccacgg gcactgttat gggagctgtt atcatggagg gcttctacgt tgcgtttgt 1200
cgggcccaa aacaattgg ctttgcgtc agcgttgcg atgtgcacga tggatcagg 1260
acggcagcgg tggaaaggccc ttttgtcacc ttggacatgg aagactgtgg ctacaacatt 1320
ccacagacag atgagtcatg a 1341

<210> 22
<211> 446
<212> PRT
<213> Homo sapiens

<400> 22
Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Gly Ser Thr Gln
 1 5 10 15

His Gly Ile Arg Leu Pro Leu Arg Ser Gly Leu Gly Gly Ala Pro Leu
 20 25 30

Gly Leu Arg Leu Pro Arg Glu Thr Asp Glu Glu Pro Glu Glu Pro Gly
 35 40 45

Arg Arg Gly Ser Phe Val Glu Met Val Asp Asn Leu Arg Gly Lys Ser
 50 55 60

- 29 -

Gly Gln Gly Tyr Tyr Val Glu Met Thr Val Gly Ser Pro Pro Gln Thr
 65 70 75 80

Leu Asn Ile Leu Val Asp Thr Gly Ser Ser Asn Phe Ala Val Gly Ala
 85 90 95

Ala Pro His Pro Phe Leu His Arg Tyr Tyr Gln Arg Gln Leu Ser Ser
 100 105 110

Thr Tyr Arg Asp Leu Arg Lys Gly Val Tyr Val Pro Tyr Thr Gln Gly
 115 120 125

Lys Trp Glu Gly Glu Leu Gly Thr Asp Leu Val Ser Ile Pro His Gly
 130 135 140

Pro Asn Val Thr Val Arg Ala Asn Ile Ala Ala Ile Thr Glu Ser Asp
 145 150 155 160

Lys Phe Phe Ile Asn Gly Ser Asn Trp Glu Gly Ile Leu Gly Leu Ala
 165 170 175

Tyr Ala Glu Ile Ala Arg Pro Asp Asp Ser Leu Glu Pro Phe Phe Asp
 180 185 190

Ser Leu Val Lys Gln Thr His Val Pro Asn Leu Phe Ser Leu His Leu
 195 200 205

Cys Gly Ala Gly Phe Pro Leu Asn Gln Ser Glu Val Leu Ala Ser Val
 210 215 220

Gly Gly Ser Met Ile Ile Gly Gly Ile Asp His Ser Leu Tyr Thr Gly
 225 230 235 240

Ser Leu Trp Tyr Thr Pro Ile Arg Arg Glu Trp Tyr Tyr Glu Val Ile
 245 250 255

Ile Val Arg Val Glu Ile Asn Gly Gln Asp Leu Lys Met Asp Cys Lys
 260 265 270

Glu Tyr Asn Tyr Asp Lys Ser Ile Val Asp Ser Gly Thr Thr Asn Leu
 275 280 285

Arg Leu Pro Lys Lys Val Phe Glu Ala Ala Val Lys Ser Ile Lys Ala
 290 295 300

Ala Ser Ser Thr Glu Lys Phe Pro Asp Gly Phe Trp Leu Gly Glu Gln
 305 310 315 320

Leu Val Cys Trp Gln Ala Gly Thr Thr Pro Trp Asn Ile Phe Pro Val
 325 330 335

Ile Ser Leu Tyr Leu Met Gly Glu Val Thr Asn Gln Ser Phe Arg Ile
 340 345 350

Thr Ile Leu Pro Gln Gln Tyr Leu Arg Pro Val Glu Asp Val Ala Thr
 355 360 365

Ser Gln Asp Asp Cys Tyr Lys Phe Ala Ile Ser Gln Ser Ser Thr Gly
 370 375 380

Thr Val Met Gly Ala Val Ile Met Glu Gly Phe Tyr Val Val Phe Asp
 385 390 395 400

- 30 -

Arg Ala Arg Lys Arg Ile Gly Phe Ala Val Ser Ala Cys His Val His
 405 410 415

Asp Glu Phe Arg Thr Ala Ala Val Glu Gly Pro Phe Val Thr Leu Asp
 420 425 430

Met Glu Asp Cys Gly Tyr Asn Ile Pro Gln Thr Asp Glu Ser
 435 440 445

<210> 23

<211> 1380

<212> DNA

<213> Homo sapiens

<400> 23

atggctagca tgactgggtgg acagcaaattg ggtcgcggat cgatgactat ctctgactct 60
 ccgcgtgaac aggacggatc caccacccac ggcacatccggc tgcccctgcg cagcggcctg 120
 gggggcgccc ccctggggct gcggctgccc cgggagaccc acgaagagcc cgaggagccc 180
 ggccggaggg gcagctttgt ggagatggtg gacaacctga ggggcaagtc gggcagggc 240
 tactacgtgg agatgaccgt gggcagcccc cccgacgc tcaacatctt ggtggataca 300
 ggcagcagta actttgcagt gggtgctgcc ccccacccct tcctgcateg ctactaccag 360
 aggccagctgt ccagcacata cccggaccc cggaaagggtg tgtatgtgcc ctacacccag 420
 ggcaagtggg aaggggagct gggcaccggac ctgttaagca tcccccatgg ccccaacgtc 480
 actgtgcgtg ccaacattgc tgccatcaact gaatcagaca agttcttcat caacggctcc 540
 aactggaaag gcatcctggg gctggcttat gctgagattt ccaggcctga cgactccctg 600
 gagcctttct ttgactctct gttaaaggcag acccacgttc ccaacctttt ctccctgcac 660
 ctttgtgtg ctggcttccc cctcaaccag tctgaagtgc tggcctctgt cggagggagc 720
 atgatcattt gaggatcgaa ccactcgctg tacacaggca gtctctgtta tacacccatc 780
 cggcgggagt ggtattatga ggtcatcatt gtgcgggtgg agatcaatgg acaggatctg 840
 aaaatggact gcaaggagta caactatgac aagagcattt tggacagtgg caccaccaac 900
 cttcgtttc ccaagaaaagt gtttgaagct gcagtcaaat ccatcaaggc agcctccctcc 960
 acggagaagt tccctgtatgg tttctggcta ggagagcagc tggtgtgctg gcaaggcaggc 1020
 accacccctt ggaacatttt cccagtcatc tcactctacc taatgggtga ggttaccaac 1080
 cagtccttcc gcatcaccat cttccgcag caatacctgc ggccagtgaa agatgtggcc 1140
 acgtcccaag acgactgtta caagttgccc attcacagt catccacggg cactgtttag 1200
 ggagctgtta tcatggaggg cttctacatt gtcttgcatt gggcccgaaa acgaattggc 1260
 ttgtctgtca ggcgttgcca tgtgcacat gagttcagga cggcagcgggt ggaaggccct 1320
 ttgtcacct tggacatggaa agactgtggc tacaacattc cacagacaga tgagtcatga 1380

<210> 24

<211> 459

<212> PRT

<213> Homo sapiens

<400> 24

Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Gly Ser Met Thr
 1 5 10 15

Ile Ser Asp Ser Pro Arg Glu Gln Asp Gly Ser Thr Gln His Gly Ile
 20 25 30

Arg Leu Pro Leu Arg Ser Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg
 35 40 45

Leu Pro Arg Glu Thr Asp Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly
 50 55 60

Ser Phe Val Glu Met Val Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly
 65 70 75 80

Tyr Tyr Val Glu Met Thr Val Gly Ser Pro Pro Gln Thr Leu Asn Ile
 85 90 95

- 31 -

Leu	Val	Asp	Thr	Gly	Ser	Ser	Asn	Phe	Ala	Val	Gly	Ala	Ala	Pro	His
100							105					110			
Pro	Phe	Leu	His	Arg	Tyr	Tyr	Gln	Arg	Gln	Leu	Ser	Ser	Thr	Tyr	Arg
115							120					125			
Asp	Leu	Arg	Lys	Gly	Val	Tyr	Val	Pro	Tyr	Thr	Gln	Gly	Lys	Trp	Glu
130							135					140			
Gly	Glu	Leu	Gly	Thr	Asp	Leu	Val	Ser	Ile	Pro	His	Gly	Pro	Asn	Val
145							150					155			160
Thr	Val	Arg	Ala	Asn	Ile	Ala	Ala	Ile	Thr	Glu	Ser	Asp	Lys	Phe	Phe
165								170					175		
Ile	Asn	Gly	Ser	Asn	Trp	Glu	Gly	Ile	Leu	Gly	Leu	Ala	Tyr	Ala	Glu
180								185					190		
Ile	Ala	Arg	Pro	Asp	Asp	Ser	Leu	Glu	Pro	Phe	Phe	Asp	Ser	Leu	Val
195							200					205			
Lys	Gln	Thr	His	Val	Pro	Asn	Leu	Phe	Ser	Leu	His	Leu	Cys	Gly	Ala
210							215					220			
Gly	Phe	Pro	Leu	Asn	Gln	Ser	Glu	Val	Leu	Ala	Ser	Val	Gly	Gly	Ser
225							230					235			240
Met	Ile	Ile	Gly	Gly	Ile	Asp	His	Ser	Leu	Tyr	Thr	Gly	Ser	Leu	Trp
245								250					255		
Tyr	Thr	Pro	Ile	Arg	Arg	Glu	Trp	Tyr	Tyr	Glu	Val	Ile	Ile	Val	Arg
260								265					270		
Val	Glu	Ile	Asn	Gly	Gln	Asp	Leu	Lys	Met	Asp	Cys	Lys	Glu	Tyr	Asn
275							280					285			
Tyr	Asp	Lys	Ser	Ile	Val	Asp	Ser	Gly	Thr	Thr	Asn	Leu	Arg	Leu	Pro
290							295					300			
Lys	Lys	Val	Phe	Glu	Ala	Ala	Val	Lys	Ser	Ile	Lys	Ala	Ala	Ser	Ser
305							310					315			320
Thr	Glu	Lys	Phe	Pro	Asp	Gly	Phe	Trp	Leu	Gly	Glu	Gln	Leu	Val	Cys
325								330					335		
Trp	Gln	Ala	Gly	Thr	Thr	Pro	Trp	Asn	Ile	Phe	Pro	Val	Ile	Ser	Leu
340								345					350		
Tyr	Leu	Met	Gly	Glu	Val	Thr	Asn	Gln	Ser	Phe	Arg	Ile	Thr	Ile	Leu
355								360					365		
Pro	Gln	Gln	Tyr	Leu	Arg	Pro	Val	Glu	Asp	Val	Ala	Thr	Ser	Gln	Asp
370							375					380			
Asp	Cys	Tyr	Lys	Phe	Ala	Ile	Ser	Gln	Ser	Ser	Thr	Gly	Thr	Val	Met
385							390					395			400
Gly	Ala	Val	Ile	Met	Glu	Gly	Phe	Tyr	Val	Val	Phe	Asp	Arg	Ala	Arg
405								410					415		
Lys	Arg	Ile	Gly	Phe	Ala	Val	Ser	Ala	Cys	His	Val	His	Asp	Glu	Phe
420								425					430		

- 32 -

Arg Thr Ala Ala Val Glu Gly Pro Phe Val Thr Leu Asp Met Glu Asp
 435 440 445

Cys Gly Tyr Asn Ile Pro Gln Thr Asp Glu Ser
 450 455

<210> 25
<211> 1302
<212> DNA
<213> Homo sapiens

<400> 25
atgactcagc atggatttcg tctgccactg cgtacggc tgggtgggc tccactgggt 60
ctgcgtctgc cccggagac cgacgaagag cccgaggagc cccggccggag gggcagctt 120
gtggagatgg tggacaacct gaggggcaag tcggggcagg gctactacgt ggagatgacc 180
gtgggcagcc ccccgagac gctcaacatc ctgtggata caggcagcag taactttgca 240
gtgggtgtcg ccccccaccc cttcctgcatt cgctactacc agaggcagct gtccagcaca 300
taccgggacc tccggaaggg tggatgtg ccctacaccc agggcaagt ggaaggggag 360
ctgggcaccc acctggtaag catccccat gcgcggcactg tcactgtgc tgccaacatt 420
gctgccatca ctgaatcaga caagtttttcaatcggc ccaactggga aggcatcctg 480
gggctggcct atgctgagat tgccaggcct gacgactccc tggagccctt ctttgactct 540
ctggtaaagc agacccacgt tcccaaccc ttctccctgc acctttgtgg tggcggcttc 600
ccccctcaacc agtctgaagt gttggccctt gtcgggggaa gcatgatcat tggaggtatc 660
gaccactcgc tggatcaggc cagtttttgcatacaccat tccggcgggaa gtggattat 720
gaggtcatca ttgtgcgggt ggagatcaat ggacaggatc tgaaaatggg ctgcaaggag 780
tacaactatg acaagagcat tggatgttgc ggcaccacca accttcgtt gccaagaaaa 840
gtgtttgaag ctgcagtcaa atccatcaag gcggcctt ccacggagaa gttccctgat 900
ggtttctggc taggagagca gttgggttgc tggcaaggcag gcaccacccc ttgaaacatt 960
ttcccagtca tctactcta cctaatgggt gaggttacca accagtccct ccgcattacc 1020
atccttcggc agaataacct gggccagtg gaagatgtgg ccacgtccca agacgactgt 1080
tacaagtttgc ccatctcaca gtcatttcacg ggactgttgc tggagctgt tatcatggag 1140
ggcttctacg ttgtcttgc tcggggccgaa aaacgaattt gctttgtgt cagcgcttgc 1200
catgtgcacg atgagttcag gacggcagcg gtggaaaggcc ctttgcac cttggacatg 1260
gaagactgtg gctacaacat tccacagaca gatgagtcat ga 1302

<210> 26
<211> 433
<212> PRT
<213> Homo sapiens

<400> 26
Met Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser Gly Leu Gly Gly
 1 5 10 15

Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp Glu Glu Pro Glu
 20 25 30

Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val Asp Asn Leu Arg
 35 40 45

Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr Val Gly Ser Pro
 50 55 60

Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser Ser Asn Phe Ala
 65 70 75 80

Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr Tyr Gln Arg Gln
 85 90 95

Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val Tyr Val Pro Tyr
 100 105 110

- 33 -

Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp Leu Val Ser Ile
 115 120 125
 Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile Ala Ala Ile Thr
 130 135 140
 Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp Glu Gly Ile Leu
 145 150 155 160
 Gly Leu Ala Tyr Ala Glu Ile Ala Arg Pro Asp Asp Ser Leu Glu Pro
 165 170 175
 Phe Phe Asp Ser Leu Val Lys Gln Thr His Val Pro Asn Leu Phe Ser
 180 185 190
 Leu His Leu Cys Gly Ala Gly Phe Pro Leu Asn Gln Ser Glu Val Leu
 195 200 205
 Ala Ser Val Gly Gly Ser Met Ile Ile Gly Gly Ile Asp His Ser Leu
 210 215 220
 Tyr Thr Gly Ser Leu Trp Tyr Thr Pro Ile Arg Arg Glu Trp Tyr Tyr
 225 230 235 240
 Glu Val Ile Ile Val Arg Val Glu Ile Asn Gly Gln Asp Leu Lys Met
 245 250 255
 Asp Cys Lys Glu Tyr Asn Tyr Asp Lys Ser Ile Val Asp Ser Gly Thr
 260 265 270
 Thr Asn Leu Arg Leu Pro Lys Lys Val Phe Glu Ala Ala Val Lys Ser
 275 280 285
 Ile Lys Ala Ala Ser Ser Thr Glu Lys Phe Pro Asp Gly Phe Trp Leu
 290 295 300
 Gly Glu Gln Leu Val Cys Trp Gln Ala Gly Thr Thr Pro Trp Asn Ile
 305 310 315 320
 Phe Pro Val Ile Ser Leu Tyr Leu Met Gly Glu Val Thr Asn Gln Ser
 325 330 335
 Phe Arg Ile Thr Ile Leu Pro Gln Gln Tyr Leu Arg Pro Val Glu Asp
 340 345 350
 Val Ala Thr Ser Gln Asp Asp Cys Tyr Lys Phe Ala Ile Ser Gln Ser
 355 360 365
 Ser Thr Gly Thr Val Met Gly Ala Val Ile Met Glu Gly Phe Tyr Val
 370 375 380
 Val Phe Asp Arg Ala Arg Lys Arg Ile Gly Phe Ala Val Ser Ala Cys
 385 390 395 400
 His Val His Asp Glu Phe Arg Thr Ala Ala Val Glu Gly Pro Phe Val
 405 410 415
 Thr Leu Asp Met Glu Asp Cys Gly Tyr Asn Ile Pro Gln Thr Asp Glu
 420 425 430
 Ser

- 34 -

<210> 27
<211> 1278
<212> DNA
<213> Homo sapiens

<400> 27
atggctagca tgactgggtgg acagcaaatg ggtcgcggat cgatgactat ctctgactct 60
ccgctggact ctggtatcgaa accgcacgga tcctttgtgg agatgggtgg caacctgagg 120
ggcaagtccgg ggcaggccta ctacgtggag atgaccgtgg gcagccccccc gcagacgctc 180
aacatccctgg tggatacagg cagcagtaac tttgcagtgg gtgctcccccc ccaccccttc 240
ctgcacgtct actaccagag gcagctgtcc agcacatacc gggacctccg gaagggtgtg 300
tatgtgccctt acacccaggg caagtgggaa gggagactgg gcaccgcacct ggttaagcatc 360
ccccatggcc ccaacgtcac tggcgtgcc aacattgctg ccatcaactga atcagacaag 420
ttcttcatca acgctccaa ctgggaaggc atcctggggc tggcctatgc tgagattgcc 480
aggcctgacg actccctggc gcctttctt gactctctgg taaagcagac ccacgttccc 540
aacctcttccctt ccctgcaccc ttgtggtgct ggcttcccccc tcaaccagtc tgaagtgt 600
gcctctgtcg gagggagcat gatcattggaa ggtatcgacc actcgctgtatc acaggcagt 660
ctctggata caccatccg gcgggaggtgg tattatgagg tcatcattgt gcgggtggag 720
atcaatggac aggatctgaa aatggactgc aaggagtaca actatgacaa gaggattgtg 780
gacagtggca ccaccaaccc tcgtttgcc aaaaaagtgt ttgaagctgc agtcaaatcc 840
atcaaggcag cctctccac ggagaagttc cctgatggtt tctggctagg agagcagctg 900
gtgtgctggc aaggaggcac cacccttgg aacattttcc cagtcatctc actctaccta 960
atgggtgagg ttaccaacca gtccttcgcg atcaccatcc ttccgcagca atacctgccc 1020
ccagtggaaag atgtggccac gtcccaagac gactgttaca agtttgcacatc ctcacagtca 1080
tccacgggca ctgttatggg agctgttatac atggagggtct tctacgttgt cttgatcgg 1140
gccccaaaac gaattggctt tgctgtcagc gcttgccatg tgcacgtga gttcaggacg 1200
gcagcgggtgg aagcccttt tgtcacccctt gacatggaaactgtggcta caacattcca 1260
cagacagatg agtcatga 1278

<210> 28
<211> 425
<212> PRT
<213> Homo sapiens

<400> 28
Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Gly Ser Met Thr
1 5 10 15
Ile Ser Asp Ser Pro Leu Asp Ser Gly Ile Glu Thr Asp Gly Ser Phe
20 25 30
Val Glu Met Val Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr
35 40 45
Val Glu Met Thr Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val
50 55 60
Asp Thr Gly Ser Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe
65 70 75 80
Leu His Arg Tyr Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu
85 90 95
Arg Lys Gly Val Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu
100 105 110
Leu Gly Thr Asp Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val
115 120 125
Arg Ala Asn Ile Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn
130 135 140

- 35 -

Gly Ser Asn Trp Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu Ile Ala
 145 150 155 160

Arg Pro Asp Asp Ser Leu Glu Pro Phe Phe Asp Ser Leu Val Lys Gln
 165 170 175

Thr His Val Pro Asn Leu Phe Ser Leu His Leu Cys Gly Ala Gly Phe
 180 185 190

Pro Leu Asn Gln Ser Glu Val Leu Ala Ser Val Gly Gly Ser Met Ile
 195 200 205

Ile Gly Gly Ile Asp His Ser Leu Tyr Thr Gly Ser Leu Trp Tyr Thr
 210 215 220

Pro Ile Arg Arg Glu Trp Tyr Tyr Glu Val Ile Ile Val Arg Val Glu
 225 230 235 240

Ile Asn Gly Gln Asp Leu Lys Met Asp Cys Lys Glu Tyr Asn Tyr Asp
 245 250 255

Lys Ser Ile Val Asp Ser Gly Thr Thr Asn Leu Arg Leu Pro Lys Lys
 260 265 270

Val Phe Glu Ala Ala Val Lys Ser Ile Lys Ala Ala Ser Ser Thr Glu
 275 280 285

Lys Phe Pro Asp Gly Phe Trp Leu Gly Glu Gln Leu Val Cys Trp Gln
 290 295 300

Ala Gly Thr Thr Pro Trp Asn Ile Phe Pro Val Ile Ser Leu Tyr Leu
 305 310 315 320

Met Gly Glu Val Thr Asn Gln Ser Phe Arg Ile Thr Ile Leu Pro Gln
 325 330 335

Gln Tyr Leu Arg Pro Val Glu Asp Val Ala Thr Ser Gln Asp Asp Cys
 340 345 350

Tyr Lys Phe Ala Ile Ser Gln Ser Ser Thr Gly Thr Val Met Gly Ala
 355 360 365

Val Ile Met Glu Gly Phe Tyr Val Val Phe Asp Arg Ala Arg Lys Arg
 370 375 380

Ile Gly Phe Ala Val Ser Ala Cys His Val His Asp Glu Phe Arg Thr
 385 390 395 400

Ala Ala Val Glu Gly Pro Phe Val Thr Leu Asp Met Glu Asp Cys Gly
 405 410 415

Tyr Asn Ile Pro Gln Thr Asp Glu Ser
 420 425

<210> 29
 <211> 1362
 <212> DNA
 <213> Homo sapiens

<400> 29
 atggcccaag ccctgccctg gtcctgtctg tggatggcg cggagtgct gcctgcccac 60
 ggcaccac agggcatccg gctgccctg cgcaaggcc tcggggggc cccccctgggg 120

- 36 -

```

ctgcggctgc cccgggagac cgacgaagag cccgaggagc cgggccggag gggcagcttt 180
gtggagatgg tggacaacct gaggggcaag tcggggcagg gctactacgt ggagatgacc 240
gtggcagcc ccccccagac gctcaacatc ctggtggata caggcagcag taactttgca 300
gtgggtgctg ccccccaccc cttcctgcat cgctactacc agagggcagct gtccagcaca 360
taccgggacc tccggaaggg tgtgtatgt ccctacaccc agggcaagt ggaaggggag 420
ctgggcaccc acctggtaag catccccat ggccccaacg tcactgtgcg tgccaacatt 480
gctgcatca ctgaatcaga caagttctc atcaacggct ccaactggga aggcatcctg 540
gggctggct atgctgagat tgccaggcct gacgactccc tggagccctt ctttgactct 600
ctggtaaagg agacccacgt tcccaaccc ttctccctgc acctttgtgg tgctggcttc 660
cccctcaacc agtctaagg gctggccctc gtggagggga gcatgatcat tggaggtatc 720
gaccactcgc tgtacacagg cagtctctgg tatacaccca tccggcgggg gtggtattat 780
gaggctcatca ttgtcggggt ggagatcaat ggacaggat taaaaatggg ctgcaaggag 840
tacaactat acaagagcat tggacactt ggcaccacca accttcgttt gccaagaaa 900
gtgtttgaag ctgcagtcaa atccatcaag gcagcctc ccacggagaa gttccctgat 960
ggttctggc taggagagca gctgggtgtc tggcaaggag gcaccacccc ttgaaacatt 1020
ttccctcgc tctcaactcta cctaattggg gaggattacca accagtccctt ccgcattcacc 1080
atccttcgc agcaataacct gcggccagtg gaagatgtgg ccacgtccca agacgactgt 1140
tacaagttt ccatctcaca gtcatccacg ggcactgtt tggagctgt tattatggag 1200
ggcttctacg ttgtcttga tcggggccga aaacgaattt gctttgtgt cagcgcttgc 1260
catgtgcacg atgagtttag gacggcagcg gtggaaaggcc cttttgtcac ctggacatg 1320
gaagactgtg gctacaacat tccacagaca gatgagtcat ga 1362

```

<210> 30

<211> 453

<212> PRT

<213> Homo sapiens

<400> 30

Met	Ala	Gln	Ala	Leu	Pro	Trp	Leu	Leu	Leu	Trp	Met	Gly	Ala	Gly	Val
1				5				10					15		

Leu	Pro	Ala	His	Gly	Thr	Gln	His	Gly	Ile	Arg	Leu	Pro	Leu	Arg	Ser
					20			25					30		

Gly	Leu	Gly	Gly	Ala	Pro	Leu	Gly	Leu	Arg	Leu	Pro	Arg	Glu	Thr	Asp
						35		40				45			

Glu	Glu	Pro	Glu	Glu	Pro	Gly	Arg	Arg	Gly	Ser	Phe	Val	Glu	Met	Val
							50	55			60				

Asp	Asn	Leu	Arg	Gly	Lys	Ser	Gly	Gln	Gly	Tyr	Tyr	Val	Glu	Met	Thr
						65		70		75			80		

Val	Gly	Ser	Pro	Pro	Gln	Thr	Leu	Asn	Ile	Leu	Val	Asp	Thr	Gly	Ser
						85			90			95			

Ser	Asn	Phe	Ala	Val	Gly	Ala	Ala	Pro	His	Pro	Phe	Leu	His	Arg	Tyr
							100		105			110			

Tyr	Gln	Arg	Gln	Leu	Ser	Ser	Thr	Tyr	Arg	Asp	Leu	Arg	Lys	Gly	Val
						115		120			125				

Tyr	Val	Pro	Tyr	Thr	Gln	Gly	Lys	Trp	Glu	Gly	Glu	Leu	Gly	Thr	Asp
							130		135		140				

Leu	Val	Ser	Ile	Pro	His	Gly	Pro	Asn	Val	Thr	Val	Arg	Ala	Asn	Ile
							145		150		155		160		

Ala	Ala	Ile	Thr	Glu	Ser	Asp	Lys	Phe	Phe	Ile	Asn	Gly	Ser	Asn	Trp
							165		170		175				

- 37 -

Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu Ile Ala Arg Pro Asp Asp
 180 185 190
 Ser Leu Glu Pro Phe Phe Asp Ser Leu Val Lys Gln Thr His Val Pro
 195 200 205
 Asn Leu Phe Ser Leu Gln Leu Cys Gly Ala Gly Phe Pro Leu Asn Gln
 210 215 220
 Ser Glu Val Leu Ala Ser Val Gly Gly Ser Met Ile Ile Gly Gly Ile
 225 230 235 240
 Asp His Ser Leu Tyr Thr Gly Ser Leu Trp Tyr Thr Pro Ile Arg Arg
 245 250 255
 Glu Trp Tyr Tyr Glu Val Ile Ile Val Arg Val Glu Ile Asn Gly Gln
 260 265 270
 Asp Leu Lys Met Asp Cys Lys Glu Tyr Asn Tyr Asp Lys Ser Ile Val
 275 280 285
 Asp Ser Gly Thr Thr Asn Leu Arg Leu Pro Lys Lys Val Phe Glu Ala
 290 295 300
 Ala Val Lys Ser Ile Lys Ala Ala Ser Ser Thr Glu Lys Phe Pro Asp
 305 310 315 320
 Gly Phe Trp Leu Gly Glu Gln Leu Val Cys Trp Gln Ala Gly Thr Thr
 325 330 335
 Pro Trp Asn Ile Phe Pro Val Ile Ser Leu Tyr Leu Met Gly Glu Val
 340 345 350
 Thr Asn Gln Ser Phe Arg Ile Thr Ile Leu Pro Gln Gln Tyr Leu Arg
 355 360 365
 Pro Val Glu Asp Val Ala Thr Ser Gln Asp Asp Cys Tyr Lys Phe Ala
 370 375 380
 Ile Ser Gln Ser Ser Thr Gly Thr Val Met Gly Ala Val Ile Met Glu
 385 390 395 400
 Gly Phe Tyr Val Val Phe Asp Arg Ala Arg Lys Arg Ile Gly Phe Ala
 405 410 415
 Val Ser Ala Cys His Val His Asp Glu Phe Arg Thr Ala Ala Val Glu
 420 425 430
 Gly Pro Phe Val Thr Leu Asp Met Glu Asp Cys Gly Tyr Asn Ile Pro
 435 440 445
 Gln Thr Asp Glu Ser
 450

<210> 31
 <211> 1380
 <212> DNA
 <213> Homo sapiens

<400> 31
 atggcccaag ccctgccctg gctcctgctg tggatggcg cgggagtgtgc gcctgcccac 60

- 38 -

ggcacccagc acggcatccg gctgccctg cgacgcggcc tggggggcgc cccccctgggg 120
 ctgcggctgc cccgggagac cgacgaagag cccgaggagc ccggccggag gggcagctt 180
 gtggagatgg tggacaacct gaggggcaag tcggggcagg gctactacgt ggagatgacc 240
 gtgggcagcc ccccgagac gctcaacatc ctgttgata caggcagcag taactttgca 300
 gtgggtgctg ccccccaccc ttccctgcat cgctactacc agaggcagct gtccagcaca 360
 taccgggacc tccggaaggg tggatgtg ccctacaccc agggcaagt ggaaggggag 420
 ctgggcacccg acctggtaag catccccat ggccccaaacg tcactgtgcg tgccaacatt 480
 gctgccatca ctgaatcaga caagttttc atcaacggct ccaactggga aggcatcctg 540
 gggctggct atgctgagat tgccaggct gacgactccc tggagccctt cttgactct 600
 ctggtaaagc agacccacgt tcccaaccc ttctccctgc acctttgtgg tgctggcttc 660
 cccctcaacc agtctgaagt gttggccctt gtcggaggg gcatgatcat tggaggtatc 720
 gaccactcgc tggatcaggc cagttctgg tatacaccct tccggcggg gttgtattat 780
 gaggtcatca ttgtgcgggt ggagatcaat ggacaggatc tggaaaatggg ctgcaaggag 840
 tacaactat acaagagcat tggatgtt ggcacccacca accttcgttt gcccaagaaa 900
 gtgttgaag ctgcagtcaa atccatcaag gcagccctt ccacggagaa gttccctgat 960
 ggtttctggc taggagagca gttgggtgtgc tggcaaggcag gcaccacccc ttgaaacatt 1020
 ttcccagtca tctcaactcta cctaatgggt gaggttacca accagtccct ccgcacatcacc 1080
 atccttcgc agcaataacct gggccagtg gaagatgtgg ccacgtccca agacgactgt 1140
 tacaagtttgc ccatctcaca gtcatccacg ggactgtta tggagctgt tattatggag 1200
 ggcttctacg ttgtcttgc tggggcccgaa aaacgaattt gctttgtgt cagcgcttgc 1260
 catgtgcacg atgagttcag gacggcagcg gtggaaaggcc ctttgcac ctggacatg 1320
 gaagactgtg gctacaacat tccacagaca gatgagtcac agcagcagca gcagcagtga 1380

<210> 32

<211> 459

<212> PRT

<213> Homo sapiens

<400> 32

Met Ala Gln Ala Leu Pro Trp Leu Leu Leu Trp Met Gly Ala Gly Val
 1 5 10 15

Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser
 20 25 30

Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp
 35 40 45

Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val
 50 55 60

Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr
 65 70 75 80

Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser
 85 90 95

Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr
 100 105 110

Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val
 115 120 125

Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp
 130 135 140

Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile
 145 150 155 160

Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp
 165 170 175

- 39 -

Glu	Gly	Ile	Leu	Gly	Leu	Ala	Tyr	Ala	Glu	Ile	Ala	Arg	Pro	Asp	Asp
180									185						190
Ser	Leu	Glu	Pro	Phe	Phe	Asp	Ser	Leu	Val	Lys	Gln	Thr	His	Val	Pro
									200						205
195															
Asn	Leu	Phe	Ser	Leu	Gln	Leu	Cys	Gly	Ala	Gly	Phe	Pro	Leu	Asn	Gln
210							215							220	
Ser	Glu	Val	Leu	Ala	Ser	Val	Gly	Gly	Ser	Met	Ile	Ile	Gly	Gly	Ile
225										235					240
Asp	His	Ser	Leu	Tyr	Thr	Gly	Ser	Leu	Trp	Tyr	Thr	Pro	Ile	Arg	Arg
245									250					255	
Glu	Trp	Tyr	Tyr	Glu	Val	Ile	Ile	Val	Arg	Val	Glu	Ile	Asn	Gly	Gln
260								265						270	
Asp	Leu	Lys	Met	Asp	Cys	Lys	Glu	Tyr	Asn	Tyr	Asp	Lys	Ser	Ile	Val
275							280						285		
Asp	Ser	Gly	Thr	Thr	Asn	Leu	Arg	Leu	Pro	Lys	Lys	Val	Phe	Glu	Ala
290							295						300		
Ala	Val	Lys	Ser	Ile	Lys	Ala	Ala	Ser	Ser	Thr	Glu	Lys	Phe	Pro	Asp
305							310			315					320
Gly	Phe	Trp	Leu	Gly	Glu	Gln	Leu	Val	Cys	Trp	Gln	Ala	Gly	Thr	Thr
325								330					335		
Pro	Trp	Asn	Ile	Phe	Pro	Val	Ile	Ser	Leu	Tyr	Leu	Met	Gly	Glu	Val
340								345					350		
Thr	Asn	Gln	Ser	Phe	Arg	Ile	Thr	Ile	Leu	Pro	Gln	Gln	Tyr	Leu	Arg
355								360					365		
Pro	Val	Glu	Asp	Val	Ala	Thr	Ser	Gln	Asp	Asp	Cys	Tyr	Lys	Phe	Ala
370								375					380		
Ile	Ser	Gln	Ser	Ser	Thr	Gly	Thr	Val	Met	Gly	Ala	Val	Ile	Met	Glu
385							390			395					400
Gly	Phe	Tyr	Val	Val	Phe	Asp	Arg	Ala	Arg	Lys	Arg	Ile	Gly	Phe	Ala
405									410					415	
Val	Ser	Ala	Cys	His	Val	His	Asp	Glu	Phe	Arg	Thr	Ala	Ala	Val	Glu
420								425					430		
Gly	Pro	Phe	Val	Thr	Leu	Asp	Met	Glu	Asp	Cys	Gly	Tyr	Asn	Ile	Pro
435								440					445		
Gln	Thr	Asp	Glu	Ser	His	His	His	His	His	His					
450								455							

<210> 33

<211> 25

<212> PRT

<213> Homo sapiens

<400> 33

- 40 -

Ser Glu Gln Gln Arg Arg Pro Arg Asp Pro Glu Val Val Asn Asp Glu
1 5 10 15

Ser Ser Leu Val Arg His Arg Trp Lys
20 25

<210> 34
<211> 19
<212> PRT
<213> Homo sapiens

<400> 34
Ser Glu Gln Leu Arg Gln Gln His Asp Asp Phe Ala Asp Asp Ile Ser
1 5 10 15

Leu Leu Lys

<210> 35
<211> 29
<212> DNA
<213> Homo sapiens

<400> 35
gtggatccac ccagcacggc atccggctg 29

<210> 36
<211> 36
<212> DNA
<213> Homo sapiens

<400> 36
gaaagtttc atgactcatc tgtctgtgga atgttg 36

<210> 37
<211> 39
<212> DNA
<213> Homo sapiens

<400> 37
gatcgatgac tatctctgac tctccgcgtg aacaggacg 39

<210> 38
<211> 39
<212> DNA
<213> Homo sapiens

<400> 38
gatccgtcct gttcacgcgg agagtcagag atagtcatc 39

<210> 39
<211> 77
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Hu-Asp2

<400> 39
cggcatccgg ctgcccctgc gtagcggctct gggtggtgct ccactgggtc tgcgtctgcc 60
ccgggagacc gacgaag 77

- 41 -

<210> 40
<211> 77
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Hu-Asp2

<400> 40
cttcgtcggt ctccggggc agacgcagac ccagtggagc accaccaga ccgctacgca 60
ggggcagccg gatgccg 77

<210> 41
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Caspase 8
Cleavage Site

<400> 41
gatcgatgac tatctctgac tctccgctgg actctggtat cgaaaccgac g 51

<210> 42
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Caspase 8
Cleavage Site

<400> 42
gatccgtcgg ttccgatacc agagtccagc ggagagtcag agatagtcac c 51

<210> 43
<211> 32
<212> DNA
<213> Homo sapiens

<400> 43
aaggatcctt tgtggagatg gtggacaacc tg 32

<210> 44
<211> 36
<212> DNA
<213> Homo sapiens

<400> 44
gaaagcttc atgactcatc tgtctgtgga atgttg 36

<210> 45
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: 6-His tag

<400> 45
gatcgcatca tcaccatcac catg 24

- 42 -

<210> 46
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: 6-His tag

<400> 46
gatccatgtt gatggtagtg atgc 24

<210> 47
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 47
gactgaccac tcgaccaggc tc 22

<210> 48
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 48
cgaattaaat tccagcacac tggctacttc ttgttctgca tctcaaagaa c 51

<210> 49
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 49
cgaattaaat tccagcacac tggcta 26

<210> 50
<211> 1287
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Hu-Asp2(b)
delta TM

<400> 50
atggcccaag ccctgccctg gctcctgctg tggatggcg cgggagtgt gcctgcccac 60
ggcacccagc acgcaccccg gctgccctg cgacgcggcc tggggggcgc cccctgggg 120
ctgcggctgc cccgggagac cgacgaagag cccgaggagc cggccggag gggcagctt 180
gtggagatgg tggacaacct gagggcaag tggggcagg gctactacgt ggagatgacc 240
gtgggcagcc ccccgccagac gctcaacatc ctggtgata cagggcagcag taactttgca 300
gtgggtgtcg cccccccaccc ctgcctgtcat cgctactacc agaggcagct gtccagcaca 360
taccgggacc tccggaaggg tgtgtatgtg ccctacacccc agggcaagtg ggaaggggag 420
ctgggcaccc acctggtaag catccccat ggccccaacg tcactgtgcg tgccaacatt 480
gctgccatca ctgaatcaga caagttttc atcaacggct ccaactggga aggcatcctg 540

- 43 -

```

gggctggcct atgctgagat tgccaggcgtt tgggtgctg gttccccctt caaccagtct 600
gaagtgcgtt cctctgtcg agggagcatg atcattggag gtatcgacca ctgcgtgtac 660
acaggcagtc tctggatac acccatccgg cgggagtggtt attatgaggt catattgtg 720
cgggtggaga tcaatggaca ggatctgaaa atggactgca aggagtacaa ctatgacaag 780
agcattgtgg acagtggcac caccaacccctt cgttgccca agaaagtgtt tgaagctgca 840
gtcaaattcca tcaaggcagc ctcctccacg gagaagttcc ctgatggttt ctggcttagga 900
gagcagctgg tggctggca agcaggcacc accccttggaa acatttttcc agtcatctca 960
ctctacccaa tgggtgaggt taccaaccag tcctccgca tcaccatctt tccgcagcaa 1020
tacctgcggc cagtggaga tggccacg tcccaagacg actgttacaa gtttgccatc 1080
tcacagtcat ccacgggcac ttgttatggga gctgttatca tggagggtt ctacgttgc 1140
tttgcgtggg cccgaaaacg aattggctt gctgtcagcg cttgcctatgt gcacgatgag 1200
ttcaggacgg cagcggtgga aggcctttt gtcaccccttgg acatggaaaga ctgtggctac 1260
aacattccac agacagatga gtcatga 1287

```

<210> 51

<211> 428

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Hu-Asp2(b)
delta TM

<400> 51

Met	Ala	Gln	Ala	Leu	Pro	Trp	Leu	Leu	Leu	Trp	Met	Gly	Ala	Gly	Val
1				5				10						15	

Leu	Pro	Ala	His	Gly	Thr	Gln	His	Gly	Ile	Arg	Leu	Pro	Leu	Arg	Ser
					20			25					30		

Gly	Leu	Gly	Gly	Ala	Pro	Leu	Gly	Leu	Arg	Leu	Pro	Arg	Glu	Thr	Asp
						35		40				45			

Glu	Glu	Pro	Glu	Glu	Pro	Gly	Arg	Arg	Gly	Ser	Phe	Val	Glu	Met	Val
						50		55			60				

Asp	Asn	Leu	Arg	Gly	Lys	Ser	Gly	Gln	Gly	Tyr	Tyr	Val	Glu	Met	Thr
						65		70		75		80			

Val	Gly	Ser	Pro	Pro	Gln	Thr	Leu	Asn	Ile	Leu	Val	Asp	Thr	Gly	Ser
						85			90			95			

Ser	Asn	Phe	Ala	Val	Gly	Ala	Ala	Pro	His	Pro	Phe	Leu	His	Arg	Tyr
						100		105			110				

Tyr	Gln	Arg	Gln	Leu	Ser	Ser	Thr	Tyr	Arg	Asp	Leu	Arg	Lys	Gly	Val
						115		120			125				

Tyr	Val	Pro	Tyr	Thr	Gln	Gly	Lys	Trp	Glu	Gly	Glu	Leu	Gly	Thr	Asp
						130		135			140				

Leu	Val	Ser	Ile	Pro	His	Gly	Pro	Asn	Val	Thr	Val	Arg	Ala	Asn	Ile
						145		150		155		160			

Ala	Ala	Ile	Thr	Glu	Ser	Asp	Lys	Phe	Phe	Ile	Asn	Gly	Ser	Asn	Trp
						165			170		175				

Glu	Gly	Ile	Leu	Gly	Leu	Ala	Tyr	Ala	Glu	Ile	Ala	Arg	Leu	Cys	Gly
						180			185		190				

Ala	Gly	Phe	Pro	Leu	Asn	Gln	Ser	Glu	Val	Leu	Ala	Ser	Val	Gly	Gly
						195			200		205				

- 44 -

Ser Met Ile Ile Gly Gly Ile Asp His Ser Leu Tyr Thr Gly Ser Leu
 210 215 220

Trp Tyr Thr Pro Ile Arg Arg Glu Trp Tyr Tyr Glu Val Ile Ile Val
 225 230 235 240

Arg Val Glu Ile Asn Gly Gln Asp Leu Lys Met Asp Cys Lys Glu Tyr
 245 250 255

Asn Tyr Asp Lys Ser Ile Val Asp Ser Gly Thr Thr Asn Leu Arg Leu
 260 265 270

Pro Lys Lys Val Phe Glu Ala Ala Val Lys Ser Ile Lys Ala Ala Ser
 275 280 285

Ser Thr Glu Lys Phe Pro Asp Gly Phe Trp Leu Gly Glu Gln Leu Val
 290 295 300

Cys Trp Gln Ala Gly Thr Thr Pro Trp Asn Ile Phe Pro Val Ile Ser
 305 310 315 320

Leu Tyr Leu Met Gly Glu Val Thr Asn Gln Ser Phe Arg Ile Thr Ile
 325 330 335

Leu Pro Gln Gln Tyr Leu Arg Pro Val Glu Asp Val Ala Thr Ser Gln
 340 345 350

Asp Asp Cys Tyr Lys Phe Ala Ile Ser Gln Ser Ser Thr Gly Thr Val
 355 360 365

Met Gly Ala Val Ile Met Glu Gly Phe Tyr Val Val Phe Asp Arg Ala
 370 375 380

Arg Lys Arg Ile Gly Phe Ala Val Ser Ala Cys His Val His Asp Glu
 385 390 395 400

Phe Arg Thr Ala Ala Val Glu Gly Pro Phe Val Thr Leu Asp Met Glu
 405 410 415

Asp Cys Gly Tyr Asn Ile Pro Gln Thr Asp Glu Ser
 420 425

<210> 52
 <211> 1305
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Hu-Asp2(b)
 delta TM

<400> 52
 atggcccaag ccctgccctg gctcctgctg tggatggcg cggagtgct gcctgcccac 60
 ggcacccagg acggcatccg gctgccctg cgacggcc tcggggggcgccccctgggg 120
 ctgcggctgc cccggagac cgacgaagag cccgaggagc cccggccggag gggcagctt 180
 gtggagatgg tggacaacct gaggggcaag tcggggcagg gctactacgt ggagatgacc 240
 gtgggcagcc ccccgagac gctcaacatc ctggtgata caggcagccag taactttgca 300
 gtgggtgctg ccccccaccc cttcctgcat cgctactacc agaggcagct gtccagcaca 360
 taccgggacc tccggaaaggg tgtgtatgt ccctacaccc agggcaagt ggaaggggag 420
 ctgggcacccg acctggtaag catccccat ggccccaaacg tcactgtgcg tgccaacatt 480
 gctgccccatca ctgaatcaga caagttcttc atcaacggct ccaactggga aggcatcctg 540
 gggctggct atgctgagat tgccaggct tggtgtcg gttccccct caaccagtct 600

- 45 -

```

gaagtgcctgg cctctgtcgg agggagcatg atcattggag gtatcgacca ctcgctgtac 660
acaggcagtc tctggatacc acccatccgg cgggagtggt attatgaggt catcattgtg 720
cgggtggaga tcaatggaca ggatctgaaa atggactgca aggagtacaa ctatgacaag 780
agcattgtgg acagtggcac caccaacctt cgtttgcaca agaaagtgtt tgaagctgca 840
gtcaaatcca tcaaggcagc ctccctccacg gagaagttcc ctgatggtt ctggctagga 900
gagcagctgg tgtgctggca agcaggcacc accccttggaa acatttccc agtcatctca 960
ctctacctaa tgggtgaggt taccAACCG tccttccgca tcaccatctt tccgcagcaa 1020
tacctgcggc cagtggaaga tgtggccacg tcccaagacg actgttacaa gttgccatc 1080
tcacagtcat ccacgggcac tggttatggaa gctgttatca tggagggttt ctacgttgc 1140
tttgatcgaa cccgaaaacg aattggctt gctgtcagcg cttgccatgt gcacgatgag 1200
ttcaggacgg cagcggtggaa aggccctttt gtcaccttgg acatggaaga ctgtggctac 1260
aacattccac agacagatga gtcacagcag cagcagcagc agtga 1305

```

<210> 53

<211> 434

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Hu-Asp2(b)
delta TM

<400> 53

Met	Ala	Gln	Ala	Leu	Pro	Trp	Leu	Leu	Leu	Trp	Met	Gly	Ala	Gly	Val
1															15

Leu	Pro	Ala	His	Gly	Thr	Gln	His	Gly	Ile	Arg	Leu	Pro	Leu	Arg	Ser
															30
20															

Gly	Leu	Gly	Gly	Ala	Pro	Leu	Gly	Leu	Arg	Leu	Pro	Arg	Glu	Thr	Asp
															45
35															

Glu	Glu	Pro	Glu	Glu	Pro	Gly	Arg	Arg	Gly	Ser	Phe	Val	Glu	Met	Val
															50
50															60

Asp	Asn	Leu	Arg	Gly	Lys	Ser	Gly	Gln	Gly	Tyr	Tyr	Val	Glu	Met	Thr
															65
															70

75

80

Val	Gly	Ser	Pro	Pro	Gln	Thr	Leu	Asn	Ile	Leu	Val	Asp	Thr	Gly	Ser
															85
															90

95

Ser	Asn	Phe	Ala	Val	Gly	Ala	Ala	Pro	His	Pro	Phe	Leu	His	Arg	Tyr
															100
															105

110

Tyr	Gln	Arg	Gln	Leu	Ser	Ser	Thr	Tyr	Arg	Asp	Leu	Arg	Lys	Gly	Val
															115
															120

125

Tyr	Val	Pro	Tyr	Thr	Gln	Gly	Lys	Trp	Glu	Gly	Glu	Leu	Gly	Thr	Asp
															130
															135

140

Leu	Val	Ser	Ile	Pro	His	Gly	Pro	Asn	Val	Thr	Val	Arg	Ala	Asn	Ile
															145
															150

155

160

Ala	Ala	Ile	Thr	Glu	Ser	Asp	Lys	Phe	Phe	Ile	Asn	Gly	Ser	Asn	Trp
															165
															170

175

Glu	Gly	Ile	Leu	Gly	Leu	Ala	Tyr	Ala	Glu	Ile	Ala	Arg	Leu	Cys	Gly
															180
															185

190

Ala	Gly	Phe	Pro	Leu	Asn	Gln	Ser	Glu	Val	Leu	Ala	Ser	Val	Gly	Gly
															195
															200

205

- 46 -

Ser Met Ile Ile Gly Gly Ile Asp His Ser Leu Tyr Thr Gly Ser Leu
 210 215 220
 Trp Tyr Thr Pro Ile Arg Arg Glu Trp Tyr Tyr Glu Val Ile Ile Val
 225 230 235 240
 Arg Val Glu Ile Asn Gly Gln Asp Leu Lys Met Asp Cys Lys Glu Tyr
 245 250 255
 Asn Tyr Asp Lys Ser Ile Val Asp Ser Gly Thr Thr Asn Leu Arg Leu
 260 265 270
 Pro Lys Lys Val Phe Glu Ala Ala Val Lys Ser Ile Lys Ala Ala Ser
 275 280 285
 Ser Thr Glu Lys Phe Pro Asp Gly Phe Trp Leu Gly Glu Gln Leu Val
 290 295 300
 Cys Trp Gln Ala Gly Thr Thr Pro Trp Asn Ile Phe Pro Val Ile Ser
 305 310 315 320
 Leu Tyr Leu Met Gly Glu Val Thr Asn Gln Ser Phe Arg Ile Thr Ile
 325 330 335
 Leu Pro Gln Gln Tyr Leu Arg Pro Val Glu Asp Val Ala Thr Ser Gln
 340 345 350
 Asp Asp Cys Tyr Lys Phe Ala Ile Ser Gln Ser Ser Thr Gly Thr Val
 355 360 365
 Met Gly Ala Val Ile Met Glu Gly Phe Tyr Val Val Phe Asp Arg Ala
 370 375 380
 Arg Lys Arg Ile Gly Phe Ala Val Ser Ala Cys His Val His Asp Glu
 385 390 395 400
 Phe Arg Thr Ala Ala Val Glu Gly Pro Phe Val Thr Leu Asp Met Glu
 405 410 415
 Asp Cys Gly Tyr Asn Ile Pro Gln Thr Asp Glu Ser His His His His
 420 425 430
 His His

<210> 54
 <211> 2310
 <212> DNA
 <213> Homo sapiens

<400> 54
 atgctccccg gttggcaact gtcctgctg gccgcctgga cggctcgccc gctggaggta 60
 cccactgatg gtaatgctgg cctgctggct gaaccccaga ttgccatgtt ctgtggcaga 120
 ctgaacatgc acatgaatgt ccagaatggg aagtggatt cagatccatc agggacaaaa 180
 acctgcattg ataccaagga aggcattctg cagattgccc aagaagtcta ccctgaactg 240
 cagatcacca atgtggtaga agccaaccaa ccagtgacca tccagaactg gtgcaagcgg 300
 ggccgcaagc agtgcacagac ccattccccac tttgtgattt cctaccgctg cttagttgg 360
 gagttttaa gtatgcccct tctcggttct gacaagtgc aattcttaca ccaggagagg 420
 atggatgttt gcgaaactca tcttcactgg cacaccgtcg ccaaagagac atgcagtgg 480
 aagagtacca actgcatga ctacggcatg ttgtggccct gcgaaatgca caagttccga 540
 gggtagagt ttgtgtgtt cccactggct gaagaaatgca acaatgtggta ttctgctgat 600

- 47 -

gcggaggagg	atgactcgga	tgtctggtgg	ggcggagca	acacagacta	tgcatgggg	660
agtgaagaca	aagttagtga	agttagcagag	gaggaagaag	tggctgaggt	ggaagaagaa	720
gaagccgatg	atgacgagga	cgtgaggat	ggtgatgagg	tagaggaaaga	ggctgaggaa	780
ccctacgaag	aagccacaga	gagaaccacc	agcattgcca	ccaccaccac	caccaccaca	840
gagttctgtgg	aagaggttgt	tcgagaggtg	tgctctgaac	aagccgagac	ggggccgtgc	900
cgagcaatga	tctcccgtg	gtactttgt	gtgactgaag	ggaagtgtgc	cccattcttt	960
tacggcggat	gtggcggcaa	ccggaacaac	tttgacacag	aagagtactg	catggccgtg	1020
tgtggcagcg	ccatgtccca	aagtttactc	aagactaccc	aggaacctct	tggccgagat	1080
cctgttaaac	tccctacaac	agcagccagt	accctgtat	cggttacaa	gtatctcgag	1140
acacctgggg	atgagaatga	acatgccccat	ttccagaaaag	ccaaagagag	gcttgaggcc	1200
aagcaccgag	agagaatgtc	ccaggtcatg	agagaatggg	aagaggcaga	acgtcaagca	1260
aagaacctgc	ctaaagctga	taagaaggca	gttatccagc	atttcaggaa	aaaagtggaa	1320
tctttggAAC	aggaagcagc	caacgagaga	cagcagctgg	tggagacaca	catggccaga	1380
gttggaaGCCA	tgctcaatga	ccggccggcgc	ctggccctgg	agaactacat	caccgtctg	1440
caggctgttc	ctccctggcc	tcgtcacgtg	tcaatatgc	taaagaagta	tgtccgcga	1500
gaacagaagg	acagacagca	caccctaaag	catttcgagc	atgtgcgcatt	gttggatccc	1560
aagaaAGCCG	ctcagatccg	gttcccagggtt	atgacacacc	tccgtgtat	ttatgagcgc	1620
atgaatcagt	ctctctccct	gctctacaac	gtgcctgcag	tggccgagga	gattcaggat	1680
gaagttgtatg	agtcgttca	gaaagagcaa	aactattcag	atgacgttct	ggccaacatg	1740
attagtgaac	caaggatcag	ttacggaaac	gatgctctca	tgccatcttt	gaccgaaacg	1800
aaaaccaccc	tggagctcct	tcccgtaat	ggagagttca	gcctggacga	tctccagccg	1860
tggcattctt	ttggggctga	ctctgtgcc	gccaacacag	aaaacaaagt	tgagcctgtt	1920
gatgcccggcc	ctgctgccga	ccgaggactg	accactcgac	cagggtctgg	gttgacaaat	1980
atcaagacgg	aggagatctc	tgaagtgaag	atggatgcag	aattccgaca	tgactcagga	2040
tatgaagttc	atcatcaaaa	attgggtttc	tttgcagaag	atgtgggttc	aaacaaaggt	2100
gcaatcattg	gactcatgg	gggcgggttt	gtcatagcga	cagtgatcgt	catcaccttg	2160
gtgatgctga	agaagaaaaca	gtacacatcc	attcatcatg	gtgtggtgg	gttgacgc	2220
gctgtcaccc	cagaggagcg	ccacctgtcc	aagatgcagc	agaacggcta	cgaaaatcca	2280
acctacaagt	tcttgagca	gatgcagaac				2310

<210> 55

<211> 770

<212> PRT

<213> Homo sapiens

<400> 55

Met Leu Pro Gly Leu Ala Leu Leu Leu Ala Ala Trp Thr Ala Arg

1

5

10

15

Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
20 25 30

Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
35 40 45

Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
50 55 60

Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
85 90 95

Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
100 105 110

Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
 115 120 125

Val	Pro	Asp	Lys	Cys	Lys	Phe	Leu	His	Gln	Glu	Arg	Met	Asp	Val	Cys
130						135						140			

- 48 -

Glu	Thr	His	Leu	His	Trp	His	Thr	Val	Ala	Lys	Glu	Thr	Cys	Ser	Glu
145						150				155					160
Lys	Ser	Thr	Asn	Leu	His	Asp	Tyr	Gly	Met	Leu	Leu	Pro	Cys	Gly	Ile
						165			170						175
Asp	Lys	Phe	Arg	Gly	Val	Glu	Phe	Val	Cys	Cys	Pro	Leu	Ala	Glu	Glu
						180			185						190
Ser	Asp	Asn	Val	Asp	Ser	Ala	Asp	Ala	Glu	Glu	Asp	Asp	Ser	Asp	Val
						195			200						205
Trp	Trp	Gly	Gly	Ala	Asp	Thr	Asp	Tyr	Ala	Asp	Gly	Ser	Glu	Asp	Lys
						210			215						220
Val	Val	Glu	Val	Ala	Glu	Glu	Glu	Glu	Val	Ala	Glu	Val	Glu	Glu	Glu
						225			230			235			240
Glu	Ala	Asp	Asp	Asp	Glu	Asp	Asp	Glu	Asp	Gly	Asp	Glu	Val	Glu	Glu
						245			250						255
Glu	Ala	Glu	Glu	Pro	Tyr	Glu	Glu	Ala	Thr	Glu	Arg	Thr	Thr	Ser	Ile
						260			265						270
Ala	Thr	Glu	Ser	Val	Glu	Glu	Val	Val	Arg						
						275			280						285
Glu	Val	Cys	Ser	Glu	Gln	Ala	Glu	Thr	Gly	Pro	Cys	Arg	Ala	Met	Ile
						290			295						300
Ser	Arg	Trp	Tyr	Phe	Asp	Val	Thr	Glu	Gly	Lys	Cys	Ala	Pro	Phe	Phe
						305			310						320
Tyr	Gly	Gly	Cys	Gly	Gly	Asn	Arg	Asn	Asn	Phe	Asp	Thr	Glu	Glu	Tyr
						325			330						335
Cys	Met	Ala	Val	Cys	Gly	Ser	Ala	Met	Ser	Gln	Ser	Leu	Leu	Lys	Thr
						340			345						350
Thr	Gln	Glu	Pro	Leu	Ala	Arg	Asp	Pro	Val	Lys	Leu	Pro	Thr	Thr	Ala
						355			360						365
Ala	Ser	Thr	Pro	Asp	Ala	Val	Asp	Lys	Tyr	Leu	Glu	Thr	Pro	Gly	Asp
						370			375						380
Glu	Asn	Glu	His	Ala	His	Phe	Gln	Lys	Ala	Lys	Glu	Arg	Leu	Glu	Ala
						385			390						400
Lys	His	Arg	Glu	Arg	Met	Ser	Gln	Val	Met	Arg	Glu	Trp	Glu	Glu	Ala
						405			410						415
Glu	Arg	Gln	Ala	Lys	Asn	Leu	Pro	Lys	Ala	Asp	Lys	Lys	Ala	Val	Ile
						420			425						430
Gln	His	Phe	Gln	Glu	Lys	Val	Glu	Ser	Leu	Glu	Gln	Glu	Ala	Ala	Asn
						435			440						445
Glu	Arg	Gln	Gln	Leu	Val	Glu	Thr	His	Met	Ala	Arg	Val	Glu	Ala	Met
						450			455						460
Leu	Asn	Asp	Arg	Arg	Arg	Leu	Ala	Leu	Glu	Asn	Tyr	Ile	Thr	Ala	Leu
						465			470						480

- 49 -

Gln Ala Val Pro Pro Arg Pro Arg His Val Phe Asn Met Leu Lys Lys
485 490 495

Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His Thr Leu Lys His Phe
500 505 510

Glu His Val Arg Met Val Asp Pro Lys Lys Ala Ala Gln Ile Arg Ser
515 520 525

Gln Val Met Thr His Leu Arg Val Ile Tyr Glu Arg Met Asn Gln Ser
530 535 540

Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala Glu Glu Ile Gln Asp
545 550 555 560

Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn Tyr Ser Asp Asp Val
565 570 575

Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser Tyr Gly Asn Asp Ala
580 585 590

Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Val Glu Leu Leu Pro
595 600 605

Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln Pro Trp His Ser Phe
610 615 620

Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn Glu Val Glu Pro Val
625 630 635 640

Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser
645 650 655

Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys Met Asp
660 665 670

Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu
675 680 685

Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly
690 695 700

Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu
705 710 715 720

Val Met Leu Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val
725 730 735

Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys Met
740 745 750

Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln Met
755 760 765

Gln Asn
770

<210> 56
<211> 2253
<212> DNA
<213> Homo sapiens

- 50 -

<400> 56

atgtggcccg	gttggcact	gctcctgctg	gccgcctgga	cggctgggc	gctggaggt	60
cccactgtatg	gtaatgtctgg	ctgtctggct	gaacccccaga	ttgccatgtt	ctgtggcaga	120
ctgaacatgc	acatgaatgt	ccagaatggg	aagtgggatt	cagatccatc	agggaccaaa	180
acctgcattt	ataccaagga	aggcatcctg	cagtattgcc	aagaagtcta	ccctgaactg	240
cagatcacca	atgtggtaga	agccaaccaa	ccagtgacca	tccagaactg	gtgcaagcgg	300
ggccgcaagc	agtgcagac	ccatccccac	tttgtgattc	cctaccgctg	cttagtgtt	360
gagtttgtaa	gtgtatccct	tctcgttct	gacaagtgc	aattcttaca	ccaggagagg	420
atggatgttt	gcgaaactca	tcttcactgg	cacaccgtcg	ccaaagagac	atgcagttag	480
aagagtacca	acttgcatga	ctacggcatg	ttgctgccc	gcggaaattga	caagttccga	540
ggggtagagt	tttgtgttg	cccactggct	gaagaaaagt	acaatgttga	ttctgctgtat	600
gcggaggagg	atgactcgga	tgtctgttgg	ggccggagcag	acacagacta	tgcatgtggg	660
agtgaagaca	aagttagtaga	agtagcagag	gaggaagaag	tggctgaggt	ggaagaagaa	720
gaagcccgat	atgacgagga	cgtatgggat	ggtgatgagg	tagaggaaga	ggctgaggaa	780
ccctacgaag	aagccacaga	gagaaccacc	agcattgc	ccaccacacc	caccaccaca	840
gagtcgttgg	aagagggtgt	tcgagaggtg	tgctctgaac	aaggccgagac	ggggccgtgc	900
cgcgaatgt	tctccgtgt	gtactttgtat	gtgactgaag	ggaagtgtgc	ccattcttt	960
tacggcggt	gtggcgccaa	ccggaaacaac	tttgacacag	aagagtactg	catggccgtg	1020
tgtggcagcg	ccattcttac	aacagcagcc	agtacccctg	atgcccgttga	caagtatctc	1080
gagacacctg	gggatgagaa	tgaacatgcc	catttccaga	aagccaaaga	gaggcttgag	1140
gccaagcacc	gagagagaat	gtcccagg	atgagagaat	ggaaagagaggc	agaacgtcaa	1200
gcaaagaact	tgcttaaaggc	tgataagaag	gcagttatcc	agcatttcca	ggagaaagt	1260
aatctttgg	aacaggaagc	agccaacgag	agacagcagc	tggtgagac	acacatggcc	1320
agagtggaaag	ccatgtctcaa	tgaccggcgc	cgccctggccc	tggagaacta	catcaccgct	1380
ctgcaggctg	ttcctccctg	gcctcg	gtgttcaata	tgctaaagaa	gtatgtccgc	1440
gcagaacaga	aggacagaca	gcacacccta	aagcatttcg	agcatgtgcg	catgttgat	1500
cccaagaaag	cgcgtcagat	ccggtcccag	gttatgacac	acctccgtgt	gatttatgag	1560
cgcatgaatc	agtctctctc	cctgctctac	aacgtgcctg	cagtggccga	ggagattcag	1620
gatgaagttg	atgagctgt	tcagaaagag	caaaaattt	catgtacgt	cttggccaa	1680
atgattatgt	aaccaaggat	cagtta	aacatgtctc	tcatgcac	tggaccgaa	1740
acgaaaacca	ccgtggact	ccttccctgt	aatggagagt	tcagccttgg	cgatctccag	1800
ccgtggcatt	ctttggggc	tgactctgt	ccagccaaaca	cagaaaacga	agtgtggcct	1860
gttgcatttgc	gcctgtgtc	cgaccggag	ctgaccactc	gaccgggtt	tgggttgaca	1920
aatatcaaga	cggaggagat	ctctgtatgt	aatgtggatg	cagaattccg	acatgactca	1980
ggatataaag	ttcatcatca	aaaatttgggt	ttctttgcag	aatgttggg	ttcaaaacaaa	2040
ggtgcaatca	ttggactcat	ggtggggcggt	gttgtcatag	cgacagtgtat	cgatcatcacc	2100
tttgtgtatgc	tgaagaagaa	acagta	catttc	atgggtgtt	ggagggttgc	2160
gccgtgtca	ccccagagga	gcccacactg	tccaagatgc	agcagaacgg	ctacgaaaat	2220
ccaacctaca	aqttcttqa	qcaqatqcq	aac			2253

<210> 57

<211> 751

<212> PRT

<213> Homo sapiens

<400> 57

Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
1 5 10 15

Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
20 25 30

Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
35 40 45

Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
50 55 60

Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
65 70 75 80

- 51 -

Gln	Ile	Thr	Asn	Val	Val	Glu	Ala	Asn	Gln	Pro	Val	Thr	Ile	Gln	Asn
				85					90					95	
Trp	Cys	Lys	Arg	Gly	Arg	Lys	Gln	Cys	Lys	Thr	His	Pro	His	Phe	Val
				100				105					110		
Ile	Pro	Tyr	Arg	Cys	Leu	Val	Gly	Glu	Phe	Val	Ser	Asp	Ala	Leu	Leu
				115			120					125			
Val	Pro	Asp	Lys	Cys	Lys	Phe	Leu	His	Gln	Glu	Arg	Met	Asp	Val	Cys
				130			135			140					
Glu	Thr	His	Leu	His	Trp	His	Thr	Val	Ala	Lys	Glu	Thr	Cys	Ser	Glu
				145			150			155			160		
Lys	Ser	Thr	Asn	Leu	His	Asp	Tyr	Gly	Met	Leu	Leu	Pro	Cys	Gly	Ile
				165			170					175			
Asp	Lys	Phe	Arg	Gly	Val	Glu	Phe	Val	Cys	Cys	Pro	Leu	Ala	Glu	Glu
				180			185					190			
Ser	Asp	Asn	Val	Asp	Ser	Ala	Asp	Ala	Glu	Glu	Asp	Asp	Ser	Asp	Val
				195			200				205				
Trp	Trp	Gly	Gly	Ala	Asp	Thr	Asp	Tyr	Ala	Asp	Gly	Ser	Glu	Asp	Lys
				210			215				220				
Val	Val	Glu	Val	Ala	Glu	Glu	Glu	Val	Ala	Glu	Val	Glu	Glu	Glu	
				225			230			235			240		
Glu	Ala	Asp	Asp	Asp	Glu	Asp	Asp	Glu	Asp	Gly	Asp	Glu	Val	Glu	Glu
				245			250				255				
Glu	Ala	Glu	Glu	Pro	Tyr	Glu	Glu	Ala	Thr	Glu	Arg	Thr	Thr	Ser	Ile
				260			265				270				
Ala	Thr	Thr	Thr	Thr	Thr	Thr	Glu	Ser	Val	Glu	Glu	Val	Val	Arg	
				275			280				285				
Glu	Val	Cys	Ser	Glu	Gln	Ala	Glu	Thr	Gly	Pro	Cys	Arg	Ala	Met	Ile
				290			295				300				
Ser	Arg	Trp	Tyr	Phe	Asp	Val	Thr	Glu	Gly	Lys	Cys	Ala	Pro	Phe	Phe
				305			310			315			320		
Tyr	Gly	Gly	Cys	Gly	Gly	Asn	Arg	Asn	Asn	Phe	Asp	Thr	Glu	Glu	Tyr
				325			330				335				
Cys	Met	Ala	Val	Cys	Gly	Ser	Ala	Ile	Pro	Thr	Thr	Ala	Ala	Ser	Thr
				340			345				350				
Pro	Asp	Ala	Val	Asp	Lys	Tyr	Leu	Glu	Thr	Pro	Gly	Asp	Glu	Asn	Glu
				355			360				365				
His	Ala	His	Phe	Gln	Lys	Ala	Lys	Glu	Arg	Leu	Glu	Ala	Lys	His	Arg
				370			375			380					
Glu	Arg	Met	Ser	Gln	Val	Met	Arg	Glu	Trp	Glu	Glu	Ala	Glu	Arg	Gln
				385			390			395			400		
Ala	Lys	Asn	Leu	Pro	Lys	Ala	Asp	Lys	Ala	Val	Ile	Gln	His	Phe	
				405			410				415				

- 52 -

Gln Glu Lys Val Glu Ser Leu Glu Gln Glu Ala Ala Asn Glu Arg Gln
 420 425 430

Gln Leu Val Glu Thr His Met Ala Arg Val Glu Ala Met Leu Asn Asp
 435 440 445

Arg Arg Arg Leu Ala Leu Glu Asn Tyr Ile Thr Ala Leu Gln Ala Val
 450 455 460

Pro Pro Arg Pro Arg His Val Phe Asn Met Leu Lys Lys Tyr Val Arg
 465 470 475 480

Ala Glu Gln Lys Asp Arg Gln His Thr Leu Lys His Phe Glu His Val
 485 490 495

Arg Met Val Asp Pro Lys Lys Ala Ala Gln Ile Arg Ser Gln Val Met
 500 505 510

Thr His Leu Arg Val Ile Tyr Glu Arg Met Asn Gln Ser Leu Ser Leu
 515 520 525

Leu Tyr Asn Val Pro Ala Val Ala Glu Glu Ile Gln Asp Glu Val Asp
 530 535 540

Glu Leu Leu Gln Lys Glu Gln Asn Tyr Ser Asp Asp Val Leu Ala Asn
 545 550 555 560

Met Ile Ser Glu Pro Arg Ile Ser Tyr Gly Asn Asp Ala Leu Met Pro
 565 570 575

Ser Leu Thr Glu Thr Lys Thr Val Glu Leu Leu Pro Val Asn Gly
 580 585 590

Glu Phe Ser Leu Asp Asp Leu Gln Pro Trp His Ser Phe Gly Ala Asp
 595 600 605

Ser Val Pro Ala Asn Thr Glu Asn Glu Val Glu Pro Val Asp Ala Arg
 610 615 620

Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu Thr
 625 630 635 640

Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys Met Asp Ala Glu Phe
 645 650 655

Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe Phe
 660 665 670

Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met Val
 675 680 685

Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu Val Met Leu
 690 695 700

Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val Glu Val Asp
 705 710 715 720

Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys Met Gln Gln Asn
 725 730 735

Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln Met Gln Asn
 740 745 750

- 53 -

<210> 58
<211> 2316
<212> DNA
<213> Homo sapiens

<400> 58
atgtgcggc gtttggcact gtcctgctg gcccctgga cggctgggc gctggaggt 60
cccaactgatg gtaatgctgg cctgctggc gaaccccaga ttgccatgtt ctgtggcaga 120
ctgaacatgc acatgaatgt ccagaatggg aagtggatt cagatccatc aggacaaaa 180
acctgcattg ataccaagga aggcacatcg cagattgcc aagaagtcta ccctgaactg 240
cagatcacca atgtggtaga agccaaccaa ccagtgacca tccagaactg gtgcaagcgg 300
ggccgcaagc agtgcacagc ccatccccac tttgtattc cttaccgctg cttagtttgt 360
gagtttgtaa gtatgcacct tctcggttct gacaagtgc aatttttaca ccaggagagg 420
atggatgttt gcgaaaactca tcttcactgg cacaccgtcg ccaaagagac atgcagttag 480
aagagtagcca acttgcacatg ctacggcatg ttgtgcctt gcggaatttg caagttccga 540
gggttagagt ttgtgtgtt cccactggct gaagaaagtg acaatgttgg ttctgctgt 600
gcggaggagg atgactcgga tgcgtgttgg ggccgacgac acacagacta tgcatgggg 660
agtgaagaca aagttagtata agtagcagag gaggagaag tggctgagggt ggaagaagaa 720
gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
ccctacgaag aagccacaga gagaaccacc agcattgcca ccaccacacc caccaccaca 840
gagtctgtgg aagagggtgt tcgagaggtg tgctctgaa aagccgac gggccgtgc 900
cgagcaatga tctcccgctg gtactttgt gtactgaa ggaagtgtgc cccatttttt 960
tacggcggat gtggcggcaa ccggaaacac tttgacacag aagactactg catggccgtg 1020
tgtggcagcg ccattgtccca aagtttactc aagactacc aggaacctt tggccgagat 1080
cctgttaaac ttccttacac agcagccagt acccctgtat ccgttgacaa gttatctcgag 1140
acacctgggg atgagaatga acatgccccat ttccagaaag ccaaagagag gcttgaggcc 1200
aagcaccggag agagaatgtc ccagggtatg agagaatggg aagaggcaga acgtcaagca 1260
aagaacttgc cttaaagctga taagaaggca gttatccagc atttccagga gaaagtggaa 1320
tctttggAAC aggaagcagc caacgagaga cagcagctgg tggagacaca catggccaga 1380
gtggaaagcca tgctcaatga ccggccggc ctggccctgg agaactacat caccgctctg 1440
caggctttc ctccctggcc tcgtcacgtt tcaatatgc taaagaagta tgcccgcc 1500
gaacagaagg acagacagca caccctaaag catttcgagc atgtgcgcattt gttggatccc 1560
aagaaaagccg ctcaagatccg gtcccaggtt atgacacacc tccgtgttat ttatgagcgc 1620
atgaatcaatgt ctcttcctt gctctacac gtcctgtcgat tggccgaggg gattcaggat 1680
gaagttgtatg agctgttca gaaagagcaa aactattcg atgacgttcc gccaacatg 1740
attagtgaac caaggatcatg ttacggaaac gatgtctca tgccatctt gaccgaaacg 1800
aaaaccaccc tggagctct tcccgttaat ggagagttca gcctggacga tctccagccg 1860
tggcattttt ttggggctga ctctgtgcca gccaacacag aaaacgaagt tgagcctgtt 1920
gatgcccgc ctgctgccc ccgaggactg accactcgac caggttctgg gttgacaaat 1980
atcaagacgg aggagatctc tgaagtgaag atggatgcag aattccgaca tgactcagga 2040
tatgaaggcc atcatcaaaa attgggtttc ttgcagaag atgtgggtt aaacaaaggt 2100
gcaatcattg gactcatgtt gggcggttt gtcatagcga cagtgtatgtt catcacctt 2160
gtgtatgtt agaagaaaaca gtacacatcc attcatcatg gtgtgggtt ggttgacgcc 2220
gctgtcaccc cagaggagcg ccacctgtcc aagatgcagc agaacggcta cgaaaatcca 2280
acctacaatgt tctttgagca gatgcagaac aagaag 2316

<210> 59
<211> 772
<212> PRT
<213> Homo sapiens

<400> 59
Met Leu Pro Gly Leu Ala Leu Leu Leu Ala Ala Trp Thr Ala Arg
1 5 10 15
Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
20 25 30
Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
35 40 45

- 54 -

Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
 50 55 60

Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
 65 70 75 80

Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
 85 90 95

Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
 100 105 110

Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
 115 120 125

Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
 130 135 140

Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
 145 150 155 160

Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
 165 170 175

Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
 180 185 190

Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
 195 200 205

Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
 210 215 220

Val Val Glu Val Ala Glu Glu Glu Val Ala Glu Val Glu Glu Glu
 225 230 235 240

Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
 245 250 255

Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
 260 265 270

Ala Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Val Arg
 275 280 285

Glu Val Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala Met Ile
 290 295 300

Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys Ala Pro Phe Phe
 305 310 315 320

Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe Asp Thr Glu Glu Tyr
 325 330 335

Cys Met Ala Val Cys Gly Ser Ala Met Ser Gln Ser Leu Leu Lys Thr
 340 345 350

Thr Gln Glu Pro Leu Ala Arg Asp Pro Val Lys Leu Pro Thr Thr Ala
 355 360 365

Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu Glu Thr Pro Gly Asp
 370 375 380

- 55 -

Glu Asn Glu His Ala His Phe Gln Lys Ala Lys Glu Arg Leu Glu Ala
 385 390 395 400

Lys His Arg Glu Arg Met Ser Gln Val Met Arg Glu Trp Glu Glu Ala
 405 410 415

Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp Lys Lys Ala Val Ile
 420 425 430

Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu Gln Glu Ala Ala Asn
 435 440 445

Glu Arg Gln Gln Leu Val Glu Thr His Met Ala Arg Val Glu Ala Met
 450 455 460

Leu Asn Asp Arg Arg Leu Ala Leu Glu Asn Tyr Ile Thr Ala Leu
 465 470 475 480

Gln Ala Val Pro Pro Arg Pro Arg His Val Phe Asn Met Leu Lys Lys
 485 490 495

Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His Thr Leu Lys His Phe
 500 505 510

Glu His Val Arg Met Val Asp Pro Lys Lys Ala Ala Gln Ile Arg Ser
 515 520 525

Gln Val Met Thr His Leu Arg Val Ile Tyr Glu Arg Met Asn Gln Ser
 530 535 540

Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala Glu Glu Ile Gln Asp
 545 550 555 560

Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn Tyr Ser Asp Asp Val
 565 570 575

Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser Tyr Gly Asn Asp Ala
 580 585 590

Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr Val Glu Leu Leu Pro
 595 600 605

Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln Pro Trp His Ser Phe
 610 615 620

Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn Glu Val Glu Pro Val
 625 630 635 640

Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser
 645 650 655

Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys Met Asp
 660 665 670

Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu
 675 680 685

Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly
 690 695 700

Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu
 705 710 715 720

- 56 -

Val Met Leu Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val
725 730 735

Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys Met
740 745 750

Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln Met
755 760 765

Gln Asn Lys Lys
770

<210> 60

<211> 2259

<212> DNA

<213> Homo sapiens

<400> 60

atgctgcccc gttggcaact gtcctgtctg gccgccttggc cggctcgccc gctggaggta 60
 cccactgatg gtaatgctgg cctgctggct gaaccccaga ttgccatgtt ctgtggcaga 120
 ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc aggacccaaa 180
 acctgcattt ataccaagga aggcattctg cagtattgcc aagaagtcta ccctgaactg 240
 cagatcacca atgtggtaga agccaaccaa ccagtgacca tccagaactg gtgcaagcgg 300
 ggccgcaagc agtcaagac ccatccccac tttgtgattc cctaccgctg cttagttgt 360
 gagttttaa gtgatgcct ttcgttctt gacaagtgc aattcttaca ccaggagagg 420
 atggatgttt gcgaaactca tcttcaactgg cacaccgtcg ccaaagagac atgcagttag 480
 aagagtacca acttgcataa ctacggcatg ttgtgtccct gcggaatgtt caagttccga 540
 gggtagatg ttgtgttgtt cccactggct gaagaaagtg acaatgttga ttctgctgt 600
 gcggaggagg atgactcgaa tgtctgttgg ggccgagcag acacagacta tgcaagatgg 660
 agtgaagaca aagtagtaga agtagcagag gaggagaag tggctgagggtt ggaagaagaa 720
 gaagccgatg atgacgagga cgatgaggat ggtgtatgagg tagaggaaga ggctgaggaa 780
 ccctacgaag aagccacaga gagaaccacc agcattgcca ccaccaccac caccaccaca 840
 gagtctgtgg aagagggtgt tcgagagggtg tgctctgaac aagccgagac gggccgtgc 900
 cgagcaatga tctcccgctg gtacttttatgtt gtactgtgaag ggaagtgtgc cccattttt 960
 tacggcggat gtggcggcaa ccggaaacaac ttgtacacacag aagagtactg catggccgtg 1020
 tgtggcagcg ccattcctac aacagcagcc agtaccctgt atgccgttga caagtatctc 1080
 gagacacctg gggatgagaa tgaacatgcc catttccaga aagccaaaga gaggcttgag 1140
 gccaagcacc gagagagaat gtcccaggtc atgagagaat gggaaagaggc agaacgtcaa 1200
 gcaaagaact tgccctaaagc tgataagaag gcagtttatcc agcatttcca ggagaaagtg 1260
 gaatcttgg aacaggaagc agccaaacgag agacagcagc tgggtggagac acacatggcc 1320
 agagtggaaag ccatgctcaa tgaccggcgc cgccctggccc tggagaacta catcaccgt 1380
 ctgcaggctg ttccctctcg gcctcgatc gtgttcaata tgctaaagaa gtatgtccgc 1440
 gcagaacaga aggacagaca gcacacccctt aagcattttcg agcatgtgcg catgggttat 1500
 cccaaagaaag ccgtcgatc cccgtccccag gttatgacac acctccgtgt gatttatgag 1560
 cgcattgtatc agtctcttc cctgtcttac aacgtgcctg cagtggccga ggagattcag 1620
 gatgaagttt atgagctgtc tcagaaaagag caaaactatt cagatgacgt cttggccaaac 1680
 atgatttagt aaccaaggat cagttacggaa aacgtgtctc tcattgcacatc tttgaccgaa 1740
 acgaaaacca ccgtggagct ctttcccgatc aatggagagt tcagccttggaa cgatctccag 1800
 ccgtggcatt ctttggggc tgactctgtc ccagccaaaca cagaaaacga agtgagcct 1860
 gttgtgtccc gcctcgatc cgaccggatc ctgaccactc gaccaggatc tgggttgcaca 1920
 aatatcaaga cggaggagat ctctgaatgt aagatggatc cagaattccg acatgactca 1980
 ggatatgaag ttcatcatca aaaattgggtt ttcttgcag aagatgtggg ttcaaacaaa 2040
 ggtgcaatca ttggactcat ggtggccgtt gttgtcatag cgacagtgtat cgtcatcacc 2100
 ttgggtatgc tgaagaagaa acagtacaca tccatttcattc atgggtgtgtt ggaggttgac 2160
 gcccgtgtca ccccaagagga gcccacactg tccaaatgtc agcagaacagg ctacgaaaat 2220
 ccaacctaca agttctttga cagatgcag aacaagaag 2259

<210> 61

<211> 753

<212> PRT

<213> Homo sapiens

- 57 -

<400> 61
 Met Leu Pro Gly Leu Ala Leu Leu Leu Ala Ala Trp Thr Ala Arg
 1 5 10 15
 Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
 20 25 30
 Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
 35 40 45
 Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
 50 55 60
 Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
 65 70 75 80
 Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
 85 90 95
 Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
 100 105 110
 Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
 115 120 125
 Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
 130 135 140
 Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
 145 150 155 160
 Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
 165 170 175
 Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
 180 185 190
 Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
 195 200 205
 Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
 210 215 220
 Val Val Glu Val Ala Glu Glu Glu Val Ala Glu Val Glu Glu Glu
 225 230 235 240
 Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
 245 250 255
 Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
 260 265 270
 Ala Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
 275 280 285
 Glu Val Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala Met Ile
 290 295 300
 Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys Ala Pro Phe Phe
 305 310 315 320

- 58 -

Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe Asp Thr Glu Glu Tyr
 325 330 335

Cys Met Ala Val Cys Gly Ser Ala Ile Pro Thr Thr Ala Ala Ser Thr
 340 345 350

Pro Asp Ala Val Asp Lys Tyr Leu Glu Thr Pro Gly Asp Glu Asn Glu
 355 360 365

His Ala His Phe Gln Lys Ala Lys Glu Arg Leu Glu Ala Lys His Arg
 370 375 380

Glu Arg Met Ser Gln Val Met Arg Glu Trp Glu Glu Ala Glu Arg Gln
 385 390 395 400

Ala Lys Asn Leu Pro Lys Ala Asp Lys Lys Ala Val Ile Gln His Phe
 405 410 415

Gln Glu Lys Val Glu Ser Leu Glu Gln Glu Ala Ala Asn Glu Arg Gln
 420 425 430

Gln Leu Val Glu Thr His Met Ala Arg Val Glu Ala Met Leu Asn Asp
 435 440 445

Arg Arg Arg Leu Ala Leu Glu Asn Tyr Ile Thr Ala Leu Gln Ala Val
 450 455 460

Pro Pro Arg Pro Arg His Val Phe Asn Met Leu Lys Lys Tyr Val Arg
 465 470 475 480

Ala Glu Gln Lys Asp Arg Gln His Thr Leu Lys His Phe Glu His Val
 485 490 495

Arg Met Val Asp Pro Lys Lys Ala Ala Gln Ile Arg Ser Gln Val Met
 500 505 510

Thr His Leu Arg Val Ile Tyr Glu Arg Met Asn Gln Ser Leu Ser Leu
 515 520 525

Leu Tyr Asn Val Pro Ala Val Ala Glu Glu Ile Gln Asp Glu Val Asp
 530 535 540

Glu Leu Leu Gln Lys Glu Gln Asn Tyr Ser Asp Asp Val Leu Ala Asn
 545 550 555 560

Met Ile Ser Glu Pro Arg Ile Ser Tyr Gly Asn Asp Ala Leu Met Pro
 565 570 575

Ser Leu Thr Glu Thr Lys Thr Val Glu Leu Leu Pro Val Asn Gly
 580 585 590

Glu Phe Ser Leu Asp Asp Leu Gln Pro Trp His Ser Phe Gly Ala Asp
 595 600 605

Ser Val Pro Ala Asn Thr Glu Asn Glu Val Glu Pro Val Asp Ala Arg
 610 615 620

Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu Thr
 625 630 635 640

Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys Met Asp Ala Glu Phe
 645 650 655

- 59 -

Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe Phe
660 665 670

Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met Val
675 680 685

Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu Val Met Leu
690 695 700

Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val Glu Val Asp
705 710 715 720

Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys Met Gln Gln Asn
725 730 735

Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln Met Gln Asn Lys
740 745 750

Lys

<210> 62
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic

<400> 62
Leu Glu Val Leu Phe Gln Gly Pro
1 5

<210> 63
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic

<400> 63
Ser Glu Val Asn Leu Asp Ala Glu Phe Arg
1 5 10

<210> 64
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic

<400> 64
Ser Glu Val Lys Met Asp Ala Glu Phe Arg
1 5 10

<210> 65
<211> 15

- 60 -

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 65

Arg Arg Gly Gly Val Val Ile Ala Thr Val Ile Val Gly Glu Arg
1 5 10 15

<210> 66

<211> 518

<212> PRT

<213> Homo sapiens

<400> 66

Met Gly Ala Leu Ala Arg Ala Leu Leu Leu Pro Leu Leu Ala Gln Trp
1 5 10 15

Leu Leu Arg Ala Ala Pro Glu Leu Ala Pro Ala Pro Phe Thr Leu Pro
20 25 30

Leu Arg Val Ala Ala Ala Thr Asn Arg Val Val Ala Pro Thr Pro Gly
35 40 45

Pro Gly Thr Pro Ala Glu Arg His Ala Asp Gly Leu Ala Leu Ala Leu
50 55 60

Glu Pro Ala Leu Ala Ser Pro Ala Gly Ala Ala Asn Phe Leu Ala Met
65 70 75 80

Val Asp Asn Leu Gln Gly Asp Ser Gly Arg Gly Tyr Tyr Leu Glu Met
85 90 95

Leu Ile Gly Thr Pro Pro Gln Lys Leu Gln Ile Leu Val Asp Thr Gly
100 105 110

Ser Ser Asn Phe Ala Val Ala Gly Thr Pro His Ser Tyr Ile Asp Thr
115 120 125

Tyr Phe Asp Thr Glu Arg Ser Ser Thr Tyr Arg Ser Lys Gly Phe Asp
130 135 140

Val Thr Val Lys Tyr Thr Gln Gly Ser Trp Thr Gly Phe Val Gly Glu
145 150 155 160

Asp Leu Val Thr Ile Pro Lys Gly Phe Asn Thr Ser Phe Leu Val Asn
165 170 175

Ile Ala Thr Ile Phe Glu Ser Glu Asn Phe Phe Leu Pro Gly Ile Lys
180 185 190

Trp Asn Gly Ile Leu Gly Leu Ala Tyr Ala Thr Leu Ala Lys Pro Ser
195 200 205

Ser Ser Leu Glu Thr Phe Phe Asp Ser Leu Val Thr Gln Ala Asn Ile
210 215 220

Pro Asn Val Phe Ser Met Gln Met Cys Gly Ala Gly Leu Pro Val Ala
225 230 235 240

- 61 -

Gly Ser Gly Thr Asn Gly Gly Ser Leu Val Leu Gly Gly Ile Glu Pro
 245 250 255

Ser Leu Tyr Lys Gly Asp Ile Trp Tyr Thr Pro Ile Lys Glu Glu Trp
 260 265 270

Tyr Tyr Gln Ile Glu Ile Leu Lys Leu Glu Ile Gly Gly Gln Ser Leu
 275 280 285

Asn Leu Asp Cys Arg Glu Tyr Asn Ala Asp Lys Ala Ile Val Asp Ser
 290 295 300

Gly Thr Thr Leu Leu Arg Leu Pro Gln Lys Val Phe Asp Ala Val Val
 305 310 315 320

Glu Ala Val Ala Arg Ala Ser Leu Ile Pro Glu Phe Ser Asp Gly Phe
 325 330 335

Trp Thr Gly Ser Gln Leu Ala Cys Trp Thr Asn Ser Glu Thr Pro Trp
 340 345 350

Ser Tyr Phe Pro Lys Ile Ser Ile Tyr Leu Arg Asp Glu Asn Ser Ser
 355 360 365

Arg Ser Phe Arg Ile Thr Ile Leu Pro Gln Leu Tyr Ile Gln Pro Met
 370 375 380

Met Gly Ala Gly Leu Asn Tyr Glu Cys Tyr Arg Phe Gly Ile Ser Pro
 385 390 395 400

Ser Thr Asn Ala Leu Val Ile Gly Ala Thr Val Met Glu Gly Phe Tyr
 405 410 415

Val Ile Phe Asp Arg Ala Gln Lys Arg Val Gly Phe Ala Ala Ser Pro
 420 425 430

Cys Ala Glu Ile Ala Gly Ala Ala Val Ser Glu Ile Ser Gly Pro Phe
 435 440 445

Ser Thr Glu Asp Val Ala Ser Asn Cys Val Pro Ala Gln Ser Leu Ser
 450 455 460

Glu Pro Ile Leu Trp Ile Val Ser Tyr Ala Leu Met Ser Val Cys Gly
 465 470 475 480

Ala Ile Leu Leu Val Leu Ile Val Leu Leu Leu Pro Phe Arg Cys
 485 490 495

Gln Arg Arg Pro Arg Asp Pro Glu Val Val Asn Asp Glu Ser Ser Leu
 500 505 510

Val Arg His Arg Trp Lys
 515

<210> 67
<211> 475
<212> PRT
<213> Homo sapiens

<400> 67
Met Gly Ala Leu Ala Arg Ala Leu Leu Pro Leu Leu Ala Gln Trp
 1 5 10 15

- 62 -

Leu	Leu	Arg	Ala	Ala	Pro	Glu	Leu	Ala	Pro	Ala	Pro	Phe	Thr	Leu	Pro
20						25								30	
Leu	Arg	Val	Ala	Ala	Ala	Thr	Asn	Arg	Val	Val	Ala	Pro	Thr	Pro	Gly
35							40						45		
Pro	Gly	Thr	Pro	Ala	Glu	Arg	His	Ala	Asp	Gly	Leu	Ala	Leu	Ala	Leu
50					55						60				
Glu	Pro	Ala	Leu	Ala	Ser	Pro	Ala	Gly	Ala	Ala	Asn	Phe	Leu	Ala	Met
65						70				75			80		
Val	Asp	Asn	Leu	Gln	Gly	Asp	Ser	Gly	Arg	Gly	Tyr	Tyr	Leu	Glu	Met
						85			90				95		
Leu	Ile	Gly	Thr	Pro	Pro	Gln	Lys	Leu	Gln	Ile	Leu	Val	Asp	Thr	Gly
								100		105			110		
Ser	Ser	Asn	Phe	Ala	Val	Ala	Gly	Thr	Pro	His	Ser	Tyr	Ile	Asp	Thr
								115		120			125		
Tyr	Phe	Asp	Thr	Glu	Arg	Ser	Ser	Thr	Tyr	Arg	Ser	Lys	Gly	Phe	Asp
						130		135			140				
Val	Thr	Val	Lys	Tyr	Thr	Gln	Gly	Ser	Trp	Thr	Gly	Phe	Val	Gly	Glu
						145		150			155			160	
Asp	Leu	Val	Thr	Ile	Pro	Lys	Gly	Phe	Asn	Thr	Ser	Phe	Leu	Val	Asn
						165			170			175			
Ile	Ala	Thr	Ile	Phe	Glu	Ser	Glu	Asn	Phe	Phe	Leu	Pro	Gly	Ile	Lys
						180			185			190			
Trp	Asn	Gly	Ile	Leu	Gly	Leu	Ala	Tyr	Ala	Thr	Leu	Ala	Lys	Pro	Ser
							195		200			205			
Ser	Ser	Leu	Glu	Thr	Phe	Phe	Asp	Ser	Leu	Val	Thr	Gln	Ala	Asn	Ile
						210		215			220				
Pro	Asn	Val	Phe	Ser	Met	Gln	Met	Cys	Gly	Ala	Gly	Leu	Pro	Val	Ala
						225		230			235			240	
Gly	Ser	Gly	Thr	Asn	Gly	Gly	Ser	Leu	Val	Leu	Gly	Gly	Ile	Glu	Pro
							245		250			255			
Ser	Leu	Tyr	Lys	Gly	Asp	Ile	Trp	Tyr	Thr	Pro	Ile	Lys	Glu	Glu	Trp
						260			265			270			
Tyr	Tyr	Gln	Ile	Glu	Ile	Leu	Lys	Leu	Glu	Ile	Gly	Gly	Gln	Ser	Leu
							275		280			285			
Asn	Leu	Asp	Cys	Arg	Glu	Tyr	Asn	Ala	Asp	Lys	Ala	Ile	Val	Asp	Ser
							290		295			300			
Gly	Thr	Thr	Leu	Leu	Arg	Leu	Pro	Gln	Lys	Val	Phe	Asp	Ala	Val	Val
							305		310			315			320
Glu	Ala	Val	Ala	Arg	Ala	Ser	Leu	Ile	Pro	Glu	Phe	Ser	Asp	Gly	Phe
							325			330			335		
Trp	Thr	Gly	Ser	Gln	Leu	Ala	Cys	Trp	Thr	Asn	Ser	Glu	Thr	Pro	Trp
								340		345			350		

- 63 -

Ser	Tyr	Phe	Pro	Lys	Ile	Ser	Ile	Tyr	Leu	Arg	Asp	Glu	Asn	Ser	Ser
355							360								365
Arg	Ser	Phe	Arg	Ile	Thr	Ile	Leu	Pro	Gln	Leu	Tyr	Ile	Gln	Pro	Met
370							375								380
Met	Gly	Ala	Gly	Leu	Asn	Tyr	Glu	Cys	Tyr	Arg	Phe	Gly	Ile	Ser	Pro
385							390								400
Ser	Thr	Asn	Ala	Leu	Val	Ile	Gly	Ala	Thr	Val	Met	Glu	Gly	Phe	Tyr
						405				410					415
Val	Ile	Phe	Asp	Arg	Ala	Gln	Lys	Arg	Val	Gly	Phe	Ala	Ala	Ser	Pro
						420				425					430
Cys	Ala	Glu	Ile	Ala	Gly	Ala	Ala	Val	Ser	Glu	Ile	Ser	Gly	Pro	Phe
						435			440						445
Ser	Thr	Glu	Asp	Val	Ala	Ser	Asn	Cys	Val	Pro	Ala	Gln	Ser	Leu	Ser
						450			455						460
Glu	Pro	Ile	Leu	Trp	His	His	His	His	His	His					
					465			470							475
<210> 68															
<211> 413															
<212> PRT															
<213> Homo sapiens															
<400> 68															
Ala	Leu	Glu	Pro	Ala	Leu	Ala	Ser	Pro	Ala	Gly	Ala	Ala	Asn	Phe	Leu
1					5					10					15
Ala	Met	Val	Asp	Asn	Leu	Gln	Gly	Asp	Ser	Gly	Arg	Gly	Tyr	Tyr	Leu
					20				25						30
Glu	Met	Leu	Ile	Gly	Thr	Pro	Pro	Gln	Lys	Leu	Gln	Ile	Leu	Val	Asp
					35				40						45
Thr	Gly	Ser	Ser	Asn	Phe	Ala	Val	Ala	Gly	Thr	Pro	His	Ser	Tyr	Ile
					50				55						60
Asp	Thr	Tyr	Phe	Asp	Thr	Glu	Arg	Ser	Ser	Thr	Tyr	Arg	Ser	Lys	Gly
					65			70			75				80
Phe	Asp	Val	Thr	Val	Lys	Tyr	Thr	Gln	Gly	Ser	Trp	Thr	Gly	Phe	Val
					85			90							95
Gly	Glu	Asp	Leu	Val	Thr	Ile	Pro	Lys	Gly	Phe	Asn	Thr	Ser	Phe	Leu
					100			105							110
Val	Asn	Ile	Ala	Thr	Ile	Phe	Glu	Ser	Glu	Asn	Phe	Phe	Leu	Pro	Gly
					115			120							125
Ile	Lys	Trp	Asn	Gly	Ile	Leu	Gly	Leu	Ala	Tyr	Ala	Thr	Leu	Ala	Lys
					130			135							140
Pro	Ser	Ser	Ser	Leu	Glu	Thr	Phe	Phe	Asp	Ser	Leu	Val	Thr	Gln	Ala
					145			150			155				160
Asn	Ile	Pro	Asn	Val	Phe	Ser	Met	Gln	Met	Cys	Gly	Ala	Gly	Leu	Pro
					165			170							175

- 64 -

Val Ala Gly Ser Gly Thr Asn Gly Gly Ser Leu Val Leu Gly Gly Ile
180 185 190

Glu Pro Ser Leu Tyr Lys Gly Asp Ile Trp Tyr Thr Pro Ile Lys Glu
195 200 205

Glu Trp Tyr Tyr Gln Ile Glu Ile Leu Lys Leu Glu Ile Gly Gly Gln
210 215 220

Ser Leu Asn Leu Asp Cys Arg Glu Tyr Asn Ala Asp Lys Ala Ile Val
225 230 235 240

Asp Ser Gly Thr Thr Leu Leu Arg Leu Pro Gln Lys Val Phe Asp Ala
245 250 255

Val Val Glu Ala Val Ala Arg Ala Ser Leu Ile Pro Glu Phe Ser Asp
260 265 270

Gly Phe Trp Thr Gly Ser Gln Leu Ala Cys Trp Thr Asn Ser Glu Thr
275 280 285

Pro Trp Ser Tyr Phe Pro Lys Ile Ser Ile Tyr Leu Arg Asp Glu Asn
290 295 300

Ser Ser Arg Ser Phe Arg Ile Thr Ile Leu Pro Gln Leu Tyr Ile Gln
305 310 315 320

Pro Met Met Gly Ala Gly Leu Asn Tyr Glu Cys Tyr Arg Phe Gly Ile
325 330 335

Ser Pro Ser Thr Asn Ala Leu Val Ile Gly Ala Thr Val Met Glu Gly
340 345 350

Phe Tyr Val Ile Phe Asp Arg Ala Gln Lys Arg Val Gly Phe Ala Ala
355 360 365

Ser Pro Cys Ala Glu Ile Ala Gly Ala Ala Val Ser Glu Ile Ser Gly
370 375 380

Pro Phe Ser Thr Glu Asp Val Ala Ser Asn Cys Val Pro Ala Gln Ser
385 390 395 400

Leu Ser Glu Pro Ile Leu Trp His His His His His His
405 410

<210> 69
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<400> 69
Gly Leu Ala Leu Ala Leu Glu Pro
1 5

<210> 70
<211> 8
<212> PRT
<213> Artificial Sequence

- 65 -

<220>
<223> Description of Artificial Sequence: Peptide

<400> 70
Glu Val Lys Met Asp Ala Glu Phe
1 5

<210> 71
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<400> 71
Glu Val Asn Leu Asp Ala Glu Phe
1 5

<210> 72
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<400> 72
Leu Val Phe Phe Ala Glu Asp Val
1 5

<210> 73
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<400> 73
Lys Leu Val Phe Phe Ala Glu Asp
1 5

<210> 74
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 74
cgctttaagc ttgccaccat gggcgactg gcccgccg

39

<210> 75
<211> 57
<212> DNA
<213> Artificial Sequence

<220>

- 66 -

<223> Description of Artificial Sequence: Primer

<400> 75

cgctttctcg agctaatgg t gatggtgatg gtgccacaaa atgggctcgc tcaaaga 57

<210> 76

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Peptide

<400> 76

Arg Arg Gly Gly Val Val Ile Ala Thr Val Ile Val Gly Glu Arg
1 5 10 15